<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Medical Model Eval Dashboard</title>
    <style>
        body { font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif; background: #f5f5f7; margin: 0; padding: 20px; }
        header { margin-bottom: 20px; background: white; padding: 20px; border-radius: 12px; box-shadow: 0 2px 10px rgba(0,0,0,0.05); }
        h1 { margin: 0 0 10px 0; font-size: 24px; color: #1d1d1f; }
        
        /* Controls */
        .controls { display: flex; gap: 15px; align-items: center; flex-wrap: wrap; }
        select { padding: 10px; font-size: 16px; border-radius: 8px; border: 1px solid #d2d2d7; min-width: 300px; max-width: 100%; }
        button { padding: 10px 20px; background: #0071e3; color: white; border: none; border-radius: 8px; cursor: pointer; font-size: 14px; transition: background 0.2s; }
        button:hover { background: #0077ed; }
        .q-display { margin-top: 15px; font-size: 18px; font-weight: 600; color: #1d1d1f; line-height: 1.4; }

        /* Grid Layout */
        .grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(300px, 1fr)); gap: 20px; margin-top: 20px; }
        
        .card { background: white; border-radius: 12px; padding: 20px; box-shadow: 0 4px 6px rgba(0,0,0,0.02); border: 1px solid #e5e5e5; display: flex; flex-direction: column; }
        .card h3 { margin-top: 0; font-size: 16px; color: #86868b; text-transform: uppercase; letter-spacing: 0.5px; border-bottom: 1px solid #eee; padding-bottom: 10px; }
        .card-content { flex-grow: 1; font-size: 15px; line-height: 1.6; color: #333; overflow-x: auto; white-space: pre-wrap; margin-top: 10px; }
        
        /* Model Specific Colors */
        .card[data-model*="GPT"] h3 { color: #10a37f; border-bottom-color: #10a37f; }
        .card[data-model*="Gemini"] h3 { color: #4285f4; border-bottom-color: #4285f4; }
        .card[data-model*="BioMed"] h3 { color: #ea4335; border-bottom-color: #ea4335; }
        .card[data-model*="MedGemma"] h3 { color: #fbbc04; border-bottom-color: #fbbc04; }
    </style>
</head>
<body>

<header>
    <h1>Medical Model Evaluation Dashboard</h1>
    <div class="controls">
        <label for="q-select">Select Question:</label>
        <select id="q-select" onchange="renderQuestion()">
            <!-- Options populated by JS -->
        </select>
        <button onclick="changeQ(-1)">← Prev</button>
        <button onclick="changeQ(1)">Next →</button>
    </div>
    <div class="q-display" id="question-text">
        <!-- Question text goes here -->
    </div>
</header>

<div class="grid" id="response-grid">
    <!-- Response cards go here -->
</div>

<script>
    // Embedded Data
    const DATA = {"1": {"question": "Which gene mutations (protein expression patterns, transcriptional RNA levels, etc.) are associated with resistance to chemotherapy and radiotherapy in breast cancer?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>Mutated genes that cause resistance include those encoding the following proteins: multidrug resistance protein 1 (MDR1), BCR-ABL kinase, p53 tumor suppressor gene, thymidylate synthetase, dihydrofolate reductase, glutathione S-transferase, and MDRassociated protein.</p>"}, {"model": "GPT-4o", "text": "<p>Resistance to chemotherapy and radiotherapy in breast cancer is a complex phenomenon influenced by various genetic and molecular factors. Several gene mutations, protein expression patterns, and transcriptional changes have been associated with this resistance:</p>\n<ol>\n<li>\n<p><strong>TP53 Mutations</strong>: TP53 is a tumor suppressor gene, and its mutations are commonly associated with resistance to both chemotherapy and radiotherapy. Mutant p53 can lead to impaired apoptosis, allowing cancer cells to survive treatment.</p>\n</li>\n<li>\n<p><strong>BRCA1/BRCA2 Mutations</strong>: While BRCA1/2 mutations are typically associated with increased sensitivity to DNA-damaging agents, secondary mutations or reversion mutations can restore BRCA function, leading to resistance, particularly to PARP inhibitors.</p>\n</li>\n<li>\n<p><strong>HER2 Overexpression</strong>: Overexpression of the HER2 protein is associated with resistance to certain chemotherapeutic agents. HER2-positive breast cancers may require targeted therapies like trastuzumab for effective treatment.</p>\n</li>\n<li>\n<p><strong>PI3K/AKT/mTOR Pathway Alterations</strong>: Mutations or activation of components in this pathway can lead to resistance by promoting cell survival and growth. Inhibitors targeting this pathway are being explored to overcome resistance.</p>\n</li>\n<li>\n<p><strong>ER/PR Status</strong>: Estrogen receptor (ER) and progesterone receptor (PR) status can influence response to hormone therapies. Changes in receptor status during treatment can lead to resistance.</p>\n</li>\n<li>\n<p><strong>Multidrug Resistance Genes (e.g., ABC Transporters)</strong>: Overexpression of ATP-binding cassette (ABC) transporters, such as P-glycoprotein (encoded by the MDR1 gene), can lead to efflux of drugs from cancer cells, reducing their efficacy.</p>\n</li>\n<li>\n<p><strong>BCL-2 Family Proteins</strong>: Overexpression of anti-apoptotic proteins like BCL-2 and BCL-XL can inhibit apoptosis, contributing to resistance to chemotherapy and radiotherapy.</p>\n</li>\n<li>\n<p><strong>EMT-Related Genes</strong>: Epithelial-mesenchymal transition (EMT) is associated with increased invasiveness and resistance. Genes involved in EMT, such as TWIST, SNAIL, and ZEB1, are often upregulated in resistant cancers.</p>\n</li>\n<li>\n<p><strong>DNA Repair Genes</strong>: Alterations in genes involved in DNA repair, such as increased expression of RAD51 or alterations in mismatch repair genes, can lead to resistance by enhancing the repair of treatment-induced DNA damage.</p>\n</li>\n<li>\n<p><strong>MicroRNAs</strong>: Dysregulation of specific microRNAs can modulate gene expression and contribute to resistance. For example, miR-21 is often upregulated in resistant breast cancer cells.</p>\n</li>\n</ol>\n<p>These factors can interact in complex ways, and resistance often involves multiple mechanisms. Understanding these molecular changes is crucial for developing strategies to overcome resistance and improve treatment outcomes.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>Resistance to chemotherapy and radiotherapy in breast cancer is a multifaceted process involving genomic alterations (mutations), transcriptomic changes (mRNA levels), and proteomic shifts (protein expression).</p>\n<p>Here is a detailed breakdown of the specific genes and mechanisms associated with resistance, categorized by their biological function.</p>\n<h3>1. DNA Damage Response and Repair</h3>\n<p>Chemotherapy (particularly platinum agents and anthracyclines) and radiotherapy work primarily by inducing DNA damage. Cancer cells that can repair this damage efficiently\u2014or tolerate it\u2014become resistant.</p>\n<ul>\n<li><strong>TP53 (p53):</strong><ul>\n<li><strong>Alteration:</strong> Mutation or deletion.</li>\n<li><strong>Mechanism:</strong> Known as the \"guardian of the genome,\" wild-type p53 triggers apoptosis in response to DNA damage. <em>TP53</em> mutations prevent cell death, allowing tumor cells to survive radiation and cytotoxic drugs. This is the most common mutation associated with resistance in Triple-Negative Breast Cancer (TNBC).</li>\n</ul>\n</li>\n<li><strong>BRCA1 and BRCA2:</strong><ul>\n<li><strong>Alteration:</strong> <em>Reversion</em> mutations.</li>\n<li><strong>Mechanism:</strong> While initial BRCA mutations make cells sensitive to DNA-damaging agents (and PARP inhibitors), resistant tumors often develop \"reversion mutations\" that restore the reading frame and functional protein, re-enabling Homologous Recombination (HR) repair and causing resistance to platinum-based chemo.</li>\n</ul>\n</li>\n<li><strong>ATM and ATR:</strong><ul>\n<li><strong>Expression:</strong> Overexpression.</li>\n<li><strong>Mechanism:</strong> These kinases sense DNA double-strand breaks caused by radiation. Their upregulation enhances repair signaling, leading to radioresistance.</li>\n</ul>\n</li>\n</ul>\n<h3>2. Drug Efflux Pumps (Multi-Drug Resistance)</h3>\n<p>One of the most direct mechanisms of chemotherapy resistance is the physical removal of the drug from the cell before it can act.</p>\n<ul>\n<li><strong>ABCB1 (MDR1/P-glycoprotein):</strong><ul>\n<li><strong>Expression:</strong> High protein and mRNA expression.</li>\n<li><strong>Mechanism:</strong> This ATP-binding cassette transporter pumps hydrophobic drugs (like <strong>taxanes</strong> and <strong>anthracyclines</strong>) out of the cell. Overexpression is a hallmark of acquired chemotherapy resistance.</li>\n</ul>\n</li>\n<li><strong>ABCC1 (MRP1) and ABCG2 (BCRP):</strong><ul>\n<li><strong>Expression:</strong> High expression.</li>\n<li><strong>Mechanism:</strong> Similar to ABCB1, these transporters efflux a wide variety of chemotherapeutics, reducing intracellular drug concentration.</li>\n</ul>\n</li>\n</ul>\n<h3>3. Survival Signaling Pathways (PI3K/AKT/mTOR)</h3>\n<p>Constitutive activation of growth pathways allows cells to bypass the stress signals induced by treatment.</p>\n<ul>\n<li><strong>PIK3CA:</strong><ul>\n<li><strong>Alteration:</strong> Activating mutations (e.g., H1047R).</li>\n<li><strong>Mechanism:</strong> These mutations hyperactivate the PI3K/AKT pathway, promoting cell survival and inhibiting apoptosis. This confers resistance to both chemotherapy and endocrine therapies (like tamoxifen).</li>\n</ul>\n</li>\n<li><strong>PTEN:</strong><ul>\n<li><strong>Alteration:</strong> Loss of function (deletion or mutation) or low protein expression.</li>\n<li><strong>Mechanism:</strong> PTEN is a tumor suppressor that inhibits PI3K. Its loss leads to unchecked AKT signaling, contributing to resistance against <strong>Trastuzumab</strong> (Herceptin) and chemotherapy.</li>\n</ul>\n</li>\n<li><strong>ERBB2 (HER2):</strong><ul>\n<li><strong>Alteration:</strong> Amplification or truncation (p95HER2).</li>\n<li><strong>Mechanism:</strong> While HER2+ cancers are treated with anti-HER2 drugs, the truncated p95HER2 form lacks the binding site for Trastuzumab, leading to resistance. Furthermore, HER2 signaling upregulates survivin, contributing to radioresistance.</li>\n</ul>\n</li>\n</ul>\n<h3>4. Apoptosis Evasion</h3>\n<p>Chemotherapy and radiotherapy aim to trigger programmed cell death. Altering the balance of pro- and anti-apoptotic proteins prevents this.</p>\n<ul>\n<li><strong>BCL2 and BCL-XL:</strong><ul>\n<li><strong>Expression:</strong> Overexpression.</li>\n<li><strong>Mechanism:</strong> These are anti-apoptotic proteins. High levels sequester pro-apoptotic proteins (like BAX and BAK), preventing mitochondrial outer membrane permeabilization and blocking cell death despite treatment.</li>\n</ul>\n</li>\n<li><strong>NF-\u03baB:</strong><ul>\n<li><strong>Expression:</strong> Constitutive activation/nuclear localization.</li>\n<li><strong>Mechanism:</strong> NF-\u03baB transcriptionally upregulates anti-apoptotic genes. Its activation is a common response to radiation, helping tumor cells survive the treatment.</li>\n</ul>\n</li>\n</ul>\n<h3>5. Epithelial-Mesenchymal Transition (EMT) and Stemness</h3>\n<p>Cells that undergo EMT become more invasive and acquire stem-cell-like properties. Cancer Stem Cells (CSCs) are naturally quiescent (slow-dividing) and have high DNA repair capacity, making them resistant to therapies that target rapidly dividing cells.</p>\n<ul>\n<li><strong>SNAIL, SLUG, TWIST, and ZEB1:</strong><ul>\n<li><strong>Expression:</strong> High transcriptional levels.</li>\n<li><strong>Mechanism:</strong> These transcription factors drive EMT. Their expression correlates with downregulation of E-cadherin and upregulation of Vimentin, leading to chemoresistance (particularly to paclitaxel).</li>\n</ul>\n</li>\n<li><strong>CD44 / CD24:</strong><ul>\n<li><strong>Pattern:</strong> CD44-high / CD24-low phenotype.</li>\n<li><strong>Mechanism:</strong> This surface marker profile identifies breast cancer stem cells. These cells are highly resistant to radiation and chemotherapy and are responsible for tumor recurrence.</li>\n</ul>\n</li>\n</ul>\n<h3>6. Hypoxia and the Tumor Microenvironment (Radio-specific)</h3>\n<p>Radiotherapy relies on oxygen to create free radicals (ROS) that damage DNA. Hypoxic (low oxygen) tumors are naturally radioresistant.</p>\n<ul>\n<li><strong>HIF1A (Hypoxia-Inducible Factor 1-alpha):</strong><ul>\n<li><strong>Expression:</strong> High protein stability/expression.</li>\n<li><strong>Mechanism:</strong> HIF1A triggers the transcription of VEGF (angiogenesis) and enzymes that switch metabolism to glycolysis (Warburg effect). It also upregulates DNA repair genes, protecting cells from radiation damage in low-oxygen environments.</li>\n</ul>\n</li>\n</ul>\n<h3>7. Estrogen Receptor Mutations (Endocrine Resistance)</h3>\n<p>While distinct from standard chemotherapy, resistance to endocrine therapy often precedes the need for chemo.</p>\n<ul>\n<li><strong>ESR1:</strong><ul>\n<li><strong>Alteration:</strong> Mutations in the ligand-binding domain (e.g., Y537S, D538G).</li>\n<li><strong>Mechanism:</strong> These mutations allow the Estrogen Receptor to remain active even without estrogen, rendering Aromatase Inhibitors ineffective and often requiring a switch to chemotherapy or SERDs (Selective Estrogen Receptor Degraders).</li>\n</ul>\n</li>\n</ul>\n<h3>Summary Table</h3>\n<p>| Mechanism | Key Gene/Protein | Alteration Type | Associated Resistance |\n| :--- | :--- | :--- | :--- |\n| <strong>DNA Repair</strong> | <em>TP53</em> | Mutation/Deletion | Chemo (Anthracyclines), Radio |\n| | <em>BRCA1/2</em> | Reversion Mutation | Platinum agents, PARP inhibitors |\n| <strong>Drug Efflux</strong> | <em>ABCB1 (MDR1)</em> | Overexpression | Taxanes, Anthracyclines |\n| <strong>Survival Signaling</strong> | <em>PIK3CA</em> | Activating Mutation | Chemo, Endocrine, Anti-HER2 |\n| | <em>PTEN</em> | Loss/Deletion | Trastuzumab, Chemo |\n| <strong>Apoptosis</strong> | <em>BCL2</em> | Overexpression | Pan-chemo resistance |\n| <strong>EMT / Stemness</strong> | <em>SNAIL, TWIST</em> | High Transcription | Paclitaxel, Radiotherapy |\n| <strong>Hypoxia</strong> | <em>HIF1A</em> | High Protein Level | Radiotherapy |</p>"}, {"model": "MedGemma 27B", "text": "<p>Breast cancer is a heterogeneous disease, meaning that it can present differently from person to person. This heterogeneity extends to how the tumor responds to treatment, including chemotherapy and radiotherapy. Resistance to these therapies is a major challenge in clinical practice, often leading to treatment failure and recurrence. Several genetic alterations have been identified as contributing factors to chemoresistance and radioresistance in breast cancer. These alterations affect various cellular processes involved in drug response, such as DNA repair, apoptosis, drug metabolism/transport, cell cycle regulation, and signaling pathways.</p>\n<p>Here's an overview of key gene mutations and molecular mechanisms associated with resistance to chemotherapy and radiotherapy in breast cancer:</p>\n<p><strong>1. Alterations in Drug Targets:</strong>\n*   Mutations or overexpression of target proteins can render them less sensitive to drugs. For example, mutations in <em>TP53</em>, which encodes the p53 protein, are common in many cancers, including breast cancer. Loss-of-function mutations in <em>TP53</em> impair its ability to induce apoptosis in response to DNA damage caused by chemotherapy or radiation, thus promoting resistance. Overexpression of HER2 (<em>ERBB2</em>) leads to increased proliferation and survival signals, making cells resistant to certain chemotherapies like anthracyclines and taxanes. While targeted therapies against HER2 exist, intrinsic or acquired resistance can still occur due to further mutations within the pathway.</p>\n<p><strong>2. Enhanced DNA Repair Mechanisms:</strong>\n*   Chemotherapy and radiotherapy primarily work by damaging DNA. Cancer cells that develop enhanced DNA repair capabilities can counteract this damage more effectively, leading to resistance. Genes involved in DNA repair include <em>BRCA1</em>, <em>BRCA2</em>, <em>RAD51</em>, and genes related to homologous recombination (HR) and non-homologous end joining (NHEJ). Mutations in <em>BRCA1/2</em> paradoxically confer sensitivity to PARP inhibitors but can be associated with resistance to platinum-based chemotherapy and some forms of radiotherapy if HR deficiency isn't fully exploited therapeutically. Increased expression of enzymes like MGMT (O6-methylguanine-DNA methyltransferase), although not typically mutated in breast cancer, plays a role in repairing alkylation damage induced by agents like temozolomide (used in other cancers but relevant conceptually).</p>\n<p><strong>3. Impaired Apoptosis Pathways:</strong>\n*   Apoptosis (programmed cell death) is a crucial mechanism for eliminating damaged cells after exposure to therapy. Defects in apoptotic machinery contribute significantly to resistance. Key players include:\n    *   <strong><em>BCL2</em> family members:</strong></p>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Which gene mutations (protein expression patterns, transcriptional RNA levels, etc.) are associated with resistance to chemotherapy and radiotherapy in breast cancer?</h1>\n<p>Breast cancer resistance to chemotherapy and radiotherapy is driven by a mix of recurrent DNA mutations, copy-number changes, and characteristic RNA/protein expression programs, many of which converge on drug metabolism, DNA damage repair, cell survival, and tumor\u2013immune interactions. Different intrinsic subtypes (luminal A/B, HER2-enriched, triple-negative/basal-like) show distinct resistance-associated patterns rather than a single universal \u201cresistance gene.\u201d<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12384436/\">^1</a><a href=\"https://aacrjournals.org/cancerres/article/84/9_Supplement/PO3-16-04/743861/Abstract-PO3-16-04-Distribution-of-intrinsic\">^3</a></p>\n<h2>Major pathways in chemoresistance</h2>\n<p>Several functional groups of genes repeatedly associate with poor response to standard anthracycline/taxane chemotherapy and to DNA\u2011damaging agents.</p>\n<ul>\n<li><strong>Drug metabolism and transport</strong><ul>\n<li>Overexpression of xenobiotic metabolism genes such as <em>CYP3A4</em> and <em>CYP2A6</em> correlates with non\u2011response to combined anthracycline\u2013taxane regimens, consistent with increased drug inactivation.<a href=\"https://pubmed.ncbi.nlm.nih.gov/38256136/\">^1</a></li>\n<li>Transporters such as the amino\u2011acid importer <em>SLC7A5</em> are upregulated in resistant tumors and metastases, and high expression distinguishes non\u2011responders from responders to anthracycline\u2013taxane therapy.<a href=\"https://pubmed.ncbi.nlm.nih.gov/38256136/\">^1</a></li>\n</ul>\n</li>\n<li><strong>Survival, inflammation, and microenvironment</strong><ul>\n<li>Resistant tumors show enrichment of inflammatory and innate immune response genes, including <em>LYN</em>, <em>LY96</em> (MD\u20112), and <em>ANXA1</em>, in patients with early relapse after anthracycline\u2013taxane chemotherapy.<a href=\"https://pubmed.ncbi.nlm.nih.gov/38256136/\">^1</a></li>\n<li>Activation of NF\u2011\u03baB signaling, with increased IKK\u03b1/IKK\u03b2 and nuclear <em>RELA/p65</em>, is a hallmark of trastuzumab\u2011resistant HER2+ luminal B cells that acquire a more basal\u2011like, aggressive phenotype.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4770917/\">^5</a></li>\n</ul>\n</li>\n<li><strong>Intrinsic subtype context</strong><ul>\n<li>Luminal A/B tumors, HER2\u2011enriched, and triple\u2011negative/basal\u2011like cancers differ systematically in proliferation, DNA repair capacity, and receptor signaling pathways, shaping their baseline sensitivity and routes to resistance.<a href=\"https://aacrjournals.org/cancerres/article/84/9_Supplement/PO3-16-04/743861/Abstract-PO3-16-04-Distribution-of-intrinsic\">^3</a></li>\n<li>For HER2\u2011negative patients receiving taxane\u2013anthracycline therapy, a 4\u2011gene signature including <em>SRPK1</em> (serine/arginine protein kinase 1) and three additional genes stratifies prognosis; resistant, basal\u2011like tumors tend to show elevated <em>SRPK1</em> and reduced expression of the other signature genes.<a href=\"https://www.oncotarget.com/article/21872/text/\">^6</a></li>\n</ul>\n</li>\n</ul>\n<h2>Selected chemoresistance-associated genes</h2>\n<p>The table highlights representative genes and expression patterns repeatedly linked to chemotherapy resistance or poor outcome, focusing on RNA/protein levels rather than single rare mutations.</p>\n<p>| Functional group | Gene / pattern | Resistance association |\n| :-- | :-- | :-- |\n| Drug metabolism | High <em>CYP3A4</em>, <em>CYP2A6</em> mRNA in pre\u2011treatment tumors | Enrichment in non\u2011responders to anthracycline\u2013taxane; supports increased drug catabolism and reduced effective dose.<a href=\"https://pubmed.ncbi.nlm.nih.gov/38256136/\">^1</a> |\n| Amino\u2011acid transport | High <em>SLC7A5</em> expression in primary and metastatic lesions | Distinguishes non\u2011responders; linked to high proliferative, metabolically active tumors with poor outcome after anthracycline\u2013taxane therapy.<a href=\"https://pubmed.ncbi.nlm.nih.gov/38256136/\">^1</a> |\n| Innate immunity / inflammation | Upregulated <em>LYN</em>, <em>LY96</em>, <em>ANXA1</em> | Overexpressed in tumors from patients relapsing within 5 years after anthracycline\u2013taxane, implicating inflammatory signaling in resistance.<a href=\"https://pubmed.ncbi.nlm.nih.gov/38256136/\">^1</a> |\n| Splicing / signaling (HER2\u2013 disease) | Elevated <em>SRPK1</em> with reduced expression of three partner genes in a 4\u2011gene signature | Signature identifies HER2\u2011negative patients with poor response and prognosis on taxane\u2013anthracycline regimens; <em>SRPK1</em> upregulation is prominent in basal\u2011like tumors.<a href=\"https://www.oncotarget.com/article/21872/text/\">^6</a> |\n| HER2 signaling and downstream survival | Persistent HER2 overexpression with constitutive NF\u2011\u03baB activation (IKK\u03b1/\u03b2\u2191, nuclear <em>RELA/p65</em>\u2191) in trastuzumab\u2011resistant luminal B cells | Defines trastuzumab\u2011resistant HER2+ clones that adopt a HER2+ basal\u2011like phenotype; NF\u2011\u03baB inhibition partially restores drug sensitivity.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4770917/\">^5</a> |</p>\n<h2>DNA repair and radiotherapy resistance</h2>\n<p>Radiotherapy and many chemotherapies kill cells by inducing DNA damage, so genes in DNA repair and cell cycle checkpoints are central to radioresistance.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12384436/\">^2</a></p>\n<ul>\n<li><strong>DNA repair gene expression and radiosensitivity</strong><ul>\n<li>A recent synthesis highlights that robust activity of homologous recombination (HR), non\u2011homologous end joining (NHEJ), and base\u2011excision repair (BER) pathways supports survival after ionizing radiation, while defects can either sensitize or, through compensatory rewiring, sometimes promote resistance.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12384436/\">^2</a></li>\n<li>A DNA\u2011repair\u2013based \u201cradiosensitivity index\u201d built from the expression of a defined panel of 10 repair genes stratifies breast tumors into more radio\u2011sensitive and radio\u2011resistant groups, with specific mutational patterns (e.g., in HR and BER components) over\u2011represented in the resistant cohort.<a href=\"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1439516/full\">^7</a></li>\n</ul>\n</li>\n<li><strong>Endocrine resistance and cross\u2011resistance to radiation</strong><ul>\n<li>In ER\u2011positive models rendered tamoxifen\u2011resistant, only a limited set of DNA damage repair genes change more than two\u2011fold, including upregulation of <em>NEIL1</em> and <em>EME2</em> and downregulation of <em>PCNA</em>, <em>BRIP1</em>, and <em>BARD1</em> at the RNA level.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7851527/\">^8</a></li>\n<li>Despite these alterations, expression of these individual genes did not significantly correlate with clinical outcome after radiotherapy in a large patient cohort, suggesting that cross\u2011resistance to radiation in tamoxifen\u2011resistant disease is not explained by simple, linear changes in repair gene expression alone.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7851527/\">^8</a></li>\n</ul>\n</li>\n</ul>\n<h2>Integrating transcriptional patterns and clinical predictors</h2>\n<p>Rather than single markers, multigene expression signatures currently provide the most robust predictors of therapy response.</p>\n<ul>\n<li>A genomic predictor constructed from pre\u2011treatment tumor expression profiles can stratify patients receiving sequential taxane followed by anthracycline into high\u2011response and low\u2011response groups, with higher scores associated with increased pathologic complete response and improved survival.<a href=\"https://jamanetwork.com/journals/jama/fullarticle/899864\">^9</a></li>\n<li>For HER2\u2011negative patients on taxane\u2013anthracycline combinations, a 4\u2011gene signature incorporating <em>SRPK1</em> yields independent prognostic information beyond tumor size, nodal status, TNM stage, and PAM50 subtype, underscoring the importance of pathway\u2011level transcriptional programs in resistance.<a href=\"https://www.oncotarget.com/article/21872/text/\">^6</a></li>\n</ul>\n<p>If you share a specific therapeutic context (e.g., neoadjuvant AC\u2011T, adjuvant radiotherapy with concurrent endocrine therapy, or HER2\u2011targeted regimens) and subtype, a more targeted list of mutations and expression patterns relevant to that setting can be outlined.\n<span style=\"display:none\"><a href=\"https://www.sciencedirect.com/science/article/pii/S0140673623002854\">^10</a></span></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p><strong>Resistance to chemotherapy and radiotherapy in breast cancer is associated with multiple gene mutations, altered protein expression patterns, and distinct transcriptional RNA profiles</strong> that vary by breast cancer subtype and treatment modality.</p>\n<h2>Gene Mutations and Genetic Alterations</h2>\n<p><strong>TP53 mutations</strong> are prominently associated with chemotherapy resistance, with somatic TP53 mutations being common in anthracycline-sensitive groups while other mutations appear in resistant groups.[1]</p>\n<p>However, p53's role is complex\u2014while mutations contribute to resistance to chemo- and radiotherapy, impaired DNA repair is offset by reduced apoptosis.[2] <strong>BRCA1 and BRCA2 mutations</strong> show contrasting effects: BRCA1- or BRCA2- deficient tumors demonstrate marked sensitivity to ionizing radiation and drugs producing double-strand breaks, though their expression decreases in post-chemotherapy residual tumors.[2][3]</p>\n<p>Mutations in <strong>CDKN1B</strong> appear only in pre-treatment samples, while <strong>APC and CTNNB1</strong> mutations emerge only post-treatment.[4]</p>\n<h2>Protein Expression Patterns</h2>\n<p><strong>Drug efflux transporters</strong> play critical roles in chemoresistance. <strong>ABCB1 (MDR1)</strong> is the most frequently overexpressed gene in resistant cells, with high MDR1 expression significantly associated with poor response (17% vs 68% in low expressors, p=0.005) and poor progression-free survival.[5][6] <strong>ABCB5, CYP1A1, and CYP4Z1</strong> are significantly upregulated in anthracycline-resistant groups.[1]</p>\n<p>Additional xenobiotic metabolism genes including <strong>CYP3A4 and CYP2A6</strong> show enrichment in non-responders to anthracycline-taxane therapy.[7] <strong>DNA repair proteins</strong> demonstrate subtype-specific patterns. Lower expression of <strong>PALB2 and ERCC1</strong> in pre-treatment biopsies correlates with pathologic complete response (p=0.005 and p=0.009).[3] <strong>P4HA2</strong> (Prolyl 4-Hydroxylase Subunit Alpha 2) is upregulated in radioresistant cells and promotes resistance through enhanced stemness and DNA damage repair; its knockdown synergizes with radiotherapy.[8] <strong>Interferon-stimulated genes (ISGs)</strong> are involved in cross-resistance between tamoxifen and radiotherapy, with increased expression in both resistant phenotypes correlating with poor outcomes in patients receiving adjuvant tamoxifen or radiotherapy.[9]</p>\n<h2>Transcriptional RNA Levels</h2>\n<p><strong>Common differentially expressed genes</strong> across chemotherapy-resistant subtypes include <strong>FOS and NR4A1</strong> .[10]</p>\n<p>In radioresistance, <strong>ORAI3 and BCAM</strong> distinguish non-responders with high AUC values (&gt;0.75), while the amino acid transporter[7] <strong>SLC7A5</strong> shows significantly higher expression in resistant tumors.[7] <strong>Pathway-specific alterations</strong> include activation of MAPK, ErbB, PI3K-Akt, mTOR, Wnt, and RAS signaling pathways in chemoresistant tumors.[11] <strong>Proliferation-associated genes</strong> are downregulated in post-treatment ER+ tumors but not in triple-negative breast cancer, while[4] <strong>extracellular matrix (ECM) genes</strong> are upregulated in the majority of post-chemotherapy samples across subtypes.[4] <strong>Immune-related genes</strong> show distinct patterns: <strong>LYN, LY96, and ANXA1</strong> are upregulated in patients with relapse within 60 months.[7]</p>\n<p>Chemoresistant tumors demonstrate increased infiltration of CD4 memory T cells, regulatory T cells, neutrophils, macrophages, and mast cells.[10] <strong>NOTCH1 and MAPK14</strong> emerge as hub genes in protein-protein interaction networks.[12]</p>\n<h2>Non-Coding RNAs</h2>\n<p><strong>MicroRNAs</strong> play substantial roles in both chemoresistance and radioresistance. <strong>miR-21</strong> promotes radioresistance via cancer stem cells, while[13][14] <strong>miR-196a-5p</strong> is upregulated and <strong>miR-4472</strong> is downregulated in chemoresistant tissues.[12]</p>\n<p>Tumor suppressor miRNAs including <strong>miR-22, miR-200c, and Let- 7</strong> increase radiotherapy efficacy.[13] <strong>Long non-coding RNAs</strong> including <strong>HOTAIR and NEAT1</strong> are associated with radioresistance, while[15][13] <strong>LINP1</strong> functions as a tumor suppressor enhancing radiotherapy effects.[13]</p>\n<p>These ncRNAs regulate cell cycle, DNA damage repair, apoptosis, autophagy, ferroptosis, and cancer stem cell properties.[16]</p>\n<p>A <strong>17-gene signature</strong> combining methylation and miRNA-regulated genes showed predictive and prognostic power in triple-negative breast cancer patients receiving anthracycline-taxane neoadjuvant chemotherapy.[17]</p>\n<p>The findings emphasize that resistance mechanisms are highly individualized, with patients exhibiting distinct molecular rewiring that converges into limited dysregulated functional modules.[18]</p>\n<p>Would you like me to summarize which of these molecular markers\u2014mutations, protein expressions, or RNA profiles\u2014have the strongest evidence for clinical utility as predictive biomarkers of therapy resistance, and whether any are currently used or validated in routine breast cancer management?</p>\n<h3>References</h3>\n<ol>\n<li>Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer. Liu Z, Gao J, Gu R, et al. Biomolecules. 2022;12(12):1834. doi:10.3390/biom12121834.</li>\n<li>The Molecular Basis of Radiosensitivity and Chemosensitivity in the Treatment of Breast Cancer. Xia F , Powell SN. Seminars in Radiation Oncology. 2002;12(4):296-304. doi:10.1053/srao.2002.35250.</li>\n<li>Predictive value of DNA repair gene expression for response to neoadjuvant chemotherapy in breast cancer. Kneubil M, Goulart K, Brollo J, et al. Journal of Clinical Oncology. 2022;40(Suppl 16):e12538. doi:10.1200/JCO.2022.40.16_suppl.e12538.</li>\n<li>Comprehensive Characterization of Pre- And Post-Treatment Samples of Breast Cancer Reveal Potential Mechanisms of Chemotherapy Resistance. Hoogstraat M, Lips EH, Mayayo-Peralta I, et al. NPJ Breast Cancer. 2022;8(1):60. doi:10.1038/s41523-022-00428-8.</li>\n<li>Systematic Review of Comparative Transcriptomic Studies of Cellular Resistance to Genotoxic Stress. Ismailov ZB, Belykh ES, Chernykh AA, et al. Mutation Research. Reviews in Mutation Research. 2023 Jul-Dec;792:108467. doi:10.1016/j.mrrev.2023.108467.</li>\n<li>RNA Expression of Breast Cancer Resistance Protein, Lung Resistance-Related Protein, Multidrug Resistance- Associated Proteins 1 and 2, and Multidrug Resistance Gene 1 in Breast Cancer: Correlation With Chemotherapeutic Response. Burger H, Foekens JA, Look MP , et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2003;9(2):827-36.</li>\n<li>Resistance to Combined Anthracycline-Taxane Chemotherapy Is Associated With Altered Metabolism and Inflammation in Breast Carcinomas. Menyh\u00e1rt O, Fekete JT, Gy\u0151rffy B. International Journal of Molecular Sciences. 2024;25(2):1063. doi:10.3390/ijms25021063.</li>\n<li>Single-Cell and Spatial Transcriptomics Reveal P4ha2-Mediated Radiotherapy Resistance Mechanisms in Breast Cancer. Li H, Liu J, Jiao Y , et al. Theranostics. 2026;16(5):2192-2220. doi:10.7150/thno.121257.</li>\n<li>Interferon-Stimulated Genes Are Involved in Cross-Resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer. Post AEM, Smid M, Nagelkerke A, et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2018;24(14):3397-3408. doi:10.1158/1078-0432.CCR-17-2551.</li>\n<li>Molecular Determinants of Neoadjuvant Chemotherapy Resistance in Breast Cancer: An Analysis of Gene Expression and Tumor Microenvironment. Guevara-Nieto HM, Orozco-Casta\u00f1o CA, Parra-Medina R, et al. PloS One. 2025;20(10):e0334335. doi:10.1371/journal.pone.0334335.</li>\n<li>Subpathway Analysis of Transcriptome Profiles Reveals New Molecular Mechanisms of Acquired Chemotherapy Resistance in Breast Cancer. Huo Y , Shao S, Liu E, et al. Cancers. 2022;14(19):4878. doi:10.3390/cancers14194878.</li>\n<li>Bioinformatic Identification of Chemoresistance-Associated microRNAs in Breast Cancer Based on Microarray Data. Wang YW, Zhang W, Ma R. Oncology Reports. 2018;39(3):1003-1010. doi:10.3892/or.2018.6205.</li>\n<li>Effects of Noncoding RNAs in Radiotherapy Response in Breast Cancer: A Systematic Review. Oghabi Bakhshaiesh T, Esmaeili R. Cell Cycle (Georgetown, Tex.). 2022;21(9):883-893. doi:10.1080/15384101.2022.2035915.</li>\n<li>Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer. Aranza-Mart\u00ednez A, S\u00e1nchez-P\u00e9rez J, Brito-Elias L, et al. Frontiers in Oncology. 2021;11:752270. doi:10.3389/fonc.2021.752270.</li>\n<li>Radiotherapy and Breast Cancer: Finally, an lncRNA Perspective on Radiosensitivity and Radioresistance. Yazarlou F , Martinez I, Lipovich L. Frontiers in Oncology. 2024;14:1437542. doi:10.3389/fonc.2024.1437542.</li>\n<li>Non-Coding RNAs in Breast Cancer Radioresistance: Mechanisms, Functional Roles and Translational Potentials. Zhao X, Qiu Y , Chen J, et al. Cell Proliferation. 2025;:e70119. doi:10.1111/cpr.70119.</li>\n<li>Genome-Wide Profiles of Methylation, microRNAs, and Gene Expression in Chemoresistant Breast Cancer. He DX, Gu F , Gao F , et al. Scientific Reports. 2016;6:24706. doi:10.1038/srep24706.</li>\n<li>Chemoresistome Mapping in Individual Breast Cancer Patients Unravels Diversity in Dynamic Transcriptional Adaptation. Dadiani M, Friedlander G, Perry G, et al. Molecular Oncology. 2025;. doi:10.1002/1878-0261.70030. 2.</li>\n</ol>"}]}, "2": {"question": "Which mutations, if any, lead to resistance to both chemotherapy and radiotherapy? Are there specific mutations that lead to cross resistance?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>Cross-resistance between radiation therapy (RT) and cytotoxic chemotherapeutics is not commonly observed. However, some drugs such as gemcitabine may sensitize tumors to RT through inhibition of the repair of DNA double strand breaks induced by ionizing radiation.</p>"}, {"model": "GPT-4o", "text": "<p>Resistance to both chemotherapy and radiotherapy can be influenced by various genetic mutations and alterations in cancer cells. While specific mutations can confer resistance to one or both treatment modalities, cross-resistance often involves complex mechanisms rather than single mutations. Here are some key factors and mutations associated with resistance:</p>\n<ol>\n<li>\n<p><strong>TP53 Mutations</strong>: The TP53 gene encodes the p53 protein, which plays a crucial role in DNA damage response and apoptosis. Mutations in TP53 can lead to impaired apoptosis and increased survival of cancer cells following chemotherapy and radiotherapy.</p>\n</li>\n<li>\n<p><strong>KRAS Mutations</strong>: KRAS is an oncogene that, when mutated, can drive cancer progression and contribute to resistance to certain chemotherapeutic agents and radiotherapy by promoting cell survival pathways.</p>\n</li>\n<li>\n<p><strong>EGFR Mutations</strong>: Alterations in the EGFR gene can lead to resistance to targeted therapies and may also affect sensitivity to radiation by influencing cell proliferation and survival.</p>\n</li>\n<li>\n<p><strong>BRCA1/2 Mutations</strong>: While BRCA1/2 mutations are often associated with increased sensitivity to DNA-damaging agents, secondary mutations or reversion mutations can restore homologous recombination repair, leading to resistance to both chemotherapy and radiotherapy.</p>\n</li>\n<li>\n<p><strong>PI3K/AKT/mTOR Pathway Alterations</strong>: Mutations or activation of components in this pathway can promote cell survival and proliferation, contributing to resistance to both chemotherapy and radiotherapy.</p>\n</li>\n<li>\n<p><strong>Mismatch Repair Deficiency (MMR)</strong>: Defects in the mismatch repair system can lead to microsatellite instability and resistance to certain chemotherapeutic agents, and may also affect radiotherapy outcomes.</p>\n</li>\n<li>\n<p><strong>Multidrug Resistance (MDR) Genes</strong>: Overexpression of MDR genes, such as ABCB1 (P-glycoprotein), can lead to efflux of chemotherapeutic drugs and potentially affect sensitivity to radiation by altering drug accumulation and cellular stress responses.</p>\n</li>\n<li>\n<p><strong>Epigenetic Changes</strong>: Methylation and histone modification can alter gene expression patterns, leading to resistance mechanisms that affect both chemotherapy and radiotherapy.</p>\n</li>\n</ol>\n<p>Cross-resistance is often the result of a combination of these genetic and epigenetic changes, along with alterations in cell cycle regulation, DNA repair capacity, and apoptotic pathways. Understanding the specific mutations and mechanisms in individual tumors is crucial for developing effective treatment strategies and overcoming resistance.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>Yes, there are specific mutations that lead to cross-resistance against both chemotherapy and radiotherapy.</p>\n<p>To understand why, it is helpful to look at the shared goal of both therapies: <strong>DNA damage.</strong>\n*   <strong>Radiotherapy</strong> works by creating Reactive Oxygen Species (ROS) that break DNA strands.\n*   <strong>Chemotherapy</strong> (specifically cytotoxic types like platinums or alkylating agents) works by binding to DNA, causing breaks, or interfering with replication.</p>\n<p>Therefore, mutations that allow a cell to <strong>repair DNA faster</strong>, <strong>scavenge free radicals</strong>, or <strong>ignore the signal to commit suicide (apoptosis)</strong> will create resistance to <em>both</em> modalities.</p>\n<p>Here are the primary mutations and genetic alterations known to cause this cross-resistance:</p>\n<h3>1. TP53 (The \"Guardian of the Genome\")</h3>\n<p>This is the single most significant mutation regarding cross-resistance. The <em>TP53</em> gene produces the p53 protein, which triggers cell cycle arrest to allow for DNA repair or, if the damage is too severe, triggers apoptosis (cell death).</p>\n<ul>\n<li><strong>The Mutation:</strong> Loss-of-function mutations in <em>TP53</em>.</li>\n<li><strong>Mechanism of Cross-Resistance:</strong><ul>\n<li><strong>Chemo:</strong> When chemotherapy damages DNA, a cell with mutant p53 fails to trigger apoptosis. Instead, it continues to divide with mutated DNA, leading to a more aggressive tumor.</li>\n<li><strong>Radio:</strong> Radiation relies heavily on p53 to kill cells via the intrinsic apoptotic pathway. Without functional p53, the cells survive the radiation-induced DNA breaks.</li>\n</ul>\n</li>\n</ul>\n<h3>2. KEAP1 and NFE2L2 (The Antioxidant Defense)</h3>\n<p>The <em>NFE2L2</em> gene encodes the transcription factor NRF2, which regulates the cell's defense against oxidative stress. <em>KEAP1</em> is the protein that normally degrades NRF2 to keep levels low.</p>\n<ul>\n<li><strong>The Mutation:</strong> Loss-of-function in <em>KEAP1</em> or gain-of-function in <em>NFE2L2</em>.</li>\n<li><strong>Mechanism of Cross-Resistance:</strong><ul>\n<li><strong>Radio:</strong> These mutations lead to constitutively high levels of antioxidants (like glutathione). These antioxidants neutralize the Reactive Oxygen Species (ROS) created by radiation before they can damage the DNA.</li>\n<li><strong>Chemo:</strong> NRF2 also upregulates drug efflux pumps (proteins that spit drugs out of the cell) and detoxification enzymes, rendering chemotherapy agents ineffective. This is frequently seen in Non-Small Cell Lung Cancer (NSCLC).</li>\n</ul>\n</li>\n</ul>\n<h3>3. PIK3CA / PTEN / AKT (The Survival Pathway)</h3>\n<p>The PI3K/AKT pathway is a major survival signaling route in cells.</p>\n<ul>\n<li><strong>The Mutation:</strong> Activating mutations in <em>PIK3CA</em> or <em>AKT</em>, or loss-of-function mutations in <em>PTEN</em> (a tumor suppressor that shuts this pathway down).</li>\n<li><strong>Mechanism of Cross-Resistance:</strong><ul>\n<li><strong>Apoptosis Inhibition:</strong> This pathway inhibits pro-apoptotic proteins (like Bad and Bax). Even if chemo or radio damages the DNA, the \"survival signal\" is so loud that the cell refuses to die.</li>\n<li><strong>Enhanced Repair:</strong> AKT activation enhances Non-Homologous End Joining (NHEJ), a mechanism used to repair DNA double-strand breaks caused by radiation and certain chemotherapies.</li>\n</ul>\n</li>\n</ul>\n<h3>4. EGFR (Epidermal Growth Factor Receptor)</h3>\n<p>While often associated with targeted therapy, <em>EGFR</em> mutations play a role in conventional resistance.</p>\n<ul>\n<li><strong>The Mutation:</strong> Constitutive activation (e.g., Exon 19 deletions or L858R).</li>\n<li><strong>Mechanism of Cross-Resistance:</strong><ul>\n<li>Mutated EGFR can translocate into the nucleus. Once there, it interacts with <strong>DNA-PK</strong> (a DNA repair enzyme). This interaction hyper-activates the DNA repair machinery, fixing the damage caused by both radiation and chemotherapy faster than the treatment can inflict it.</li>\n</ul>\n</li>\n</ul>\n<h3>5. RAS (KRAS, NRAS, HRAS)</h3>\n<p>RAS mutations are among the most common drivers of cancer (especially pancreatic, lung, and colorectal).</p>\n<ul>\n<li><strong>The Mutation:</strong> Activating mutations (e.g., KRAS G12C).</li>\n<li><strong>Mechanism of Cross-Resistance:</strong><ul>\n<li>RAS mutations drive constant cell proliferation. However, they also increase the threshold for apoptosis. Cells with <em>KRAS</em> mutations have been shown to be inherently more resistant to radiation-induced cell death and platinum-based chemotherapy due to alterations in mitochondrial function and apoptotic signaling.</li>\n</ul>\n</li>\n</ul>\n<h3>6. Bcl-2 Family (The Anti-Death Proteins)</h3>\n<p>While often driven by translocations (like t(14;18) in lymphoma) rather than point mutations, overexpression or mutation of these genes is a key factor.</p>\n<ul>\n<li><strong>The Alteration:</strong> Overexpression of <em>BCL2</em> or <em>BCL-XL</em>.</li>\n<li><strong>Mechanism of Cross-Resistance:</strong><ul>\n<li>These proteins sit on the mitochondria and physically block the release of Cytochrome C. Both chemotherapy and radiotherapy ultimately try to punch holes in the mitochondria to kill the cell; high levels of Bcl-2 act as a shield, preventing death regardless of the upstream damage.</li>\n</ul>\n</li>\n</ul>\n<h3>Summary of Cross-Resistance Mechanisms</h3>\n<p>| Gene Mutation | Function | Why it resists Chemo | Why it resists Radio |\n| :--- | :--- | :--- | :--- |\n| <strong>TP53</strong> (Loss) | Apoptosis Regulator | Cell refuses to die despite drug damage. | Cell refuses to die despite radiation damage. |\n| <strong>KEAP1</strong> (Loss) / <strong>NRF2</strong> (Gain) | Antioxidant Response | Increases drug detoxification/efflux. | Neutralizes radiation-induced free radicals (ROS). |\n| <strong>PIK3CA / PTEN</strong> | Survival Signaling | Inhibits apoptotic triggers. | Accelerates DNA double-strand break repair. |\n| <strong>EGFR</strong> (Activation) | Growth Factor | Promotes survival signaling. | Translocates to nucleus to boost DNA repair enzymes. |</p>\n<h3>A Note on \"Acquired\" vs. \"Intrinsic\" Resistance</h3>\n<p>It is important to note that tumors often evolve. A tumor might start sensitive to therapy, but under the selective pressure of chemotherapy, a sub-clone of cells containing a <strong>TP53</strong> or <strong>KEAP1</strong> mutation may survive, multiply, and result in a recurrent tumor that is now resistant to both further chemo and radiotherapy.</p>"}, {"model": "MedGemma 27B", "text": "<p><strong>Mutations Leading to Resistance to Both Chemotherapy and Radiotherapy:</strong></p>\n<p>Several genetic alterations can confer resistance to <em>both</em> chemotherapy (CT) and radiotherapy (RT). This often happens because the underlying mechanisms involved in DNA damage repair or cell death pathways are targeted by both treatment modalities. Here's a breakdown of key examples:</p>\n<ol>\n<li><strong>DNA Damage Repair Pathway Mutations:</strong><ul>\n<li><strong>BRCA1/2 Germline Mutations:</strong> These are well-known for conferring sensitivity to certain chemotherapies like platinum agents (cisplatin, carboplatin) and PARP inhibitors. However, paradoxically, they can also be associated with some degree of intrinsic resistance to RT in certain contexts (e.g., breast cancer), potentially due to impaired homologous recombination repair which is crucial after radiation-induced double-strand breaks. The relationship is complex and context-dependent. Loss of BRCA function impairs HR, leading to accumulation of DSBs. While this makes cells sensitive to drugs targeting HR (like PARPi), it might make them less responsive to RT in some cases as the primary mechanism of killing (HR failure) is already compromised. Conversely, loss of BRCA can sensitize tumors to RT by impairing NHEJ backup pathway. Overall effect depends on tumor type and specific therapy regimen.</li>\n<li><strong>ATM Gene Mutations:</strong> ATM plays a central role in detecting and signaling DNA double-strand breaks (DSBs) caused by both CT (especially platinum agents) and RT. Inactivating mutations in ATM can reduce the cellular response to these therapies. Cells lacking functional ATM may fail to activate downstream checkpoints and repair pathways effectively, leading to reduced apoptosis upon DNA damage. This results in increased survival despite exposure to damaging treatments.</li>\n<li><strong>CHK2 Gene Mutations:</strong> CHK2 is another kinase activated by ATM following DSB detection. It acts further downstream in the checkpoint activation cascade. Mutations inactivating CHK2 can similarly blunt the response to DNA damaging agents used in CT and RT.</li>\n<li><strong>RAD51 Mutations/Alterations:</strong> RAD51 is essential for Homologous Recombination (HR), a major pathway for repairing DSBs induced by CT and RT. Alterations affecting RAD51 expression or function can impact the effectiveness of both treatments. For example, overexpression or copy number gains of RAD51 have been linked to chemoresistance and radioresistance in various cancers.</li>\n<li><strong>Other DDR Genes:</strong> Mutations in genes involved in other DNA repair pathways like Base Excision Repair (BER - e.</li>\n</ul>\n</li>\n</ol>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Which mutations, if any, lead to resistance to both chemotherapy and radiotherapy? Are there specific mutations that lead to cross resistance?</h1>\n<p>Several well-characterized mutations and pathway alterations can confer resistance to both chemotherapy and radiotherapy, but there is no single universal \u201ccross\u2011resistance mutation.\u201d Most cross resistance arises from changes in DNA\u2011damage response, apoptosis regulation, and cell\u2011cycle control that blunt the effects of both genotoxic drugs and ionizing radiation.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11976711/\">^1</a><a href=\"https://www.oaepublish.com/articles/cdr.2020.89\">^3</a></p>\n<h2>Key shared mechanisms</h2>\n<ul>\n<li>Both cytotoxic chemotherapy (e.g., platinum drugs, alkylators, anthracyclines) and radiotherapy kill tumor cells mainly by inducing DNA damage, especially double\u2011strand breaks.<a href=\"https://www.oaepublish.com/articles/cdr.2020.89\">^3</a></li>\n<li>Mutations that enhance DNA repair, disable apoptosis, or alter checkpoints can therefore protect against both modalities and lead to cross resistance.<a href=\"https://www.oaepublish.com/articles/cdr.2020.89\">^1</a></li>\n</ul>\n<h2>TP53 and p53\u2011pathway alterations</h2>\n<ul>\n<li>Loss\u2011of\u2011function <em>TP53</em> mutations are among the clearest examples associated with reduced response to both chemotherapy and radiation, because mutant p53 fails to induce cell\u2011cycle arrest and apoptosis after DNA damage.<a href=\"https://pubmed.ncbi.nlm.nih.gov/25201193/\">^4</a></li>\n<li>Clinical data in sarcomas and other tumors show that <em>TP53</em> mutations correlate with radioresistance and poorer local control after irradiation, and numerous studies link mutant p53 to poorer responses to DNA\u2011damaging drugs.<a href=\"https://pubmed.ncbi.nlm.nih.gov/25201193/\">^6</a></li>\n<li>Alterations that suppress p53 signaling without mutating <em>TP53</em> directly (e.g., <em>MDM2</em> amplification, <em>CDKN2A</em> loss) can similarly promote resistance, although their association with radioresponse can be weaker or context\u2011dependent.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5352454/\">^6</a></li>\n</ul>\n<h2>DNA\u2011damage response and repair genes</h2>\n<ul>\n<li>Upregulation or activating changes in DNA\u2011damage response (DDR) pathways (e.g., homologous recombination, non\u2011homologous end\u2011joining, nucleotide excision repair) can make tumor cells more efficient at repairing lesions produced by both chemotherapy and radiation.<a href=\"https://www.oaepublish.com/articles/cdr.2020.89\">^2</a></li>\n<li>Reviews of genetic determinants of chemo\u2011 and radioresistance highlight elevated expression or activity of DDR genes such as <em>RAD51</em> (HR repair), <em>ERCC1</em> (nucleotide excision repair), and DNA\u2011PK components as contributors to resistance to both treatments.<a href=\"https://www.oaepublish.com/articles/cdr.2020.89\">^7</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5760393/\">^1</a></li>\n<li>In some settings, DDR hyperactivation is acquired under treatment pressure (for example, cisplatin\u2011resistant tumors with broadly increased DDR gene expression that show cross resistance to other DNA\u2011damaging agents).<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11976711/\">^8</a></li>\n</ul>\n<h2>Anti\u2011apoptotic and survival signaling</h2>\n<ul>\n<li>Overexpression or activating changes in anti\u2011apoptotic proteins (e.g., BCL\u20112 family members, survivin) can blunt death signaling after DNA damage, contributing to cross resistance.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5760393/\">^1</a></li>\n<li>In lung adenocarcinoma models, docetaxel\u2011resistant cells that became cross\u2011resistant to radiotherapy showed increased expression of survivin and RAD51, driven by c\u2011MYC, and downregulation of miR\u2011451; restoring miR\u2011451 resensitized them to radiation.<a href=\"https://www.oncotarget.com/article/2176/text/\">^9</a></li>\n<li>Activation of pro\u2011survival pathways such as NF\u2011\u03baB, PI3K\u2013AKT, and others is frequently implicated in resistance to both chemo\u2011 and radiotherapy in multiple tumor types.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5760393/\">^10</a></li>\n</ul>\n<h2>Examples of documented cross resistance</h2>\n<ul>\n<li>In nasopharyngeal carcinoma, cells surviving radiotherapy display increased radioresistance and cross resistance to paclitaxel and cisplatin, linked to enhanced survival and repair mechanisms rather than a single recurrent gene mutation.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8554658/\">^10</a></li>\n<li>In lung adenocarcinoma, the miR\u2011451\u2013c\u2011MYC\u2013survivin/RAD51 axis is a defined molecular route by which acquired chemoresistance (to docetaxel) leads to acquired radioresistance.<a href=\"https://www.oncotarget.com/article/2176/text/\">^9</a></li>\n<li>Reviews of cross resistance highlight that prolonged exposure to one genotoxic agent (e.g., cisplatin) can select for clones with globally heightened DDR capacity, which then resist multiple DNA\u2011damaging drugs and often show radioresistance as well.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9259985/\">^2</a></li>\n</ul>\n<h2>Take\u2011home points</h2>\n<ul>\n<li>There are recurrent <strong>pathways</strong> rather than a single universal mutation: defective p53 signaling, enhanced DDR, and increased anti\u2011apoptotic signaling are the main shared mechanisms behind cross resistance to chemotherapy and radiotherapy.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11976711/\">^3</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5760393/\">^1</a></li>\n<li>Specific alterations frequently linked to cross resistance include <em>TP53</em> loss\u2011of\u2011function, high <em>RAD51</em> and other HR/NHEJ components, elevated <em>ERCC1</em>, overexpression of survivin/BCL\u20112 family members, and regulatory changes such as loss of miR\u2011451 in lung adenocarcinoma.<a href=\"https://www.oncotarget.com/article/2176/text/\">^4</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5760393/\">^3</a></li>\n<li>The precise mutations vary by tumor type, and cross resistance is often an acquired, polygenic phenotype emerging under treatment pressure rather than being driven by a single mutation in isolation.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5760393/\">^2</a></li>\n</ul>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>h chemotherapy and radiotherapy? a. Are there specific mutations that lead to cross resistance? <strong>TP53 mutations and alterations in DNA repair genes, particularly BRCA1/BRCA2, are associated with cross- resistance to both chemotherapy and radiotherapy in breast cancer</strong> , though their effects can be complex and context-dependent.</p>\n<h2>TP53 Mutations TP53 mutations contribute to resistance to both chemo- and radiotherapy, though the mechanism involves a trade-off:</h2>\n<p><strong>impaired DNA repair is offset by reduced apoptosis</strong> .[1]</p>\n<p>Somatic TP53 mutations are common in anthracycline-sensitive groups, while other mutations appear in resistant groups.[2]</p>\n<p>In triple-negative breast cancer, TP53 mutations are frequently observed and may influence treatment response.[3]</p>\n<h2>BRCA1/BRCA2 Alterations The role of BRCA1 and BRCA2 in cross-resistance is paradoxical.</h2>\n<p><strong>BRCA1- or BRCA2-deficient tumors demonstrate marked sensitivity to ionizing radiation and drugs producing double-strand breaks</strong> .[1]</p>\n<p>However, BRCA1 dysfunction leads to enhanced sensitivity to DNA damaging therapeutic agents, while p53 mutations contribute to resistance.[4]</p>\n<p>Notably, <strong>BRCA1 and BRCA2 expression decreases in post-chemotherapy residual tumors</strong> , and BRCA2 shows lower expression in post-treatment samples compared to pre-treatment biopsies (p=0.009).[5]</p>\n<h2>DNA Repair Pathway Genes Several DNA repair genes show altered expression patterns associated with treatment resistance: -</h2>\n<p><strong>ATM</strong>: Shows lower expression in post-treatment residual tumors (p=0.004), though ATM protein plays a significant role in determining response to therapy[5][1] - <strong>PALB2 and ERCC1</strong>: Lower expression in pre-treatment biopsies correlates with pathologic complete response (p=0.005 and p=0.009)[5] - <strong>FANCA and PARP1</strong>: Demonstrate lower expression in post-treatment samples[5]</p>\n<h2>Interferon-Stimulated Genes</h2>\n<p><strong>Interferon-stimulated genes (ISGs) are involved in cross-resistance between tamoxifen and radiotherapy</strong> .[6]</p>\n<p>Increased ISG expression in both resistant phenotypes correlates with poor outcomes in patients receiving adjuvant tamoxifen or radiotherapy, suggesting a shared resistance mechanism across treatment modalities.[6]</p>\n<h2>Drug Metabolism Genes</h2>\n<p><strong>Xenobiotic metabolism genes including CYP3A4, CYP2A6, ABCB5, CYP1A1, and CYP4Z1</strong> are significantly upregulated in anthracycline-resistant groups, and may contribute to broader treatment resistance patterns.[2][7]</p>\n<p>The molecular mechanisms underlying cross-resistance appear highly individualized, with patients exhibiting distinct molecular rewiring that converges into limited dysregulated functional modules.[8]</p>\n<p>This heterogeneity suggests that single-agent targeted therapy is unlikely to be effective, and combination strategies targeting multiple resistance pathways simultaneously may be necessary.[9]</p>\n<p>Would you like me to summarize the latest clinical evidence on how these specific gene mutations (such as TP53, BRCA1/2, and DNA repair pathway genes) impact the effectiveness of current targeted therapies or combination regimens in breast cancer patients with documented cross-resistance? This could help guide treatment decisions for cases where standard chemotherapy and radiotherapy have failed.</p>\n<h3>References</h3>\n<ol>\n<li>The Molecular Basis of Radiosensitivity and Chemosensitivity in the Treatment of Breast Cancer. Xia F , Powell SN. Seminars in Radiation Oncology. 2002;12(4):296-304. doi:10.1053/srao.2002.35250.</li>\n<li>Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer. Liu Z, Gao J, Gu R, et al. Biomolecules. 2022;12(12):1834. doi:10.3390/biom12121834.</li>\n<li>Mutational signature differences in paired tissues of triple-negative breast cancer receiving neoadjuvant therapy: Preliminary analysis. Baskarane H, Divakar M, Batra A, et al. Journal of Clinical Oncology. 2025;43(Suppl 16):e12555. doi:10.1200/JCO.2025.43.16_suppl.e12555.</li>\n<li>P53, BRCA1 and Breast Cancer Chemoresistance. Scata KA, El-Deiry WS. Advances in Experimental Medicine and Biology. 2007;608:70-86. doi:10.1007/978-0-387-74039-3_5.</li>\n<li>Predictive value of DNA repair gene expression for response to neoadjuvant chemotherapy in breast cancer. Kneubil M, Goulart K, Brollo J, et al. Journal of Clinical Oncology. 2022;40(Suppl 16):e12538. doi:10.1200/JCO.2022.40.16_suppl.e12538.</li>\n<li>Interferon-Stimulated Genes Are Involved in Cross-Resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer. Post AEM, Smid M, Nagelkerke A, et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2018;24(14):3397-3408. doi:10.1158/1078-0432.CCR-17-2551.</li>\n<li>Resistance to Combined Anthracycline-Taxane Chemotherapy Is Associated With Altered Metabolism and Inflammation in Breast Carcinomas. Menyh\u00e1rt O, Fekete JT, Gy\u0151rffy B. International Journal of Molecular Sciences. 2024;25(2):1063. doi:10.3390/ijms25021063.</li>\n<li>Comprehensive Characterization of Pre- And Post-Treatment Samples of Breast Cancer Reveal Potential Mechanisms of Chemotherapy Resistance. Hoogstraat M, Lips EH, Mayayo-Peralta I, et al. NPJ Breast Cancer. 2022;8(1):60. doi:10.1038/s41523-022-00428-8.</li>\n<li>Mechanisms of Resistance of Chemotherapy in Early-Stage Triple Negative Breast Cancer (TNBC). Wein L, Loi S. Breast (Edinburgh, Scotland). 2017;34 Suppl 1:S27-S30. doi:10.1016/j.breast.2017.06.023. 3.</li>\n</ol>"}]}, "3": {"question": "Which resistance mechanisms, if any, are unique to chemotherapy vs radiotherapy?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>Resistance to chemotherapeutic agents can be intrinsic (innate) or acquired. Intrinsic resistance refers to the inherent ability of a tumor cell to resist a particular cytotoxic agent and is related to qualitative differences in molecular structure of the target. Acquired resistance may arise through mutation or selection and has been discussed above with regard to gene-specific therapies. Some examples include myc-gene translocations in Burkitt's lymphoma that confer resistance to methotrexate; multidrug resistance genes mediating resistance to natural product anticancer drugs such as the vinca alkaloids and taxanes; and amplification of the bcl2 oncogene which confers resistance to apoptosis induced by cytotoxic agents.</p>"}, {"model": "GPT-4o", "text": "<p>Chemotherapy and radiotherapy are both common cancer treatments, but they have different mechanisms of action and, consequently, different resistance mechanisms. Here are some resistance mechanisms that are more specific to each treatment:</p>\n<h3>Chemotherapy Resistance Mechanisms:</h3>\n<ol>\n<li>\n<p><strong>Drug Efflux</strong>: Cancer cells can develop resistance to chemotherapy by increasing the expression of efflux pumps, such as P-glycoprotein, which actively transport drugs out of the cell, reducing their intracellular concentration and effectiveness.</p>\n</li>\n<li>\n<p><strong>Drug Inactivation</strong>: Some cancer cells can increase the expression of enzymes that inactivate chemotherapy drugs, such as glutathione S-transferase, which can conjugate drugs with glutathione, making them less effective.</p>\n</li>\n<li>\n<p><strong>Altered Drug Targets</strong>: Mutations or alterations in the target molecules of chemotherapy drugs can reduce drug binding and efficacy. For example, mutations in the topoisomerase enzyme can confer resistance to topoisomerase inhibitors.</p>\n</li>\n<li>\n<p><strong>DNA Repair Enhancement</strong>: Cancer cells can enhance their DNA repair mechanisms to counteract the DNA damage caused by certain chemotherapeutic agents, such as alkylating agents and platinum-based drugs.</p>\n</li>\n<li>\n<p><strong>Apoptosis Inhibition</strong>: Resistance can occur if cancer cells develop mechanisms to evade apoptosis, the programmed cell death that chemotherapy aims to induce. This can involve alterations in pro-apoptotic and anti-apoptotic proteins.</p>\n</li>\n</ol>\n<h3>Radiotherapy Resistance Mechanisms:</h3>\n<ol>\n<li>\n<p><strong>DNA Repair Enhancement</strong>: Similar to chemotherapy, cancer cells can enhance their DNA repair capabilities to fix the DNA damage caused by ionizing radiation. This is particularly relevant for radiotherapy, which primarily causes DNA double-strand breaks.</p>\n</li>\n<li>\n<p><strong>Hypoxia</strong>: Tumor hypoxia (low oxygen levels) can make cancer cells more resistant to radiotherapy. Oxygen is a potent radiosensitizer, and its absence can reduce the effectiveness of radiation-induced DNA damage.</p>\n</li>\n<li>\n<p><strong>Cell Cycle Redistribution</strong>: Radiotherapy is most effective against cells in certain phases of the cell cycle (e.g., G2/M phase). Cancer cells can develop resistance by altering their cell cycle distribution to spend less time in these sensitive phases.</p>\n</li>\n<li>\n<p><strong>Antioxidant Production</strong>: Increased production of antioxidants, such as glutathione, can help cancer cells neutralize the reactive oxygen species generated by radiotherapy, reducing its effectiveness.</p>\n</li>\n</ol>\n<p>While there is some overlap in resistance mechanisms, such as enhanced DNA repair, the specific pathways and molecular changes involved can differ between chemotherapy and radiotherapy. Understanding these differences is crucial for developing strategies to overcome resistance and improve treatment efficacy.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>To understand the unique resistance mechanisms of chemotherapy versus radiotherapy, one must look at the fundamental difference in how they work: <strong>Chemotherapy is a chemical interaction</strong>, while <strong>Radiotherapy is a physical energy deposition.</strong></p>\n<p>While there is significant overlap (both can fail if a cell has defective apoptosis pathways or super-efficient DNA repair), there are distinct mechanisms unique to each modality.</p>\n<p>Here are the resistance mechanisms unique to chemotherapy and radiotherapy.</p>\n<hr />\n<h3>1. Mechanisms Unique to Chemotherapy</h3>\n<p>Chemotherapy resistance is largely defined by <strong>Pharmacokinetics</strong> (how the body moves the drug) and <strong>Pharmacodynamics</strong> (how the drug interacts with its specific protein target). Radiation cannot be \"pumped out\" or \"metabolized,\" making the following unique to drugs:</p>\n<h4>A. Drug Efflux (The \"Sump Pump\")</h4>\n<p>This is the most distinct mechanism unique to chemotherapy. Cancer cells can overexpress transmembrane proteins (specifically ATP-binding cassette or <strong>ABC transporters</strong>, such as <strong>P-glycoprotein</strong>).\n*   <strong>The Mechanism:</strong> These pumps physically detect the chemotherapy agent entering the cell and actively pump it back out before it can reach the nucleus or its target.\n*   <strong>Why it\u2019s unique:</strong> You cannot pump physical energy (radiation) out of a cell.</p>\n<h4>B. Metabolic Inactivation (The \"Antidote\")</h4>\n<p>Many chemotherapy drugs are introduced as \"prodrugs\" that need activation, or active drugs that can be deactivated.\n*   <strong>The Mechanism:</strong> Cancer cells may upregulate enzymes (like <strong>Glutathione S-transferase</strong> or the <strong>CYP450</strong> system) that chemically conjugate the drug, rendering it non-toxic or water-soluble so it can be excreted. Alternatively, they may downregulate the enzymes required to convert a prodrug into its active toxic form.\n*   <strong>Why it\u2019s unique:</strong> Radiation is ionizing energy; it cannot be enzymatically digested or chemically neutralized by a metabolic enzyme.</p>\n<h4>C. Target Modification</h4>\n<p>Chemotherapy drugs usually work like a key in a lock\u2014they bind to a specific protein (e.g., Methotrexate binds to Dihydrofolate Reductase; Taxanes bind to Tubulin).\n*   <strong>The Mechanism:</strong> Cancer cells can mutate the gene coding for the target protein. This changes the shape of the \"lock\" so the drug \"key\" no longer fits, but the protein still functions for the cell.\n*   <strong>Why it\u2019s unique:</strong> Radiation does not bind to a specific protein pocket; it indiscriminately smashes DNA and creates free radicals.</p>\n<hr />\n<h3>2. Mechanisms Unique (or Dominant) to Radiotherapy</h3>\n<p>Radiotherapy resistance is largely defined by <strong>Physics</strong> and <strong>Oxygen chemistry</strong>. While chemo resistance focuses on the drug molecule, RT resistance focuses on the cellular environment and the cell cycle phase.</p>\n<h4>A. The Oxygen Effect (Hypoxia)</h4>\n<p>While hypoxia hinders chemo delivery (due to poor blood flow), it causes a fundamental <strong>chemical failure</strong> in radiotherapy. This is known as the \"Oxygen Fixation Hypothesis.\"\n*   <strong>The Mechanism:</strong> Radiation (specifically photons/X-rays) works largely by creating free radicals. These radicals cause DNA damage. For that damage to become permanent (\"fixed\"), oxygen must be present to react with the free radical on the DNA. Without oxygen (hypoxia), the DNA damage spontaneously repairs itself chemically.\n*   <strong>Why it\u2019s unique:</strong> Hypoxic cells are 2\u20133 times more resistant to radiation than oxygenated cells. While hypoxia affects chemo <em>delivery</em>, it does not stop a chemo molecule from working if it manages to arrive; for radiation, the lack of oxygen stops the mechanism of action itself.</p>\n<h4>B. Free Radical Scavenging Capacity</h4>\n<p>While some chemo drugs generate free radicals, radiotherapy relies almost entirely on the generation of Reactive Oxygen Species (ROS) via the hydrolysis of water (indirect action).\n*   <strong>The Mechanism:</strong> Radio-resistant cells often maintain abnormally high levels of intracellular antioxidants (like <strong>Glutathione</strong> or <strong>Superoxide Dismutase</strong>). These molecules \"mop up\" the free radicals created by the radiation beam before they can damage the DNA.\n*   <strong>Why it\u2019s unique:</strong> This is a direct counter to the indirect ionization process of radiation. While this can affect some specific chemo drugs (like anthracyclines), it is a universal resistance mechanism against standard photon radiation.</p>\n<h4>C. Cell Cycle Phase Specificity (S-Phase Resistance)</h4>\n<p>Both therapies are affected by the cell cycle, but the pattern of resistance in Radiotherapy is distinct and predictable based on DNA content.\n*   <strong>The Mechanism:</strong> Cells are most resistant to radiation in the <strong>late S-phase</strong> (Synthesis phase). This is because the cell has replicated its DNA, providing a \"spare copy\" (sister chromatid) that allows for Homologous Recombination repair of the double-strand breaks caused by radiation.\n*   <strong>Why it\u2019s unique:</strong> While chemo drugs are also phase-specific, many target S-phase to <em>kill</em> the cell (antimetabolites). In contrast, S-phase is where radiation is <em>least</em> effective.</p>\n<hr />\n<h3>Summary Comparison Table</h3>\n<p>| Feature | Chemotherapy Resistance | Radiotherapy Resistance |\n| :--- | :--- | :--- |\n| <strong>Efflux Pumps</strong> | <strong>Yes</strong> (P-glycoprotein pumps drug out) | <strong>No</strong> (Cannot pump out energy) |\n| <strong>Metabolism</strong> | <strong>Yes</strong> (Enzymes degrade the drug) | <strong>No</strong> (Cannot metabolize a beam) |\n| <strong>Target Mutation</strong> | <strong>Yes</strong> (Mutated binding sites) | <strong>No</strong> (Target is DNA generally) |\n| <strong>Hypoxia</strong> | <strong>Delivery Issue</strong> (Drug can't reach cell) | <strong>Mechanism Failure</strong> (No O2 to fix damage) |\n| <strong>Repair Focus</strong> | Specific to drug damage (e.g., adducts) | Double-Strand Break Repair (NHEJ/HR) |\n| <strong>Sanctuary Sites</strong> | <strong>Yes</strong> (Blood-brain barrier, testes) | <strong>No</strong> (Radiation penetrates tissue) |</p>"}, {"model": "MedGemma 27B", "text": "<p>Okay, let's break down the differences in resistance mechanisms between chemotherapy and radiotherapy. While there is some overlap (like increased DNA repair), several key mechanisms are more prominent or specific to one modality over the other.</p>\n<p><strong>Chemotherapy Resistance Mechanisms:</strong></p>\n<p>These often involve preventing the drug from reaching its target, reducing its effectiveness at the target site, or increasing the cell's ability to survive despite damage.</p>\n<ol>\n<li>\n<p><strong>Decreased Drug Uptake/Increased Efflux:</strong></p>\n<ul>\n<li>Cancer cells can reduce the expression of transporters that bring drugs into the cell.</li>\n<li>They can <em>increase</em> the expression of efflux pumps (like P-glycoprotein, MRP1) which actively pump the drug out of the cell before it reaches effective concentrations. This is a major mechanism for many chemo agents. <strong>(More characteristic of Chemo)</strong></li>\n</ul>\n</li>\n<li>\n<p><strong>Target Alteration:</strong></p>\n<ul>\n<li>Mutations in the drug's molecular target (e.g., EGFR mutations conferring resistance to tyrosine kinase inhibitors).</li>\n<li>Changes in protein levels or post-translational modifications affecting the target. <strong>(Common to both but very significant in targeted chemo)</strong></li>\n</ul>\n</li>\n<li>\n<p><strong>Drug Inactivation:</strong></p>\n<ul>\n<li>Cells may increase enzymes that metabolize or conjugate the chemotherapeutic agent, rendering it inactive. For example, glutathione S-transferases inactivating platinum compounds. <strong>(More characteristic of Chemo)</strong></li>\n</ul>\n</li>\n<li>\n<p><strong>Enhanced DNA Repair:</strong></p>\n<ul>\n<li>Upregulation of various DNA repair pathways (e.g., homologous recombination, non-homologous end joining, base excision repair) allows cells to fix the DNA damage caused by chemotherapy faster than the drug can cause further damage. <strong>(Overlap - also important in Radioresistance)</strong></li>\n</ul>\n</li>\n<li>\n<p><strong>Apoptosis Evasion:</strong></p>\n<ul>\n<li>Downregulation of pro-apoptotic proteins (e.g., Bax, Bak) or upregulation of anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL) prevents programmed cell death even when damaged.</li>\n<li>Defects in p53 pathway, crucial for initiating apoptosis after DNA damage. <strong>(Overlap - also relevant to Radiosensitivity)</strong></li>\n</ul>\n</li>\n<li>\n<p><strong>Cell Cycle Checkpoint Modulation:</strong></p>\n<ul>\n<li>Alterations in checkpoint controls allow cells with damaged DNA to progress through mitosis instead of undergoing arrest and repair/apoptosis. <strong>(Overlap - also relevant to Radiosensitivity)</strong></li>\n</ul>\n</li>\n<li>\n<p><strong>Epigenetic Modifications:</strong></p>\n</li>\n</ol>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Which resistance mechanisms, if any, are unique to chemotherapy vs radiotherapy?</h1>\n<p>Chemotherapy and radiotherapy share several resistance pathways, but each also has mechanisms that are largely modality\u2011specific. Chemotherapy has unique resistance related to drug handling and target modification, whereas radiotherapy has unique resistance linked to oxygen dependence and physical aspects of energy deposition.<a href=\"https://tcr.amegroups.org/article/view/21791/html\">^1</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8573967/\">^3</a></p>\n<h2>Chemotherapy\u2011specific resistance</h2>\n<p>These mechanisms depend on the fact that chemotherapy agents are exogenous chemicals that must enter cells, interact with specific molecular targets, and be metabolized.<a href=\"https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.265\">^5</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3573517/\">^1</a></p>\n<ul>\n<li><strong>Drug efflux by ABC transporters</strong><ul>\n<li>Overexpression of ATP\u2011binding cassette transporters (e.g., ABCB1/P\u2011gp, ABCG2) pumps many structurally unrelated drugs out of tumor cells, reducing intracellular drug levels.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3573517/\">^7</a><a href=\"https://www.sciencedirect.com/science/article/abs/pii/S0304419X25000149\">^5</a></li>\n<li>This is considered a central mechanism of chemoresistance and is specific to agents that must accumulate inside the cell at high concentrations.<a href=\"https://www.nature.com/articles/s41467-021-23071-6\">^1</a></li>\n</ul>\n</li>\n<li><strong>Altered drug uptake and metabolism</strong><ul>\n<li>Reduced expression or mutation of influx transporters or channels can limit entry of drugs such as platinum agents or nucleoside analogs.<a href=\"https://www.sciencedirect.com/science/article/abs/pii/S0304419X25000149\">^6</a></li>\n<li>Increased detoxification (e.g., by glutathione\u2011S\u2011transferases, aldehyde dehydrogenases, or other metabolizing enzymes) can inactivate drugs before they damage DNA or other targets.<a href=\"https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.265\">^2</a></li>\n</ul>\n</li>\n<li><strong>Modification or loss of the drug target</strong><ul>\n<li>Point mutations, amplification, or isoform switching in drug targets (e.g., topoisomerase II, tubulin, hormone receptors, kinases) can reduce drug binding while preserving target function.<a href=\"https://tcr.amegroups.org/article/view/21791/html\">^8</a><a href=\"https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.265\">^6</a></li>\n<li>These mechanisms are inherently tied to the presence of a defined molecular drug target and have no direct parallel for ionizing radiation, which damages DNA and other macromolecules more diffusely.<a href=\"https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.265\">^8</a></li>\n</ul>\n</li>\n</ul>\n<h2>Radiotherapy\u2011specific resistance</h2>\n<p>These mechanisms stem from the physics of ionizing radiation, which relies heavily on oxygen to fix DNA damage and is delivered as localized energy rather than a diffusible molecule.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8573967/\">^9</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3668666/\">^8</a></p>\n<ul>\n<li><strong>Tumor hypoxia and oxygen effect</strong><ul>\n<li>Hypoxia is a hallmark of many solid tumors and reduces the formation and \u201cfixation\u201d of radiation\u2011induced DNA damage, leading to radioresistance.<a href=\"https://www.oaepublish.com/articles/cdr.2020.49\">^4</a></li>\n<li>In low oxygen, fewer reactive oxygen species are generated and damaged DNA can be chemically restored, whereas in normoxia oxygen converts transient DNA radicals into non\u2011repairable lesions.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3668666/\">^4</a></li>\n</ul>\n</li>\n<li><strong>Dose\u2011fractionation and repopulation dynamics</strong><ul>\n<li>Radioresistance can arise from accelerated repopulation of clonogenic tumor cells between fractions, sublethal damage repair, and redistribution through the cell cycle, which are tightly linked to how radiation is fractionated over time.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3668666/\">^8</a></li>\n<li>These time\u2011 and dose\u2011structure effects are specific to radiotherapy delivery schedules and do not have a direct analogue with most standard bolus chemotherapy regimens.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3668666/\">^8</a></li>\n</ul>\n</li>\n<li><strong>Radiation field and microenvironmental factors</strong><ul>\n<li>Heterogeneous dose distribution, shielding by stromal components, and vascular damage within the irradiated volume can create locally radioresistant niches that are spatially defined by the radiation field.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8573967/\">^9</a></li>\n<li>These spatially constrained resistance patterns are distinct from systemic chemoresistance, which is determined more by whole\u2011body drug exposure than by local dose gradients.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3668666/\">^4</a></li>\n</ul>\n</li>\n</ul>\n<h2>Shared but differently weighted mechanisms</h2>\n<p>Some mechanisms operate in both settings but are more characteristic of one modality.<a href=\"https://tcr.amegroups.org/article/view/21791/html\">^3</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3668666/\">^8</a></p>\n<ul>\n<li>Enhanced DNA repair, survival signaling (e.g., PI3K\u2013AKT, NF\u2011\u03baB), cancer stem cell phenotypes, and autophagy can contribute to resistance to both chemotherapy and radiation.<a href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.904063/full\">^2</a></li>\n<li>However, drug efflux/target modification are strongly chemotherapy\u2011skewed, while hypoxia/oxygen dependence and fractionation\u2011driven effects are strongly radiotherapy\u2011skewed.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8573967/\">^1</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3668666/\">^8</a>\n<span style=\"display:none\"><a href=\"https://www.sciencedirect.com/science/article/abs/pii/S1044579X23001487\">^10</a></span></li>\n</ul>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>**Chemotherapy-unique resistance mechanisms center on drug efflux, metabolism, and target alterations, while radiotherapy-unique mechanisms emphasize DNA repair capacity, cancer stem cell properties, and specific microenvironmental adaptations. **</p>\n<h2>Chemotherapy-Specific Resistance Mechanisms</h2>\n<p><strong>Drug efflux and metabolism</strong> are hallmark chemotherapy resistance mechanisms. The ATP-binding cassette (ABC) transporter family, particularly <strong>ABCB1 (MDR1/P-glycoprotein)</strong> , actively pumps chemotherapeutic agents out of cancer cells, reducing intracellular drug concentrations.[1][2][3]</p>\n<p>Drug-metabolizing enzymes catalyze reactions that inactivate chemotherapeutic drugs, rendering them ineffective.[4]</p>\n<p>The <strong>glutathione detoxification system</strong> conjugates with platinum-based drugs, causing insensitivity to these agents.[4] <strong>Drug target alterations</strong> represent another chemotherapy-specific mechanism. Changes in HER2 receptor expression lead to poorer efficacy of HER2 receptor inhibitors.[4]</p>\n<p>Mutations in drug targets can render chemotherapeutic agents ineffective at their intended molecular sites.[2] <strong>Epithelial-mesenchymal transition (EMT)</strong> contributes specifically to chemoresistance by altering cellular phenotypes and enhancing migratory capacity.[4]</p>\n<p>Exosomal RNA transfer between cancer cells can propagate chemoresistance phenotypes.[5]</p>\n<h2>Radiotherapy-Specific Resistance Mechanisms</h2>\n<p><strong>Enhanced DNA repair capacity</strong> is the primary radiotherapy-specific resistance mechanism. Radioresistant cells demonstrate <strong>higher DNA repair potential</strong> with altered levels of DNA repair proteins including pATM, KU70, and RAD51.[6]</p>\n<p>Drug-resistant cells that are cross-resistant to radiation show lower levels of \u03b3H2AX foci upon irradiation, indicating more efficient DNA damage repair.[6] <strong>P4HA2 (Prolyl 4-Hydroxylase Subunit Alpha 2)</strong> is specifically upregulated in radioresistant cells and promotes resistance through enhanced stemness and DNA damage repair; its knockdown synergizes with radiotherapy.[7]</p>\n<p>Radioresistant cells harbor <strong>DNA polymerases with significantly low fidelity</strong> , seemingly sacrificing specificity to gain higher survival potential.[6] <strong>TGF-\u03b2 signaling</strong> plays a unique role in radioresistance. Irradiated breast cancer cells show increased expression of TGF-\u03b2 isoforms (\u03b21, \u03b22, \u03b23) and their receptors (TGF-\u03b2R1, TGF-\u03b2R2), which mediate both proliferation and apoptosis resistance.[8]</p>\n<p>This pathway drives a <strong>hybrid epithelial-mesenchymal phenotype</strong> specifically in radioresistant cells.[8] <strong>Cancer stem cell enrichment</strong> appears more prominent in radioresistance. Radiation exposure induces stem cell-like properties in non-stem cells, with radioresistant populations showing increased expression of Oct4, Sox2, Nanog, aldehyde dehydrogenase activity, and CD44+/CD24- populations.[9][8]</p>\n<p>Treatment with TGF-\u03b2RI inhibitors can abrogate radiation-induced proliferation increases.[8]</p>\n<h2>Overlapping Mechanisms While some mechanisms overlap\u2014including</h2>\n<p><strong>TP53 mutations, BRCA1/BRCA2 alterations, interferon-stimulated genes, and general cancer stem cell properties</strong>\u2014the specific molecular pathways and their relative importance differ between chemotherapy and radiotherapy resistance.[10][11][12]</p>\n<p>The tumor microenvironment contributes to both, but through distinct mechanisms: immune cell infiltration patterns differ, and hypoxia affects radiotherapy more directly than chemotherapy.[13][14]</p>\n<p>Would you like me to summarize the latest therapeutic strategies or agents that specifically target these unique resistance mechanisms in breast cancer, such as inhibitors of ABC transporters for chemotherapy resistance or modulators of DNA repair pathways and TGF-\u03b2 signaling for radiotherapy resistance?</p>\n<h3>References</h3>\n<ol>\n<li>Recent Strategies to Overcome Breast Cancer Resistance. Khan MM, Yalamarty SSK, Rajmalani BA, Filipczak N, Torchilin VP . Critical Reviews in Oncology/Hematology. 2024;197:104351. doi:10.1016/j.critrevonc.2024.104351.</li>\n<li>Drug Resistance in Breast Cancer: Mechanisms and Strategies for Management. Wu GY , Xiao MZ, Hao WC, et al. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2025;83:101288. doi:10.1016/j.drup.2025.101288.</li>\n<li>Decoding the Key Hallmarks of Chemoresistance: A Proteomic Tale From Breast Cancer Research. Bhavsar PP , Kalita B, Taunk K, Rapole S. Biochimica Et Biophysica Acta. Reviews on Cancer. 2025;:189404. doi:10.1016/j.bbcan.2025.189404.</li>\n<li>New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. An J, Peng C, Tang H, Liu X, Peng F . International Journal of Molecular Sciences. 2021;22(17):9644. doi:10.3390/ijms22179644.</li>\n<li>The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer. Kannan K, Srinivasan A, Kannan A, Ali N. Cancers. 2025;17(17):2938. doi:10.3390/cancers17172938.</li>\n<li>Molecular Mechanisms of Radiation Resistance in Doxorubicin-Resistant Breast Adenocarcinoma Cells. Luzhna L, Golubov A, Ilnytskyy S, Chekhun VF , Kovalchuk O. International Journal of Oncology. 2013;42(5):1692-</li>\n<li>doi:10.3892/ijo.2013.1845.</li>\n<li>Single-Cell and Spatial Transcriptomics Reveal P4ha2-Mediated Radiotherapy Resistance Mechanisms in Breast Cancer. Li H, Liu J, Jiao Y , et al. Theranostics. 2026;16(5):2192-2220. doi:10.7150/thno.121257.</li>\n<li>Radio Resistance in Breast Cancer Cells Is Mediated Through TGF-\u03b2 Signalling, Hybrid Epithelial-Mesenchymal Phenotype and Cancer Stem Cells. Yadav P , Shankar BS. Biomedicine &amp; Pharmacotherapy = Biomedecine &amp; Pharmacotherapie. 2019;111:119-130. doi:10.1016/j.biopha.2018.12.055.</li>\n<li>Determinants of Resistance to Chemotherapy and Ionizing Radiation in Breast Cancer Stem Cells. Pavlopoulou A, Oktay Y , Vougas K, et al. Cancer Letters. 2016;380(2):485-493. doi:10.1016/j.canlet.2016.07.018.</li>\n<li>P53-Dependent Cytoprotective Mechanisms Behind Resistance to Chemo-Radiotherapeutic Agents Used in Cancer Treatment. Krishnaraj J, Yamamoto T, Ohki R. Cancers. 2023;15(13):3399. doi:10.3390/cancers15133399.</li>\n<li>The Molecular Basis of Radiosensitivity and Chemosensitivity in the Treatment of Breast Cancer. Xia F , Powell SN. Seminars in Radiation Oncology. 2002;12(4):296-304. doi:10.1053/srao.2002.35250.</li>\n<li>Interferon-Stimulated Genes Are Involved in Cross-Resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer. Post AEM, Smid M, Nagelkerke A, et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2018;24(14):3397-3408. doi:10.1158/1078-0432.CCR-17-2551.</li>\n<li>Emerging Mechanisms of Triple-Negative Breast Cancer Radioresistance: Interplay Between Cancer Cell Mechanisms and the Tumor Immune Microenvironment. Canha-Borges A, Nunes B, Quintas ST, et al. Cancer Treatment Reviews. 2025;140:103026. doi:10.1016/j.ctrv.2025.103026.</li>\n<li>The Molecular Mechanisms Underlying the Therapeutic Resistance of Cancer Stem Cells. Kim JK, Jeon HY , Kim H. Archives of Pharmacal Research. 2015;38(3):389-401. doi:10.1007/s12272-014-0531-1. 4.</li>\n</ol>"}]}, "4": {"question": "What percentage of metastatic breast cancer patients eventually develop resistance to 1st line systemic therapy?  What about 2nd, 3rd, or even 4th line therapy?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>After a variable period of time as long as several years, nearly all patients treated with 1st and subsequent lines of chemotherapy will become resistant.</p>"}, {"model": "GPT-4o", "text": "<p>In metastatic breast cancer, resistance to systemic therapy is a significant challenge. While specific percentages can vary based on the subtype of breast cancer, the type of therapy, and individual patient factors, some general trends are observed:</p>\n<ol>\n<li>\n<p><strong>First-line therapy</strong>: A substantial proportion of patients with metastatic breast cancer will eventually develop resistance to first-line systemic therapy. Studies suggest that most patients will experience disease progression within 12 to 18 months of starting first-line treatment, indicating that a majority develop resistance over time.</p>\n</li>\n<li>\n<p><strong>Second-line therapy</strong>: Resistance to second-line therapy tends to occur more quickly than with first-line therapy. The median time to progression is often shorter, typically around 6 to 12 months, suggesting that a significant percentage of patients will develop resistance within this timeframe.</p>\n</li>\n<li>\n<p><strong>Third-line and beyond</strong>: As patients move to third-line and subsequent lines of therapy, the likelihood of developing resistance increases, and the duration of response generally decreases. The median time to progression can be as short as 3 to 6 months, indicating that resistance is common and occurs relatively quickly.</p>\n</li>\n</ol>\n<p>Overall, while exact percentages can vary, it is generally observed that resistance becomes more common and occurs more rapidly with each successive line of therapy. This highlights the need for ongoing research into new treatments and strategies to overcome or delay resistance in metastatic breast cancer.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>The short answer is that <strong>nearly 100%</strong> of patients with metastatic breast cancer (MBC) will eventually develop resistance to 1st, 2nd, 3rd, and 4th line therapies, provided they survive long enough to receive them.</p>\n<p>Because metastatic breast cancer is currently considered treatable but not curable, the goal of therapy is to control the disease for as long as possible. \"Resistance\" in this context is clinically defined as <strong>disease progression</strong> (the tumor starts growing again).</p>\n<p>Here is the breakdown of how resistance develops across different lines of therapy, using <strong>Progression-Free Survival (PFS)</strong> and <strong>Objective Response Rates (ORR)</strong> as the metrics.</p>\n<h3>The General Trend: Diminishing Returns</h3>\n<p>As a patient moves from 1st line to 4th line therapy, two things happen:\n1.  <strong>Resistance happens faster:</strong> The duration of disease control (PFS) becomes shorter with each line.\n2.  <strong>Response rates drop:</strong> The percentage of patients whose tumors shrink (ORR) decreases significantly.</p>\n<hr />\n<h3>1st Line Therapy</h3>\n<ul>\n<li><strong>Resistance Rate:</strong> Eventually <strong>~100%</strong> (Acquired Resistance).</li>\n<li><strong>Intrinsic Resistance:</strong> <strong>15\u201320%</strong> of patients do not respond at all to the initial treatment (the drug never works).</li>\n<li><strong>Duration of Control:</strong> This is the \"gold standard\" period where treatments work the longest.<ul>\n<li><em>HR+/HER2- (e.g., CDK4/6 inhibitors + Endocrine Therapy):</em> The median time to resistance is roughly <strong>24\u201328 months</strong>.</li>\n<li><em>HER2+ (e.g., Taxane + Trastuzumab + Pertuzumab):</em> The median time to resistance is roughly <strong>18\u201324 months</strong> (though some patients have exceptional long-term responses).</li>\n<li><em>Triple Negative (TNBC):</em> Resistance develops quickly, often within <strong>5\u20138 months</strong>.</li>\n</ul>\n</li>\n</ul>\n<h3>2nd Line Therapy</h3>\n<p>By the time a patient reaches 2nd line, the tumor has evolved mechanisms to evade treatment.\n*   <strong>Resistance Rate:</strong> <strong>~100%</strong>.\n*   <strong>Efficacy:</strong> The probability of the drug shrinking the tumor drops significantly compared to the first line.\n*   <strong>Duration:</strong>\n    *   For HR+ patients, the time to resistance drops to approximately <strong>6\u201310 months</strong>.\n    *   Response rates generally hover around <strong>20\u201330%</strong>. This means 70\u201380% of patients have tumors that either stay the same size or grow despite treatment.</p>\n<h3>3rd Line Therapy</h3>\n<ul>\n<li><strong>Clinical Context:</strong> At this stage, the cancer is highly resistant and heterogeneous (different cells within the tumor have different mutations).</li>\n<li><strong>Duration:</strong> The median time to progression is often <strong>3\u20135 months</strong>.</li>\n<li><strong>Response Rate:</strong> Only about <strong>10\u201315%</strong> of patients will see their tumors shrink significantly.</li>\n<li><strong>Primary Resistance:</strong> A large percentage (often &gt;50%) of patients will see no benefit at all; the cancer will simply continue to grow through the medication.</li>\n</ul>\n<h3>4th Line Therapy and Beyond</h3>\n<ul>\n<li><strong>Clinical Context:</strong> Treatment is often palliative chemotherapy.</li>\n<li><strong>Duration:</strong> The median time to resistance is very short, often <strong>2\u20133 months</strong>.</li>\n<li><strong>Response Rate:</strong> Often <strong>&lt;10%</strong>.</li>\n<li><strong>Attrition:</strong> It is important to note that many patients do not make it to 4th line therapy. Due to the cumulative toxicity of previous treatments and the decline in physical health (performance status), only about <strong>15\u201325%</strong> of patients who start 1st line therapy remain healthy enough to receive 4th line therapy.</li>\n</ul>\n<h3>Summary Table: The \"Cascade\" of Resistance</h3>\n<p>| Therapy Line | Approx. Response Rate (Tumor Shrinkage) | Median Time to Resistance (PFS) |\n| :--- | :--- | :--- |\n| <strong>1st Line</strong> | 50\u201380% (depending on subtype) | 12\u201328 months |\n| <strong>2nd Line</strong> | 20\u201340% | 6\u201310 months |\n| <strong>3rd Line</strong> | 10\u201320% | 3\u20135 months |\n| <strong>4th Line</strong> | &lt;10% | 2\u20133 months |</p>\n<p><em><strong>Disclaimer:</strong> These figures are averages based on large clinical trials and vary heavily based on the biology of the cancer (HR+ vs. TNBC vs. HER2+) and the specific drugs used (e.g., antibody-drug conjugates like Enhertu are currently changing these statistics by offering better response rates in later lines).</em></p>"}, {"model": "MedGemma 27B", "text": "<p>Okay, let's break down the development of treatment resistance in metastatic breast cancer (MBC). It's a complex process and varies significantly based on several factors. Here\u2019s an overview covering first through fourth-line therapies:</p>\n<p><strong>Understanding Treatment Resistance in MBC:</strong></p>\n<ul>\n<li><strong>Heterogeneity:</strong> Metastatic tumors are not uniform. They contain diverse populations of cells with different genetic mutations and characteristics. Some may be inherently resistant to certain drugs from the start, while others acquire resistance over time.</li>\n<li><strong>Evolutionary Process:</strong> Cancer cells evolve under selective pressure from treatments. Drugs kill susceptible cells, leaving behind those that can survive and proliferate, leading to acquired resistance.</li>\n<li><strong>Mechanisms of Resistance:</strong> Resistance can arise through various mechanisms, including target mutation/alteration, drug efflux pumps, pathway activation bypasses, epigenetic changes, and alterations in cell death pathways.</li>\n<li><strong>Tumor Biology Matters:</strong> The specific subtype of breast cancer (e.g., HR+/HER2-, HER2+, Triple Negative) heavily influences which therapies are used and how quickly resistance develops. Hormone receptor status, HER2 amplification, and other biomarkers play crucial roles.</li>\n</ul>\n<p><strong>Resistance Rates by Line of Therapy (Approximate Estimates):</strong></p>\n<p>It's important to note these are <em>estimates</em>, as precise percentages vary widely across studies, patient populations, tumor subtypes, and definitions of \"resistance\" (clinical progression vs. biomarker change). Also, data often focuses on specific lines rather than cumulative rates across all lines.</p>\n<ol>\n<li><strong>First-Line Systemic Therapy:</strong><ul>\n<li><strong>HR+/HER2- MBC:</strong> This is the most common type (~60-70% of MBC cases). First-line typically involves endocrine therapy (ET), sometimes combined with CDK4/6 inhibitors (like palbociclib, ribociclib, abemacicib) or PI3K inhibitors (alpelisib if PIK3CA mutated).<ul>\n<li><strong>Endocrine Therapy Alone:</strong> A significant proportion of patients will progress within <strong>~9-18 months</strong>. While exact figures vary, it's reasonable to estimate that <strong>a large majority (&gt;50%, potentially up to ~80%)</strong> will experience clinical progression requiring a switch in therapy within this timeframe.</li>\n<li><strong>Endocrine Therapy + CDK4/6 Inhibitor:</strong> These combinations have improved PFS compared to ET alone, but resistance still occurs. Progression might take longer (**~18-30+ months</li>\n</ul>\n</li>\n</ul>\n</li>\n</ol>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>What percentage of metastatic breast cancer patients eventually develop resistance to 1st line systemic therapy?  What about 2nd, 3rd, or even 4th line therapy?</h1>\n<p>Published studies do not report a single, simple percentage of metastatic breast cancer (MBC) patients who \u201ceventually\u201d develop resistance at each line; instead they show that <strong>nearly all</strong> patients who live long enough on systemic therapy ultimately progress on each given line, with attrition and biology determining how many ever reach later lines. Numerically, real\u2011world and trial data imply that the proportion of patients who progress on 1st\u2011line is already well over 70\u201380% over several years, and those who remain controlled without ever becoming resistant are a small minority.<a href=\"https://ascopubs.org/doi/10.1200/GO.23.00285\">^1</a><a href=\"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1080684/full\">^7</a></p>\n<h2>Why exact percentages are hard to give</h2>\n<ul>\n<li>Resistance is usually inferred from disease progression (radiographic/clinical) rather than directly measured, and follow\u2011up times differ across studies.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9247497/\">^1</a></li>\n<li>Rates also vary markedly by subtype (HR+/HER2\u2212 vs HER2+ vs triple\u2011negative), treatment backbone (endocrine + CDK4/6 inhibitor vs chemotherapy vs HER2\u2011targeted therapy), and patient fitness, so a single \u201cuniversal\u201d number is misleading.<a href=\"https://ascopubs.org/doi/10.1200/GO.23.00285\">^3</a><a href=\"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1080684/full\">^7</a></li>\n</ul>\n<h2>First\u2011line systemic therapy</h2>\n<ul>\n<li>For HR\u2011positive/HER2\u2011negative MBC, current standards use endocrine therapy plus a CDK4/6 inhibitor; median progression\u2011free survival (PFS) in major trials is on the order of 20\u201328 months, which implies that most patients eventually progress on 1st\u2011line over a few years.<a href=\"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1080684/full\">^6</a></li>\n<li>In broader mixed\u2011subtype cohorts, first\u2011line objective response rates are typically 40\u201360% and median PFS around 10\u201318 months; consequently, the vast majority of patients progressing through long\u2011term follow\u2011up are considered to have developed resistance to that first regimen.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9247497/\">^3</a></li>\n</ul>\n<h2>Second\u2011line and beyond</h2>\n<ul>\n<li>With each additional line, both PFS and response rates fall; for example, trials of second\u2011 or third\u2011line targeted or chemotherapeutic regimens in HER2+ or triple\u2011negative MBC often report median PFS in the 4\u20139\u2011month range, indicating rapid acquisition or selection of resistant disease.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10814066/\">^3</a></li>\n<li>Real\u2011world data show that a high proportion of patients who are well enough to receive a second line will also progress on that regimen within a year or two, and only a subset survive and remain fit to receive third\u2011 or fourth\u2011line therapy.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10814066/\">^1</a></li>\n</ul>\n<h2>Attrition across lines of therapy</h2>\n<ul>\n<li>Observational work on treatment \u201cattrition\u201d suggests that a large majority of patients started on 1st\u2011line systemic therapy do reach 2nd\u2011line, but the fraction reaching 3rd or 4th line drops progressively because of both resistance and declining performance status.<a href=\"https://www.sciencedirect.com/science/article/pii/S2059702924018969\">^8</a></li>\n<li>Practically, among patients who live long enough and remain eligible for further treatment, progression (i.e., functional resistance) after 2nd, 3rd, and later lines becomes nearly universal, with benefit windows that shrink with each successive regimen.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10814066/\">^8</a></li>\n</ul>\n<h2>How to interpret this clinically</h2>\n<ul>\n<li>Conceptually, systemic therapy in MBC is almost always palliative and time\u2011limited in efficacy; resistance to each line is expected, not exceptional, and treatment planning focuses on sequencing effective options rather than preventing resistance entirely.<a href=\"https://ascopubs.org/doi/10.1200/GO.23.00285\">^7</a></li>\n<li>When thinking in percentages, it is more accurate to ask, \u201cWhat proportion of patients are progression\u2011free at time X on line N?\u201d rather than \u201cWhat fraction never become resistant?\u201d, because over long enough time horizons almost all metastatic tumors eventually escape each line of therapy.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10814066/\">^1</a>\n<span style=\"display:none\"><a href=\"https://www.cancertodaymag.org/spring-2025/overcoming-resistance/\">^2</a><a href=\"https://www.sciencedirect.com/science/article/abs/pii/S1368764625000913\">^5</a></span></li>\n</ul>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p><strong>Virtually all patients with metastatic breast cancer eventually develop resistance to first-line systemic therapy</strong> , though the timeline and subsequent treatment patterns vary considerably by breast cancer subtype and initial treatment regimen.</p>\n<h2>Resistance Rates by Treatment Line In a real-world cohort of 1,545 patients with HR+/HER2- metastatic breast cancer initiating first-line chemotherapy,</h2>\n<p><strong>57% subsequently required second-line chemotherapy, 31% required third-line, and 17% required fourth-line chemotherapy</strong> .[1]</p>\n<p>However, these percentages reflect only those who received subsequent chemotherapy during the study period and underestimate total progression rates, as many patients who progressed did not receive further treatment. The <strong>clinical benefit rate (complete response + partial response + stable disease) progressively declines</strong> with each treatment line. In one retrospective analysis, clinical benefit decreased from 85% at first-line to 54% at fourth-line chemotherapy.[2]</p>\n<p>Response rates show even steeper declines: from 20% at first-line to 0% at fourth- line in this cohort.[2]</p>\n<h2>Resistance Patterns by Subtype</h2>\n<p><strong>HR+/HER2- Disease:</strong> For patients receiving first-line CDK4/6 inhibitor plus endocrine therapy, resistance inevitably develops in most patients despite approximately 20% achieving long-term disease control at five years.[3]</p>\n<p>After CDK4/6 inhibitor progression, <strong>only 40.5% of patients achieved at least 6 months of benefit from second-line therapy</strong> .[4]</p>\n<p>Notably, <strong>61% of patients with progressive disease at first evaluation did not receive subsequent treatment</strong> , suggesting either appropriate clinical judgment to avoid futility or potential undertreatment.[2] <strong>Triple-Negative Breast Cancer:</strong> The National Comprehensive Cancer Network guidelines outline sequential treatment options, but specific resistance rates are not well-quantified in the literature.[5] <strong>HER2+ Disease:</strong> Multiple lines of HER2-targeted therapy plus chemotherapy offer clinical benefit, though <strong>the optimal sequence and true benefit beyond standard first and second lines remain unknown</strong> , particularly after progression on pertuzumab-based chemotherapy and antibody-drug conjugates.[5]</p>\n<h2>Survival by Treatment Line In HR+/HER2- metastatic breast cancer patients receiving chemotherapy,</h2>\n<p><strong>median overall survival from first-line chemotherapy start was 23.3 months</strong> . For those receiving second, third, and fourth-line chemotherapy, median overall survival from each treatment initiation was <strong>16.5 months, 11.8 months, and 9.1 months</strong> , respectively.[1]</p>\n<p>The <strong>absence of at least 6 months of progression-free survival benefit with first-line therapy predicts reduced probability of benefit from subsequent lines</strong> (OR: 0.39; 95% CI: 0.24-0.62, p[4]</p>\n<p>Would you like me to summarize the latest evidence on molecular mechanisms of resistance in metastatic breast cancer, particularly focusing on how these mechanisms differ by subtype and how they inform selection of subsequent lines of therapy? This could help guide more personalized treatment strategies beyond standard sequencing.</p>\n<h3>References</h3>\n<ol>\n<li>Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US). Tolaney S, Punie K, Kurian A, et al. Journal of Clinical Oncology. 2023;41(Suppl 16):e18871. doi:10.1200/JCO.2023.41.16_suppl.e18871.</li>\n<li>What Is the Benefit of Treatment With Multiple Lines of Chemotherapy for Patients With Metastatic Breast Cancer? A Retrospective Cohort Study. Bakker JL, Wever K, van Waesberghe JH, et al. Cancer Epidemiology. 2015;39(6):848-53. doi:10.1016/j.canep.2015.09.010.</li>\n<li>Efficacy and Safety of Systemic Therapies Following Progression on CDK4/6 Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis. Buonaiuto R, Fordellone M, Caltavituro A, et al. EClinicalMedicine. 2025;89:103535. doi:10.1016/j.eclinm.2025.103535.</li>\n<li>Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?. Bonotto M, Gerratana L, Iacono D, et al. The Oncologist. 2015;20(7):719-24. doi:10.1634/theoncologist.2015-0002.</li>\n<li>Breast Cancer. National Comprehensive Cancer Network. Updated 2025-10-16. 5.</li>\n</ol>"}]}, "5": {"question": "Are these resistance patterns (or genes, proteins, transcriptional RNA, etc.) correlated with TNM stage, grade, and ER/PR/HER2 status?  How do these clinical factors affect resistance mechanisms?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>Yes. The authors discuss the relationship between various biomarkers of intrinsic or acquired resistance and patient characteristics such as age, race, menopausal status, tumor histology, hormone receptor status, HER-2 status, tumor grade, and stage in some detail. For example, they note that high expression levels of P-glycoprotein are associated with poor prognosis and increased risk for recurrence among node-negative patients but not among node-positive patients; this may be due to chemotherapy treatment effects on nodal disease burden. They also describe how different combinations of markers predict response to specific therapies better than single markers alone.</p>"}, {"model": "GPT-4o", "text": "<p>The relationship between resistance patterns (including genes, proteins, transcriptional RNA, etc.) and clinical factors such as TNM stage, grade, and ER/PR/HER2 status is a complex and active area of research, particularly in the context of cancer. Here's a general overview of how these clinical factors can affect resistance mechanisms:</p>\n<ol>\n<li>\n<p><strong>TNM Stage</strong>: The TNM staging system classifies cancer based on tumor size (T), lymph node involvement (N), and the presence of metastasis (M). Advanced stages often correlate with more aggressive disease and can be associated with increased genetic and molecular alterations that contribute to drug resistance. For example, metastatic tumors might exhibit different resistance mechanisms compared to localized tumors due to the selection pressures of different microenvironments.</p>\n</li>\n<li>\n<p><strong>Grade</strong>: Tumor grade refers to how much the cancer cells resemble normal cells under a microscope. High-grade tumors tend to be more aggressive and may have a higher propensity for developing resistance due to increased genetic instability and mutation rates. These tumors might express different sets of resistance genes or proteins compared to low-grade tumors.</p>\n</li>\n<li>\n<p><strong>ER/PR/HER2 Status</strong>: These are key biomarkers in breast cancer that guide treatment decisions. </p>\n</li>\n<li><strong>ER (Estrogen Receptor) and PR (Progesterone Receptor) Status</strong>: ER-positive and/or PR-positive tumors often respond to hormone therapies. Resistance in these tumors can develop through various mechanisms, such as mutations in the estrogen receptor gene (ESR1), activation of alternative signaling pathways, or changes in co-regulator proteins.</li>\n<li><strong>HER2 Status</strong>: HER2-positive tumors are treated with targeted therapies like trastuzumab. Resistance can occur through mechanisms such as HER2 gene amplification, activation of downstream signaling pathways (e.g., PI3K/AKT), or compensatory upregulation of other receptor tyrosine kinases.</li>\n</ol>\n<p>Overall, these clinical factors can influence the molecular landscape of a tumor, affecting how it responds to treatment and develops resistance. Understanding these relationships is crucial for developing personalized treatment strategies and overcoming resistance in cancer therapy. Researchers continue to investigate these correlations to improve therapeutic outcomes.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>Yes, resistance patterns (genes, proteins, and RNA expression profiles) are <strong>strongly correlated</strong> with TNM stage, histological grade, and receptor status (ER/PR/HER2).</p>\n<p>In oncology, clinical factors are essentially the \"phenotypic readout\" of the underlying molecular biology. Therefore, the mechanism by which a tumor resists therapy changes drastically depending on its subtype and how advanced it is.</p>\n<p>Here is a breakdown of how these clinical factors correlate with and affect resistance mechanisms, specifically within the context of breast cancer (given your reference to ER/PR/HER2).</p>\n<hr />\n<h3>1. Receptor Status (ER/PR/HER2)</h3>\n<p>Receptor status is the primary determinant of the <em>type</em> of therapy used; consequently, it dictates the specific evolutionary pressure placed on the tumor, leading to specific resistance pathways.</p>\n<h4><strong>ER+/PR+ (Luminal A/B)</strong></h4>\n<ul>\n<li><strong>Primary Therapy:</strong> Endocrine therapy (Tamoxifen, Aromatase Inhibitors).</li>\n<li><strong>Correlated Resistance Mechanisms:</strong><ul>\n<li><strong>ESR1 Mutations:</strong> In metastatic settings, tumors often develop mutations in the <em>ESR1</em> gene (e.g., Y537S), allowing the Estrogen Receptor to remain active even without estrogen.</li>\n<li><strong>Growth Factor Crosstalk:</strong> Upregulation of <strong>HER2</strong>, <strong>EGFR</strong>, or <strong>IGF1R</strong> pathways to bypass the blocked ER pathway.</li>\n<li><strong>Cell Cycle Dysregulation:</strong> Overexpression of <strong>Cyclin D1</strong> and <strong>CDK4/6</strong>, leading to resistance against hormone therapies (hence the use of CDK4/6 inhibitors).</li>\n<li><strong>PI3K/AKT/mTOR Pathway:</strong> Mutations in <em>PIK3CA</em> are highly correlated with Luminal tumors that resist endocrine therapy.</li>\n</ul>\n</li>\n</ul>\n<h4><strong>HER2 Positive</strong></h4>\n<ul>\n<li><strong>Primary Therapy:</strong> Anti-HER2 antibodies (Trastuzumab, Pertuzumab) and TKIs.</li>\n<li><strong>Correlated Resistance Mechanisms:</strong><ul>\n<li><strong>Truncated Receptors (p95HER2):</strong> The tumor produces a version of the HER2 protein that lacks the extracellular binding site for Trastuzumab but remains constitutively active.</li>\n<li><strong>PTEN Loss:</strong> Loss of the tumor suppressor <em>PTEN</em> leads to hyperactive PI3K signaling, rendering HER2 blockade ineffective.</li>\n<li><strong>Epitope Masking:</strong> Proteins like Mucin-4 (MUC4) can physically block the drug from binding to the receptor.</li>\n</ul>\n</li>\n</ul>\n<h4><strong>Triple Negative (TNBC)</strong></h4>\n<ul>\n<li><strong>Primary Therapy:</strong> Chemotherapy (Anthracyclines, Taxanes) and Immunotherapy.</li>\n<li><strong>Correlated Resistance Mechanisms:</strong><ul>\n<li><strong>Efflux Pumps:</strong> High expression of <strong>ABC Transporters</strong> (P-glycoprotein) pumps chemotherapy out of the cell.</li>\n<li><strong>DNA Repair:</strong> Upregulation of DNA repair enzymes (like PARP) allows cells to survive DNA-damaging chemo.</li>\n<li><strong>Stemness:</strong> TNBC is highly correlated with <strong>Cancer Stem Cell (CSC)</strong> markers (CD44+/CD24-), which are intrinsically resistant to chemotherapy.</li>\n</ul>\n</li>\n</ul>\n<hr />\n<h3>2. Histological Grade (Differentiation)</h3>\n<p>Grade indicates how fast the cells are dividing and how \"abnormal\" they look. This correlates with proliferation markers and apoptotic thresholds.</p>\n<h4><strong>Low Grade (Well-Differentiated)</strong></h4>\n<ul>\n<li><strong>Resistance Pattern:</strong> <strong>Chemotherapy Resistance.</strong></li>\n<li><strong>Mechanism:</strong> Chemotherapy targets rapidly dividing cells. Low-grade tumors have low <strong>Ki-67</strong> (proliferation marker) and often high <strong>Bcl-2</strong> (anti-apoptotic protein). They simply do not divide fast enough for mitotic poisons (like Taxanes) to kill them effectively.</li>\n</ul>\n<h4><strong>High Grade (Poorly Differentiated)</strong></h4>\n<ul>\n<li><strong>Resistance Pattern:</strong> <strong>Rapid Acquired Resistance.</strong></li>\n<li><strong>Mechanism:</strong> These tumors have high genomic instability (e.g., <strong>p53 mutations</strong>). While they often respond well to chemo initially (high kill rate), their high mutation rate allows resistant clones to evolve and dominate quickly (Darwinian selection).</li>\n</ul>\n<hr />\n<h3>3. TNM Stage (Tumor, Node, Metastasis)</h3>\n<p>Stage correlates with tumor burden and heterogeneity. As stage increases, the complexity of resistance mechanisms increases.</p>\n<h4><strong>Tumor Size (T-Stage)</strong></h4>\n<ul>\n<li><strong>Correlation:</strong> Larger tumors have higher <strong>Intratumoral Heterogeneity</strong>.</li>\n<li><strong>Mechanism:</strong> A large tumor contains many different sub-clones of cells. Statistically, it is more likely that a pre-existing resistant clone exists in a T3 tumor than a T1 tumor.</li>\n<li><strong>Hypoxia:</strong> Large tumors often have necrotic centers with low oxygen. This triggers <strong>HIF-1\u03b1</strong> (Hypoxia-Inducible Factor), which upregulates drug efflux pumps and induces angiogenesis (VEGF), promoting resistance.</li>\n</ul>\n<h4><strong>Nodal/Metastatic Involvement (N and M Stage)</strong></h4>\n<ul>\n<li><strong>Correlation:</strong> <strong>Epithelial-to-Mesenchymal Transition (EMT).</strong></li>\n<li><strong>Mechanism:</strong> To metastasize, cells must undergo EMT.<ul>\n<li><strong>Markers:</strong> Loss of <strong>E-cadherin</strong>, gain of <strong>Vimentin</strong>, <strong>Snail</strong>, <strong>Slug</strong>, and <strong>Twist</strong>.</li>\n<li><strong>Effect:</strong> Cells in the \"Mesenchymal\" state are significantly more resistant to both chemotherapy and radiation than cells in the \"Epithelial\" state.</li>\n</ul>\n</li>\n<li><strong>Microenvironment:</strong> Metastatic sites (bone, liver, brain) provide a protective niche. For example, interaction with bone marrow stromal cells can induce dormancy, protecting cancer cells from treatments that target dividing cells.</li>\n</ul>\n<hr />\n<h3>Summary: How Clinical Factors Affect Resistance</h3>\n<ol>\n<li><strong>Selection Pressure:</strong> The receptor status determines the drug used, which forces the tumor to activate specific bypass pathways (e.g., ER+ tumors activating mTOR).</li>\n<li><strong>Clonal Evolution:</strong> Higher stage and grade imply more cell divisions and more mutations. This increases the statistical probability of a \"resistance mutation\" occurring.</li>\n<li><strong>Plasticity:</strong> Metastatic (Stage IV) tumors often revert to a \"stem-like\" state (EMT), which is naturally resistant to standard cytotoxic therapies.</li>\n</ol>\n<p><strong>In conclusion:</strong> You cannot view resistance markers in isolation. A <em>PIK3CA</em> mutation implies a different resistance mechanism in an ER+ tumor (endocrine resistance) than it does in a HER2+ tumor (Trastuzumab resistance). Therefore, clinical staging and typing provide the necessary context to interpret molecular resistance patterns.</p>"}, {"model": "MedGemma 27B", "text": "<p><strong>Correlation of Resistance Patterns with Clinical Factors:</strong></p>\n<p>Yes, there is a significant correlation between specific resistance patterns (genes, proteins, transcriptional RNA) and various clinical factors in breast cancer, including TNM stage, histological grade, and hormone receptor (ER/PR)/HER2 status. These correlations are complex and can vary depending on the specific resistance mechanism being studied. Here's a breakdown:</p>\n<ul>\n<li><strong>TNM Stage:</strong> Advanced stages (higher T, N, or M values) often correlate with increased genomic instability and heterogeneity, leading to a higher likelihood of developing multiple resistance mechanisms. For example, patients with metastatic disease (Stage IV) are more likely to have acquired resistance mutations than those with early-stage disease. Specific gene amplifications associated with aggressive phenotypes might be enriched in later stages.</li>\n<li><strong>Histological Grade:</strong> Higher grades (Grade 3) typically indicate faster-growing, less differentiated tumors. These tumors may inherently possess characteristics that predispose them to treatment resistance, such as elevated expression of drug efflux pumps (e.g., P-glycoprotein), altered DNA repair pathways, or activation of pro-survival signaling networks. Certain molecular subtypes strongly associated with high grade (like triple-negative breast cancer - TNBC) also frequently exhibit intrinsic resistance to chemotherapy.</li>\n<li><strong>Hormone Receptor Status (ER/PR):</strong><ul>\n<li><strong>ER+/PR+ Tumors:</strong> While initially sensitive to endocrine therapy, they commonly develop resistance through mechanisms like ESR1 mutations, upregulation of alternative growth factor receptors (e.g., IGF1R), alterations in downstream signaling pathways (e.g., PIK3CA mutations activating the PI3K pathway), or epigenetic changes affecting ER transcription. The presence of PR positivity generally indicates better prognosis but doesn't preclude eventual resistance development.</li>\n<li><strong>ER-/PR- Tumors (including Triple-Negative Breast Cancer - TNBC):</strong> These tumors lack the primary target for endocrine therapies and rely heavily on cytotoxic chemotherapy. They often exhibit intrinsic resistance due to defects in DNA damage response (DDR) pathways (e.g., BRCA1/2 mutations), basal-like phenotype features, or overexpression of certain oncogenes. Acquired resistance during chemotherapy involves similar mechanisms seen in other types, plus potential epithelial-mesenchymal transition (EMT).</li>\n</ul>\n</li>\n<li><strong>HER2 Status:</strong><ul>\n<li><strong>HER2+ Tumors:</strong> Initially treated effectively with anti-HER2 targeted therapies (trastuzumab, pertuzumab, lapatinib,</li>\n</ul>\n</li>\n</ul>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Are these resistance patterns (or genes, proteins, transcriptional RNA, etc.) correlated with TNM stage, grade, and ER/PR/HER2 status?  How do these clinical factors affect resistance mechanisms?</h1>\n<p>Resistance mechanisms in breast cancer are strongly shaped by ER/PR/HER2 status and grade, and more weakly and indirectly by TNM stage. The same broad families of mechanisms (e.g., DNA repair, efflux, EMT, stemness, epigenetic change) are used across tumors, but which ones dominate and which genes/RNAs are involved depend heavily on subtype and tumor aggressiveness.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9360230/\">^1</a><a href=\"https://academic.oup.com/bib/article/16/3/461/244930\">^6</a></p>\n<h2>Relationship to ER/PR/HER2 status</h2>\n<p>Hormone receptor and HER2 status largely define both the initial therapy and the resistance programs that emerge.</p>\n<ul>\n<li>ER\u2011positive / HER2\u2011negative (luminal)<ul>\n<li>Resistance is often driven by alterations in <strong>ER signaling</strong> (ESR1 mutations, ER downregulation, loss of ER co\u2011factors) and activation of alternative growth pathways (PI3K\u2013AKT\u2013mTOR, CDK4/6, MAPK).<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^4</a></li>\n<li>Epigenetic changes and non\u2011coding RNAs that suppress ER\u03b1 expression (e.g., ZEB1\u2011mediated promoter methylation, lncRNAs such as H19 and TINCR) are enriched in endocrine\u2011resistant luminal tumors and correlate with loss of ER and endocrine failure.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^1</a></li>\n</ul>\n</li>\n<li>HER2\u2011positive<ul>\n<li>Resistance to trastuzumab and other HER2\u2011targeted agents is associated with HER2 pathway re\u2011wiring, activation of parallel receptors (IGF1R, ERBB family), and downstream PI3K\u2013AKT signaling.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^4</a></li>\n<li>HER2\u2011specific epigenetic events such as hypermethylation and silencing of TGFBI, and upregulation of certain lncRNAs (e.g., AGAP2\u2011AS1) are reported largely in HER2\u2011positive, trastuzumab\u2011resistant tumors, not in other subtypes.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^1</a></li>\n</ul>\n</li>\n<li>Triple\u2011negative breast cancer (TNBC)<ul>\n<li>TNBC lacks ER, PR, and HER2, and shows prominent use of <strong>EMT, cancer stem cell traits, and DNA damage response</strong> programs to resist chemotherapy and radiotherapy.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^4</a></li>\n<li>m6A\u2011modified non\u2011coding RNAs and specific lncRNA/miRNA networks that promote EMT, stemness, and DNA repair are especially highlighted in TNBC chemoresistance (e.g., to anthracyclines and taxanes).<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9360230/\">^1</a></li>\n</ul>\n</li>\n</ul>\n<h2>Relationship to grade and biological aggressiveness</h2>\n<p>Histologic grade captures proliferation and differentiation, which correlate with certain resistance genes and programs.</p>\n<ul>\n<li>High\u2011grade tumors<ul>\n<li>High grade associates with frequent TP53 mutations, HER2 (c\u2011erbB\u20112) overexpression, Bcl\u20112 negativity, and other features linked to doxorubicin and chemotherapy resistance.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^3</a></li>\n<li>Highly proliferative, poorly differentiated tumors are more likely to use EMT, stemness, and robust DNA repair/DDR activation, and to exhibit complex epigenetic reprogramming and non\u2011coding RNA changes that drive multidrug resistance.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^4</a></li>\n</ul>\n</li>\n<li>Low\u2011grade tumors<ul>\n<li>Low\u2011grade, luminal tumors more often exhibit endocrine\u2011specific resistance pathways (ER pathway rewiring, ESR1 mutations, co\u2011regulator changes) and may acquire chemoresistance later in disease course.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^6</a></li>\n<li>Gene\u2011expression\u2011based indices that combine grade with nodal status (e.g., prognostic indices) link higher grade with molecular signatures of proliferation and therapy resistance.<a href=\"https://academic.oup.com/bib/article/16/3/461/244930\">^6</a></li>\n</ul>\n</li>\n</ul>\n<h2>Relationship to TNM stage</h2>\n<p>Stage (especially metastatic vs early) correlates with resistance mainly through exposure history and underlying biology, rather than a unique \u201cstage\u2011specific\u201d gene.</p>\n<ul>\n<li>Early vs advanced local disease<ul>\n<li>TNM primarily reflects tumor size and lymph\u2011node involvement; these are prognostic but do not correspond to one specific resistance gene set.<a href=\"https://academic.oup.com/bib/article/16/3/461/244930\">^3</a></li>\n<li>Nonetheless, higher T/N categories often co\u2011occur with more aggressive molecular subtypes (e.g., HER2+, TNBC) and higher grade, which carry more intrinsic resistance mechanisms such as strong DDR, EMT, and immune evasion pathways.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9360230/\">^6</a></li>\n</ul>\n</li>\n<li>Metastatic (M1) disease<ul>\n<li>By the time breast cancer is metastatic, resistance patterns are shaped by prior therapies and clonal selection; metastatic lesions often show enrichment of resistance drivers (ESR1 mutations in pretreated ER+ disease, PI3K pathway mutations, epigenetic silencing of drug\u2011sensitivity genes, overexpression of efflux pumps).<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9360230/\">^1</a></li>\n<li>Metastatic site preferences also differ by subtype (e.g., higher liver metastasis rates in TNBC and HER2+), reflecting underlying molecular programs (angiogenesis, invasion, DDR) that also contribute to resistance.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9360230/\">^4</a></li>\n</ul>\n</li>\n</ul>\n<h2>How clinical factors modulate mechanisms</h2>\n<ul>\n<li>Clinical factors such as ER/PR/HER2 status and grade determine first\u2011line therapy (endocrine, HER2\u2011targeted, or chemotherapy) and therefore which resistance pathways are under selection pressure (hormone signaling vs HER2 signaling vs generic DNA damage tolerance).<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9360230/\">^1</a></li>\n<li>These clinical variables correlate with specific genomic, epigenomic, and transcriptomic landscapes (e.g., luminal vs HER2\u2011enriched vs basal\u2011like), which in turn dictate the dominant resistance machinery: ER\u2011centric changes in luminal disease, HER2 pathway and epigenetic silencing in HER2+, and EMT/DDR/stemness/ncRNA reprogramming in TNBC.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9360230/\">^6</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^1</a>\n<span style=\"display:none\"><a href=\"https://www.sciencedirect.com/science/article/pii/S2590098625000077\">^2</a></span></li>\n</ul>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>transcriptional RNA, etc.) **Resistance patterns\u2014including gene mutations, protein expression, and transcriptional RNA profiles\u2014show strong correlations with ER/PR/HER2 status and tumor grade, with more limited associations with TNM stage. ** correlated with TNM stage, grade, and ER/PR/HER2 status? How do these clinical factors affect resistance mechanisms? These clinical factors fundamentally shape the molecular mechanisms underlying chemotherapy and radiotherapy resistance.</p>\n<h2>ER/PR/HER2 Status and Resistance Mechanisms</h2>\n<p>**Subtype-specific resistance patterns are pronounced. ** In ER+ breast cancer, resistance mechanisms center on ESR1 mutations (acquired in 20-30% of metastatic cases), alterations in ER transcription, upregulation of FOXA1, cyclin D, c-myc, and altered receptor tyrosine kinase expression.[1]</p>\n<p>Resistant ER+ tumors show elevated pathways including ER, HER2, GATA3, AKT, RAS, and p63 signaling.[2]</p>\n<p>Specific defects in single-strand break repair proteins disrupt estrogen-regulated cell cycle control through the ATM, CHK2, CDK4 axis, directly coupling endocrine resistance to DNA repair defects.[3] <strong>In HER2+ tumors</strong> , low ER expression, high tumor-infiltrating lymphocytes (TILs), and low cT-stage are associated with pathologic complete response (pCR).[4]</p>\n<p>ER expression correlates with residual cancer burden (p=0.046), while PIK3CA mutations predict response to PI3K inhibitors in metastatic disease and pathological complete response in early disease.[5] <strong>Triple-negative breast cancer (TNBC)</strong> demonstrates distinct resistance profiles. Low PR expression (1-10%) pre-treatment associates with higher residual cancer burden (p[4]</p>\n<p>TNBC shows common differentially expressed genes including FOS and NR4A1 across chemotherapy-resistant subtypes.[6]</p>\n<p>Unlike ER+ tumors, proliferation- associated genes are not downregulated in post-treatment TNBC samples.[7]</p>\n<p>TNBC is associated with germline BRCA1 or BRCA2 mutations in 15-20% of cases.[5]</p>\n<h2>Tumor Grade and Resistance</h2>\n<p>**Higher tumor grades correlate with distinct resistance profiles. ** Grade 3 tumors demonstrate higher Ki-67 proliferation indices (&gt;20%), lower ER/PR expression, and higher recurrence scores compared to grade 1 tumors.[1]</p>\n<p>Resistant patients show significantly higher tumor grades, intrinsic subtype risk scores, and upregulated cell-cycle gene sets in primary tumors.[8]</p>\n<p>The molecular classification closely corresponds with tumor grade: <strong>luminal A tumors (low-grade) are indolent and sensitive to antiestrogens, while luminal B and HER2+ tumors have incomplete sensitivity to endocrine therapy</strong> .[9]</p>\n<p>Basal-like tumors (typically high-grade) have aggressive natural history but can be especially sensitive to chemotherapy.[9]</p>\n<h2>TNM Stage and Resistance</h2>\n<p><strong>TNM stage shows more limited direct correlation with specific resistance mechanisms</strong> , though clinical and pathological T-stage (cpT-stage) has prognostic capacity in HER2+ tumors, and pre-treatment cpT-stage affects prognosis in TNBC.[4]</p>\n<p>Low cT-stage is associated with pCR in HER2+ tumors (p=0.005).[4]</p>\n<p>A systems biology analysis identified stage-specific gene modules: 21 genes for stage I, 17 genes for stage II, 10 genes for stage III, and 7 genes for stage IV , with hub genes including SMC4, FN1, FOS, JUN, KIF11, and RACGAP1.[10]</p>\n<p>However, <strong>the clinical prognostic stage integrates grade, HER2, ER, and PR status with TNM classification</strong> , indicating that molecular features are more determinative than anatomic extent alone.[11]</p>\n<h2>Integration of Clinical Factors</h2>\n<p><strong>The interplay between these factors is complex. ** Treatment-na\u00efve samples reveal that expression levels of proliferation, immune response, and extracellular matrix (ECM) organization combined predict chemotherapy response, but </strong>the direction of effect differs by subtype**: TNBC patients with high proliferation, high immune response, and low ECM expression have better response and survival (HR 0.29, 95% CI 0.10-0.85; p=0.02), while in ER+ patients the opposite pattern predicts better outcomes (HR 4.73, 95% CI 1.51-14.8; p=0.008).[7]</p>\n<p>Post-treatment changes also vary by subtype: <strong>proliferation-associated genes are downregulated in post- treatment ER+ tumors but not in TNBC</strong> , while ECM genes are upregulated across subtypes.[7]</p>\n<p>Metabolism- associated gene sets are upregulated and estrogen-response gene sets downregulated in resistant patients' relapses compared to primary tumors.[8]</p>\n<p>Would you like me to summarize the latest evidence on how specific resistance-associated gene mutations (such as ESR1, PIK3CA, and BRCA1/2) directly impact therapeutic decision-making and outcomes in different breast cancer subtypes, particularly regarding the selection and efficacy of targeted therapies?</p>\n<h3>References</h3>\n<ol>\n<li>Systemic Therapy for Estrogen Receptor\u2013Positive, HER2-Negative Breast Cancer. Burstein HJ. The New England Journal of Medicine. 2020;383(26):2557-2570. doi:10.1056/NEJMra1307118.</li>\n<li>Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer. Xia Y , He X, Renshaw L, et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2022;28(16):3618-3629. doi:10.1158/1078-0432.CCR-21-3189.</li>\n<li>Endocrine Therapy Resistance: New Insights. Lei JT, Anurag M, Haricharan S, Gou X, Ellis MJ. Breast (Edinburgh, Scotland). 2019;48 Suppl 1:S26-S30. doi:10.1016/S0960-9776(19)31118-X.</li>\n<li>Pre- And Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer. Pons L, Hern\u00e1ndez L, Urbizu A, et al. Cancers. 2023;15(12):3068. doi:10.3390/cancers15123068.</li>\n<li>Breast Cancer. Loibl S, Poortmans P , Morrow M, Denkert C, Curigliano G. Lancet (London, England). 2021;397(10286):1750-1769. doi:10.1016/S0140-6736(20)32381-3.</li>\n<li>Molecular Determinants of Neoadjuvant Chemotherapy Resistance in Breast Cancer: An Analysis of Gene Expression and Tumor Microenvironment. Guevara-Nieto HM, Orozco-Casta\u00f1o CA, Parra-Medina R, et al. PloS One. 2025;20(10):e0334335. doi:10.1371/journal.pone.0334335.</li>\n<li>Comprehensive Characterization of Pre- And Post-Treatment Samples of Breast Cancer Reveal Potential Mechanisms of Chemotherapy Resistance. Hoogstraat M, Lips EH, Mayayo-Peralta I, et al. NPJ Breast Cancer. 2022;8(1):60. doi:10.1038/s41523-022-00428-8.</li>\n<li>Transcriptomic Profiles of Endocrine-Resistant Breast Cancer. Schagerholm Stanev C, Sifakis EG, Hases L, et al. BMC Cancer. 2025;25(1):1556. doi:10.1186/s12885-025-14826-1.</li>\n<li>Gene-Expression Signatures in Breast Cancer. Sotiriou C, Pusztai L. The New England Journal of Medicine. 2009;360(8):790-800. doi:10.1056/NEJMra0801289.</li>\n<li>Systems Biology Comprehensive Analysis on Breast Cancer for Identification of Key Gene Modules and Genes Associated With TNM-based Clinical Stages. Amjad E, Asnaashari S, Sokouti B, Dastmalchi S. Scientific Reports. 2020;10(1):10816. doi:10.1038/s41598-020-67643-w.</li>\n<li>Breast Cancer. National Comprehensive Cancer Network. Updated 2025-10-16. 6.</li>\n</ol>"}]}, "6": {"question": "Is there a subset of breast cancer patients that is more likely to develop resistance (ie triple negative metastatic cases)?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>Yes. Triple-negative breast cancers are associated with higher rates of local and distant recurrence, as well as shorter disease-free survival compared with other tumor subtypes.</p>"}, {"model": "GPT-4o", "text": "<p>Yes, certain subsets of breast cancer patients are more likely to develop resistance to treatments. Triple-negative breast cancer (TNBC) is one such subset. TNBC lacks estrogen receptors, progesterone receptors, and excess HER2 protein, which makes it unresponsive to some of the most effective hormonal and targeted therapies available for other types of breast cancer. This often leads to a more aggressive disease course and a higher likelihood of developing resistance to chemotherapy, which is the primary treatment option for TNBC.</p>\n<p>Metastatic breast cancer, regardless of subtype, also tends to develop resistance over time. As cancer cells are exposed to treatments, they can undergo genetic changes that allow them to survive and proliferate despite therapy. This is a significant challenge in managing metastatic disease, as it often requires changing treatment strategies and exploring clinical trials for new therapies.</p>\n<p>Research is ongoing to better understand the mechanisms of resistance in these and other subsets of breast cancer, with the goal of developing more effective treatments and overcoming resistance.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>Yes, you are correct. While resistance can develop in any subtype of breast cancer, <strong>Triple-Negative Breast Cancer (TNBC)</strong>\u2014particularly in the metastatic setting\u2014is the subset most clinically associated with rapid development of drug resistance and limited treatment options.</p>\n<p>However, the concept of \"resistance\" looks different depending on the subtype. Here is a breakdown of which patients are most likely to develop resistance and why.</p>\n<h3>1. Triple-Negative Breast Cancer (TNBC)</h3>\n<p>TNBC is defined by the lack of Estrogen receptors (ER), Progesterone receptors (PR), and HER2 protein.</p>\n<ul>\n<li><strong>Why resistance is high:</strong> Because TNBC lacks these three targets, physicians cannot use hormonal therapies (like Tamoxifen) or HER2-targeted therapies (like Herceptin). Historically, the only option was chemotherapy.</li>\n<li><strong>The \"Paradox\":</strong> TNBC often responds <em>better</em> to chemotherapy initially than other types (the tumor shrinks fast). However, it is highly prone to developing <strong>acquired resistance</strong> very quickly.</li>\n<li><strong>The Mechanism:</strong> TNBC tumors are genetically unstable and have a high mutation rate. When chemotherapy kills the sensitive cancer cells, a small sub-population of resistant cells (often called cancer stem cells) survives, multiplies, and creates a new tumor that is immune to the previous drugs.</li>\n<li><strong>Metastatic Outlook:</strong> Once TNBC becomes metastatic (Stage IV), the window of time before the cancer becomes resistant to chemotherapy is often shorter than in other subtypes.</li>\n</ul>\n<h3>2. Hormone Receptor-Positive (HR+), HER2-Negative</h3>\n<p>This is the most common form of breast cancer (Luminal A and B).</p>\n<ul>\n<li><strong>The Resistance Profile:</strong> These patients are less likely to have \"primary\" resistance (meaning the drugs usually work at first). However, they are the primary group for <strong>Endocrine (Hormone) Resistance</strong>.</li>\n<li><strong>Late Recurrence:</strong> Unlike TNBC, where resistance usually happens within the first 3\u20135 years, HR+ breast cancer can develop resistance 10, 15, or even 20 years later.</li>\n<li><strong>Mechanism:</strong> The tumor cells mutate (specifically <em>ESR1</em> mutations) so they can utilize estrogen even in the presence of blockers, or they activate alternative survival pathways (like the CDK4/6 or PI3K pathways) to bypass the need for estrogen entirely.</li>\n</ul>\n<h3>3. HER2-Positive</h3>\n<p>HER2+ cancer was historically the most deadly until the invention of targeted therapies like trastuzumab (Herceptin).</p>\n<ul>\n<li><strong>The Resistance Profile:</strong> While targeted therapies are very effective, roughly 15\u201320% of patients have primary resistance (the drug never works), and many metastatic patients eventually develop acquired resistance.</li>\n<li><strong>Mechanism:</strong> The tumor may \"mask\" the HER2 protein so the drug cannot find it, or it may mutate downstream signaling pathways so the cell continues to grow even if the HER2 receptor is blocked.</li>\n</ul>\n<h3>Summary: Who is \"Most\" Likely?</h3>\n<p>If we define \"likely to develop resistance\" by <strong>speed and lack of subsequent options</strong>, the answer is <strong>Metastatic Triple-Negative Breast Cancer</strong>.</p>\n<ul>\n<li><strong>TNBC</strong> has the fewest \"backup plans.\" Once resistance to standard chemo develops, options become scarce (though new Antibody-Drug Conjugates like Trodelvy and immunotherapy are improving this).</li>\n<li><strong>HR+ Metastatic</strong> patients eventually develop resistance, but physicians can often switch them to a second, third, or fourth line of hormone therapy combined with targeted agents (like CDK4/6 inhibitors) before running out of options.</li>\n</ul>\n<h3>Other High-Risk Factors for Resistance</h3>\n<p>Regardless of the subtype (TNBC, HR+, or HER2+), a patient is more likely to develop resistance if:\n1.  <strong>High Tumor Burden:</strong> The more cancer cells present, the higher the statistical probability that one cell possesses a mutation that confers resistance.\n2.  <strong>Visceral Metastasis:</strong> Patients with spread to the liver or brain often face harder-to-treat resistance than those with spread only to the bones.\n3.  <strong>BRCA Mutations:</strong> While BRCA carriers (often TNBC) respond well to a specific class of drugs called PARP inhibitors, resistance to these drugs can develop if the tumor creates a \"reversion mutation\" that fixes its own DNA repair mechanism.</p>\n<p><em><strong>Disclaimer:</strong> I am an AI, not a doctor. Oncology is a rapidly changing field. If you or a loved one are concerned about treatment resistance, these questions should be discussed with an oncologist who understands the specific molecular profile of the tumor.</em></p>"}, {"model": "MedGemma 27B", "text": "<p>Yes, absolutely. Triple-negative breast cancer (TNBC) is known for its aggressive nature and higher likelihood of developing treatment resistance compared to other subtypes like hormone receptor-positive or HER2-positive breast cancers.</p>\n<p>Here's why TNBC patients are considered at higher risk for resistance development:</p>\n<ol>\n<li><strong>Lack of Targeted Therapies:</strong> Unlike HR+ (hormone receptor-positive) tumors which can be treated with endocrine therapy (like tamoxifen or aromatase inhibitors), or HER2+ tumors which respond well to targeted therapies like trastuzumab (Herceptin), TNBC lacks these specific molecular targets. This leaves chemotherapy as the primary systemic treatment option.</li>\n<li><strong>High Heterogeneity:</strong> TNBC encompasses a diverse group of genetically distinct cancers. While they all lack ER, PR, and HER2 expression, they have various underlying mutations and pathways driving their growth. This heterogeneity makes it harder to find universally effective treatments and increases the chance that some tumor cells will inherently resist certain drugs or quickly evolve resistance mechanisms.</li>\n<li><strong>Stem Cell-Like Properties:</strong> Some studies suggest that TNBC may contain a population of cancer stem cells (CSCs). These CSCs often exhibit characteristics associated with drug resistance, such as slower proliferation rates, increased DNA repair capacity, and ability to survive in harsh microenvironments. They might contribute significantly to relapse and metastasis after initial treatment appears successful.</li>\n<li><strong>Tumor Microenvironment (TME):</strong> The TME surrounding TNBC tumors can play a role in promoting resistance. Interactions between cancer cells and stromal cells, immune cells, and extracellular matrix components within the TME can influence chemoresistance and facilitate invasion/metastasis.</li>\n<li><strong>Intrinsic Resistance Mechanisms:</strong> Certain genetic alterations common in TNBC, such as mutations in <em>TP53</em> (a crucial tumor suppressor gene frequently mutated in TNBC) or activation of signaling pathways like PI3K/AKT/mTOR, can confer intrinsic resistance to chemotherapy agents from the outset.</li>\n<li><strong>Metastatic Potential</strong>: TNBC has a high propensity for early distant metastases, particularly to visceral organs like the lungs, liver, brain, and bone marrow. Once metastasized, treating the disease becomes much more challenging, and the potential for acquired resistance during subsequent lines of therapy is significant.</li>\n</ol>\n<p>Therefore, while any type of breast cancer can become resistant to treatment, TNBC stands out due to its biological features, making it particularly prone to both inherent and acquired resistance, especially when it progresses to a metastatic</p>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Is there a subset of breast cancer patients that is more likely to develop resistance (ie triple negative metastatic cases)?</h1>\n<p>Yes. Certain biological subsets of breast cancer\u2014especially triple\u2011negative and some HER2\u2011positive tumors\u2014are more likely to develop rapid or multi\u2011drug resistance than typical hormone\u2011receptor\u2011positive disease. The tendency to develop resistance reflects both intrinsic tumor biology (subtype, grade, genomics) and treatment exposures rather than subtype alone.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12048392/\">^3</a><a href=\"https://pubmed.ncbi.nlm.nih.gov/33069769/\">^7</a></p>\n<h2>Subsets prone to resistance</h2>\n<ul>\n<li><strong>Triple\u2011negative breast cancer (TNBC)</strong><ul>\n<li>TNBC shows relatively high initial chemotherapy response and pathologic complete response (pCR) rates, but patients who do not achieve pCR have a much higher risk of early recurrence and death than non\u2011TNBC\u2014this \u201ctriple\u2011negative paradox\u201d reflects very rapid emergence of resistance.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6770896/\">^10</a></li>\n<li>Mechanistically, TNBC is enriched for EMT, cancer stem cells, strong NF\u2011\u03baB and PI3K/AKT signaling, and robust DNA\u2011damage tolerance, all of which support rapid adaptation and resistance to chemotherapy and, in metastatic disease, to immunotherapy as well.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12048392/\">^4</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6770896/\">^3</a></li>\n</ul>\n</li>\n<li><strong>HER2\u2011positive disease (especially heavily pretreated)</strong><ul>\n<li>HER2\u2011positive tumors initially respond well to HER2\u2011targeted therapy, but with prolonged exposure many develop resistance via HER2 pathway rewiring, activation of parallel receptors, and PI3K\u2011pathway alterations.<a href=\"https://www.sciencedirect.com/science/article/abs/pii/S1368764625000913\">^7</a></li>\n<li>In the metastatic setting, sequential HER2\u2011targeted line use (trastuzumab, pertuzumab, T\u2011DM1, TKIs, ADCs) creates strong selection pressure, so late\u2011line HER2\u2011positive disease is often highly resistant even if the subtype is targetable.<a href=\"https://www.sciencedirect.com/science/article/abs/pii/S1368764625000913\">^7</a></li>\n</ul>\n</li>\n<li><strong>High\u2011grade / highly proliferative tumors</strong><ul>\n<li>High\u2011grade and basal\u2011like tumors (overlapping strongly with TNBC) carry frequent TP53 mutations, higher genomic instability, and aggressive transcriptional programs (EMT, stemness, hypoxia), which correlate with poor long\u2011term response and early development of resistance.<a href=\"https://www.sciencedirect.com/science/article/abs/pii/S1368764625000913\">^5</a></li>\n</ul>\n</li>\n</ul>\n<h2>Subsets relatively less prone to rapid resistance</h2>\n<ul>\n<li><strong>Hormone\u2011receptor\u2011positive / HER2\u2011negative (classic luminal)</strong><ul>\n<li>These tumors often have more indolent biology and can stay controlled on endocrine\u2011based regimens for years before resistant clones dominate, especially when treated with CDK4/6 inhibitors.<a href=\"https://www.sciencedirect.com/science/article/abs/pii/S1368764625000913\">^7</a></li>\n<li>Resistance still almost always emerges over time, but the tempo is generally slower than in TNBC, and some patients cycle through multiple endocrine\u2011based lines before needing intensive chemotherapy.<a href=\"https://www.sciencedirect.com/science/article/abs/pii/S1368764625000913\">^7</a></li>\n</ul>\n</li>\n</ul>\n<h2>Why TNBC metastatic cases stand out</h2>\n<ul>\n<li>In metastatic TNBC, chemotherapy is usually the backbone; there are few durable, \u201cmaintenance\u2011like\u201d targeted options, so resistance to cytotoxic drugs translates quickly into clinical progression.<a href=\"https://pubmed.ncbi.nlm.nih.gov/33069769/\">^3</a></li>\n<li>TNBC\u2019s inherent features\u2014lack of ER/PR/HER2, high heterogeneity, strong EMT/CSC programs, frequent PI3K/AKT and DNA\u2011repair alterations, and immune\u2011escape mechanisms\u2014create a microenvironment where new resistant clones arise and dominate quickly under treatment pressure.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12048392/\">^4</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6770896/\">^3</a></li>\n</ul>\n<h2>Clinical implications</h2>\n<ul>\n<li>Patients with TNBC, basal\u2011like, high\u2011grade, or heavily pretreated HER2\u2011positive metastatic disease are, in practice, at highest short\u2011term risk of developing treatment resistance and rapid progression.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6770896/\">^5</a><a href=\"https://www.sciencedirect.com/science/article/abs/pii/S1368764625000913\">^7</a></li>\n<li>In contrast, many ER\u2011positive/HER2\u2011negative patients experience slower development of resistance but can still become highly refractory after multiple endocrine and targeted lines, emphasizing that virtually any subtype can become resistant with time and therapy exposure.<a href=\"https://www.sciencedirect.com/science/article/abs/pii/S1368764625000913\">^7</a>\n<span style=\"display:none\"><a href=\"https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0297260\">^1</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10327275/\">^6</a><a href=\"https://www.massgeneral.org/news/press-release/researchers-identify-mechanisms-of-resistance-to-drug-for-triple-negative-breast-cancer\">^9</a></span></li>\n</ul>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p><strong>Yes, triple-negative breast cancer (TNBC) is significantly more likely to develop resistance to therapy compared to other breast cancer subtypes</strong> , characterized by high recurrence rates, rapid metastatic progression, and poor overall survival. TNBC shows a 77% 4-year survival rate compared to 82.7-92.5% for other breast cancer subtypes, and only around 15% of patients with metastatic TNBC survive 5 years after diagnosis.[1][2] <strong>Approximately 50% of patients with metastatic TNBC do not receive second-line treatment</strong> due to death in approximately 30% of cases or lack of viable options.[2]</p>\n<p>This aggressive disease trajectory reflects both intrinsic and rapidly acquired chemoresistance, with patients developing resistance to taxane and anthracycline- containing chemotherapy\u2014the mainstay of TNBC treatment.[3][1]</p>\n<p>Real-world studies demonstrate that even among those who do receive subsequent therapy, treatment efficacy progressively declines with each line. The heightened resistance propensity in TNBC stems from multiple molecular mechanisms. <strong>Cancer stem cells (BCSCs) are enriched after neoadjuvant chemotherapy</strong> and exploit key signaling pathways including Wnt, Hedgehog, Notch, TGF-\u03b2, PI3K/AKT/mTOR, and Hippo-YAP/TAZ to survive treatment.[4][5]</p>\n<p>These stem cells demonstrate self-renewal capacity and utilize mechanisms such as drug efflux via ATP-binding cassette (ABC) transporters and enhanced DNA repair.[3][4] <strong>Epithelial-mesenchymal transition (EMT) contributes specifically to chemoresistance</strong> by altering cellular phenotypes and enhancing migratory capacity, while the CXCR4/CXCL12 chemokine axis promotes tumor cell proliferation, metastasis, immune evasion, and stromal remodeling.[6][7] <strong>The PI3K/Akt/mTOR pathway, dysregulated in nearly 60% of TNBC cases</strong> , plays a central role in chemoresistance development by enhancing protein synthesis, inhibiting apoptosis, dysregulating autophagy, and promoting DNA repair.[8]</p>\n<p>Additional resistance mechanisms include activation of compensatory pathways such as MAPK, metabolic reprogramming, and complex interactions within the tumor microenvironment.[9][1]</p>\n<p>While targeted therapies have improved outcomes for specific TNBC subgroups\u2014<strong>PARP inhibitors (olaparib, talazoparib) for germline BRCA1/2 mutations (15-20% of TNBC), pembrolizumab plus chemotherapy for PD-L1- positive disease (CPS \u226510), and sacituzumab govitecan for previously treated patients</strong>[3][10][11][12]\u2014the majority of TNBC patients remain at high risk for therapeutic resistance and relapse. PD-L1-negative tumors, which account for approximately 60% of metastatic TNBC, have limited treatment options beyond chemotherapy, and resistance to immunotherapy can develop even in initially responsive patients.[2]</p>\n<p>The extensive intra-tumoral heterogeneity characteristic of TNBC further complicates treatment, as patients exhibit distinct molecular rewiring that converges into limited dysregulated functional modules.[9]</p>\n<p>This heterogeneity, combined with the lack of targetable receptors that define TNBC, makes single-agent targeted therapy unlikely to be effective and necessitates combination strategies targeting multiple resistance pathways simultaneously.[3][6][13]</p>\n<p>Would you like me to summarize the latest clinical trial evidence on combination therapies\u2014particularly those targeting multiple resistance pathways in metastatic triple-negative breast cancer\u2014to help identify promising strategies for overcoming therapeutic resistance?</p>\n<h3>References</h3>\n<ol>\n<li>Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs. Wu Q, Siddharth S, Sharma D. Cancers. 2021;13(15):3697. doi:10.3390/cancers13153697.</li>\n<li>Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. Cort\u00e9s J, Punie K, Barrios C, et al. The New England Journal of Medicine. 2025;. doi:10.1056/NEJMoa2511734.</li>\n<li>Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. Ferrari P , Scatena C, Ghilli M, et al. International Journal of Molecular Sciences. 2022;23(3):1665. doi:10.3390/ijms23031665.</li>\n<li>An Update on Cancer Stem Cell Survival Pathways Involved in Chemoresistance in Triple-Negative Breast Cancer. Jan A, Sofi S, Jan N, Mir MA. Future Oncology (London, England). 2025;21(6):715-735. doi:10.1080/14796694.2025.2461443.</li>\n<li>An Insight Into the Cancer Stem Cell Survival Pathways Involved in Chemoresistance in Triple-Negative Breast Cancer. Qayoom H, Wani NA, Alshehri B, Mir MA. Future Oncology (London, England). 2021;17(31):4185-4206. doi:10.2217/fon-2021-0172.</li>\n<li>Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial-Mesenchymal Transition. B\u0142aszczak E, Miziak P , Odrzywolski A, et al. Cancers. 2025;17(2):228. doi:10.3390/cancers17020228.</li>\n<li>Targeting the CXCR4/CXCL12 Axis to Overcome Drug Resistance in Triple-Negative Breast Cancer. Singh DD, Yadav DK, Shin D. Cells. 2025;14(18):1482. doi:10.3390/cells14181482.</li>\n<li>The PI3K/Akt/mTOR Signaling Pathway in Triple-Negative Breast Cancer: A Resistance Pathway and a Prime Target for Targeted Therapies. Hassan A, Aubel C. Cancers. 2025;17(13):2232. doi:10.3390/cancers17132232.</li>\n<li>Triple Negative Breast Cancer (TNBC): Non-Genetic Tumor Heterogeneity and Immune Microenvironment: Emerging Treatment Options. So JY , Ohm J, Lipkowitz S, Yang L. Pharmacology &amp; Therapeutics. 2022;237:108253. doi:10.1016/j.pharmthera.2022.108253.</li>\n<li>Breast Cancer. National Comprehensive Cancer Network. Updated 2025-10-16.</li>\n<li>Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. Moy B, Rumble RB, Come SE, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2021;39(35):3938-3958. doi:10.1200/JCO.21.01374.</li>\n<li>FDA Orange Book. FDA Orange Book.</li>\n<li>Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?. Newton EE, Mueller LE, Treadwell SM, Morris CA, Machado HL. Cancers. 2022;14(3):482. doi:10.3390/cancers14030482. 7.</li>\n</ol>"}]}, "7": {"question": "Multiple mutations are already known to affect sensitivity to various targeted agents (ie BRCA 1/2, MSI-H, RET, PIK3CA, etc). How do expression levels of these genes/mutations change when a tumor develops resistance?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>The development of drug resistance is an ongoing process during cancer treatment. As the tumor cells proliferate and evolve in order to evade the effects of chemotherapy, they acquire increasing numbers of mutations that allow them to survive despite exposure to cytotoxic drugs. Some of these mutations may involve genes whose protein products are directly or indirectly involved with cellular defense mechanisms against chemotherapeutic agents. For example, some breast cancers exhibit increased expression of genes such as ERBB2 and GRB7, which encode proteins involved with signal transduction pathways downstream from EGFR family receptors; this finding has been correlated with relative resistance to antiEGFR therapies like trastuzumab. Similarly, overexpression of the RAS gene product HRAS has been associated with decreased response rates to cetuximab in colorectal cancer patients. Other examples include amplification of the BRAF gene, leading to constitutive activation of the mitogen-activated protein kinase cascade, which confers resistance to MEK inhibitors, and upregulation of the MYC gene, resulting in enhanced apoptosis and reduced responses to antiangiogenic agents.</p>"}, {"model": "GPT-4o", "text": "<p>When a tumor develops resistance to targeted therapies, the expression levels and mutation status of genes like BRCA1/2, MSI-H, RET, and PIK3CA can change in various ways, contributing to the resistance mechanism. Here are some general patterns observed:</p>\n<ol>\n<li><strong>BRCA1/2</strong>: Tumors with BRCA1/2 mutations are often sensitive to PARP inhibitors. However, resistance can develop through several mechanisms, such as:</li>\n<li>Restoration of homologous recombination repair through secondary mutations that restore the open reading frame of BRCA1/2.</li>\n<li>Upregulation of drug efflux pumps, reducing drug accumulation.</li>\n<li>\n<p>Increased expression of other DNA repair proteins that compensate for BRCA1/2 deficiency.</p>\n</li>\n<li>\n<p><strong>MSI-H (Microsatellite Instability-High)</strong>: Tumors with MSI-H are often sensitive to immune checkpoint inhibitors. Resistance can occur through:</p>\n</li>\n<li>Loss of neoantigen expression, reducing immune recognition.</li>\n<li>Upregulation of alternative immune checkpoints or immunosuppressive pathways.</li>\n<li>\n<p>Changes in the tumor microenvironment that inhibit immune cell infiltration or function.</p>\n</li>\n<li>\n<p><strong>RET</strong>: RET mutations or fusions can be targeted by specific RET inhibitors. Resistance mechanisms may include:</p>\n</li>\n<li>Secondary mutations in the RET gene that prevent drug binding.</li>\n<li>Activation of bypass signaling pathways, such as MET or EGFR, that can sustain tumor growth despite RET inhibition.</li>\n<li>\n<p>Histological transformation to a different tumor type that is less dependent on RET signaling.</p>\n</li>\n<li>\n<p><strong>PIK3CA</strong>: Mutations in PIK3CA can activate the PI3K/AKT/mTOR pathway, and inhibitors targeting this pathway can initially be effective. Resistance mechanisms include:</p>\n</li>\n<li>Secondary mutations in PIK3CA or other components of the pathway that reduce drug binding or efficacy.</li>\n<li>Activation of compensatory pathways, such as the MAPK pathway, that can drive tumor growth independently of PI3K signaling.</li>\n<li>Alterations in feedback loops that enhance survival signaling.</li>\n</ol>\n<p>Overall, the development of resistance is often associated with genetic and epigenetic changes that restore or bypass the inhibited pathway, enhance drug efflux, or alter the tumor microenvironment. Understanding these mechanisms is crucial for developing strategies to overcome resistance and improve treatment outcomes.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>When a tumor develops resistance to a targeted therapy, the expression levels of the target gene\u2014or the nature of the mutation itself\u2014rarely stay static. The tumor evolves under the \"selective pressure\" of the drug.</p>\n<p>While the specific mechanisms vary by gene and drug class, the changes generally fall into three categories: <strong>Restoration of Function</strong> (fixing the broken gene), <strong>Target Modification</strong> (changing the lock so the key doesn't fit), or <strong>Bypass Signaling</strong> (using a different road).</p>\n<p>Here is how expression levels and mutational status change for the specific markers you mentioned upon the development of resistance.</p>\n<hr />\n<h3>1. BRCA1/2 (Context: PARP Inhibitors)</h3>\n<p><em>Therapy:</em> PARP inhibitors (e.g., olaparib) rely on \"synthetic lethality.\" Because BRCA-mutant cells cannot repair double-strand DNA breaks, blocking PARP (which repairs single-strand breaks) kills the cell.\n<em>Resistance Mechanism:</em> <strong>Reversion Mutations (Restoration of Function)</strong></p>\n<ul>\n<li><strong>How it changes:</strong> The most common mechanism of resistance is not a change in the <em>amount</em> of BRCA protein, but a change in its <em>sequence</em>. The tumor acquires a secondary mutation that \"corrects\" the original frameshift mutation.</li>\n<li><strong>The Result:</strong> The tumor starts expressing <strong>functional BRCA protein</strong> again.<ul>\n<li><em>Expression Level:</em> The level of <strong>functional</strong> protein increases (restoring Homologous Recombination repair).</li>\n<li><em>Alternative:</em> Sometimes the tumor does not change BRCA, but instead decreases the expression of <strong>53BP1</strong>. 53BP1 normally blocks DNA resection; when its expression drops, the cell can bypass the need for BRCA1, leading to resistance.</li>\n</ul>\n</li>\n</ul>\n<h3>2. MSI-H / dMMR (Context: Immunotherapy/Checkpoint Inhibitors)</h3>\n<p><em>Therapy:</em> Microsatellite Instability-High (MSI-H) tumors have broken Mismatch Repair (MMR) systems. This creates many mutations (neoantigens), making them highly visible to the immune system and sensitive to PD-1/PD-L1 inhibitors.\n<em>Resistance Mechanism:</em> <strong>Antigen Presentation Loss (Hiding from the Immune System)</strong></p>\n<ul>\n<li><strong>How it changes:</strong> Resistance here is rarely about \"fixing\" the MMR genes. Instead, the tumor stops expressing the machinery required to show those antigens to T-cells.</li>\n<li><strong>The Result:</strong><ul>\n<li><strong>B2M (Beta-2-microglobulin) Loss:</strong> The tumor acquires mutations that stop the expression of B2M. Without B2M, the cell cannot express MHC Class I on its surface. The expression level of surface MHC <strong>decreases to near zero</strong>.</li>\n<li><strong>JAK1/JAK2 Mutation:</strong> The tumor mutates these genes to shut down the Interferon-Gamma signaling pathway. This prevents the immune system from upregulating PD-L1, rendering the checkpoint inhibitor useless.</li>\n</ul>\n</li>\n</ul>\n<h3>3. RET Fusions/Mutations (Context: RET Inhibitors)</h3>\n<p><em>Therapy:</em> Drugs like selpercatinib or pralsetinib target RET fusions (lung cancer) or mutations (thyroid cancer).\n<em>Resistance Mechanism:</em> <strong>Target Modification or Bypass</strong></p>\n<ul>\n<li><strong>How it changes:</strong><ul>\n<li><strong>Solvent Front Mutations:</strong> The tumor develops a secondary mutation <em>on top of</em> the original RET mutation (e.g., RET G810). The expression level of RET remains high, but the protein's physical shape changes, preventing the drug from binding.</li>\n<li><strong>Bypass Amplification:</strong> The tumor may keep RET expression the same but drastically <strong>increase the expression (amplification)</strong> of other drivers like <strong>MET</strong> or <strong>KRAS</strong>. This allows the tumor to grow even if RET is successfully blocked.</li>\n</ul>\n</li>\n</ul>\n<h3>4. PIK3CA (Context: PI3K Inhibitors)</h3>\n<p><em>Therapy:</em> Drugs like alpelisib target the alpha isoform of PI3K in breast cancer.\n<em>Resistance Mechanism:</em> <strong>Pathway Reactivation</strong></p>\n<ul>\n<li><strong>How it changes:</strong><ul>\n<li><strong>PTEN Loss:</strong> PTEN is the natural \"brake\" for the PI3K pathway. Resistance often involves the loss of PTEN expression. Even if you inhibit PI3K, the lack of the brake keeps the pathway running.</li>\n<li><strong>PIK3CA Amplification:</strong> In some cases, the tumor simply amplifies the gene, producing <strong>massive amounts of the mutated PIK3CA protein</strong>. This creates a stoichiometric problem: there is simply too much target protein for the drug to inhibit effectively.</li>\n<li><strong>Insulin Feedback:</strong> Systemic insulin levels rise in response to the drug (a side effect), which activates insulin receptors on the tumor, increasing upstream signaling that overwhelms the inhibitor.</li>\n</ul>\n</li>\n</ul>\n<hr />\n<h3>Summary Table of Changes</h3>\n<p>| Gene/Target | Primary Therapy | Mechanism of Resistance | Change in Expression/Status |\n| :--- | :--- | :--- | :--- |\n| <strong>BRCA1/2</strong> | PARP Inhibitors | Reversion | <strong>Functional protein expression returns</strong> (reading frame restored). |\n| <strong>MSI-H</strong> | Immunotherapy | Immune Evasion | <strong>Decrease</strong> in MHC Class I expression (via B2M loss). |\n| <strong>RET</strong> | RET Inhibitors | Secondary Mutation | Expression stays high, but <strong>protein structure changes</strong> (drug cannot bind). |\n| <strong>PIK3CA</strong> | PI3K Inhibitors | Amplification or Bypass | <strong>Increase</strong> in target protein (amplification) or <strong>Decrease</strong> in suppressor (PTEN). |</p>\n<h3>The \"Phenotypic Switch\"</h3>\n<p>Finally, it is important to note that sometimes the tumor changes its \"identity\" entirely to resist drugs.\n*   <strong>Example:</strong> In EGFR-mutant lung cancer treated with targeted therapy (Osimertinib), the tumor may undergo <strong>Small Cell Transformation</strong>. It stops expressing EGFR markers and starts expressing neuroendocrine markers (like Synaptophysin). The original mutation is still there, but the cell no longer relies on it for survival.</p>"}, {"model": "MedGemma 27B", "text": "<p>This is a complex question with no single definitive answer, as the changes in gene expression and mutation status upon development of resistance can vary significantly depending on several factors. Here's a breakdown of the key concepts and common scenarios observed:</p>\n<p><strong>Factors Influencing Changes:</strong></p>\n<ul>\n<li><strong>Targeted Agent Mechanism of Action:</strong> The specific way the drug works dictates which pathways become relevant for resistance. For example, drugs targeting kinases might lead to upstream pathway activation or downstream effector alterations. Drugs inhibiting DNA repair might select for alternative repair mechanisms.</li>\n<li><strong>Specific Gene/Mutation Involved:</strong> Different genes have different roles, and their alteration during resistance will reflect that role. A driver mutation like <em>PIK3CA</em> might be lost, while a passenger mutation could potentially gain importance.</li>\n<li><strong>Tumor Type &amp; Context:</strong> Resistance mechanisms differ across cancer types (e.g., breast vs. lung) and even within subtypes.</li>\n<li><strong>Initial Sensitivity Profile:</strong> Was the initial response strong or weak? Did the tumor initially rely heavily on the target pathway?</li>\n<li><strong>Time Course:</strong> Changes may occur rapidly or gradually over time.</li>\n</ul>\n<p><strong>Common Scenarios Observed During Resistance Development:</strong></p>\n<ol>\n<li>\n<p><strong>Loss of Target Mutation / Allelic Loss:</strong></p>\n<ul>\n<li><strong>Mechanism:</strong> If the drug targets a specific activating mutation (like <em>EGFR</em>, <em>BRAF</em>, <em>PIK3CA</em>), the tumor cells might lose one copy of the mutated allele through loss of heterozygosity (LOH) or other genetic events. This reduces the amount of the target protein available for the drug to bind to.</li>\n<li><strong>Expression Change:</strong> Decreased mRNA and protein expression of the mutated gene product.</li>\n<li><strong>Example:</strong> Acquired resistance to EGFR inhibitors in NSCLC often involves secondary mutations in <em>EGFR</em> itself (<em>T790M</em>) or amplification of MET, but LOH of the original sensitizing mutation can also contribute. Similarly, loss of <em>PIK3CA</em> mutations has been seen in some cases of acquired resistance to PI3K inhibitors.</li>\n</ul>\n</li>\n<li>\n<p><strong>Acquisition of Secondary Mutations in the Target Pathway:</strong></p>\n<ul>\n<li><strong>Mechanism:</strong> Tumors develop new mutations elsewhere in the same signaling pathway, bypassing the block imposed by the targeted agent. These mutations activate the pathway independently of the primary target.</li>\n<li><strong>Expression Change:</strong> Can involve increased or decreased expression of involved proteins depending on the nature of the mutation (activating vs. inactivating) and its effect</li>\n</ul>\n</li>\n</ol>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Multiple mutations are already known to affect sensitivity to various targeted agents (ie BRCA 1/2, MSI-H, RET, PIK3CA, etc). How do expression levels of these genes/mutations change when a tumor develops resistance?</h1>\n<p>Changes in expression or function at resistance are highly context\u2011 and drug\u2011specific, but several recurring patterns are seen across targeted biomarkers. Most resistant tumors either restore the inhibited pathway (e.g., HR repair in BRCA\u2011mutant tumors) or bypass it through parallel signaling routes, rather than simply continuing the same baseline profile.</p>\n<h2>BRCA1/2 and PARP\u2011 or platinum\u2011resistant tumors</h2>\n<p>In BRCA1/2\u2011deficient tumors initially sensitive to PARP inhibitors or platinum, resistance often reflects <strong>re\u2011establishment of homologous recombination (HR)</strong> rather than further loss.</p>\n<ul>\n<li>Secondary \u201creversion\u201d mutations in <em>BRCA1</em> or <em>BRCA2</em> can restore an open reading frame and functional protein, effectively increasing BRCA function from absent to partially restored and leading to PARP/platinum resistance.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3095365/\">^9</a></li>\n<li>Other mechanisms upregulate HR without fixing the original mutation, for example by altered promoter control leading to re\u2011expression of <em>BRCA1</em>, or by changes in other HR factors (e.g., RAD51) that compensate functionally.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3095365/\">^5</a></li>\n</ul>\n<p>In contrast, in BRCA\u2011wild\u2011type sporadic breast cancers treated with DNA\u2011damaging chemotherapy, <strong>lower BRCA1 expression at baseline</strong> is associated with greater sensitivity to anthracyclines, and higher expression correlates with relative resistance. This suggests that selection under therapy can enrich for clones with higher effective BRCA1/2 activity.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5765306/\">^3</a></p>\n<h2>PIK3CA and PI3K\u2011pathway\u2013targeted therapy</h2>\n<p>For PI3K inhibitors (e.g., against PIK3CA\u2011mutant ER\u2011positive breast cancer), resistance frequently evolves by <strong>bypassing PI3K dependence</strong>, not necessarily by losing the original mutation.</p>\n<ul>\n<li>The <em>PIK3CA</em> mutation itself typically persists; expression levels of the mutant allele may not change dramatically, but downstream pathway output (AKT/mTOR) gets restored via amplification or activation of parallel RTKs (HER2, IGF1R), PTEN loss, or RAS/MAPK activation.</li>\n<li>In some models, feedback relief leads to increased upstream receptor expression and signaling, so total pathway activity can be higher at resistance despite continued PI3K inhibition.</li>\n</ul>\n<p>Functionally, the driver mutation remains present, but the tumor\u2019s transcriptional profile shifts toward a broader survival/DDR/EMT signature that makes PI3K signaling less uniquely essential.</p>\n<h2>MSI\u2011H/dMMR and immune checkpoint resistance</h2>\n<p>For tumors with high microsatellite instability (MSI\u2011H) or mismatch\u2011repair deficiency (dMMR) treated with PD\u20111/PD\u2011L1 blockade, resistance often involves <strong>altering antigen presentation and interferon signaling</strong>, rather than simply \u201closing\u201d MSI\u2011H.</p>\n<ul>\n<li>The core MSI/dMMR genotype usually persists; however, resistant tumors can downregulate components of antigen presentation (e.g., B2M, HLA class I) or acquire JAK/STAT pathway alterations that reduce response to interferon\u2011\u03b3.</li>\n<li>The net effect is a transcriptional shift from an inflamed, T\u2011cell\u2013inflamed expression pattern to a more immune\u2011excluded or immune\u2011cold phenotype, even while MSI\u2011associated mutation burden remains high.</li>\n</ul>\n<p>Thus, MSI\u2011H status is relatively stable, but the immune\u2011response gene signature changes dramatically at resistance.</p>\n<h2>RET and other kinase targets</h2>\n<p>For kinase\u2011targeted therapies (RET, HER2, EGFR, ALK), resistance patterns are more analogous to classic TKI resistance in lung cancer:</p>\n<ul>\n<li>On\u2011target: Secondary mutations in the kinase domain can reduce drug binding while preserving kinase activity; these often change the qualitative behavior of the kinase rather than its overall expression level.</li>\n<li>Off\u2011target: Amplification or upregulation of bypass kinases and downstream nodes (e.g., MET, FGFR, RAS/RAF/MEK) can restore proliferation signals; expression of these bypass players is typically increased at resistance.</li>\n</ul>\n<p>The original driver mutation generally remains detectable, but the \u201cdependency\u201d on that target is diluted by new amplified or overexpressed signaling alternatives.</p>\n<h2>General patterns across these genes</h2>\n<p>Across BRCA1/2, PIK3CA, MSI\u2011H, RET, and similar markers:</p>\n<ul>\n<li>The <strong>mutational status</strong> of the predictive biomarker is often stable; resistance more commonly reflects secondary mutations, epigenetic changes, or network rewiring rather than complete loss of the original alteration.</li>\n<li><strong>Expression levels and transcriptional programs of surrounding pathways</strong> (HR repair partners, RTKs, immune signaling genes, EMT/stemness factors) change more dramatically than the biomarker gene itself when resistance emerges.</li>\n<li>In BRCA\u2011deficient settings, resistance is characterized by <em>increased functional HR activity</em> (via reversion or compensation), whereas in kinase\u2011 and PI3K\u2011targeted settings, resistance is characterized by <em>restored downstream signaling</em> and upregulation of bypass tracks; in MSI\u2011H, resistance is characterized by <em>loss of effective immune recognition</em> rather than loss of MSI.\n<span style=\"display:none\"><a href=\"https://www.mskcc.org/cancer-care/risk-assessment-screening/genetic-counseling-and-testing/hereditary-cancer-genes-and-hereditary-cancer-syndromes/brca1-and-brca2-genes\">^1</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5505673/\">^2</a><a href=\"https://www.ncbi.nlm.nih.gov/books/NBK470239/\">^6</a><a href=\"https://www.ncbi.nlm.nih.gov/books/NBK1247/\">^8</a></span></li>\n</ul>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p><strong>BRCA1/BRCA2 reversion mutations are the most well-documented mechanism of acquired resistance to targeted therapies in breast cancer</strong> , occurring in approximately 40-60% of patients who develop resistance to PARP inhibitors or platinum chemotherapy. These reversions restore homologous recombination function and represent a dynamic evolutionary process during treatment.</p>\n<h2>BRCA1/BRCA2 Reversion Mutations</h2>\n<p><strong>BRCA1/2 reversion mutations emerge during treatment</strong> and are detected in 60% of patients with metastatic BRCA1-, BRCA2-, or PALB2-mutant breast cancer who develop progressive disease on HRD-targeted therapy.[1]</p>\n<p>In clinical trials, BRCA reversion mutations were detected at progression in <strong>34/79 (43%) breast cancer patients</strong> receiving olaparib, compared to only 3/34 (9%) receiving chemotherapy.[2]</p>\n<p>Importantly, <strong>reversions can be detected in circulating tumor DNA before clinical progression</strong> in some cases, with 10 patients showing detectable reversions prior to radiographic progression.[1]</p>\n<p>The mechanisms generating these reversions are diverse. <strong>A large proportion (68%) of BRCA reversion mutations are mediated by microhomology-mediated end joining (MMEJ)</strong> , suggesting that DNA polymerase \u03b8 (POL\u03b8) plays a key role.[2][3]</p>\n<p>Novel reversion mechanisms include: (i) intragenic BRCA1/2 deletions with intronic breakpoints, and (ii) intragenic BRCA1/2 secondary mutations forming novel splice acceptor sites.[1]</p>\n<p>Additionally, <strong>de novo gene fusions can place BRCA1 under transcriptional control of a heterologous promoter</strong> , resulting in BRCA1 re- expression despite retained promoter hypermethylation.[4] <strong>When reversions are detected before commencing subsequent treatment, they associate with significantly shorter time to progression</strong> .[1]</p>\n<p>Tumors with reversions retain HRD mutational signatures but have functional homologous recombination based on RAD51 status.[1][5]</p>\n<p>All patients whose tumors demonstrated RAD51 foci post-resistance were intrinsically resistant to subsequent lines of DNA-damaging therapy.[5]</p>\n<h2>Non-Reversion Resistance Mechanisms in BRCA-Mutant Tumors</h2>\n<p><strong>Loss-of-function mutations in TP53BP1, RIF1, or PAXIP1</strong> represent non-reversion mechanisms that restore homologous recombination through increased DNA end resection.[1][5]</p>\n<p>These alterations were evident in patients with acquired resistance and <strong>occasionally coexisted with reversions</strong> , challenging the notion that singular resistance mechanisms emerge in each patient.[1]</p>\n<p>One patient acquired amplification of MRE11A, another mechanism promoting DNA end resection.[5] <strong>Hypomorphic BRCA1 mutations</strong> can also mediate resistance. The BRCA1^185delAG mutation can express a RING-less BRCA1 protein that confers resistance to HRD-targeted therapies.[6]</p>\n<p>Partial reduction in BRCA1 gene dose can modulate DNA replication stress levels, with some mutations resulting in both increased sensitivity and resistance depending on the specific functional consequences.[7]</p>\n<h2>PIK3CA Mutations</h2>\n<p><strong>PIK3CA mutations are among the most common alterations in breast cancer</strong> and show dynamic changes during treatment. In metastatic breast cancer patients with multiline resistance, <strong>PIK3CA mutations are frequent in HR+ patients</strong> and appear in resistance profiles alongside TP53, MLL3, ERBB2, NOTCH2, and ESR1 mutations in patients progressing within 3-6 months of treatment.[8]</p>\n<p>PIK3CA mutations are classified as <strong>tier IA evidence for actionability</strong> based on large randomized trials showing benefit of PI3K inhibitors.[9]</p>\n<p>However, the relationship between PIK3CA mutations and chemotherapy resistance is complex. PIK3CA mutations were found in 27.9% of breast cancer patients and correlated with older age, but their direct role in chemoresistance requires further investigation.[10]</p>\n<p>The <strong>PI3K/Akt/mTOR pathway is dysregulated in nearly 60% of TNBC cases</strong> and plays a central role in chemoresistance by enhancing protein synthesis, inhibiting apoptosis, and promoting DNA repair.</p>\n<h2>MSI-H/dMMR Status</h2>\n<p><strong>Microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) is rare in breast cancer</strong> , occurring in only 1-2% of cases.[11]</p>\n<p>These alterations are FDA-approved indications for pembrolizumab and dostarlimab.[12]</p>\n<p>There is limited data on how MSI-H/dMMR status changes with treatment resistance in breast cancer specifically, though the rarity of this phenotype suggests it is not a major driver of acquired resistance in most patients.</p>\n<h2>RET Fusions</h2>\n<p><strong>RET fusions are exceedingly rare in breast cancer</strong> , and there is minimal published data on their prevalence or changes during treatment resistance. Selpercatinib is FDA-approved for RET fusion-positive solid tumors but is classified as category 2A evidence in breast cancer.[12]</p>\n<p>The scarcity of RET fusions in breast cancer limits understanding of resistance mechanisms specific to this alteration.</p>\n<h2>Changes in Expression Levels Beyond mutations,</h2>\n<p><strong>expression levels of BRCA1/BRCA2 change significantly during resistance development</strong> . BRCA1 protein is not detected in therapy-sensitive tumors but is found in <strong>31 out of 42 (74%) resistant cases</strong> .[4]</p>\n<p>BRCA1 and BRCA2 expression decreases in post-chemotherapy residual tumors compared to pre- treatment samples (p=0.009 for BRCA2). <strong>The genomic landscape of metastatic breast cancer shows that tumor mutational burden doubles compared to primary tumors</strong> , and the contribution of specific mutational signatures shifts.[13]</p>\n<p>Signature 17 is significantly enriched in patients pretreated with fluorouracil, taxanes, platinum, and/or eribulin, while a de novo signature is associated with platinum-based chemotherapy pretreatment.[13]</p>\n<p>Would you like me to summarize the latest therapeutic strategies targeting these resistance mechanisms, particularly combination approaches using POL\u03b8 inhibitors to prevent BRCA reversions or WEE1 inhibitors that remain effective against revertant tumors? Would you like me to review the most recent clinical evidence on the utility and timing of circulating tumor DNA (ctDNA) monitoring for early detection of resistance mutations\u2014such as BRCA reversions\u2014in breast cancer patients undergoing targeted therapy? This could help guide intervention strategies before clinical progression.</p>\n<h3>References</h3>\n<ol>\n<li>Longitudinal Profiling Identifies Co-Occurring BRCA1/2 Reversions, TP53BP1, RIF1 and PAXIP1 Mutations in PARP Inhibitor-Resistant Advanced Breast Cancer. Harvey-Jones E, Raghunandan M, Robbez-Masson L, et al. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2024;35(4):364-380. doi:10.1016/j.annonc.2024.01.003.</li>\n<li>BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer. Lukashchuk N, Armenia J, Tobalina L, et al. Journal of Clinical Oncology. 2022;40(Suppl 16):5559. doi:10.1200/JCO.2022.40.16_suppl.5559.</li>\n<li>A Meta-Analysis of Reversion Mutations in BRCA Genes Identifies Signatures of DNA End-Joining Repair Mechanisms Driving Therapy Resistance. Tobalina L, Armenia J, Irving E, O'Connor MJ, Forment JV . Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2021;32(1):103-112. doi:10.1016/j.annonc.2020.10.470.</li>\n<li>Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. Ter Brugge P , Kristel P , van der Burg E, et al. Journal of the National Cancer Institute. 2016;108(11). doi:10.1093/jnci/djw148.</li>\n<li>Reversion and Non-Reversion Mechanisms of Resistance to PARP Inhibitor or Platinum Chemotherapy in BRCA1/2-mutant Metastatic Breast Cancer. Waks AG, Cohen O, Kochupurakkal B, et al. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2020;31(5):590-598. doi:10.1016/j.annonc.2020.02.008.</li>\n<li>BRCA1185delAG Tumors May Acquire Therapy Resistance Through Expression of RING-less BRCA1. Drost R, Dhillon KK, van der Gulden H, et al. The Journal of Clinical Investigation. 2016;126(8):2903-18. doi:10.1172/JCI70196.</li>\n<li>Partial Reduction in BRCA1 Gene Dose Modulates DNA Replication Stress Level and Thereby Contributes to Sensitivity or Resistance. Classen S, Rahlf E, Jungwirth J, et al. International Journal of Molecular Sciences. 2022;23(21):13363. doi:10.3390/ijms232113363.</li>\n<li>Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients With Multiline Resistance. Hu ZY , Xie N, Tian C, et al. EBioMedicine. 2018;32:111-118. doi:10.1016/j.ebiom.2018.05.015.</li>\n<li>Genomic Alterations in Breast Cancer: Level of Evidence for Actionability According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). Condorelli R, Mosele F , Verret B, et al. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2019;30(3):365-373. doi:10.1093/annonc/mdz036.</li>\n<li>PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance. Santarpia M, Altavilla G, Margeli M, et al. Cancer Investigation. 2008;26(10):1044-51. doi:10.1080/07357900802112701.</li>\n<li>Breast Cancer Treatment: A Review. Waks AG, Winer EP . JAMA. 2019;321(3):288-300. doi:10.1001/jama.2018.19323.</li>\n<li>Breast Cancer. National Comprehensive Cancer Network. Updated 2025-10-16.</li>\n<li>The Genomic Landscape of Metastatic Breast Cancer Highlights Changes in Mutation and Signature Frequencies. Angus L, Smid M, Wilting SM, et al. Nature Genetics. 2019;51(10):1450-1458. doi:10.1038/s41588- 019-0507-7. 8.</li>\n</ol>"}]}, "8": {"question": "Where do mutation patterns overlap and differ between the various histologies: IDC, ILC, inflammatory, etc?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>Mutations in common pathways may be shared across different breast cancer subtypes. However, there are differences as well. For example, triple-negative (TN) tumors have more copy number variations than other molecular subtypes of breast cancer.</p>"}, {"model": "GPT-4o", "text": "<p>In breast cancer, different histological subtypes exhibit distinct mutation patterns, although there are some overlaps. Here's a general overview of how mutation patterns can vary among different histologies:</p>\n<ol>\n<li><strong>Invasive Ductal Carcinoma (IDC):</strong></li>\n<li>IDC is the most common type of breast cancer and often shows mutations in genes such as TP53, PIK3CA, and GATA3.</li>\n<li>TP53 mutations are associated with more aggressive forms of IDC.</li>\n<li>\n<p>PIK3CA mutations are common in hormone receptor-positive subtypes of IDC.</p>\n</li>\n<li>\n<p><strong>Invasive Lobular Carcinoma (ILC):</strong></p>\n</li>\n<li>ILC is characterized by mutations in the CDH1 gene, which encodes the protein E-cadherin. Loss of E-cadherin function is a hallmark of ILC.</li>\n<li>PIK3CA mutations are also common in ILC, similar to IDC.</li>\n<li>\n<p>Mutations in FOXA1 and GATA3 can also be present, although less frequently than in IDC.</p>\n</li>\n<li>\n<p><strong>Inflammatory Breast Cancer (IBC):</strong></p>\n</li>\n<li>IBC is a rare and aggressive form of breast cancer. It often shows high rates of TP53 mutations.</li>\n<li>There is also a higher prevalence of mutations in genes involved in cell cycle regulation and DNA repair.</li>\n<li>\n<p>The molecular profile of IBC can overlap with that of triple-negative breast cancer (TNBC), which lacks estrogen, progesterone, and HER2 receptors.</p>\n</li>\n<li>\n<p><strong>Triple-Negative Breast Cancer (TNBC):</strong></p>\n</li>\n<li>TNBC is not a histological subtype but a molecular one, often associated with basal-like histology.</li>\n<li>It frequently exhibits TP53 mutations and may have BRCA1/2 mutations, especially in hereditary cases.</li>\n<li>\n<p>Other mutations can include those in genes like RB1 and PTEN.</p>\n</li>\n<li>\n<p><strong>HER2-Enriched Subtypes:</strong></p>\n</li>\n<li>These subtypes are characterized by amplification of the HER2 gene.</li>\n<li>They often have concurrent mutations in PIK3CA and TP53.</li>\n</ol>\n<p><strong>Overlap and Differences:</strong>\n- <strong>Overlap:</strong> PIK3CA mutations are common across several subtypes, particularly in hormone receptor-positive cancers. TP53 mutations are also prevalent in more aggressive forms like TNBC and IBC.\n- <strong>Differences:</strong> CDH1 mutations are specific to ILC due to the loss of E-cadherin. HER2 amplification is specific to HER2-enriched subtypes. The presence of BRCA1/2 mutations is more common in TNBC, especially in hereditary cases.</p>\n<p>These mutation patterns can influence treatment decisions and prognostic assessments, as certain mutations may confer sensitivity or resistance to specific therapies. It's important to note that the molecular landscape of breast cancer is complex, and ongoing research continues to refine our understanding of these patterns.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>This is a complex area of genomic oncology because breast cancer classification is moving from purely histological (what cells look like) to molecular (what genes are expressing). However, distinct histological subtypes do harbor specific genomic footprints.</p>\n<p>Here is a breakdown of where mutation patterns overlap and differ between <strong>Invasive Ductal Carcinoma (IDC)</strong>, <strong>Invasive Lobular Carcinoma (ILC)</strong>, <strong>Inflammatory Breast Cancer (IBC)</strong>, and select rare subtypes.</p>\n<hr />\n<h3>1. The Common Ground (Overlap)</h3>\n<p>Regardless of histology, breast cancers share a \"background\" of mutations driven largely by their molecular subtype (Luminal A/B, HER2-enriched, or Basal-like).</p>\n<ul>\n<li><strong>PIK3CA:</strong> This is the most common mutation in breast cancer overall (approx. 30-40%). It is heavily present in both IDC and ILC, particularly in Estrogen Receptor-positive (ER+) tumors.</li>\n<li><strong>TP53:</strong> The hallmark of genomic instability. It is the dominant mutation in Triple-Negative (TNBC) and HER2+ cancers across all histological types.</li>\n<li><strong>MAP3K1 and MAP2K4:</strong> Mutations in these stress-kinase pathways are common in ER+ tumors of both ductal and lobular origins, though frequencies differ.</li>\n</ul>\n<hr />\n<h3>2. Invasive Ductal Carcinoma (IDC - No Special Type)</h3>\n<p>IDC is the most common histology (approx. 75-80% of cases). Because it is a \"diagnosis of exclusion\" (it lacks the specific features of other types), it is genetically heterogeneous.</p>\n<ul>\n<li><strong>The Pattern:</strong> It generally mirrors the standard molecular subtype distribution.<ul>\n<li><strong>Luminal IDC:</strong> High <em>PIK3CA</em>, <em>GATA3</em>, and <em>MAP3K1</em>.</li>\n<li><strong>Basal-like IDC:</strong> Near-universal <em>TP53</em> mutations; high frequency of <em>BRCA1/2</em> germline or somatic alterations.</li>\n</ul>\n</li>\n<li><strong>Key Difference from ILC:</strong> IDC retains E-cadherin expression (<em>CDH1</em> is wild-type/intact). This allows the cells to form cohesive glandular structures and ducts.</li>\n<li><strong>GATA3:</strong> Mutations in <em>GATA3</em> (a transcription factor required for luminal cell differentiation) are highly specific to breast cancer and are seen frequently in IDC (approx. 10-15%).</li>\n</ul>\n<hr />\n<h3>3. Invasive Lobular Carcinoma (ILC)</h3>\n<p>ILC (approx. 10-15% of cases) has the most distinct mutation profile compared to IDC.</p>\n<ul>\n<li><strong>The Defining Difference (<em>CDH1</em>):</strong> The hallmark of ILC is the biallelic loss of <em>CDH1</em>, the gene encoding <strong>E-cadherin</strong>. This loss causes the cells to lose adhesion (discohesive), leading to the \"single-file\" growth pattern seen under a microscope. This mutation is rare in IDC.</li>\n<li><strong>Enriched Mutations (vs. IDC):</strong><ul>\n<li><strong>PIK3CA:</strong> Slightly more frequent in ILC than IDC.</li>\n<li><strong>PTEN:</strong> Loss of <em>PTEN</em> is more common in ILC, leading to higher activation of the Akt pathway.</li>\n<li><strong>FOXA1 &amp; TBX3:</strong> Mutations in these transcriptional regulators are significantly enriched in ILC compared to IDC.</li>\n<li><strong>ERBB2/ERBB3 (HER2/HER3):</strong> While HER2 <em>amplification</em> is less common in ILC, <strong>activating mutations</strong> in <em>ERBB2</em> and <em>ERBB3</em> are significantly more common in ILC than IDC. This has therapeutic implications for tyrosine kinase inhibitors.</li>\n</ul>\n</li>\n</ul>\n<hr />\n<h3>4. Inflammatory Breast Cancer (IBC)</h3>\n<p>IBC is a clinical diagnosis (redness, swelling, peau d'orange) rather than a distinct histology (most IBCs look like IDCs under the microscope). However, they have a distinct, aggressive molecular profile.</p>\n<ul>\n<li><strong>The Pattern:</strong> IBC is characterized by massive genomic instability rather than a single unique point mutation.</li>\n<li><strong>TP53:</strong> Extremely high frequency (significantly higher than stage-matched non-inflammatory IDC).</li>\n<li><strong>MYC:</strong> High rates of <em>MYC</em> amplification.</li>\n<li><strong>RhoC GTPase:</strong> While not a mutation, the overexpression of <em>RhoC</em> is a molecular signature of IBC, driving its high metastatic potential.</li>\n<li><strong>E-Cadherin Paradox:</strong> Unlike ILC, IBC usually retains <em>CDH1</em> (E-cadherin). In fact, E-cadherin is often overexpressed, which allows IBC cells to form tight \"tumor emboli\" that block lymph vessels (causing the swelling).</li>\n<li><strong>TME Interactions:</strong> IBC is defined heavily by mutations that affect the tumor microenvironment (TME), specifically signaling pathways involving <em>EGFR</em> and <em>NF-kB</em>.</li>\n</ul>\n<hr />\n<h3>5. Rare Histologies (The \"Etc\")</h3>\n<h4>Metaplastic Breast Cancer</h4>\n<ul>\n<li><strong>Differentiation:</strong> These are aggressive tumors where cells change from epithelial to mesenchymal types (spindle cells, squamous, etc.).</li>\n<li><strong>Wnt Pathway:</strong> High frequency of <strong>CTNNB1</strong> (Beta-catenin) mutations and Wnt pathway activation.</li>\n<li><strong>PIK3CA &amp; TP53:</strong> Very high frequency of both, often co-occurring.</li>\n<li><strong>RPL39:</strong> A specific mutation (A14V) in <em>RPL39</em> is rare generally but enriched in metaplastic breast cancer.</li>\n</ul>\n<h4>Mucinous Carcinoma</h4>\n<ul>\n<li><strong>Differentiation:</strong> Generally less aggressive, ER+ tumors.</li>\n<li><strong>GATA3:</strong> Very high frequency of <em>GATA3</em> mutations.</li>\n<li><strong>TP53:</strong> <em>TP53</em> mutations are very rare (explaining the indolent nature).</li>\n</ul>\n<h4>Medullary Carcinoma</h4>\n<ul>\n<li><strong>Differentiation:</strong> Often Triple Negative but with a better prognosis than standard TNBC; heavy immune infiltration.</li>\n<li><strong>TP53:</strong> Almost universal <em>TP53</em> mutation.</li>\n<li><strong>BRCA1:</strong> Strong association with <em>BRCA1</em> germline mutations or promoter methylation.</li>\n</ul>\n<hr />\n<h3>Summary Table: Key Genomic Drivers</h3>\n<p>| Histology | Primary \"Signature\" Mutation | Enriched Mutations | Key Absent/Intact Gene |\n| :--- | :--- | :--- | :--- |\n| <strong>IDC (NST)</strong> | Mirrors molecular subtype | <em>PIK3CA, TP53, GATA3</em> | <em>CDH1</em> is Intact |\n| <strong>ILC</strong> | <strong>CDH1 (Loss)</strong> | <em>FOXA1, TBX3, ERBB2/3</em> (mutations) | <em>CDH1</em> is Lost |\n| <strong>IBC</strong> | Genomic Instability / TME signaling | <em>TP53</em> (very high), <em>MYC</em> amp | <em>CDH1</em> Intact (Overexpressed) |\n| <strong>Metaplastic</strong> | EMT Pathway activation | <em>CTNNB1</em> (Wnt), <em>PIK3CA</em> | N/A |\n| <strong>Mucinous</strong> | Luminal drivers | <em>GATA3</em> (High) | <em>TP53</em> (Rare) |</p>"}, {"model": "MedGemma 27B", "text": "<p>Okay, let's break down the overlapping and differing mutation patterns across various breast cancer histologies. This is a complex area with ongoing research, but here\u2019s a summary of key findings based on current understanding (primarily from large-scale genomic studies like TCGA, METABRIC, and others).</p>\n<p><strong>Key Histologies to Consider:</strong></p>\n<ul>\n<li><strong>Invasive Ductal Carcinoma (IDC):</strong> The most common type (~80% of invasive cancers), characterized by ducts forming solid sheets or cords. Often further subdivided into subtypes like Luminal A/B, HER2-enriched, Basal-like, Triple Negative Breast Cancer (TNBC - often overlaps significantly with Basal-like).</li>\n<li><strong>Invasive Lobular Carcinoma (ILC):</strong> Characterized by small, uniform cells infiltrating tissues in single files (\"Indian file\" pattern) due to loss of E-cadherin function. Accounts for ~10-15%.</li>\n<li><strong>Inflammatory Breast Cancer (IBC):</strong> Rare (&lt;5%), aggressive form where cancer cells block lymph vessels causing skin changes (redness, swelling, warmth). Can be any underlying histology (often IDC) but has distinct clinical behavior.</li>\n<li><strong>Metastatic Breast Cancer (MBC):</strong> Not a primary histology <em>per se</em>, but represents advanced disease that can arise from any initial histology. Mutation profiles evolve during metastasis.</li>\n<li><strong>Triple-Negative Breast Cancer (TNBC):</strong> Defined by lack of ER, PR, and HER2 expression. It encompasses several molecular subtypes, including basal-like, claudin-low, metaplastic, medullary, and some unclassified types. TNBC is not strictly defined by histology alone, though it frequently corresponds to IDC or less commonly other histologies.</li>\n</ul>\n<p><strong>Overlapping Mutations Across Most Invasive Breast Cancers (IDC, ILC, IBC, TNBC):</strong></p>\n<p>These are mutations found relatively frequently across many different histological types, although their prevalence might vary slightly depending on subtype within those histologies.</p>\n<ol>\n<li><strong>PIK3CA:</strong> Activating mutations in this gene encoding the p110\u03b1 catalytic subunit of PI3K are very common overall (~20-40%). They are particularly frequent in hormone receptor-positive (HR+) tumors (Luminal A/B) regardless of histology (IDC vs. ILC). These mutations contribute to activation of the PI3K pathway, promoting cell growth and survival.</li>\n<li><strong>TP53:</strong> In</li>\n</ol>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Where do mutation patterns overlap and differ between the various histologies: IDC, ILC, inflammatory, etc?</h1>\n<p>Across histologic types like invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and inflammatory breast cancer, there is substantial overlap in core driver mutations, but each subtype has characteristic patterns in certain genes and mutational processes. In practice, histology \u201ctilts\u201d the probability of specific alterations and signatures rather than defining entirely unique, non\u2011overlapping genetic landscapes.<a href=\"https://www.sciencedirect.com/science/article/pii/S2666979X21000835\">^1</a><a href=\"https://www.sciencedirect.com/science/article/pii/S1574789110000268\">^8</a></p>\n<h2>Shared core alterations across histologies</h2>\n<ul>\n<li>Many common invasive types (IDC of no special type, classic ILC, micropapillary, mucinous, metaplastic) share frequent mutations in <strong>PIK3CA, TP53, GATA3, and ER\u2011pathway genes</strong>, with differences in exact frequencies rather than presence vs absence.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^6</a></li>\n<li>Copy\u2011number alterations (e.g., gains and losses across the genome) show broadly similar patterns between metastatic ILC, mucinous, micropapillary, metaplastic cancers and metastatic IDC of no special type when stage and ER/HER2 status are matched; overall fraction of genome altered (FGA) is comparable, though certain subsets (e.g., metastatic ILC) can have higher FGA.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^1</a></li>\n</ul>\n<h2>IDC vs ILC</h2>\n<ul>\n<li><strong>Cadherin and adhesion genes</strong><ul>\n<li>ILC is strongly associated with inactivation of <em>CDH1</em> (E\u2011cadherin), which is much less frequent in classic IDC.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^6</a></li>\n<li>IDC typically lacks the near\u2011pathognomonic combination of E\u2011cadherin loss plus the lobular growth pattern that characterizes ILC.</li>\n</ul>\n</li>\n<li><strong>ESR1 and ERBB2 in metastatic ILC</strong><ul>\n<li>Metastatic ILC frequently harbors alterations in <em>CDH1</em> (\u224870\u201380%), <em>PIK3CA</em> (\u224850%), and additional changes in <em>TP53, ERBB2, TBX3, NCOR1</em>, and <em>NF1</em>; some of these, like <em>ERBB2</em> and <em>ESR1</em> hotspot mutations, are enriched in metastatic ILC compared with matched metastatic IDC\u2011NST.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^1</a></li>\n<li><em>ESR1</em> and <em>ERBB2</em> mutations in ER\u2011positive ILC tend to be mutually exclusive and act as acquired resistance mechanisms to endocrine therapy; similar patterns can occur in IDC, but the specific spectrum and frequencies differ.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^1</a></li>\n</ul>\n</li>\n<li><strong>Mutational processes</strong><ul>\n<li>Metastatic ILC has been reported to show a higher mutational burden and more frequent APOBEC mutational signatures than primary ILC and matched metastatic IDC\u2011NST, suggesting histology\u2011linked differences in how mutational processes shape progression.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^1</a></li>\n</ul>\n</li>\n</ul>\n<h2>Special histologic types (micropapillary, metaplastic, mucinous)</h2>\n<ul>\n<li><strong>Micropapillary carcinomas</strong><ul>\n<li>Metastatic micropapillary cancers show frequent alterations in <em>PIK3CA</em> (~50\u201360%) and <em>TP53</em> (~40%), similar to common forms of breast cancer, but metastatic lesions can acquire additional <em>ESR1</em> and <em>ERBB2</em> mutations and alterations in <em>KDR, ARID1B,</em> and <em>ATR</em> that are less prominent in primary tumors.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^1</a></li>\n</ul>\n</li>\n<li><strong>Metaplastic carcinomas</strong><ul>\n<li>Metaplastic breast cancers, compared with triple\u2011negative IDC\u2011NST, more often harbor mutations affecting the <strong>PI3K/AKT/mTOR and canonical Wnt pathways</strong>.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^1</a></li>\n<li><em>TP53</em> is extremely frequent (approaching 80\u2013100%), and metastatic metaplastic tumors can acquire additional alterations such as <em>CCND1</em> and <em>SOX9</em> not seen in matched primaries; <em>PIK3CA</em> mutations can be enriched in metastatic chondroid or squamous metaplastic subtypes.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^1</a></li>\n</ul>\n</li>\n<li><strong>Mucinous and other special types</strong><ul>\n<li>Mixed mucinous carcinomas can accumulate <em>ESR1</em> and <em>NCOR</em> mutations in the metastatic setting, reflecting endocrine\u2011therapy resistance, whereas many of their baseline drivers overlap with ER\u2011positive IDC.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^1</a></li>\n</ul>\n</li>\n</ul>\n<h2>Inflammatory breast cancer</h2>\n<ul>\n<li>Inflammatory breast cancer (IBC) is defined clinically/pathologically more than by a single histologic pattern, but molecular studies suggest:<ul>\n<li>High frequency of <strong>ERBB2 amplification and overexpression</strong>, frequent <strong>TP53 mutations</strong>, and signatures of high proliferation and angiogenesis, overlapping considerably with aggressive HER2\u2011positive or basal\u2011like IDC.<a href=\"https://www.sciencedirect.com/science/article/pii/S2666979X21000835\">^8</a></li>\n<li>Distinct transcriptional patterns involving immune, angiogenic, and invasion pathways that are more characteristic of IBC than of classic IDC or ILC, even when ER/HER2 status is similar.<a href=\"https://www.sciencedirect.com/science/article/pii/S1574789110000268\">^8</a></li>\n</ul>\n</li>\n</ul>\n<h2>How overlap vs difference is best understood</h2>\n<ul>\n<li>Overlap: Many histologies share a common \u201ctoolbox\u201d of drivers and resistance genes\u2014<em>PIK3CA, TP53, ERBB2, ESR1, GATA3, NCOR1, NF1, RB1</em>, among others\u2014with variations in frequency and combinations rather than unique gene sets.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^6</a></li>\n<li>Differences:<ul>\n<li>ILC is distinguished by <em>CDH1</em> loss plus enrichment for <em>PIK3CA</em> and specific <em>ERBB2</em> and <em>ESR1</em> mutation patterns and higher APOBEC/HRD influence in the metastatic setting.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^1</a></li>\n<li>Metaplastic cancers are skewed toward PI3K and Wnt pathway mutations and very high <em>TP53</em> rates.<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^1</a></li>\n<li>Micropapillary and mixed mucinous carcinomas show IDC\u2011like cores but acquire subtype\u2011specific patterns (e.g., <em>ESR1/ERBB2</em> mutations in metastatic lesions).<a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^1</a></li>\n<li>Inflammatory breast cancer overlays a strong angiogenesis/immune/invasion program on top of IDC\u2011like or HER2\u2011enriched or basal\u2011like backgrounds.<a href=\"https://www.sciencedirect.com/science/article/pii/S2666979X21000835\">^8</a></li>\n</ul>\n</li>\n</ul>\n<p>Overall, histology modifies the probability and combination of key mutations and mutational signatures, while ER/HER2 status and intrinsic molecular subtype remain the primary axes along which mutation patterns and resistance mechanisms are organized.<a href=\"https://www.sciencedirect.com/science/article/pii/S1574789110000268\">^6</a><a href=\"https://www.nature.com/articles/s41523-020-00195-4\">^1</a>\n<span style=\"display:none\"><a href=\"https://aacrjournals.org/cebp/article/15/10/1899/260784/Comparison-of-Age-Distribution-Patterns-for\">^2</a><a href=\"https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/2056-4538.70043\">^4</a><a href=\"https://pubmed.ncbi.nlm.nih.gov/17035397/\">^7</a></span></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p><strong>Invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and inflammatory breast cancer (IBC) exhibit distinct mutation patterns that reflect their unique biological characteristics and clinical behaviors</strong> , though some alterations overlap across histological subtypes.</p>\n<h2>Invasive Lobular Carcinoma vs. Invasive Ductal Carcinoma</h2>\n<p><strong>CDH1 mutations are the defining genetic hallmark of ILC</strong> , occurring in approximately 56% of cases compared to only 6% in IDC.[1]</p>\n<p>Among ILC cases with wild-type CDH1 (44%), 90% demonstrate low CDH1 expression through alternative mechanisms including promoter methylation or gene fusions.[2][3]</p>\n<p>CDH1 truncating mutations correlate with radiohistologic size discordance and represent an independent poor prognosis factor for metastasis risk and breast cancer-related mortality.[4] <strong>PIK3CA mutations are significantly enriched in ILC</strong> across molecular subtypes. In HR+/HER2- disease, PIK3CA mutations occur in 37.9% of metastatic ILC versus 27.0% of metastatic IDC (p[1]</p>\n<p>This enrichment persists in triple-negative disease (23.8% vs 12.8%).[1]</p>\n<p>ILC demonstrates the highest AKT phosphorylation among all breast cancer subtypes, consistent with PI3K pathway activation.[2]</p>\n<p>Additional ILC-enriched mutations include <strong>PTEN, TBX3, FOXA1, and NF1</strong> .[2][5]</p>\n<p>NF1 variants occur in 6.6% of HR+/HER2- ILC versus 3.0% of IDC.[1] <strong>TP53 mutations are more prevalent in IDC than ILC</strong> across subtypes. In HR+/HER2- disease, TP53 mutations occur in 21.9% of IDC versus 13.9% of ILC; in triple-negative disease, the difference is even more pronounced (51.0% vs 4.8%).[1] <strong>GATA3 mutations characterize luminal A IDC</strong> (3.7% vs 0.3% in ILC), suggesting differential modulation of ER activity between histotypes.[1][2] <strong>FGFR amplifications</strong> are more frequent in IDC (5.9% vs 2.8% in ILC), while paradoxically,[1] <strong>ERBB2 variants are more common in ILC</strong> (6.2% vs 2.5%), despite HER2 protein overexpression being less frequent in ILC.[1]</p>\n<p>At the transcriptional level, ILC demonstrates <strong>higher expression of TFAP2B, SOCS2, NOSTRIN, THBS4, SCUBE2, and GDF9</strong> , while IDC shows elevated <strong>CDCA4, PSMG1, LMOD1, and SLC7A5</strong> .[3]</p>\n<p>ILC tumors are less genomically rearranged and heterogeneous than IDC, with distinct copy number alteration patterns.[6]</p>\n<p>Two main ILC subtypes exist: (1) an immune-related subtype with upregulation of PD-L1, PD-1, and CTLA-4 (44% of cases), and (2) a hormone-related subtype associated with EMT and specific chromosomal gains/losses.[7]</p>\n<h2>Inflammatory Breast Cancer</h2>\n<p><strong>IBC demonstrates a distinct genomic landscape characterized by exceptionally high TP53 mutation rates</strong> (72% overall), significantly enriched compared to non-IBC even after adjusting for molecular subtype and stage.[8][9]</p>\n<p>In HER2+ disease specifically, TP53 mutations show particular enrichment in IBC.[8] <strong>ERBB2 alterations occur in 32% of IBC cases</strong> , with overexpression twice as frequent in IBC compared to non- inflammatory tumors (independent of molecular subtype).[8][10]</p>\n<p>Additional frequent alterations include <strong>PIK3CA (24%), CCND1 (12%), MYC (9%), FGFR1 (8%), and GATA3 (8%)</strong> .[8] <strong>NOTCH pathway alterations are enriched in IBC</strong> , particularly in HER2+ disease.[8][9]</p>\n<p>DNA repair pathway genes, including <strong>BRCA2 (14%)</strong> , are more frequently altered in IBC than non-IBC.[8][9]</p>\n<p>The tumor mutational burden is higher in IBC compared to non-IBC.[8][9]</p>\n<p>Ninety-seven percent of IBCs display at least one actionable genetic alteration, higher than the 87% observed in non-IBC.[9]</p>\n<p>Pathways more frequently altered in IBC include DNA repair, NOTCH signaling, and CDK4/6.[9] <strong>TP53, CCND1, and RB1 alterations associate with poor outcomes in IBC</strong> .[8]</p>\n<h2>Overlapping Features Despite histological differences,</h2>\n<p><strong>molecular subtype (ER/PR/HER2 status) remains a dominant determinant of mutation patterns</strong> . For example, TP53 mutations are enriched in triple-negative disease regardless of histology, while PIK3CA mutations predominate in HR+ tumors across histotypes.[1][11]</p>\n<p>Mixed ductal-lobular carcinomas demonstrate spatial heterogeneity with distinct intrinsic subtypes in different regions (e.g., triple-negative ductal and ER+ luminal lobular components within the same tumor), highlighting that molecular classification can transcend histological boundaries.[12]</p>\n<p>The genomic landscape reveals that breast tumors fall along a continuum constrained by three genomic archetypes: (1) ER+ high-risk with complex focal amplifications, (2) HER2+ with similar complex rearrangements, and (3) triple-negative with genome-wide instability.[13]</p>\n<p>These archetypes are established early during tumorigenesis and are conserved in metastatic disease.[13]</p>\n<p>Would you like me to summarize the latest evidence on how these distinct mutation patterns influence therapeutic decision-making and response to targeted therapies across the different histological subtypes of breast cancer?</p>\n<h3>References</h3>\n<ol>\n<li>Clinical Characteristics and Survival Outcomes of Metastatic Invasive Lobular and Ductal Carcinoma. Raghavendra AS, Bassett R, Damodaran S, et al. JAMA Network Open. 2025;8(4):e251888. doi:10.1001/jamanetworkopen.2025.1888.</li>\n<li>Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Ciriello G, Gatza ML, Beck AH, et al. Cell. 2015;163(2):506-19. doi:10.1016/j.cell.2015.09.033.</li>\n<li>Differential genomic and transcriptomic analysis of invasive lobular and ductal carcinomas. Mouabbi J, Meric- Bernstam F , Khorkova S, et al. Journal of Clinical Oncology. 2023;41(Suppl 16):579. doi:10.1200/JCO.2023.41.16_suppl.579.</li>\n<li>E-Cadherin Mutational Landscape and Outcomes in Breast Invasive Lobular Carcinoma. Djerroudi L, Bendali A, Fuhrmann L, et al. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 2024;37(10):100570. doi:10.1016/j.modpat.2024.100570.</li>\n<li>Multi-Omics Analyses Provide Novel Biological Insights to Distinguish Lobular Ductal Types of Invasive Breast Cancers. Sivadas A, Kok VC, Ng KL. Breast Cancer Research and Treatment. 2022;193(2):361-379. doi:10.1007/s10549-022-06567-7.</li>\n<li>Lobular and Ductal Carcinomas of the Breast Have Distinct Genomic and Expression Profiles. Bertucci F , Orsetti B, N\u00e8gre V , et al. Oncogene. 2008;27(40):5359-72. doi:10.1038/onc.2008.158.</li>\n<li>Integration of Genomic, Transcriptomic and Proteomic Data Identifies Two Biologically Distinct Subtypes of Invasive Lobular Breast Cancer. Michaut M, Chin SF , Majewski I, et al. Scientific Reports. 2016;6:18517. doi:10.1038/srep18517.</li>\n<li>Clinicogenomic Characterization of Inflammatory Breast Cancer. Priedigkeit N, Harrison B, Shue R, et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2025;31(14):3072-3083. doi:10.1158/1078-0432.CCR-24-2081.</li>\n<li>NOTCH and DNA Repair Pathways Are More Frequently Targeted by Genomic Alterations in Inflammatory Than in Non-Inflammatory Breast Cancers. Bertucci F , Rypens C, Finetti P , et al. Molecular Oncology. 2020;14(3):504-</li>\n<li>doi:10.1002/1878-0261.12621.</li>\n<li>Increased Incidence of ERBB2 Overexpression and TP53 Mutation in Inflammatory Breast Cancer. Turpin E, Bi\u00e8che I, Bertheau P , et al. Oncogene. 2002;21(49):7593-7. doi:10.1038/sj.onc.1205932.</li>\n<li>Comprehensive Molecular Portraits of Human Breast Tumours. Nature. 2012;490(7418):61-70. doi:10.1038/nature11412.</li>\n<li>Spatial Molecular Profiling of Mixed Invasive Ductal and Lobular Breast Cancers Reveals Heterogeneity in Intrinsic Molecular Subtypes, Oncogenic Signatures, and Mutations. Shah OS, Nasrazadani A, Foldi J, et al. Proceedings of the National Academy of Sciences of the United States of America. 2024;121(31):e2322068121. doi:10.1073/pnas.2322068121.</li>\n<li>Complex Rearrangements Fuel ER+ and HER2+ Breast Tumours. Houlahan KE, Mangiante L, Sotomayor-Vivas C, et al. Nature. 2025;638(8050):510-518. doi:10.1038/s41586-024-08377-x. 9.</li>\n</ol>"}]}, "9": {"question": "Is there a correlation between radionomics and resistance patterns?  Is there literature that demonstrates a consistent and statistically significant correlation between radinomics and resistance mechanisms?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>There is no direct evidence of such a relationship.</p>"}, {"model": "GPT-4o", "text": "<p>Radionomics is an emerging field that involves extracting large amounts of quantitative features from medical imaging data, which can then be used to inform clinical decision-making. The concept is that these imaging features can reveal underlying tumor characteristics, including genetic and molecular profiles, which might not be visible to the naked eye.</p>\n<p>The relationship between radionomics and resistance patterns, particularly in oncology, is an area of active research. Resistance patterns refer to how tumors resist treatment, which can be due to various mechanisms, including genetic mutations, changes in the tumor microenvironment, or other molecular alterations.</p>\n<p>There is growing interest in using radionomics to predict or understand resistance mechanisms. Some studies have suggested that radionomic features can correlate with certain genetic mutations or molecular profiles that are known to confer resistance to therapies. For example, in some cancers, specific imaging features have been associated with mutations in genes like EGFR or KRAS, which are known to influence treatment response.</p>\n<p>However, while there is promising research, the field is still developing, and more studies are needed to establish consistent and statistically significant correlations between radionomics and resistance mechanisms across different types of cancer and treatments. The current literature includes a mix of retrospective studies, pilot studies, and some prospective trials, but larger, multicenter studies are necessary to validate these findings and integrate them into clinical practice.</p>\n<p>In summary, while there is some evidence suggesting a correlation between radionomics and resistance patterns, the field is still evolving, and more robust research is needed to confirm these findings and understand their clinical implications fully.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>Yes, there is a strong and growing body of literature demonstrating a correlation between <strong>radiomics</strong> (the high-throughput extraction of quantitative features from medical imaging) and <strong>therapeutic resistance patterns</strong> in oncology.</p>\n<p>However, while the literature frequently demonstrates <strong>statistical significance</strong> within individual studies, the <strong>consistency</strong> (reproducibility and generalizability) of these correlations across different institutions and scanner types remains the primary challenge in the field.</p>\n<p>Here is a breakdown of the current state of the science regarding radiomics and resistance mechanisms.</p>\n<h3>1. The Biological Basis: Why is there a correlation?</h3>\n<p>The central hypothesis linking radiomics to resistance is <strong>tumor heterogeneity</strong>.\n*   <strong>Genotype-Phenotype Link:</strong> Resistance is often driven by specific genetic mutations (e.g., EGFR, KRAS) or the tumor microenvironment (e.g., hypoxia, vascularization).\n*   <strong>Imaging Expression:</strong> These microscopic biological properties manifest macroscopically on images. For example, a tumor with high genetic heterogeneity (prone to resistance) often displays high textural entropy (irregularity) on a CT or MRI scan.</p>\n<h3>2. Literature Evidence by Therapy Type</h3>\n<p>Literature has demonstrated statistically significant correlations in several key areas:</p>\n<h4>A. Targeted Therapy (Genomic Resistance)</h4>\n<ul>\n<li><strong>NSCLC (Lung Cancer):</strong> This is the most studied area. Research has shown that CT-based radiomic signatures can predict <strong>EGFR</strong> mutation status and <strong>KRAS</strong> mutations.<ul>\n<li><em>Significance:</em> Tumors with EGFR mutations (sensitive to TKIs) have different texture patterns than wild-type or KRAS-mutated tumors (resistant to EGFR-TKIs).</li>\n<li><em>Literature:</em> Studies published in <em>Radiology</em> and <em>Clinical Cancer Research</em> have reported Area Under the Curve (AUC) values ranging from 0.75 to 0.85 for predicting these mutations non-invasively.</li>\n</ul>\n</li>\n</ul>\n<h4>B. Chemotherapy (Neoadjuvant Resistance)</h4>\n<ul>\n<li><strong>Breast Cancer:</strong> MRI radiomics are widely used to predict Pathological Complete Response (pCR) to neoadjuvant chemotherapy.<ul>\n<li><em>Mechanism:</em> Features related to tumor enhancement kinetics and intratumoral heterogeneity correlate with the tumor's proliferation rate and sensitivity to cytotoxic drugs.</li>\n<li><em>Literature:</em> A 2021 meta-analysis in <em>Nature Scientific Reports</em> confirmed that radiomics models generally outperform clinical models in predicting response, though validation varies.</li>\n</ul>\n</li>\n</ul>\n<h4>C. Immunotherapy (Checkpoint Inhibitor Resistance)</h4>\n<ul>\n<li><strong>Tumor Microenvironment:</strong> Resistance to immunotherapy is often driven by \"cold\" tumors (lack of CD8+ T-cell infiltration).</li>\n<li><strong>Radiomic Correlation:</strong> CT and PET radiomics have been correlated with <strong>PD-L1 expression</strong> levels and <strong>Tumor Mutational Burden (TMB)</strong>.</li>\n<li><em>Literature:</em> A landmark study in <em>The Lancet Oncology</em> (Sun et al.) demonstrated that a radiomic signature of CD8 cells could predict immunotherapy response better than standard biopsy in some cohorts.</li>\n</ul>\n<h4>D. Radiotherapy (Radioresistance)</h4>\n<ul>\n<li><strong>Hypoxia:</strong> Hypoxic tumors are resistant to radiation.</li>\n<li><strong>Correlation:</strong> PET/CT radiomics (using tracers like FMISO or standard FDG) can identify sub-regions of the tumor that are hypoxic based on intensity and texture distribution, predicting local failure.</li>\n</ul>\n<h3>3. The Critical Caveat: \"Consistent and Statistically Significant\"</h3>\n<p>You asked if the literature demonstrates a <em>consistent</em> correlation. This is where the science is currently struggling.</p>\n<p>While individual studies show high statistical significance (p &lt; 0.05), the field suffers from a <strong>reproducibility crisis</strong>.</p>\n<ol>\n<li><strong>Lack of Standardization:</strong> Radiomic features are highly sensitive to image acquisition parameters. A scan taken on a GE scanner may yield different texture values than one taken on a Siemens scanner, even for the same patient. This makes a \"signature\" found in one paper fail when applied to a different hospital's data.</li>\n<li><strong>Overfitting:</strong> Many studies use small datasets (n &lt; 200). They find a statistically significant correlation within their specific dataset, but the model fails to generalize to the outside world.</li>\n<li><strong>Segmentation Variability:</strong> The correlation depends heavily on how the tumor is outlined (segmented). Manual vs. automated segmentation can alter the radiomic features, changing the correlation results.</li>\n</ol>\n<h3>Summary</h3>\n<p><strong>Is there a correlation?</strong>\n<strong>Yes.</strong> Radiomics serves as a non-invasive surrogate for the underlying biological heterogeneity that drives resistance.</p>\n<p><strong>Is it consistent and statistically significant in the literature?</strong>\n*   <strong>Statistically Significant:</strong> <strong>Yes</strong>, in the vast majority of published retrospective studies.\n*   <strong>Consistent:</strong> <strong>Not yet.</strong> While the signal is real, the \"signatures\" (the specific combination of features) often vary between studies.</p>\n<p><strong>Current Trend:</strong> The field is moving toward <strong>Deep Learning (CNNs)</strong> and multi-center standardization (IBSI guidelines) to solve the consistency problem, aiming to create robust biomarkers that can predict resistance before treatment begins.</p>"}, {"model": "MedGemma 27B", "text": "<p>Yes, there is growing evidence suggesting a correlation between radiomic features extracted from medical images (like CT or MRI) and tumor resistance to therapy. Several studies have demonstrated statistically significant correlations between specific radiomic signatures and various aspects of treatment response, including the development of resistance.</p>\n<p>Here's a breakdown of the key points regarding this correlation:</p>\n<ol>\n<li>\n<p><strong>Radiomics as Biomarkers for Resistance:</strong> Radiomics involves extracting large amounts of quantitative data from medical images. These features can capture subtle variations in tissue texture, shape, intensity distribution, and spatial relationships within tumors that might not be apparent to the human eye. Researchers hypothesize that these complex characteristics reflect underlying biological processes related to tumor heterogeneity, angiogenesis, metabolism, and immune infiltration \u2013 all factors influencing therapeutic response and resistance.</p>\n</li>\n<li>\n<p><strong>Specific Examples &amp; Studies:</strong> Numerous studies across different cancer types have explored the link between radiomics and resistance:</p>\n<ul>\n<li><strong>Lung Cancer:</strong> Some research has shown that certain radiomic features derived from pre-treatment CT scans correlate with EGFR mutation status and subsequent response/resistance to targeted therapies like gefitinib or erlotinib. Other studies suggest associations between radiomic profiles and resistance to chemotherapy or immunotherapy. For example, features reflecting increased vascularity or metabolic activity might predict poorer outcomes or faster progression after initial response.</li>\n<li><strong>Breast Cancer:</strong> Radiomic analysis of mammograms or MRIs has been linked to HER2 status, hormone receptor expression, and chemoresistance. Features capturing tumor irregularity or spiculated margins sometimes correlate with more aggressive phenotypes and potential resistance.</li>\n<li><strong>Glioblastoma:</strong> In brain tumors, radiomics has been investigated to predict MGMT methylation status (a biomarker for temozolomide sensitivity) and overall survival. Certain textural features may indicate higher cellular density or necrosis, potentially correlating with resistance.</li>\n<li><strong>Colorectal Cancer:</strong> Studies are exploring how radiomic features on CT scans relate to KRAS mutations, microsatellite instability (MSI), and response to treatments like anti-EGFR antibodies (cetuximab).</li>\n<li><strong>Head and Neck Cancers:</strong> Research suggests links between radiomic features and HPV status, smoking history, and response to chemoradiotherapy.</li>\n</ul>\n</li>\n<li>\n<p><strong>Mechanisms Linking Radiomics and Resistance:</strong> The proposed connection lies in how imaging features represent underlying biology:</p>\n<ul>\n<li><strong>Tumor Heterogeneity:</strong> Radiomic textures can quantify intra-tumoral heterogeneity, which is a major driver of acquired resistance. Different cell populations within a tumor respond</li>\n</ul>\n</li>\n</ol>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Is there a correlation between radionomics and resistance patterns?  Is there literature that demonstrates a consistent and statistically significant correlation between radinomics and resistance mechanisms?</h1>\n<p>Radiomics features do show correlations with some resistance\u2011related phenotypes, but evidence that they consistently and robustly track specific molecular resistance mechanisms is still emerging and not yet definitive. Existing studies are promising but mostly single\u2011center, modest in size, and require external validation before being considered clinically established.</p>\n<h2>What has been shown so far</h2>\n<ul>\n<li>MRI\u2011based radiomics signatures have been developed to predict endocrine resistance risk in hormone\u2011receptor\u2011positive, non\u2011metastatic breast cancer, with models achieving statistically significant discrimination between patients who did and did not develop endocrine therapy resistance.<a href=\"https://pubs.rsna.org/doi/abs/10.1148/radiol.2016152110\">^3</a></li>\n<li>Radiomics features from multiparametric MRI have been correlated with genomic characteristics and receptor status (e.g., HER2 expression, proliferation markers), providing an imaging surrogate for some molecular profiles that themselves are linked to resistance risk.<a href=\"https://www.auntminnie.com/imaging-informatics/advanced-visualization/image-processing/article/15633971/mri-radiomics-features-predicts-breast-cancer-tumor-expressions\">^4</a></li>\n</ul>\n<h2>Correlation with resistance mechanisms</h2>\n<ul>\n<li>Radiomics\u2013genomics (\u201cradiogenomics\u201d) studies in breast cancer report associations between MR radiomics clusters and underlying transcriptomic or genomic signatures, including proliferation, immune and stromal pathways, and intrinsic subtypes that influence therapy response and resistance patterns.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9431911/\">^5</a></li>\n<li>Some radiomics signatures associated with endocrine resistance appear to reflect more aggressive biology (higher proliferation, lower hormone dependence) rather than directly encoding a specific mutation such as ESR1, PIK3CA, or BRCA; in other words, they correlate with resistance\u2011prone phenotypes more than with discrete resistance mutations.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9431911/\">^3</a></li>\n</ul>\n<h2>How consistent and statistically strong is the evidence?</h2>\n<ul>\n<li>Across published work, many models report statistically significant associations (AUCs typically in the 0.7\u20130.8 range) between pre\u2011treatment radiomics features and outcomes such as endocrine failure or recurrence, indicating non\u2011trivial predictive signal.<a href=\"https://www.sciencedirect.com/science/article/pii/S0960977621004616\">^6</a></li>\n<li>However, most studies are retrospective, use limited cohorts, and often lack multi\u2011institutional external validation; performance can drop when tested on independent datasets, highlighting concerns about reproducibility and generalizability.<a href=\"https://www.nature.com/articles/s41523-024-00678-8\">^4</a></li>\n</ul>\n<h2>Current limitations and gaps</h2>\n<ul>\n<li>There is not yet a widely accepted, clinically validated radiomics signature that maps directly and reliably onto specific resistance mechanisms (e.g., HR\u2011repair restoration, ESR1 mutation, PI3K pathway activation) in breast cancer.</li>\n<li>Radiomics features are high\u2011dimensional and affected by acquisition parameters, reconstruction, and segmentation; without robust standardization and large multicenter validation, associations with resistance mechanisms may be unstable across sites and scanners.</li>\n</ul>\n<h2>Practical interpretation</h2>\n<ul>\n<li>At present, radiomics is best viewed as a complementary tool that can non\u2011invasively capture aspects of tumor heterogeneity and biology that correlate with risk of treatment failure or aggressive/resistant phenotypes.</li>\n<li>The literature does support statistically significant correlations between certain radiomics signatures and resistance\u2011related outcomes (especially endocrine resistance), but it does <strong>not</strong> yet establish a consistent, mechanistically specific link between radiomics patterns and defined molecular resistance mechanisms across cohorts.\n<span style=\"display:none\"><a href=\"https://pubs.rsc.org/en/content/articlehtml/2021/an/d1an00387a\">^1</a></span></li>\n</ul>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>istance patterns? Is there literature that demonstrates a consistent and statistically <strong>Yes, there is a consistent and statistically significant association between radiomics features and resistance mechanisms to chemotherapy in breast cancer</strong> , with multiple published studies demonstrating that radiomic analysis can predict treatment response, though the evidence for radiotherapy resistance is more limited.</p>\n<h2>Radiomics and Chemotherapy Resistance significant correlation between radinomics and resistance mechanisms?</h2>\n<p><strong>Radiomics has been spotlighted as an imaging biomarker for estimation of intratumoral heterogeneity (ITH), which is regarded as the main reason for resistance to tumor treatment</strong> .[1]</p>\n<p>Multiple studies demonstrate consistent predictive performance across different imaging modalities and patient cohorts. <strong>Prediction of Pathological Complete Response:</strong> Radiomics effectively predicts pathological complete response (pCR) to neoadjuvant chemotherapy with high accuracy. A multicenter study of 586 patients showed that radiomics of multiparametric MRI (RMM) achieved an AUC of 0.86 for predicting pCR, significantly higher than clinical models in external validation cohorts.[2]</p>\n<p>Meta- analysis of 14 studies including 2,722 breast cancers confirmed that all MRI-derived radiomic features improved predictive accuracy compared to conventional biomarkers.[3] <strong>Intratumoral and peritumoral radiomic analysis yields AUCs of 0.74-0.78 for pCR prediction</strong> , with receptor status-specific analysis improving performance to AUCs of 0.83 in HR+/HER2- tumors and 0.93 in triple- negative/HER2+ tumors.[4]</p>\n<p>Post-NAC MRI radiomics are the most accurate imaging method, with during-NAC and post-NAC MRI showing significantly better predictive accuracy than pre-NAC MRI (OR: 0.14 and 0.26, respectively).[3] <strong>Temporal Dynamics and Resistance Patterns:</strong> <strong>Longitudinal radiomics analysis demonstrates superior performance in predicting treatment response</strong> . Studies using multiparametric MRI before and during NAC achieved AUCs of 0.909-0.981 for distinguishing different residual cancer burden (RCB) categories.[5]</p>\n<p>Delta-radiomics features (changes during treatment) from synthetic MRI outperformed pre-treatment features, with the optimal noncontrast clinical-radiomics model achieving AUCs of 0.916/0.914/0.850 across training/validation/test cohorts.[6] <strong>Radiomic signatures predict diverse tumor shrinkage patterns associated with survival outcomes</strong> . A multitask learning model using 17 radiomic signatures achieved AUCs of 0.886 for predicting tumor shrinkage patterns and 0.760 for pCR.[7]</p>\n<p>Critically, nonpCR patients with concentric shrinkage had significantly better survival than those with non-concentric shrinkage (p=0.00012 for OS, p=0.00063 for RFS).[7]</p>\n<h2>Biological Mechanisms Underlying Radiomics</h2>\n<p><strong>Radiogenomics analysis reveals that radiomic features correlate with specific molecular pathways and resistance mechanisms</strong> . Gene expression analysis demonstrated that IL-17 and estrogen signaling pathways are involved in response variability.[7]</p>\n<p>Radio-multiomic studies uncovered metabolic dysregulation underlying radiomic signatures, including ATP metabolic processes (NES=1.84, p-adjust=0.02) and cholesterol biosynthesis (NES=1.79, p-adjust=0.01).[8]</p>\n<p>A significant correlation exists between radiomics and long non-coding RNAs (lncRNAs), with deep learning- based radiomics models achieving AUCs of 0.79 and 0.77 for noninvasive quantification of key lncRNAs in training and testing cohorts.[9]</p>\n<p>This demonstrates that <strong>radiomic features reflect underlying epigenetic molecular characteristics</strong> that drive treatment resistance. Predicted pCR groups show active immune and inflammatory pathways, while non-pCR groups demonstrate stronger cell proliferation and tumor invasion processes.[10]</p>\n<p>The direction of effect differs by subtype: TNBC patients with high proliferation, high immune response, and low extracellular matrix expression have better response (HR 0.29, 95% CI 0.10-0.85), while ER+ patients show the opposite pattern (HR 4.73, 95% CI 1.51- 14.8).[7]</p>\n<h2>Prognostic Value and Clinical Utility</h2>\n<p><strong>Radiomic signatures demonstrate independent prognostic value for recurrence-free survival and overall survival</strong> . A thirteen-feature radiomic signature validated across three cohorts (FUSCC, DUKE, I-SPY1) significantly predicted RFS and OS (all p[8]</p>\n<p>The Radiomic DeepSurv Net model achieved AUCs of 0.98, 0.94, and 0.92 for 1-, 2-, and 3-year RFS prediction, with validation AUCs of 0.91-0.94.[9]</p>\n<p>CT-based radiomics nomograms incorporating clinical characteristics achieved AUCs of 0.82 in training and 0.79 in validation cohorts for NAC response prediction, with significantly higher overall net benefit than clinical models alone (z=2.811, p=0.005).[11]</p>\n<h2>Radiotherapy Resistance The provided literature focuses predominantly on chemotherapy resistance, with</h2>\n<p><strong>limited published evidence specifically addressing radiomics prediction of radiotherapy resistance in breast cancer</strong> . The metabolic radiomics study using F-FDG PET/CT demonstrated associations with Ki67 expression and recurrence risk, but did not specifically evaluate radiotherapy resistance patterns.[1]</p>\n<p>Would you like me to summarize the latest evidence on how specific radiomic features\u2014such as texture heterogeneity patterns or peritumoral characteristics\u2014could be integrated into clinical decision-making algorithms to guide treatment selection and identify patients at highest risk for developing resistance to neoadjuvant chemotherapy? Would you like me to review and synthesize the literature on radiomics-based prediction of resistance specifically to radiotherapy in breast cancer, including any emerging imaging biomarkers or multi-omics approaches that may help identify patients at risk for radiotherapy failure?</p>\n<h3>References</h3>\n<ol>\n<li>Metabolic Radiomics for Pretreatment F-FDG PET/CT to Characterize Locally Advanced Breast Cancer: Histopathologic Characteristics, Response to Neoadjuvant Chemotherapy, and Prognosis. Ha S, Park S, Bang JI, Kim EK, Lee HY . Scientific Reports. 2017;7(1):1556. doi:10.1038/s41598-017-01524-7.</li>\n<li>Radiomics of Multiparametric MRI for Pretreatment Prediction of Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Multicenter Study. Liu Z, Li Z, Qu J, et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2019;25(12):3538-3547. doi:10.1158/1078-0432.CCR-18-3190.</li>\n<li>The Accuracy of Breast MRI Radiomic Methodologies in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy: A Systematic Review and Network Meta-Analysis. O'Donnell JPM, Gasior SA, Davey MG, et al. European Journal of Radiology. 2022;157:110561. doi:10.1016/j.ejrad.2022.110561.</li>\n<li>Intratumoral and Peritumoral Radiomics for the Pretreatment Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy Based on Breast DCE-MRI. Braman NM, Etesami M, Prasanna P , et al. Breast Cancer Research : BCR. 2017;19(1):57. doi:10.1186/s13058-017-0846-1.</li>\n<li>Multiparametric MRI-based Longitudinal-Radiomics Analysis for Early Prediction of Treatment Response of Breast Cancers to Neoadjuvant Chemotherapy. Li W, Huang Y , Zhu T, Ye G, Wang K. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine. 2025;227:112278. doi:10.1016/j.apradiso.2025.112278.</li>\n<li>Radiomics Analysis of Contrast-Free Synthetic MRI and Apparent Diffusion Coefficient for Early Predicting Neoadjuvant Chemotherapy Response in Breast Cancer. Zhang Y , Zhao R, Du S, et al. European Journal of Radiology. 2025;191:112344. doi:10.1016/j.ejrad.2025.112344.</li>\n<li>Radiomic Analysis Reveals Diverse Prognostic and Molecular Insights Into the Response of Breast Cancer to Neoadjuvant Chemotherapy: A Multicohort Study. Fan M, Wang K, Pan D, et al. Journal of Translational Medicine. 2024;22(1):637. doi:10.1186/s12967-024-05487-y.</li>\n<li>Multicenter Radio-Multiomic Analysis for Predicting Breast Cancer Outcome and Unravelling Imaging- Biological Connection. You C, Su GH, Zhang X, et al. NPJ Precision Oncology. 2024;8(1):193. doi:10.1038/s41698- 024-00666-y.</li>\n<li>Machine Learning Radiomics of Magnetic Resonance Imaging Predicts Recurrence-Free Survival After Surgery and Correlation of LncRNAs in Patients With Breast Cancer: A Multicenter Cohort Study. Yu Y , Ren W, He Z, et al. Breast Cancer Research : BCR. 2023;25(1):132. doi:10.1186/s13058-023-01688-3.</li>\n<li>MR Imaging of Breast Cancer: Interpretable Radiomics Analysis to Assess Treatment Response and Survival Prognosis After Neoadjuvant Therapy. Hou J, Yang F , Gao Y , et al. International Journal of Cancer. 2025;. doi:10.1002/ijc.35514.</li>\n<li>Computed Tomography-Based Radiomics Analysis for Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Duan Y , Yang G, Miao W, et al. Journal of Computer Assisted Tomography. 2023 Mar-Apr 01;47(2):199-204. doi:10.1097/RCT.0000000000001426. 10.</li>\n</ol>"}]}, "10": {"question": "How long, on average, does it take metastatic patients to develop resistance? We can specify the type of resistance here, ie, to immunotherapy (PF-L1 inhibitors), chemotherapy (doxorubicin, paclitaxel, capecitabine, etc), and targeted therapy (PARP inhibitors, NTRK inhibitors, etc).", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>It is difficult to estimate how much time elapses between a patient becoming MT and developing drug resistance. However, there are several factors that influence this process. Firstly, different tumors have varying intrinsic rates at which they acquire secondary mutations; secondly, some drugs induce specific mechanisms of resistance more frequently than others; thirdly, host genotype influences both rate of acquiring resistance as well as susceptibility to particular agents; finally, other treatment related variables such as dose intensity and schedule may impact emergence of resistance</p>"}, {"model": "GPT-4o", "text": "<p>The development of resistance in metastatic cancer patients varies significantly depending on the type of therapy, the specific cancer type, and individual patient factors. Here's a general overview:</p>\n<ol>\n<li>\n<p><strong>Immunotherapy (PD-1/PD-L1 inhibitors):</strong> Resistance to immunotherapy can develop within months to a few years. Some patients may experience primary resistance (no initial response), while others may develop acquired resistance after an initial period of response. On average, progression-free survival (PFS) for patients on PD-1/PD-L1 inhibitors can range from 6 to 24 months, but this varies widely.</p>\n</li>\n<li>\n<p><strong>Chemotherapy (e.g., doxorubicin, paclitaxel, capecitabine):</strong> Resistance to chemotherapy often develops more quickly, typically within a few months to a year. The timeframe can depend on the specific drug, cancer type, and prior treatments. For example, resistance to paclitaxel in breast cancer might develop after 6 to 12 months of treatment.</p>\n</li>\n<li>\n<p><strong>Targeted Therapy (e.g., PARP inhibitors, NTRK inhibitors):</strong> Resistance to targeted therapies can also vary. For PARP inhibitors used in BRCA-mutated cancers, resistance might develop after 8 to 16 months. NTRK inhibitors, used for tumors with NTRK gene fusions, may show resistance after a similar timeframe, although some patients experience longer durations of response.</p>\n</li>\n</ol>\n<p>It's important to note that these are average estimates and individual patient experiences can differ significantly. Additionally, ongoing research and new treatment combinations continue to evolve the landscape of cancer therapy and resistance patterns.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>To determine how long it takes for metastatic patients to develop resistance, oncologists look at <strong>Median Progression-Free Survival (mPFS)</strong>. This metric represents the length of time during and after the treatment that a patient lives with the disease but it does not get worse.</p>\n<p>However, \"time to resistance\" varies wildly based on the <strong>cancer type</strong> (biology), the <strong>line of therapy</strong> (1st line vs. 3rd line), and the <strong>tumor burden</strong>.</p>\n<p>Here is the breakdown of average time to resistance by therapeutic class, based on major Phase III clinical trial data.</p>\n<hr />\n<h3>1. Immunotherapy (PD-1/PD-L1 Inhibitors)</h3>\n<p><em>Examples: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Atezolizumab (Tecentriq)</em></p>\n<p>Immunotherapy is unique. Unlike chemotherapy, which has a bell-curve response, immunotherapy often has a \"long tail.\" A significant percentage of patients have <strong>primary resistance</strong> (it never works), while a smaller subset has durable responses that last for years.</p>\n<ul>\n<li><strong>Average Time to Resistance (mPFS):</strong> <strong>6 to 12 months</strong> (for the general population).</li>\n<li><strong>The \"Super-Responder\" Nuance:</strong> If a patient responds initially, the <strong>Duration of Response (DoR)</strong> is often much longer than the median PFS, frequently exceeding <strong>24+ months</strong>.</li>\n</ul>\n<p><strong>Specific Contexts:</strong>\n*   <strong>Metastatic Non-Small Cell Lung Cancer (NSCLC):</strong>\n    *   <em>Monotherapy:</em> ~7\u201310 months.\n    *   <em>Combo (Chemo + Immuno):</em> ~9\u201312 months.\n*   <strong>Metastatic Melanoma:</strong>\n    *   Resistance often develops later; mPFS is roughly <strong>11\u201315 months</strong>, but ~50% of patients may remain progression-free for years.</p>\n<hr />\n<h3>2. Chemotherapy (Cytotoxics)</h3>\n<p><em>Examples: Doxorubicin, Paclitaxel, Capecitabine</em></p>\n<p>Chemotherapy resistance usually follows the law of diminishing returns. First-line therapy lasts the longest; subsequent lines fail faster as the tumor evolves and develops efflux pumps (mechanisms to spit the drug out of the cell).</p>\n<ul>\n<li><strong>Average Time to Resistance (mPFS):</strong> <strong>6 to 9 months</strong> (1st line).</li>\n<li><strong>Later Lines:</strong> Drops to <strong>3 to 5 months</strong>.</li>\n</ul>\n<p><strong>Specific Contexts:</strong>\n*   <strong>Metastatic Breast Cancer (Taxanes/Anthracyclines):</strong>\n    *   <em>Paclitaxel/Doxorubicin:</em> Resistance typically develops within <strong>6\u201310 months</strong>.\n    *   <em>Capecitabine:</em> Often used in later lines; resistance typically develops in <strong>4\u20136 months</strong>.\n*   <strong>Metastatic Pancreatic Cancer:</strong>\n    *   Resistance is very rapid; mPFS is often only <strong>3\u20136 months</strong>.</p>\n<hr />\n<h3>3. Targeted Therapy</h3>\n<p>Targeted therapies often have high initial response rates (the tumor shrinks quickly), but the cancer almost inevitably finds a \"bypass track\" (a secondary mutation) to overcome the drug.</p>\n<h4>A. PARP Inhibitors</h4>\n<p><em>Examples: Olaparib (Lynparza), Talazoparib, Niraparib</em>\nThese are most effective in BRCA-mutated cancers (Ovarian, Breast, Prostate, Pancreatic).</p>\n<ul>\n<li><strong>Metastatic Breast Cancer (BRCA+):</strong><ul>\n<li>Time to resistance: <strong>~7 to 9 months</strong>.</li>\n<li><em>Note:</em> While effective, resistance develops relatively quickly in metastatic breast cancer compared to ovarian cancer.</li>\n</ul>\n</li>\n<li><strong>Ovarian Cancer (Platinum-Sensitive Relapse):</strong><ul>\n<li>Time to resistance: <strong>~15 to 19 months</strong>.</li>\n<li><em>Note:</em> In ovarian cancer, PARP inhibitors are often used as \"maintenance\" (to keep the cancer away after chemo), resulting in much longer intervals before resistance returns.</li>\n</ul>\n</li>\n</ul>\n<h4>B. NTRK Inhibitors</h4>\n<p><em>Examples: Larotrectinib (Vitrakvi), Entrectinib</em>\nThese are used in \"tumor-agnostic\" settings (treating the mutation, not the organ). These drugs are incredibly potent for the rare patients who have NTRK fusions.</p>\n<ul>\n<li><strong>Average Time to Resistance:</strong> <strong>Very Long (12 to 35+ months).</strong></li>\n<li><strong>Data:</strong> In pooled analyses, the median duration of response is often <strong>35 months</strong> or median has not yet been reached. Resistance eventually occurs via \"solvent front mutations\" (changes in the kinase shape), but these drugs provide some of the longest protection against resistance in modern oncology.</li>\n</ul>\n<h4>C. Other Common Targeted Therapies (Contextual Benchmarks)</h4>\n<ul>\n<li><strong>EGFR Inhibitors (Lung Cancer - Osimertinib):</strong> Resistance typically develops in <strong>~18 months</strong>.</li>\n<li><strong>CDK4/6 Inhibitors (Breast Cancer - Palbociclib + Hormonal Therapy):</strong> Resistance typically develops in <strong>~24 to 28 months</strong>.</li>\n</ul>\n<hr />\n<h3>Summary Table: Estimated Time to Resistance (mPFS)</h3>\n<p>| Therapy Type | Drug Examples | Typical Indication | Approx. Time to Resistance |\n| :--- | :--- | :--- | :--- |\n| <strong>Immunotherapy</strong> | Pembrolizumab | Lung Cancer (1st Line) | <strong>8 \u2013 10 Months</strong> |\n| <strong>Immunotherapy</strong> | Nivolumab+Ipi | Melanoma | <strong>11 \u2013 15 Months</strong> |\n| <strong>Chemotherapy</strong> | Paclitaxel / Doxorubicin | Breast Cancer (Metastatic) | <strong>6 \u2013 9 Months</strong> |\n| <strong>Chemotherapy</strong> | Capecitabine | GI / Breast (Later lines) | <strong>4 \u2013 6 Months</strong> |\n| <strong>Targeted (PARP)</strong> | Olaparib | Breast Cancer (BRCA+) | <strong>7 \u2013 9 Months</strong> |\n| <strong>Targeted (PARP)</strong> | Olaparib | Ovarian (Maintenance) | <strong>15 \u2013 19 Months</strong> |\n| <strong>Targeted (NTRK)</strong>| Larotrectinib | Solid Tumors (NTRK+) | <strong>25 \u2013 35+ Months</strong> |</p>\n<h3>Why does resistance happen?</h3>\n<ol>\n<li><strong>Target Alteration:</strong> The tumor mutates the specific protein the drug is attacking (common in Targeted Therapy).</li>\n<li><strong>Drug Efflux:</strong> The tumor cells build pumps to push chemotherapy out of the cell.</li>\n<li><strong>Microenvironment Changes:</strong> The tumor recruits immune-suppressing cells to block T-cells (common in Immunotherapy).</li>\n</ol>"}, {"model": "MedGemma 27B", "text": "<p>The time it takes for metastatic cancer patients to develop treatment resistance varies significantly depending on several factors. These include:</p>\n<ul>\n<li><strong>Type of Cancer:</strong> Different cancers have different intrinsic rates of mutation and adaptation. Some types are inherently more prone to developing resistance quickly than others. For example, certain lung cancers or melanomas might show rapid resistance development compared to some slower-growing sarcomas.</li>\n<li><strong>Specific Treatment Used:</strong> The mechanism of action of the drug influences how quickly resistance develops. Targeted therapies often face resistance due to specific mutations in the target pathway, while chemotherapy resistance is typically multifactorial involving mechanisms like increased drug efflux, altered metabolism, DNA repair enhancement, or apoptosis evasion. Immunotherapy resistance involves complex immune escape mechanisms.</li>\n<li><strong>Patient Factors:</strong> Individual genetic makeup, overall health status, prior treatments, and even lifestyle factors can influence susceptibility to resistance.</li>\n<li><strong>Tumor Heterogeneity:</strong> Tumors are rarely uniform; they consist of various subclones with differing sensitivities to treatment. Pre-existing resistant clones may survive initial therapy and drive relapse.</li>\n<li><strong>Treatment Schedule/Dosage:</strong> Suboptimal dosing or inconsistent adherence can contribute to faster resistance development.</li>\n</ul>\n<p>Given this complexity, providing a single \"average\" timeframe is difficult. However, we can discuss typical ranges observed clinically for different classes of drugs:</p>\n<p><strong>Chemotherapy Resistance:</strong></p>\n<ul>\n<li>Resistance to standard chemotherapies (like doxorubicin, paclitaxel, cisplatin) can emerge relatively <strong>quickly</strong>, sometimes within <strong>weeks to months</strong> of starting treatment. This is particularly true if the tumor was initially sensitive but then stops responding. In many cases, response durations before progression (indicating resistance) range from <strong>3 to 6 months</strong>. Longer responses (&gt;6 months) are possible but less common in advanced disease.</li>\n</ul>\n<p><strong>Targeted Therapy Resistance:</strong></p>\n<ul>\n<li>For targeted therapies (e.g., EGFR inhibitors in lung cancer, BRAF inhibitors in melanoma, PARP inhibitors in ovarian/breast cancer):<ul>\n<li>Initial responses can be quite good, lasting <strong>several months to over a year</strong> in some cases.</li>\n<li>However, acquired resistance is almost inevitable in most settings. The median duration of benefit before resistance emerges often falls between <strong>6 to 18 months</strong>, heavily dependent on the specific drug, target, and cancer type.</li>\n<li>Examples:<ul>\n<li>EGFR TKIs (lung cancer): Median PFS around 9-12 months before resistance.</li>\n<li>BRAF/</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>How long, on average, does it take metastatic patients to develop resistance? We can specify the type of resistance here, ie, to immunotherapy (PF-L1 inhibitors), chemotherapy (doxorubicin, paclitaxel, capecitabine, etc), and targeted therapy (PARP inhibitors, NTRK inhibitors, etc).</h1>\n<p>Typical time to resistance in metastatic breast cancer is inferred from progression\u2011free survival (PFS) on each regimen rather than measured directly, and it varies substantially by subtype and drug class. The numbers below are approximate \u201caverage\u201d times until resistance/progression for patients who initially benefit, not guarantees for any given individual.<a href=\"https://www.cancertodaymag.org/spring-2025/overcoming-resistance/\">^2</a><a href=\"https://www.sciencedirect.com/science/article/pii/S0167488922001380\">^8</a></p>\n<h2>Chemotherapy (doxorubicin, taxanes, capecitabine)</h2>\n<p>In metastatic breast cancer, cytotoxic regimens usually give responses that last months, not years, before resistance emerges.</p>\n<ul>\n<li>Anthracyclines and taxanes (e.g., doxorubicin, paclitaxel)<ul>\n<li>First\u2011line anthracycline\u2011 or taxane\u2011based chemotherapy in metastatic disease typically yields time to progression of about 6\u201310 months on average, reflecting the interval before clinical resistance is evident.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2972556/\">^2</a></li>\n<li>Subsequent lines (e.g., after prior anthracycline/taxane exposure) have shorter median PFS, often in the 3\u20136 month range, as increasingly resistant clones dominate.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2972556/\">^2</a></li>\n</ul>\n</li>\n<li>Capecitabine and other later\u2011line agents<ul>\n<li>Phase II/III data for capecitabine in previously treated metastatic breast cancer report median time to progression around 3\u20134 months in many cohorts, again reflecting rapid emergence of resistance in late\u2011line settings.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2972556/\">^2</a></li>\n<li>As patients move through more lines, the expected duration of benefit from each new chemotherapy often shrinks to just a few months in heavily pretreated, resistant disease.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2972556/\">^2</a></li>\n</ul>\n</li>\n</ul>\n<h2>Targeted therapy</h2>\n<h3>Endocrine + CDK4/6 inhibitors (HR\u2011positive / HER2\u2011negative)</h3>\n<ul>\n<li>In first\u2011line metastatic HR\u2011positive/HER2\u2011negative disease treated with an aromatase inhibitor plus a CDK4/6 inhibitor, median PFS is roughly 20\u201328 months; clinically, many patients remain controlled for about 2 years before acquired resistance and progression.<a href=\"https://www.sciencedirect.com/science/article/pii/S0167488922001380\">^4</a></li>\n<li>A minority have de novo resistance (progression within the first few months), but the majority develop acquired resistance after 2+ years on therapy, with some outliers remaining controlled &gt;5 years.<a href=\"https://www.cancertodaymag.org/spring-2025/overcoming-resistance/\">^8</a></li>\n</ul>\n<h3>HER2\u2011targeted therapy</h3>\n<ul>\n<li>For HER2\u2011positive metastatic disease, modern HER2\u2011targeted regimens (trastuzumab\u2011based combinations, T\u2011DM1, trastuzumab deruxtecan, tucatinib combinations) can achieve PFS on the order of 1\u20131.5 years in earlier lines, with later lines often providing median PFS in the 6\u201316 month range depending on the regimen and prior exposure.<a href=\"https://www.cwcare.net/renewed-hope-for-metastatic-breast-cancer/\">^1</a></li>\n<li>Historically, resistance to trastuzumab monotherapy or early combinations frequently emerged within about 1 year in metastatic patients; newer antibody\u2013drug conjugates and combinations have extended that window, but resistance still eventually appears.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2972556/\">^3</a></li>\n</ul>\n<h3>PARP inhibitors (BRCA\u2011mutated)</h3>\n<ul>\n<li>In germline BRCA\u2011mutated HER2\u2011negative metastatic breast cancer, PARP inhibitor trials typically show median PFS around 7\u20139 months, indicating that many patients develop PARP resistance in under a year, though some have more prolonged benefit.<a href=\"https://tbcr.amegroups.org/article/view/102886/html\">^1</a></li>\n<li>In patients pretreated with multiple prior lines, PFS can be shorter, reflecting prior selection of resistant clones and cross\u2011resistance with platinum.<a href=\"https://tbcr.amegroups.org/article/view/102886/html\">^1</a></li>\n</ul>\n<h3>NTRK and other rare kinase fusions</h3>\n<ul>\n<li>For tumors harboring NTRK fusions treated with TRK inhibitors, data are more limited in breast cancer specifically, but across solid tumors median PFS is often around 10\u201312 months before resistance via on\u2011target or bypass mechanisms.<a href=\"https://tbcr.amegroups.org/article/view/102886/html\">^1</a></li>\n<li>In general, highly \u201caddicted\u201d kinase\u2011fusion tumors often respond quickly but acquire resistance mutations within roughly a year on average, though individual durations vary widely.<a href=\"https://tbcr.amegroups.org/article/view/102886/html\">^1</a></li>\n</ul>\n<h2>Immunotherapy (PD\u20111/PD\u2011L1 inhibitors)</h2>\n<ul>\n<li>In metastatic triple\u2011negative breast cancer treated with PD\u20111/PD\u2011L1 inhibitors plus chemotherapy, median PFS in trials has been in the range of ~5\u20139 months depending on PD\u2011L1 status and line of therapy, indicating that many patients progress within the first year despite initial responses.<a href=\"https://tbcr.amegroups.org/article/view/102886/html\">^1</a></li>\n<li>Durable responses beyond 1\u20132 years do occur in a subset of immunotherapy\u2011responsive patients, but they are a minority; primary or early acquired resistance is common in TNBC.<a href=\"https://tbcr.amegroups.org/article/view/102886/html\">^5</a></li>\n</ul>\n<h2>How to interpret \u201ctime to resistance\u201d across modalities</h2>\n<ul>\n<li>For most cytotoxic chemotherapies in metastatic breast cancer, average time to resistance is on the order of <strong>3\u201310 months</strong>, shorter with later lines.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2972556/\">^2</a></li>\n<li>For targeted endocrine\u2011based regimens (CDK4/6 + endocrine) and some HER2\u2011targeted combinations, the typical window before resistance is <strong>around 1.5\u20132+ years</strong> in first\u2011line settings.<a href=\"https://www.cancertodaymag.org/spring-2025/overcoming-resistance/\">^3</a><a href=\"https://www.sciencedirect.com/science/article/pii/S0167488922001380\">^8</a></li>\n<li>For PARP inhibitors, many patients develop resistance within <strong>~6\u201312 months</strong>, especially in pretreated settings.<a href=\"https://tbcr.amegroups.org/article/view/102886/html\">^1</a></li>\n<li>For immunotherapy in TNBC, <strong>most progression occurs within the first year</strong>, though a subset have long\u2011term control.<a href=\"https://tbcr.amegroups.org/article/view/102886/html\">^5</a></li>\n</ul>\n<p>Conceptually, these are population medians: resistance can arise much earlier in aggressive biology (e.g., metastatic TNBC) and much later in indolent HR\u2011positive disease, and any individual patient may fall well above or below the median curve.<a href=\"https://www.nature.com/articles/s41416-020-01161-4\">^6</a><a href=\"https://tbcr.amegroups.org/article/view/102886/html\">^1</a>\n<span style=\"display:none\"><a href=\"https://www.fredhutch.org/en/diseases/breast-cancer/metastatic-breast-cancer.html\">^7</a></span></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>ents to develop resistance? a. We can specify the type of resistance here, ie, to immunotherapy (PF-L1 inhibitors), chemotherapy (doxorubicin, paclitaxel, capecitabine, etc), and targeted therapy (PARP inhibitors, NTRK inhibitors, etc). <strong>The time to resistance development in metastatic breast cancer varies substantially by therapy type and breast cancer subtype</strong> , with median progression-free survival ranging from approximately 3-11 months across different treatment modalities.</p>\n<h2>Immunotherapy (PD-1/PD-L1 Inhibitors)</h2>\n<p><strong>For pembrolizumab plus chemotherapy in PD-L1-positive (CPS \u226510) triple-negative breast cancer</strong> , the KEYNOTE-355 study demonstrated a progression-free survival benefit, though the exact median PFS varies by chemotherapy backbone used. In the IMpassion130 trial, <strong>atezolizumab plus nab-paclitaxel improved progression-free survival by approximately 2.5 months in PD-L1-positive TNBC</strong> (&gt;1% expression).[1]</p>\n<p>However, the overall survival analysis showed no significant difference between treatment groups, though it suggested a clinically meaningful OS benefit of about 10 months with atezolizumab plus nab-paclitaxel in the PD-L1-positive population.[1]</p>\n<p>In a real-world cohort of TMB-high metastatic breast cancer patients treated with immune checkpoint inhibitors, <strong>median progression-free survival was only 3.17 months (95% CI 2.27-5.5)</strong> across all patients, though this was a heavily pretreated population (median 5th line therapy).[2]</p>\n<p>Notably, shorter PFS was significantly associated with later treatment lines (HR 1.22 per line, 95% CI 1.11-1.36, p=0.0001).[2]</p>\n<h2>Chemotherapy</h2>\n<p><strong>Time to resistance varies considerably by agent and breast cancer subtype:</strong> <strong>Doxorubicin-containing regimens:</strong> In a large reference cohort of 1,581 patients with metastatic breast cancer, <strong>median progression-free survival was 11.5 months (95% CI 10.9-12.3 months)</strong> with doxorubicin-containing combination chemotherapy.[3]</p>\n<p>Median overall survival was 21.3 months.[3] <strong>Paclitaxel:</strong> In metastatic breast cancer patients receiving paclitaxel-containing chemotherapy, <strong>median time to treatment failure was 11.2 months (95% CI 9.5-12.9) in patients who developed early peripheral neuropathy</strong> versus 5.7 months (95% CI 4.6-6.8) in those without early neuropathy.[4] <strong>Capecitabine:</strong> As monotherapy for HER2-normal metastatic breast cancer, <strong>median progression-free survival was 4.3 months overall</strong> , with significant differences by ER status: 5.3 months for ER-positive versus 2.5 months for ER-negative disease (p=0.006).[5]</p>\n<p>Median overall survival was 14 months overall, 17.8 months for ER- positive versus 7.6 months for ER-negative disease (p\u22640.0001).[5]</p>\n<p>Treatment schedule influences resistance development. <strong>Intermittent doxorubicin exposure induced resistance more readily than continuous exposure</strong> , with ER-positive MCF-7 cells developing resistance earlier and at higher levels compared to triple-negative MDA-MB-231 cells.[6]</p>\n<h2>PARP Inhibitors</h2>\n<p><strong>For olaparib and talazoparib in germline BRCA1/2-mutant metastatic breast cancer</strong> , these agents are recommended as category 1, preferred first-line therapy for triple-negative disease with PD-L1 CPS [7]</p>\n<p>While specific median PFS data varies by trial, <strong>approximately 40-60% of patients develop resistance to PARP inhibitors</strong> , with BRCA reversion mutations detected in 43% of breast cancer patients at progression on olaparib (compared to only 9% receiving chemotherapy).[8] <strong>BRCA reversion mutations can be detected in circulating tumor DNA before clinical progression</strong> in some cases, with 10 patients showing detectable reversions prior to radiographic progression.[8]</p>\n<p>When reversions are detected before commencing subsequent treatment, they associate with significantly shorter time to progression.[8]</p>\n<h2>NTRK Inhibitors</h2>\n<p><strong>For larotrectinib in NTRK fusion-positive solid tumors</strong> (including breast cancer), an integrated analysis showed <strong>median progression-free survival of 11 months (95% CI 8.0-14.9)</strong> and median overall survival of 21 months (95% CI 14.9 to not estimable). [9] <strong>For entrectinib</strong> , updated analysis demonstrated <strong>median progression-free survival of 13.8 months (95% CI 10.1-19.9)</strong> and median overall survival of 33.8 months (95% CI 23.4-46.4).[9]</p>\n<p>The median duration of response was 20.0 months (95% CI 13.0-38.2).[9]</p>\n<h2>Clinical Context The likelihood and timing of resistance development is influenced by multiple factors including treatment line, tumor burden, receptor status, and prior therapies.</h2>\n<p><strong>In HR+/HER2- metastatic breast cancer receiving first-line CDK4/6 inhibitor plus endocrine therapy, resistance inevitably develops in most patients despite approximately 20% achieving long-term disease control at five years</strong> . After CDK4/6 inhibitor progression, only 40.5% of patients achieved at least 6 months of benefit from second-line therapy. Would you like me to summarize the mechanisms underlying these different timelines to resistance, or discuss strategies for predicting and potentially delaying resistance development based on biomarkers or treatment sequencing? Would you like me to review the latest evidence on clinical and molecular biomarkers that can predict early resistance to these therapies in metastatic breast cancer, and how they might guide personalized treatment selection or sequencing?</p>\n<h3>References</h3>\n<ol>\n<li>Breast Cancer. Loibl S, Poortmans P , Morrow M, Denkert C, Curigliano G. Lancet (London, England). 2021;397(10286):1750-1769. doi:10.1016/S0140-6736(20)32381-3.</li>\n<li>Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response. Mai N, Safonov A, Marra A, et al. Journal of Clinical Oncology. 2024;42(Suppl 16):1078. doi:10.1200/JCO.2024.42.16_suppl.1078.</li>\n<li>Results and Long Term Follow-Up for 1581 Patients With Metastatic Breast Carcinoma Treated With Standard Dose Doxorubicin-Containing Chemotherapy: A Reference. Rahman ZU, Frye DK, Smith TL, et al. Cancer. 1999;85(1):104-11. doi:10.1002/(sici)1097-0142(19990101)85:13.0.co;2-r.</li>\n<li>The Early Onset of Peripheral Neuropathy Might Be a Robust Predictor for Time to Treatment Failure in Patients With Metastatic Breast Cancer Receiving Chemotherapy Containing Paclitaxel. Fukada I, Ito Y , Kobayashi K, et al. PloS One. 2017;12(9):e0184322. doi:10.1371/journal.pone.0184322.</li>\n<li>Effect of Capecitabine as Monotherapy for HER2 Normal Metastatic Breast Cancer. Knudsen AM, Modvig MW, Vogsen M, Kodahl AR. Medical Oncology (Northwood, London, England). 2024;41(5):99. doi:10.1007/s12032-024- 02356-y.</li>\n<li>Treatment Schedule and Estrogen Receptor-Status Influence Acquisition of Doxorubicin Resistance in Breast Cancer Cells. Ponnusamy L, Mahalingaiah PKS, Singh KP . European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences. 2017;104:424-433. doi:10.1016/j.ejps.2017.04.020.</li>\n<li>Breast Cancer. National Comprehensive Cancer Network. Updated 2025-10-16.</li>\n<li>Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches. Dilmac S, Ozpolat B. Cancers. 2023;15(14):3642. doi:10.3390/cancers15143642.</li>\n<li>Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Henry NL, Somerfield MR, Dayao Z, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2022;40(27):3205-3221. doi:10.1200/JCO.22.01063. 11.</li>\n</ol>"}]}, "11": {"question": "Does Oncotype Dx, or the various mutations it tests for, predict future resistance? Oncotype Dx is a category 1 recommendation and thus the gold standard.  It assesses 21 different genes and provides both prognostic and predictive information.  For example, it is clinically used to determine what patients will benefit from chemotherapy bui is not necessarily used to determine resistance.  However, it may be useful to assess these core 21 genes.  There are other assays as well, such as MammaPrint, Prosigna, EndoPredict, and BCI.  Do these assays test for any unique genes not already covered by Oncotype, that may predict resistance?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>No, all of these assays cover similar ground as Oncotype Dx with respect to prediction of recurrence and response to therapy.</p>"}, {"model": "GPT-4o", "text": "<p>Oncotype DX is a genomic test that analyzes the expression of 21 genes to provide both prognostic and predictive information for breast cancer patients, particularly those with early-stage, hormone receptor-positive, HER2-negative breast cancer. It helps determine the likelihood of benefit from chemotherapy and the risk of recurrence. However, it is not specifically designed to predict resistance to therapy.</p>\n<p>Regarding the prediction of resistance, Oncotype DX primarily focuses on assessing the risk of recurrence and the potential benefit from chemotherapy rather than directly predicting resistance mechanisms. Resistance to therapy often involves complex biological processes and may require more specific assays or research to identify.</p>\n<p>Other genomic assays like MammaPrint, Prosigna (PAM50), EndoPredict, and Breast Cancer Index (BCI) also provide prognostic and/or predictive information but differ in the genes they analyze and their specific applications:</p>\n<ol>\n<li>\n<p><strong>MammaPrint</strong>: Analyzes 70 genes to assess the risk of distant metastasis in early-stage breast cancer. It provides prognostic information but does not specifically predict resistance.</p>\n</li>\n<li>\n<p><strong>Prosigna (PAM50)</strong>: Based on the expression of 50 genes, it classifies breast cancer into intrinsic subtypes and provides a risk of recurrence score. It offers prognostic information and some predictive insights but is not specifically designed to predict resistance.</p>\n</li>\n<li>\n<p><strong>EndoPredict</strong>: Evaluates 12 genes to provide prognostic information for distant recurrence in hormone receptor-positive, HER2-negative breast cancer. It focuses on prognosis rather than resistance prediction.</p>\n</li>\n<li>\n<p><strong>Breast Cancer Index (BCI)</strong>: Combines two gene expression profiles to assess the risk of late recurrence and the potential benefit from extended endocrine therapy. It provides prognostic and some predictive information but is not specifically focused on resistance.</p>\n</li>\n</ol>\n<p>These assays may include some unique genes not covered by Oncotype DX, but their primary focus is on prognosis and treatment benefit rather than directly predicting resistance. Predicting resistance often requires a more detailed understanding of specific mutations or pathways involved in resistance mechanisms, which may not be fully captured by these assays. Research into specific mutations or pathways associated with resistance is ongoing, and new assays or biomarkers may emerge to address this need in the future.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>This is a sophisticated question that touches on the nuance between <strong>intrinsic resistance</strong> (the tumor is resistant from the start) and <strong>acquired resistance</strong> (the tumor develops resistance over time), as well as the difference between predicting <strong>recurrence</strong> versus predicting <strong>drug benefit</strong>.</p>\n<p>Here is the breakdown of how Oncotype DX relates to resistance, and how other assays (specifically Breast Cancer Index) analyze unique genes to answer questions Oncotype cannot.</p>\n<h3>1. Does Oncotype DX predict future resistance?</h3>\n<p><strong>Short Answer:</strong> It predicts <strong>intrinsic sensitivity</strong>, not acquired resistance.</p>\n<p>Oncotype DX analyzes the expression of 21 genes (16 cancer-related, 5 reference). These genes fall into specific groups: Proliferation, Invasion, HER2, and Estrogen.</p>\n<ul>\n<li><strong>Intrinsic Resistance (Primary):</strong> A high Recurrence Score (RS) essentially tells us that the tumor is biologically aggressive and has <strong>intrinsic resistance to endocrine therapy alone</strong>. The estrogen signaling pathway is overwhelmed by proliferation signals. Therefore, the assay predicts that the patient will likely be resistant to Tamoxifen or Aromatase Inhibitors (AIs) unless chemotherapy is added.</li>\n<li><strong>Acquired Resistance (Secondary):</strong> Oncotype DX <strong>does not</strong> predict if a tumor will mutate later (e.g., developing an <em>ESR1</em> mutation) to become resistant after 5 years of treatment. It provides a snapshot of the tumor's biology at the time of surgery.</li>\n</ul>\n<p><strong>Key Limitation:</strong> Oncotype DX is excellent at predicting recurrence in the first 5 years. It is statistically weaker at predicting \"late recurrence\" (years 5\u201310), which is the window where endocrine resistance typically manifests.</p>\n<h3>2. Do other assays test for unique genes that predict resistance?</h3>\n<p>Yes. While MammaPrint, Prosigna, and EndoPredict are largely concordant with Oncotype regarding risk stratification, <strong>Breast Cancer Index (BCI)</strong> and <strong>Prosigna</strong> offer unique genomic insights regarding resistance and late recurrence that Oncotype does not cover.</p>\n<p>Here is the breakdown of the competitors and their unique contributions:</p>\n<h4>A. Breast Cancer Index (BCI) \u2013 The Standout for Resistance</h4>\n<p>BCI is the most distinct from Oncotype regarding the prediction of endocrine resistance. It is currently the only assay recognized by the NCCN to predict the benefit of <strong>extended</strong> endocrine therapy (years 5\u201310).</p>\n<ul>\n<li><strong>Unique Genes:</strong> BCI analyzes a two-gene ratio: <strong>HOXB13</strong> and <strong>IL17BR</strong> (the H/I ratio).</li>\n<li><strong>The Mechanism:</strong> These genes are <strong>not</strong> in the Oncotype 21-gene panel.<ul>\n<li><strong>IL17BR</strong> is associated with estrogen signaling.</li>\n<li><strong>HOXB13</strong> suppresses estrogen receptor signaling.</li>\n</ul>\n</li>\n<li><strong>Predicting Resistance:</strong> The H/I ratio measures the tumor's dependence on estrogen signaling.<ul>\n<li><strong>High H/I Ratio:</strong> The tumor remains sensitive to endocrine therapy; the patient benefits from extending therapy to 10 years.</li>\n<li><strong>Low H/I Ratio:</strong> The tumor has likely developed <strong>endocrine resistance</strong> (or was never fully dependent); extending therapy offers no benefit and only toxicity.</li>\n</ul>\n</li>\n</ul>\n<h4>B. Prosigna (PAM50)</h4>\n<p>Prosigna looks at 50 genes to classify the tumor into an \"Intrinsic Subtype\" (Luminal A, Luminal B, HER2-enriched, Basal-like).</p>\n<ul>\n<li><strong>Unique Insight:</strong> It distinguishes between <strong>Luminal A</strong> and <strong>Luminal B</strong>.</li>\n<li><strong>Resistance Connection:</strong> Luminal B tumors express higher proliferation genes and lower progesterone receptor levels than Luminal A. While Oncotype might lump some of these into intermediate scores, Prosigna identifies Luminal B as having a distinct, higher risk of late recurrence (post-5 years), implying a form of resistance to standard endocrine suppression that requires more aggressive management.</li>\n</ul>\n<h4>C. EndoPredict</h4>\n<p>EndoPredict analyzes 12 genes. Unlike Oncotype, which heavily weighs proliferation, EndoPredict integrates tumor size and nodal status into its final score (EPclin).</p>\n<ul>\n<li><strong>Resistance Connection:</strong> EndoPredict has been shown to be superior to Oncotype DX in predicting <strong>late recurrence</strong> (years 5\u201310). While it doesn't necessarily identify a unique \"resistance gene\" like BCI's H/I ratio, its algorithm is better tuned to identify slow-growing tumors that survive initial endocrine therapy and recur later (a hallmark of dormancy and resistance).</li>\n</ul>\n<h4>D. MammaPrint</h4>\n<p>MammaPrint assesses 70 genes. It is a binary test (High Risk vs. Low Risk).</p>\n<ul>\n<li><strong>Resistance Connection:</strong> It is primarily a prognostic tool for chemotherapy benefit (similar to Oncotype). It does not offer a specific predictive value for endocrine resistance or the benefit of extended endocrine therapy distinct from its general risk assessment.</li>\n</ul>\n<h3>Summary Comparison</h3>\n<p>| Assay | Key Genes/Mechanism | Unique from Oncotype? | Predicts Resistance? |\n| :--- | :--- | :--- | :--- |\n| <strong>Oncotype DX</strong> | 21 Genes (Proliferation, ER, HER2) | N/A (Gold Standard) | Predicts <strong>Intrinsic</strong> resistance to endocrine therapy (need for chemo). |\n| <strong>Breast Cancer Index (BCI)</strong> | <strong>HOXB13 / IL17BR Ratio</strong> | <strong>YES</strong> | <strong>YES.</strong> Specifically predicts sensitivity/resistance to extended endocrine therapy (years 5-10). |\n| <strong>Prosigna</strong> | PAM50 (Subtyping) | Yes (Subtypes) | Identifies Luminal B (prone to late recurrence/resistance). |\n| <strong>EndoPredict</strong> | 12 Genes + Clinical features | Algorithm | Better predictor of late recurrence (resistance) than Oncotype. |</p>\n<h3>Conclusion</h3>\n<p>If you are looking for a test that predicts <strong>future resistance</strong> to help decide on extending anti-hormonal therapy beyond 5 years, <strong>Oncotype DX is not the right tool.</strong></p>\n<p>The <strong>Breast Cancer Index (BCI)</strong> is the assay that tests for unique genes (HOXB13/IL17BR) specifically validated to determine if the tumor retains sensitivity to endocrine therapy or has become resistant.</p>"}, {"model": "MedGemma 27B", "text": "<p>This is an excellent question delving into the nuances of genomic testing in breast cancer treatment decisions. Let's break down the key points regarding Oncotype DX, its relationship to predicting future resistance, and how it compares to other available assays like MammaPrint, Prosigna, EndoPredict, and Breast Cancer Index (BCI).</p>\n<p><strong>Oncotype DX and Resistance Prediction:</strong></p>\n<ul>\n<li><strong>Primary Purpose:</strong> The primary clinical use of Oncotype DX is <em>not</em> directly predicting future drug resistance. Its main goal is to provide <strong>prognostic</strong> (risk of recurrence without adjuvant therapy) and <strong>predictive</strong> (likelihood of benefiting from specific adjuvant therapies, primarily chemotherapy) information for early-stage, hormone receptor-positive (HR+), HER2-negative invasive breast cancers.</li>\n<li><strong>Recurrence Score Calculation:</strong> The Recurrence Score (RS) generated by Oncotype DX integrates expression levels across 21 genes (including proliferation genes like Ki67, cell cycle regulators, and wound response genes) to estimate the risk of distant recurrence over 9 years if no systemic therapy beyond endocrine therapy is given. It also helps stratify patients based on their potential benefit from adding chemotherapy to endocrine therapy.</li>\n<li><strong>Indirect Link to Resistance:</strong> While Oncotype DX doesn't explicitly measure known mechanisms of chemoresistance, certain gene signatures within the panel can indirectly correlate with outcomes related to resistance. For instance:<ul>\n<li>High proliferative activity (indicated by high scores on genes involved in cell division) might suggest tumors that respond less favorably to some chemotherapies initially but could potentially develop resistance more quickly due to rapid growth dynamics.</li>\n<li>Specific patterns of gene expression might reflect underlying biological pathways associated with intrinsic or acquired resistance, although this isn't the assay's designed purpose.</li>\n</ul>\n</li>\n<li><strong>Focus on Benefit vs. Risk:</strong> The RS focuses on whether the <em>benefit</em> of chemotherapy outweighs the risks/side effects for a particular patient profile. A low score suggests minimal benefit, while a high score indicates significant benefit. This implicitly considers factors influencing overall outcome, which includes sensitivity to initial therapy. However, it does not pinpoint <em>why</em> a tumor might become resistant later.</li>\n</ul>\n<p><strong>Comparison with Other Assays &amp; Unique Genes:</strong></p>\n<p>Let's look at the other mentioned assays and see if they offer insights into resistance through different genetic markers:</p>\n<ul>\n<li><strong>MammaPrint (70-gene signature):</strong> Focuses heavily on proliferation and differentiation status using a larger set of genes than Oncotype</li>\n</ul>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Does Oncotype Dx, or the various mutations it tests for, predict future resistance? Oncotype Dx is a category 1 recommendation and thus the gold standard.  It assesses 21 different genes and provides both prognostic and predictive information.  For example, it is clinically used to determine what patients will benefit from chemotherapy bui is not necessarily used to determine resistance.  However, it may be useful to assess these core 21 genes.  There are other assays as well, such as MammaPrint, Prosigna, EndoPredict, and BCI.  Do these assays test for any unique genes not already covered by Oncotype, that may predict resistance?</h1>\n<p>Oncotype DX and other multigene assays are validated to predict recurrence risk and (for some assays) chemotherapy benefit, but they are not currently used as direct, mechanistic predictors of future molecular resistance (e.g., which resistance mutation will emerge or when). They do, however, enrich for biology that is more or less likely to become treatment\u2011refractory over time, and some assays include genes not present in Oncotype that may better reflect endocrine or late recurrence risk.</p>\n<h2>What Oncotype DX actually predicts</h2>\n<ul>\n<li>Oncotype DX (21\u2011gene Recurrence Score, RS) is validated in ER+/HER2\u2011, early\u2011stage disease as:<ul>\n<li>Prognostic for distant recurrence risk.</li>\n<li>Predictive for <em>benefit</em> from adjuvant chemotherapy versus endocrine therapy alone.</li>\n</ul>\n</li>\n<li>High RS captures high proliferation and lower hormone dependence (via Ki\u201167\u2011like genes, cell\u2011cycle genes, and lower ER\u2011related gene expression), which corresponds to a tumor more likely to:<ul>\n<li>Relapse despite endocrine therapy.</li>\n<li>Derive meaningful benefit from chemotherapy.</li>\n</ul>\n</li>\n</ul>\n<p>In practice, a high RS signals biology that is <em>prone</em> to endocrine resistance and early recurrence, but the assay is not calibrated to predict specific resistance mechanisms (e.g., ESR1 mutation, PI3K activation) or resistance timing; it is a composite risk index rather than a resistance\u2011mechanism panel.</p>\n<h3>The 21\u2011gene panel and resistance</h3>\n<p>Oncotype\u2019s 21 genes fall into groups:</p>\n<ul>\n<li>Proliferation: Ki\u201167 (MKI67), STK15, Survivin (BIRC5), CCNB1, MYBL2.</li>\n<li>ER group: ER (ESR1), PGR, BCL2, SCUBE2.</li>\n<li>HER2 group: HER2 (ERBB2), GRB7.</li>\n<li>Others: GSTM1, CD68, BAG1, plus reference genes.</li>\n</ul>\n<p>Mechanistically:</p>\n<ul>\n<li>High proliferation and low ER\u2011group expression are consistent with reduced endocrine sensitivity and earlier endocrine resistance.</li>\n<li>HER2/GRB7 signal more HER2\u2011like biology, which is associated with greater chemo benefit and potentially more aggressive disease.</li>\n</ul>\n<p>But Oncotype does not test many canonical resistance genes (e.g., ESR1 hotspot mutations, PIK3CA, PTEN, BRCA1/2, RB1, NF1, FGFRs), so it cannot directly indicate which resistance pathways will be activated.</p>\n<h2>Other assays vs Oncotype: do they add resistance\u2011related genes?</h2>\n<p>Each multigene test uses a different gene set and algorithm, designed with slightly different goals (early vs late recurrence, endocrine vs chemo benefit, etc.). Some include biology that is closer to \u201cresistance signaling\u201d than Oncotype.</p>\n<h3>MammaPrint (70\u2011gene signature)</h3>\n<ul>\n<li>Primarily prognostic (high vs low risk of early metastasis) in both ER+ and ER\u2013 disease.</li>\n<li>Gene content is heavily weighted toward cell cycle, invasion, and metastasis biology rather than specific resistance genes.</li>\n<li>It does not directly assay canonical resistance drivers like ESR1 mutations or PI3K\u2011pathway genes; instead, like Oncotype, it captures a global \u201caggressive vs indolent\u201d phenotype that correlates with risk of failure on standard therapy, not specific mechanisms.</li>\n</ul>\n<h3>Prosigna (PAM50 / ROR score)</h3>\n<ul>\n<li>Uses 50 classifier genes to assign intrinsic subtype (Luminal A/B, HER2\u2011enriched, Basal\u2011like) and provide a Risk of Recurrence score.</li>\n<li>Because intrinsic subtype is strongly linked to patterns of resistance (e.g., Luminal A \u2192 endocrine\u2011sensitive, Basal\u2011like/TNBC \u2192 more chemo\u2011dependent and resistance\u2011prone), Prosigna indirectly stratifies resistance risk.</li>\n<li>It includes genes that characterize basal and HER2\u2011enriched biology (e.g., proliferation, HER2, basal cytokeratins) not explicitly targeted in Oncotype; that can point to tumors more likely to develop rapid chemo/endocrine resistance than classic Luminal A.</li>\n</ul>\n<h3>EndoPredict (EP/EPclin)</h3>\n<ul>\n<li>Designed specifically to predict distant recurrence, including late recurrence (5\u201310 years) in ER+/HER2\u2011 patients treated with endocrine therapy.</li>\n<li>Includes proliferation\u2011related and ER\u2011signaling genes, but also genes involved in growth factor signaling and invasion.</li>\n<li>Because it is tuned to late recurrence under endocrine therapy, it may be more informative than Oncotype about long\u2011term endocrine resistance risk, even though it still does not genotype specific resistance mutations.</li>\n</ul>\n<h3>Breast Cancer Index (BCI)</h3>\n<ul>\n<li>Combines HOXB13/IL17BR ratio (H/I) with a proliferation module.</li>\n<li>BCI is used to:<ul>\n<li>Prognosticate late distant recurrence risk beyond 5 years.</li>\n<li>Predict benefit from extended endocrine therapy (e.g., continuing tamoxifen or AI to 10 years).</li>\n</ul>\n</li>\n<li>The H/I component reflects ER pathway and growth factor signaling balance: higher H/I is associated with endocrine resistance biology and greater benefit from extended endocrine therapy.</li>\n<li>In that sense, BCI gives more <em>directly resistance\u2011relevant</em> information than Oncotype for endocrine therapy decisions (who is at risk for late endocrine escape and who gains from continued therapy).</li>\n</ul>\n<h2>Unique or additional biology vs Oncotype</h2>\n<p>At a gene\u2011set level:</p>\n<ul>\n<li>Oncotype, MammaPrint, Prosigna, EndoPredict, and BCI each have largely non\u2011overlapping gene lists, but many genes map to overlapping pathways: proliferation, ER signaling, HER2 signaling, invasion, stromal/immune components.</li>\n<li>None of the standard commercial assays is designed as a targeted \u201cresistance gene panel\u201d (e.g., they do not systematically test for ESR1, PIK3CA, BRCA, or acquired resistance mutations), so they do not uniquely identify specific molecular resistance mechanisms.</li>\n<li>The main <em>added value</em> versus Oncotype is:<ul>\n<li>Better characterization of intrinsic subtype (Prosigna) \u2192 stronger link to long\u2011term therapy response patterns.</li>\n<li>More emphasis on late recurrence and endocrine resistance (EndoPredict, BCI).</li>\n<li>Broader risk stratification across ER+/ER\u2013 and node\u2011positive disease (MammaPrint).</li>\n</ul>\n</li>\n</ul>\n<h2>Practical answer to your question</h2>\n<ul>\n<li>Oncotype DX and related assays are best viewed as <strong>risk and treatment\u2011benefit stratifiers</strong>, not as precise resistance\u2011mechanism predictors.</li>\n<li>High\u2011risk scores on any of these assays correlate with biology that tends to become resistant sooner (higher proliferation, less ER dependence, more aggressive signature), but they are not validated to predict <em>which</em> resistance pathway will emerge or <em>exactly</em> when.</li>\n<li>Other assays (especially Prosigna and BCI) include gene sets and design goals that are more focused on endocrine\u2011response phenotype and late recurrence, and thus may better approximate long\u2011term endocrine resistance risk than Oncotype alone, but they still stop short of being true \u201cresistance panels.\u201d</li>\n</ul>\n<p>If you want to use these assays to think about resistance, the current evidence supports using them to:</p>\n<ul>\n<li>Identify patients with more indolent, endocrine\u2011sensitive biology (low scores, Luminal A, low H/I).</li>\n<li>Flag those with more aggressive or endocrine\u2011refractory biology (high scores, non\u2011Luminal, high H/I).</li>\n</ul>\n<p>But for specific resistance mechanisms or for tailoring therapy after resistance emerges, sequencing\u2011based assays and focused mutation testing (ESR1, PIK3CA, BRCA1/2, etc.) are far more informative than the 21\u2011gene or 50\u2011gene expression panels.\n<span style=\"display:none\"><a href=\"https://www.oncotypedxtest.com/en-ca/healthcare-professionals/what-is-prognosis-and-prediction\">^1</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10139850/\">^2</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5827461/\">^4</a><a href=\"https://www.sciencedirect.com/science/article/abs/pii/S030573722500009X\">^6</a><a href=\"https://ascopubs.org/doi/10.1200/GO.24.00112\">^8</a></span></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>s for, predict future resistance? a. Oncotype Dx is a category 1 recommendation and thus the gold standard. It assesses 21 different genes and provides both prognostic and predictive information. For example, it is clinically used to determine what patients will benefit from chemotherapy bui is not necessarily used to determine resistance. However, it may be useful to assess these core 21 genes. There are other assays as well, such as MammaPrint, Prosigna, EndoPredict, and BCI. Do these assays test for any unique genes not already covered by Oncotype, that <strong>Oncotype DX's 21-gene panel provides prognostic information about recurrence risk but was not specifically designed to predict resistance to therapy</strong> , though its molecular drivers offer some insights into potential resistance mechanisms. The other commercially available assays (MammaPrint, Prosigna, EndoPredict, and Breast Cancer Index) evaluate different gene sets that may capture complementary aspects of tumor biology relevant to treatment response.</p>\n<h2>Oncotype DX and Resistance Prediction</h2>\n<p>**Oncotype DX is primarily predictive of chemotherapy benefit rather than resistance per se. ** The TAILORx and RxPONDER trials demonstrated that patients with low recurrence scores (RS [1]</p>\n<p>However, this reflects initial chemosensitivity rather than acquired resistance mechanisms. <strong>The molecular drivers of the Oncotype DX recurrence score reveal important limitations for resistance prediction. ** In contrast to common understanding, </strong>RS is determined more strongly by estrogen-related features (\u03c1 = -0.79) and only weakly by proliferation markers (\u03c1 = 0.36)** .[2]</p>\n<p>The estrogen module explains only 0.6% of variance in other prognostic tests, while the proliferation module explains 72.5% of ROR's variance.[2]</p>\n<p>This means Oncotype DX may miss proliferation-driven resistance mechanisms that are better captured by other assays. Notably, <strong>race-based disparities in outcomes exist even with similar RS values</strong> . In TAILORx, Black patients with RS 11-25 had significantly worse outcomes compared to White patients for invasive disease-free survival and distant recurrence-free interval, yet showed no evidence of chemotherapy benefit.[3]</p>\n<p>This suggests that the 21- gene panel may not fully capture all resistance mechanisms across diverse populations.</p>\n<h2>Unique Genes in Other Assays</h2>\n<p><strong>Each assay evaluates distinct gene sets that may provide complementary information about resistance:</strong> <strong>MammaPrint (70-gene assay):</strong> Evaluates a broader genomic profile than Oncotype DX and is prognostic for distant recurrence in both node-negative and node-positive disease.[1]</p>\n<p>The MINDACT trial showed that patients with high clinical risk but low genomic risk had 8-year distant metastasis-free survival of 89.4% without chemotherapy.[1]</p>\n<p>However, <strong>MammaPrint has not been validated to predict chemotherapy benefit</strong> , limiting its utility for resistance prediction.[1] may predict resistance? <strong>Prosigna (PAM50, 50-gene assay):</strong> <strong>Is determined largely by proliferative features (72.5% of variance explained by proliferation module)</strong> , which may better capture proliferation-driven resistance mechanisms than Oncotype DX.[2]</p>\n<p>Prosigna provides intrinsic subtype classification (luminal A, luminal B, HER2-enriched, basal- like) and risk of recurrence scores.[1]</p>\n<p>In node-positive patients with low ROR scores treated with endocrine therapy alone, distant recurrence risk was less than 3.5% at 10 years.[1]</p>\n<p>Like MammaPrint, it has not been validated to predict chemotherapy benefit.[1] <strong>EndoPredict (12-gene assay):</strong> <strong>50.0% of its variance is accounted for by the proliferation module and 20.2% by the estrogen module</strong> , providing a different balance than Oncotype DX.[2]</p>\n<p>The assay is prognostic in patients treated with both endocrine and chemo-endocrine therapy.[1]</p>\n<p>In low-risk patients, distant recurrence risk was 4% at 10 years (ABCSG 6/8) and 5.6% in node-positive patients (TransATAC).[1] <strong>Breast Cancer Index (BCI):</strong> <strong>54.3% of variance explained by proliferation and only 2.7% by estrogen features</strong> .[2]</p>\n<p>Uniquely, BCI is <strong>predictive of benefit from extended adjuvant endocrine therapy</strong> .[1]</p>\n<p>Patients with BCI (H/I) high demonstrated significant improvements in disease-free survival when adjuvant endocrine therapy was extended in secondary analyses of MA.17, Trans-aTTom, and IDEAL trials.[1]</p>\n<p>This addresses late resistance to endocrine therapy specifically.</p>\n<h2>Potential Utility for Resistance Prediction</h2>\n<p><strong>The core 21 genes in Oncotype DX could theoretically inform resistance risk, but with important caveats:</strong> The genes include proliferation markers (Ki-67, STK15, Survivin, Cyclin B1, MYBL2), invasion genes (MMP11, CTSL2), HER2 group (GRB7, HER2), and estrogen group (ER, PGR, BCL2, SCUBE2).[2]</p>\n<p>However, since <strong>RS correlates weakly with proliferation (the primary driver of most resistance mechanisms discussed earlier in our conversation)</strong> , it may underestimate resistance risk in highly proliferative tumors. <strong>Gene expression signatures can change after neoadjuvant treatment</strong> , with proliferation-associated genes downregulated in post-treatment ER+ tumors but not in triple-negative breast cancer, and extracellular matrix genes upregulated across subtypes.[4]</p>\n<p>This suggests that <strong>serial assessment of gene expression profiles could potentially track emerging resistance</strong> , though this is not current standard practice. **The benefit of testing these assays for predicting resistance to specific targeted therapies is unknown. ** The NCCN guidelines note that the benefit of BCI testing for extended endocrine therapy is unknown in patients who received ovarian function suppression, CDK4/6 inhibitors, or olaparib in addition to adjuvant endocrine therapy.[1]</p>\n<p>This limitation likely extends to other assays and resistance scenarios. Would you like me to summarize emerging research on dynamic or serial gene expression profiling during treatment to detect early molecular changes that might predict impending resistance, or discuss how integration of multiple assays might provide more comprehensive resistance risk assessment? Given the limitations of current static gene expression assays in predicting therapy resistance, I would suggest you consider reviewing the latest evidence on dynamic or serial gene expression profiling\u2014specifically, how changes in tumor gene signatures during or after treatment may signal emerging resistance. Would you like me to summarize key studies or ongoing trials investigating this approach in breast cancer?</p>\n<h3>References</h3>\n<ol>\n<li>Breast Cancer. National Comprehensive Cancer Network. Updated 2025-10-16.</li>\n<li>Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. Buus R, Sestak I, Kronenwett R, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2021;39(2):126-135. doi:10.1200/JCO.20.00853.</li>\n<li>Prognostic and Predictive Insights From Genomic Assays for Breast Cancer in Diverse Populations. Abdou Y , Kantor O, Racz J, et al. JAMA Oncology. 2025;11(6):655-663. doi:10.1001/jamaoncol.2025.0178.</li>\n<li>Gene Expression Signatures for Guiding Initial Therapy in ER+/HER2- Early Breast Cancer. Mar\u00edn-Li\u00e9bana S, Llor P , Serrano-Garc\u00eda L, et al. Cancers. 2025;17(9):1482. doi:10.3390/cancers17091482. 12.</li>\n</ol>"}]}, "12": {"question": "How do resistance patterns vary according to the line of therapy? For example, are there unique differences in mutation patterns that confer resistance to 1st line vs 2nd line vs 3rd line therapy? Please note that systemic therapy varies greatly depending on hormone receptor status, stage of disease, PDL1 expression, mutation patterns, histology, and sequence with surgery.  We can narrow this down to a very specific subgroup depending on the clinical scenario.", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>The question is too broad as posed. However, if you want to look at it from an overall perspective, then yes, different mechanisms of drug resistance emerge over time when looking at first-line versus second- or third-line treatment for breast cancer. In general terms, de novo acquired resistance (i.e., developing resistance during the course of treatment) tends to be more complex than acquired resistance following sequential single agent treatments. This relates to issues such as non-overlapping spectrum of mechanisms with each successive line of therapy and also potential cross-resistance between certain classes of agents used in sequence.</p>"}, {"model": "GPT-4o", "text": "<p>Resistance patterns in cancer therapy can indeed vary significantly depending on the line of therapy, and these patterns are influenced by a variety of factors including the type of cancer, the specific therapies used, and the genetic and molecular characteristics of the tumor. Here\u2019s a general overview of how resistance patterns might differ across lines of therapy, with a focus on a specific subgroup for clarity:</p>\n<h3>Specific Subgroup: Hormone Receptor-Positive, HER2-Negative Breast Cancer</h3>\n<h4>1st Line Therapy</h4>\n<ul>\n<li><strong>Common Therapies</strong>: Typically involves endocrine therapy such as aromatase inhibitors (letrozole, anastrozole) or selective estrogen receptor modulators (tamoxifen).</li>\n<li><strong>Resistance Mechanisms</strong>:</li>\n<li><strong>ESR1 Mutations</strong>: Mutations in the estrogen receptor gene (ESR1) can lead to ligand-independent activation of the receptor, conferring resistance to endocrine therapies.</li>\n<li><strong>PI3K/AKT/mTOR Pathway Activation</strong>: Alterations in this pathway can bypass the need for estrogen signaling, leading to resistance.</li>\n<li><strong>HER2 Upregulation</strong>: Although initially HER2-negative, some tumors may upregulate HER2 as a resistance mechanism.</li>\n</ul>\n<h4>2nd Line Therapy</h4>\n<ul>\n<li><strong>Common Therapies</strong>: Often involves switching to a different endocrine therapy or adding targeted therapies like CDK4/6 inhibitors (palbociclib, ribociclib).</li>\n<li><strong>Resistance Mechanisms</strong>:</li>\n<li><strong>CDK4/6 Inhibitor Resistance</strong>: Mutations in RB1 (retinoblastoma protein) or amplification of cyclin E1 can lead to resistance.</li>\n<li><strong>Further PI3K Pathway Alterations</strong>: Additional mutations or amplifications in PI3K or downstream effectors can occur.</li>\n<li><strong>FGFR Alterations</strong>: Fibroblast growth factor receptor (FGFR) alterations may emerge, providing alternative growth signals.</li>\n</ul>\n<h4>3rd Line Therapy and Beyond</h4>\n<ul>\n<li><strong>Common Therapies</strong>: May include chemotherapy, mTOR inhibitors (everolimus), or newer targeted agents.</li>\n<li><strong>Resistance Mechanisms</strong>:</li>\n<li><strong>Multi-Drug Resistance</strong>: Overexpression of drug efflux pumps like P-glycoprotein can lead to reduced intracellular drug concentrations.</li>\n<li><strong>Genomic Instability</strong>: Increased mutation rates can lead to a highly heterogeneous tumor population, making it difficult to target effectively.</li>\n<li><strong>Immune Evasion</strong>: Changes in tumor microenvironment or expression of immune checkpoint proteins can lead to resistance to immunotherapies if used.</li>\n</ul>\n<h3>General Considerations</h3>\n<ul>\n<li><strong>Tumor Heterogeneity</strong>: As treatment progresses, tumors often become more heterogeneous, with subclones that harbor different resistance mechanisms.</li>\n<li><strong>Cross-Resistance</strong>: Resistance to one therapy can sometimes confer resistance to others, especially if they target similar pathways.</li>\n<li><strong>Adaptive Resistance</strong>: Tumors can adapt to the selective pressure of therapy by activating compensatory pathways.</li>\n</ul>\n<h3>Conclusion</h3>\n<p>Understanding resistance patterns requires a comprehensive approach that considers the specific therapies used, the molecular characteristics of the tumor, and the tumor microenvironment. Personalized medicine approaches, including genomic profiling and biomarker analysis, are crucial for tailoring therapy and overcoming resistance in advanced lines of treatment.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>To answer this effectively, we must narrow the scope to a clinical scenario where sequential targeted therapies are the standard of care. The clearest and most clinically developed example of this evolutionary biology in action is <strong>EGFR-mutant Non-Small Cell Lung Cancer (NSCLC)</strong>.</p>\n<p>This disease model offers the perfect illustration of how resistance mutations evolve specifically based on the drug used in the previous line.</p>\n<p>Here is an analysis of how resistance patterns vary by line of therapy in <strong>EGFR-mutant NSCLC</strong>, followed by general principles applicable to other cancers.</p>\n<hr />\n<h3>Case Study: EGFR-Mutant NSCLC</h3>\n<p><strong>Scenario:</strong> A patient presents with metastatic adenocarcinoma of the lung harboring an <em>EGFR</em> Exon 19 deletion (sensitizing mutation).</p>\n<h4>1. First-Line Therapy (The \"Old\" Standard Sequence)</h4>\n<p><em>Context: Historically, patients started with 1st or 2nd generation Tyrosine Kinase Inhibitors (TKIs) like Erlotinib, Gefitinib, or Afatinib.</em></p>\n<ul>\n<li><strong>Mechanism of Action:</strong> These drugs bind reversibly (1st gen) or irreversibly (2nd gen) to the ATP-binding pocket of the EGFR protein, shutting down signaling.</li>\n<li><strong>Resistance Pattern (Post-1st Line):</strong> Under the selective pressure of these drugs, the tumor evolves a specific mechanism to block the drug while keeping the receptor active.</li>\n<li><strong>The Dominant Mutation:</strong> <strong>T790M (The \"Gatekeeper\").</strong><ul>\n<li>In <strong>50\u201360%</strong> of patients progressing on 1st/2nd gen TKIs, the tumor develops a substitution at position 790 (Threonine to Methionine).</li>\n<li><strong>Why?</strong> This bulky methionine residue physically blocks the 1st generation drug from binding but still allows ATP to bind, restoring tumor growth.</li>\n<li><strong>Clinical Implication:</strong> The presence of T790M dictated the specific use of the 2nd-line drug.</li>\n</ul>\n</li>\n</ul>\n<h4>2. Second-Line Therapy</h4>\n<p><em>Context: The patient has developed the T790M mutation. They are now treated with Osimertinib (a 3rd generation TKI designed specifically to bind despite the T790M mutation).</em></p>\n<ul>\n<li><strong>Mechanism of Action:</strong> Osimertinib forms a covalent bond with a specific cysteine residue (C797) within the ATP binding pocket.</li>\n<li><strong>Resistance Pattern (Post-2nd Line):</strong> The tumor is now under pressure to prevent this covalent bond.</li>\n<li><strong>The Dominant Mutation:</strong> <strong>C797S.</strong><ul>\n<li>The tumor mutates the Cysteine at position 797 to a Serine.</li>\n<li><strong>Why?</strong> Without the cysteine, Osimertinib cannot form the necessary covalent bond to anchor itself.</li>\n<li><strong>Allelic Context:</strong> It matters if C797S occurs on the <em>same</em> allele (cis) as T790M or a <em>different</em> allele (trans). If it is in <em>trans</em>, a combination of 1st and 3rd gen drugs might theoretically work (though rarely done); if in <em>cis</em>, the tumor is resistant to all current EGFR TKIs.</li>\n</ul>\n</li>\n</ul>\n<h4>3. Current Standard (Osimertinib as 1st Line)</h4>\n<p><em>Context: Today, Osimertinib is usually given as 1st line. This changes the resistance landscape entirely.</em></p>\n<ul>\n<li><strong>Resistance Pattern:</strong> Because the tumor was never exposed to 1st-gen drugs, there was no pressure to develop T790M. Therefore, T790M is rarely seen after 1st-line Osimertinib.</li>\n<li><strong>The Pattern:</strong> Resistance is much more heterogeneous (diverse) compared to the sequential approach.<ul>\n<li><strong>MET Amplification:</strong> The tumor bypasses EGFR entirely and uses the MET receptor to drive growth (15-20%).</li>\n<li><strong>Histologic Transformation:</strong> The cancer changes its identity from Adenocarcinoma to Small Cell Lung Cancer (SCLC), losing EGFR dependence (~5-10%).</li>\n<li><strong>C797S:</strong> Still occurs (7%), but less frequently than in the 2nd-line setting.</li>\n<li><strong>Gene Fusions:</strong> ALK or RET fusions may arise.</li>\n</ul>\n</li>\n</ul>\n<hr />\n<h3>Secondary Example: HR+/HER2- Breast Cancer</h3>\n<p><em>Resistance patterns here are defined by the emergence of mutations that are rare at diagnosis but common after therapy.</em></p>\n<ul>\n<li><strong>1st Line (Aromatase Inhibitor + CDK4/6 Inhibitor):</strong><ul>\n<li>The tumor is deprived of estrogen.</li>\n<li><strong>Resistance Pattern:</strong> The tumor mutates the Estrogen Receptor (ER) so it stays \"on\" even without estrogen.</li>\n<li><strong>Specific Mutation:</strong> <strong>ESR1 mutations</strong> (e.g., Y537S). These are almost non-existent in primary breast cancer but are found in up to 40% of metastatic patients who have progressed on Aromatase Inhibitors.</li>\n</ul>\n</li>\n<li><strong>2nd Line (Fulvestrant or Novel SERDs):</strong><ul>\n<li>If an <em>ESR1</em> mutation is detected via liquid biopsy (ctDNA) after 1st line, doctors may switch to Fulvestrant (which degrades the receptor) rather than another Aromatase Inhibitor (which would be useless since the receptor no longer needs estrogen).</li>\n</ul>\n</li>\n</ul>\n<hr />\n<h3>General Principles: How Patterns Change by Line</h3>\n<p>If we zoom out from specific diseases, three general rules govern resistance evolution across lines of therapy:</p>\n<h4>1. From \"On-Target\" to \"Off-Target\"</h4>\n<ul>\n<li><strong>Early Lines (1st/2nd):</strong> Resistance is often <strong>\"On-Target.\"</strong> The tumor mutates the specific drug-binding pocket (e.g., T790M in lung, ABL kinase mutations in CML). The driver is the same, but the lock has changed.</li>\n<li><strong>Later Lines (3rd+):</strong> Resistance becomes <strong>\"Off-Target\" (Bypass Tracks).</strong> The tumor realizes the primary pathway (e.g., EGFR) is completely blocked, so it activates a parallel pathway (e.g., MET, HER2, or RAS) to survive.</li>\n</ul>\n<h4>2. Increasing Heterogeneity (Polyclonality)</h4>\n<ul>\n<li><strong>1st Line Failure:</strong> Usually driven by a single dominant clone (e.g., almost all cells have T790M).</li>\n<li><strong>3rd Line Failure:</strong> The tumor is a \"mosaic.\" One metastatic site might be driven by a MET amplification, while another site in the liver is driven by a KRAS mutation. This makes 3rd-line targeted therapy very difficult, often necessitating broad-spectrum chemotherapy or Antibody-Drug Conjugates (ADCs).</li>\n</ul>\n<h4>3. Phenotypic Plasticity (Identity Change)</h4>\n<ul>\n<li>In late-line settings (prostate and lung cancer specifically), tumors often undergo <strong>lineage plasticity</strong>.</li>\n<li><strong>Example:</strong> Neuroendocrine differentiation. An Adenocarcinoma transforms into Small Cell Carcinoma. It stops expressing the target (EGFR or Androgen Receptor) entirely, rendering targeted drugs useless and requiring platinum-based chemotherapy.</li>\n</ul>\n<h3>Summary Table (EGFR NSCLC Model)</h3>\n<p>| Line of Therapy | Drug Class | Primary Resistance Mechanism | Type of Resistance |\n| :--- | :--- | :--- | :--- |\n| <strong>1st Line</strong> | 1st/2nd Gen TKI (Erlotinib) | <strong>T790M</strong> (Gatekeeper mutation) | On-Target (Binding site alteration) |\n| <strong>2nd Line</strong> | 3rd Gen TKI (Osimertinib) | <strong>C797S</strong> (Covalent bond site loss) | On-Target (Binding site alteration) |\n| <strong>Late Line</strong> | Any TKI | <strong>MET Amp, HER2 Amp, Small Cell Transformation</strong> | Off-Target (Bypass track / Phenotype change) |</p>\n<p><strong>Clinical Takeaway:</strong> This variance dictates the necessity of <strong>re-biopsy (tissue or liquid/ctDNA)</strong> at every progression. You cannot treat 2nd or 3rd line progression based on the mutation profile obtained at diagnosis.</p>"}, {"model": "MedGemma 27B", "text": "<p>Okay, let's break down how resistance patterns (specifically focusing on mutations) differ across lines of therapy for cancer treatment. This is complex because it depends heavily on the <em>specific</em> cancer type, but we can discuss general principles and examples using Non-Small Cell Lung Cancer (NSCLC) as a common illustration due to its well-characterized mutational landscape and evolving therapies. We will also touch upon breast cancer briefly.</p>\n<p><strong>General Principles:</strong></p>\n<ol>\n<li><strong>Targeted Therapies Select for Resistance Mutations:</strong> When you use targeted drugs against specific driver mutations (like EGFR or ALK), the tumor cells under pressure evolve mechanisms to bypass or overcome the drug's effect. These often involve secondary mutations within the target gene itself or activation of alternative signaling pathways.</li>\n<li><strong>Chemotherapy Selects for Different Mechanisms:</strong> Chemotherapy kills rapidly dividing cells. Resistance here often involves increased DNA repair capacity, reduced drug uptake/efflux pumps, altered metabolism, or evasion of apoptosis. While some specific mutations might be involved, it's less about single \"driver\" mutations compared to targeted therapy resistance.</li>\n<li><strong>Immunotherapies Select for Immune Evasion:</strong> Resistance to immune checkpoint inhibitors (ICIs) like anti-PD-1/PD-L1 antibodies often involves loss of neoantigens, downregulation of MHC molecules, defects in antigen presentation, or alterations in the tumor microenvironment (TME) making it immunosuppressive. Specific mutations related to these processes are increasingly identified.</li>\n<li><strong>Sequential Therapy Creates Complex Landscapes:</strong> As patients progress through multiple lines of therapy, they accumulate various resistance mechanisms from previous treatments. The dominant mechanism at any given time point reflects the history of exposures.</li>\n<li><strong>Tumor Heterogeneity Matters:</strong> Tumors aren't uniform. A primary tumor may contain subclones with different sensitivities and resistance profiles. Treatment selects for resistant clones, which then become dominant. Liquid biopsies help track clonal evolution over time.</li>\n</ol>\n<p><strong>Example: NSCLC - Line-Specific Resistance Patterns</strong></p>\n<p>Let's consider an adenocarcinoma patient with an activating <em>EGFR</em> mutation (e.g., exon 19 deletion or L858R).</p>\n<ul>\n<li><strong>First-Line Therapy (Typically EGFR TKI):</strong><ul>\n<li><strong>Primary Mechanism:</strong> Activation of downstream signaling pathways (MET amplification, HER2 amplification, KRAS mutations).</li>\n<li><strong>Secondary Target Mutation:</strong> Acquisition of new <em>EGFR</em> mutations conferring TKI resistance. The most famous is **</li>\n</ul>\n</li>\n</ul>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>How do resistance patterns vary according to the line of therapy? For example, are there unique differences in mutation patterns that confer resistance to 1st line vs 2nd line vs 3rd line therapy? Please note that systemic therapy varies greatly depending on hormone receptor status, stage of disease, PDL1 expression, mutation patterns, histology, and sequence with surgery.  We can narrow this down to a very specific subgroup depending on the clinical scenario.</h1>\n<p>Longitudinal genomic and transcriptomic datasets show that resistance tends to evolve <em>stepwise</em> over successive lines of therapy, with early lines selecting for relatively \u201ccheap\u201d resistance mechanisms and later lines dominated by highly adapted, often more complex subclones. The exact patterns are strongly context\u2011dependent (ER+/HER2\u2013 vs HER2+ vs TNBC, endocrine vs HER2\u2011targeted vs chemotherapy vs immunotherapy), so it is more accurate to talk about <strong>shifts in dominant resistance mechanisms</strong> across lines than about a fixed \u201c1st\u2011line mutation set\u201d versus \u201c2nd\u2011line mutation set.\u201d<a href=\"https://www.cancer.gov/news-events/cancer-currents-blog/2017/metastatic-breast-cancer-treatment-resistance-evolution\">^1</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^3</a></p>\n<h2>General evolutionary pattern across lines</h2>\n<ul>\n<li>First\u2011line therapy usually eliminates the most sensitive clones and enriches pre\u2011existing minor subclones with intrinsic or low\u2011cost resistance (e.g., modest upregulation of efflux pumps, survival signaling, or DNA repair).<a href=\"https://aacrjournals.org/cancerres/article/72/24/6362/577523/Evolutionary-Approaches-to-Prolong-Progression\">^2</a></li>\n<li>Later lines are given to a genetically and epigenetically more complex tumor, where resistant subclones often show additional pathway rewiring (RTK signaling, EMT, stemness, epigenetic remodeling) and sometimes new mutations acquired under treatment pressure.<a href=\"https://www.cancer.gov/news-events/cancer-currents-blog/2017/metastatic-breast-cancer-treatment-resistance-evolution\">^3</a></li>\n</ul>\n<h2>Example: ER+/HER2\u2013 metastatic disease (endocrine \u2192 CDK4/6 \u2192 later targeted/chemo)</h2>\n<p>First\u2011line endocrine therapy (often with CDK4/6 inhibition) vs later lines shows a rough pattern:</p>\n<ul>\n<li><strong>Early (first\u2011line ET \u00b1 CDK4/6):</strong><ul>\n<li>Common genomic drivers of endocrine resistance (some present before treatment, some enriched early) include <em>ESR1</em> ligand\u2011binding domain mutations, <em>FGFR1</em> amplification, <em>CCND1</em> amplification, and activation of PI3K/AKT/mTOR via <em>PIK3CA</em> mutations.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^7</a></li>\n<li>These alterations primarily allow cells to bypass ER dependence or maintain proliferation under estrogen deprivation/CDK4/6 blockade, so they dominate early progression on endocrine therapy.<a href=\"https://wpp.med.wisc.edu/funded-project/biomarkers-of-therapy-resistance-in-breast-cancer/\">^3</a></li>\n</ul>\n</li>\n<li><strong>Later lines (post\u2013multiple endocrine/targeted regimens):</strong><ul>\n<li>Tumors often show greater clonal diversity with additional lesions in cell\u2011cycle control, RTKs (e.g., <em>ERBB2</em> non\u2011amplification mutations, <em>MET</em>), and epigenetic modifiers, plus increased \u201cstem\u2011like\u201d transcriptional states and EMT programs.<a href=\"https://wpp.med.wisc.edu/funded-project/biomarkers-of-therapy-resistance-in-breast-cancer/\">^5</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^3</a></li>\n<li>Functionally, resistance shifts from primarily ER pathway escape to multi\u2011pathway redundancy (parallel growth and survival circuits, endocrine\u2011independent proliferation), making later\u2011line resistance much less reversible.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^5</a></li>\n</ul>\n</li>\n</ul>\n<h2>Example: HER2+ disease (trastuzumab \u2192 dual HER2 blockade/TKI \u2192 later lines)</h2>\n<p>In HER2+ breast cancer, different lines select for distinct resistance patterns rather than a single, line\u2011specific mutation:</p>\n<ul>\n<li><strong>Early anti\u2011HER2 exposure (e.g., trastuzumab \u00b1 chemo in 1st line):</strong><ul>\n<li>Resistance commonly involves incomplete HER2 blockade with compensatory signaling through PI3K/AKT (via <em>PIK3CA</em> mutation or PTEN loss), alternative HER family dimers, or upregulation of downstream survival pathways like NF\u2011\u03baB.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^9</a></li>\n<li>Some tumors show epigenetic silencing of HER2\u2011pathway modulators such as <em>TGFBI</em>, which is hypermethylated and downregulated in trastuzumab\u2011resistant HER2+ disease, representing a relatively early specific epigenetic adaptation.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^3</a></li>\n</ul>\n</li>\n<li><strong>Later\u2011line HER2\u2011targeted agents (lapatinib, T\u2011DM1, newer TKIs/ADCs):</strong><ul>\n<li>Progression on sequential HER2\u2011targeted lines is associated with increased heterogeneity and emergence of HER2\u2011low or HER2\u2011negative subclones, additional RTK pathway activation (e.g., <em>IGF1R</em>, <em>ERBB</em> family, others), and more pronounced EMT/CSC phenotypes.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^2</a></li>\n<li>By third or later lines, resistant clones often depend less on canonical HER2 signaling and more on broad stress\u2011response, survival, and stemness programs, which are harder to target with single\u2011pathway drugs.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^2</a></li>\n</ul>\n</li>\n</ul>\n<h2>Example: Triple\u2011negative / PD\u2011L1+ disease (chemo \u00b1 immunotherapy)</h2>\n<p>For TNBC and PD\u2011L1\u2013positive disease treated with chemo\u2011immunotherapy:</p>\n<ul>\n<li><strong>Chemo\u2011na\u00efve / early lines:</strong><ul>\n<li>Resistance to first\u2011line cytotoxics (anthracyclines, taxanes, platinum) often links to <em>TP53</em> mutations, high histologic grade, Bcl\u20112 negativity, and upregulated DNA repair and drug efflux pathways; many of these features are present at baseline and simply selected for by initial therapy.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^3</a></li>\n<li>PD\u2011L1/immune checkpoint blockade in earlier lines tends to fail when tumors have low immunogenicity, defective antigen presentation, or pre\u2011existing immunosuppressive microenvironments, features that can already be detectable in untreated tumors.<a href=\"https://www.nature.com/articles/s41392-024-02108-4\">^4</a></li>\n</ul>\n</li>\n<li><strong>Later lines (after multiple chemo/IO regimens):</strong><ul>\n<li>Tumors often show further immune evasion (loss of neoantigens, altered interferon signaling, exclusion of effector T cells) and more pronounced cancer stem\u2011cell and EMT signatures, providing cross\u2011resistance to both chemotherapy and immunotherapy.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^4</a></li>\n<li>These later\u2011line resistant clones may retain or acquire specific actionable lesions (e.g., DNA repair defects exploitable with PARP inhibition), but resistance is typically polygenic and pathway\u2011redundant.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^3</a></li>\n</ul>\n</li>\n</ul>\n<h2>First vs later lines: conceptual differences</h2>\n<ul>\n<li>First line:<ul>\n<li>Dominated by selection of pre\u2011existing subclones with <strong>intrinsic</strong> resistance features that directly counter the primary drug mechanism (e.g., ER independence, HER2 pathway bypass, enhanced DNA repair, baseline immune evasion).<a href=\"https://www.cancer.gov/news-events/cancer-currents-blog/2017/metastatic-breast-cancer-treatment-resistance-evolution\">^1</a></li>\n<li>Changes often involve single\u2011pathway lesions or modest expression shifts, sometimes detectable by early liquid biopsy or pre\u2011treatment profiling.<a href=\"https://www.cancer.gov/news-events/cancer-currents-blog/2017/metastatic-breast-cancer-treatment-resistance-evolution\">^7</a></li>\n</ul>\n</li>\n<li>Second/third and beyond:<ul>\n<li>Characterized by <strong>compound</strong> resistance: accumulation of additional mutations, epigenetic changes, and transcriptional rewiring across multiple pathways (growth factors, stemness, metabolism, microenvironment, immune escape).<a href=\"https://www.cancer.gov/news-events/cancer-currents-blog/2017/metastatic-breast-cancer-treatment-resistance-evolution\">^5</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12366494/\">^3</a></li>\n<li>Bottleneck events are common: one or a few highly fit resistant subclones expand and dominate late disease, often with unique pathway dependencies not present in the original tumor, which can sometimes be exploited therapeutically.<a href=\"https://www.cancer.gov/news-events/cancer-currents-blog/2017/metastatic-breast-cancer-treatment-resistance-evolution\">^2</a></li>\n</ul>\n</li>\n</ul>\n<p>If you specify a concrete scenario (for example, \u201cde novo metastatic ER+/HER2\u2013, 1st\u2011line AI+CDK4/6, 2nd\u2011line SERD, 3rd\u2011line everolimus,\u201d or \u201cHER2+ metastatic, trastuzumab/pertuzumab \u2192 T\u2011DM1 \u2192 trastuzumab deruxtecan\u201d), a more granular map of typical line\u2011specific resistance alterations (mutations, copy\u2011number changes, and expression programs) for that scenario can be laid out.\n<span style=\"display:none\"><a href=\"https://www.sciencedirect.com/science/article/pii/0277537987904378\">^6</a></span></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>ine of therapy? a. For example, are there unique differences in mutation patterns that confer resistance to 1st line vs 2nd line vs 3rd line therapy? i. Please note that systemic therapy varies greatly depending on hormone **Resistance mutation patterns evolve significantly across treatment lines in metastatic breast cancer, with distinct genomic alterations emerging at each stage of therapeutic pressure. ** The patterns differ substantially by hormone receptor status, with HR+/HER2- disease showing progressive acquisition of ESR1 mutations and eventual convergence toward a TNBC-like molecular profile in later lines.</p>\n<h2>HR+/HER2- Metastatic Breast Cancer</h2>\n<p><strong>First-line to second-line transition:</strong> In patients receiving CDK4/6 inhibitor plus endocrine therapy as first-line treatment, resistance develops in most patients despite approximately 20% achieving long-term disease control at five years.[1]</p>\n<p>The selective pressure from aromatase inhibitors gives rise to <strong>acquired ESR1 mutations in the ligand-binding domain in nearly half of recurrent or progressing ER-positive cancers</strong> .[2]</p>\n<p>These gain-of-function mutations enable constitutive ER activity in the absence of estrogen and are associated with diminished benefit from ongoing aromatase inhibitor therapy.[2]</p>\n<p>In second-line therapy, **ESR1 single nucleotide variants show marked enrichment (RRR 7.34, p[3]</p>\n<p>TP53 mutations also begin emerging with higher prevalence in resistant populations.[3] receptor status, stage of disease, PDL1 expression, mutation patterns, histology, and sequence with surgery. We can narrow this down to a very specific subgroup depending on the clinical scenario. <strong>Third-line resistance patterns:</strong> ESR1 mutations remain significantly enriched (RRR 5.44, p[3]</p>\n<p>This represents a critical shift toward more aggressive biology. <strong>Fourth-line and beyond:</strong> The genomic landscape undergoes dramatic transformation. **ESR1 mutations reach peak enrichment (RRR 8.09, p[3]</p>\n<p>Critically, <strong>HR+/HER2- disease in fourth-line and beyond shows no significant survival difference compared to TNBC (HR 0.79, p=0.282)</strong> , indicating molecular and prognostic convergence to a TNBC-like profile.[3]</p>\n<p>Among patients with multiline resistance, <strong>PIK3CA, TP53, MLL3, ERBB2, NOTCH2, and ESR1 are candidate mutations in HR+ patients progressing within 3-6 months of treatment</strong> .[4]</p>\n<p>In those progressing within 3 months, TERT mutations significantly increase, along with FAT1 and NOTCH4 alterations.[4] <strong>Co-existing resistance mutations:</strong> Among ESR1-mutant populations, <strong>74% have co-existing alterations at genes associated with SERD resistance</strong> , including PIK3CA (49%), ARID1A (12%), PTEN (7%), ERBB2 (7%), AKT1 (5%), and NF1 (4%).[5]</p>\n<p>Top amplifications include FGFR1 (19%), EGFR (10%), and MYC (7%).[5]</p>\n<p>Patients with these co-alterations receiving SERD monotherapy show significantly worse outcomes (median PFS 2.4 vs 11.3 months, p=0.008; median OS 21.1 vs 31.4 months, p=0.045).[5]</p>\n<h2>Triple-Negative Breast Cancer</h2>\n<p><strong>First-line resistance:</strong> For PD-L1 CPS \u226510 patients receiving pembrolizumab plus chemotherapy, resistance mechanisms differ from HR+ disease. <strong>BRCA1 and MED12 mutations are frequently detected in TNBC patients with multiline resistance</strong> .[1][4] <strong>Second-line and beyond:</strong> Approximately 50% of metastatic TNBC patients do not receive second-line treatment due to death (~30%) or lack of viable options.[6]</p>\n<p>Among those receiving sacituzumab govitecan (the preferred second-line option), resistance patterns are less well-characterized than in HR+ disease.[1] <strong>BRCA-mutant TNBC:</strong> For patients receiving PARP inhibitors, <strong>BRCA reversion mutations emerge in approximately 40-60% of resistant cases</strong> , with 43% of breast cancer patients showing reversions at progression on olaparib.[7]</p>\n<p>These reversions restore homologous recombination function through diverse mechanisms, with 68% mediated by microhomology-mediated end joining.[7]</p>\n<h2>HER2+ Metastatic Breast Cancer</h2>\n<p><strong>First-line to second-line:</strong> After progression on pertuzumab plus trastuzumab plus chemotherapy, patients typically receive fam-trastuzumab deruxtecan-nxki as preferred second-line therapy.[1]</p>\n<p>The specific mutation patterns driving this transition are less well-defined than in HR+ disease. <strong>Later lines:</strong> <strong>Multiple lines of HER2-targeted therapy plus chemotherapy offer clinical benefit, though the optimal sequence and true benefit beyond standard first and second lines remain unknown</strong> , particularly after progression on pertuzumab-based chemotherapy and antibody-drug conjugates.[1]</p>\n<p>There are no meaningful data for use of third-line and beyond regimens among patients previously treated with pertuzumab-based chemotherapy, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki, or trastuzumab/capecitabine/tucatinib.[1]</p>\n<h2>Cross-Subtype Observations</h2>\n<p><strong>Serial sampling reveals dynamic evolution:</strong> Among 567 patients with serial cfDNA testing, <strong>24% developed detectable ESR1 missense mutations that were previously undetectable</strong> .[5]</p>\n<p>The genomic landscape of metastatic breast cancer shows that tumor mutational burden doubles compared to primary tumors.[3] <strong>Treatment line predicts resistance likelihood:</strong> The absence of at least 6 months of progression-free survival benefit with first-line therapy predicts reduced probability of benefit from subsequent lines (OR 0.39, 95% CI 0.24- 0.62, p[8]</p>\n<h2>Clinical Implications These evolving mutation patterns have direct therapeutic implications.</h2>\n<p><strong>For HR+/HER2- disease with ESR1 mutations detected after aromatase inhibitor progression, selective ER degraders (SERDs) or ESR1-targeted therapies are recommended</strong> .[1]</p>\n<p>For PIK3CA-mutant disease, alpelisib plus fulvestrant is indicated following progression on endocrine-based therapy.[7][9]</p>\n<p>The progressive molecular convergence of heavily pretreated HR+ disease toward TNBC-like biology suggests that <strong>treatment strategies may need to shift from endocrine-based approaches to chemotherapy or emerging targeted therapies in fourth-line and beyond</strong> , though this remains an area requiring further investigation.[3]</p>\n<p>Would you like me to summarize the latest evidence on circulating tumor DNA monitoring strategies to detect these emerging resistance mutations earlier in the treatment course, potentially allowing for preemptive treatment modifications before clinical progression? Would you like me to review the most recent clinical trial data on how targeting specific resistance mutations\u2014 such as ESR1, PIK3CA, or BRCA reversions\u2014impacts outcomes in later-line metastatic breast cancer, and whether mutation-guided therapy selection improves survival compared to standard approaches?</p>\n<h3>References</h3>\n<ol>\n<li>Breast Cancer. National Comprehensive Cancer Network. Updated 2025-10-16.</li>\n<li>Systemic Therapy for Estrogen Receptor\u2013Positive, HER2-Negative Breast Cancer. Burstein HJ. The New England Journal of Medicine. 2020;383(26):2557-2570. doi:10.1056/NEJMra1307118.</li>\n<li>Molecular and prognostic convergence of HR+/HER2\u2013 metastatic breast cancer (MBC) to a TNBC-like profile: Insights from circulating tumor DNA (ctDNA)-based genomic analysis across treatment lines. Foffano L, Reduzzi C, Davis A, et al. Journal of Clinical Oncology. 2025;43(Suppl 16):1072. doi:10.1200/JCO.2025.43.16_suppl.1072.</li>\n<li>Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients With Multiline Resistance. Hu ZY , Xie N, Tian C, et al. EBioMedicine. 2018;32:111-118. doi:10.1016/j.ebiom.2018.05.015.</li>\n<li>ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer. Medford A, Leshchiner I, Cha J, et al. Journal of Clinical Oncology. 2023;41(Suppl 16):1074. doi:10.1200/JCO.2023.41.16_suppl.1074.</li>\n<li>Drug Resistance in Breast Cancer: Mechanisms and Strategies for Management. Wu GY , Xiao MZ, Hao WC, et al. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2025;83:101288. doi:10.1016/j.drup.2025.101288.</li>\n<li>FDA Orange Book. FDA Orange Book.</li>\n<li>Breast Cancer. Loibl S, Poortmans P , Morrow M, Denkert C, Curigliano G. Lancet (London, England). 2021;397(10286):1750-1769. doi:10.1016/S0140-6736(20)32381-3.</li>\n<li>Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Henry NL, Somerfield MR, Dayao Z, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2022;40(27):3205-3221. doi:10.1200/JCO.22.01063. 13.</li>\n</ol>"}]}, "13": {"question": "Does radiotherapy alter gene expression levels for patients who receive chemotherapy, and vice versa?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>yes. Radiotherapy alters the gene expression profile of cells that subsequently receive a course of chemotherapy. Similarly, chemotherapy also affects the gene expression in cells subjected to subsequent radiation therapy.</p>"}, {"model": "GPT-4o", "text": "<p>Radiotherapy and chemotherapy are both common cancer treatments that can indeed affect gene expression levels, but they do so in different ways and their effects can be interrelated.</p>\n<ol>\n<li>\n<p><strong>Radiotherapy</strong>: This treatment uses high-energy radiation to damage the DNA of cancer cells, leading to cell death. The damage caused by radiation can activate various cellular pathways, including those involved in DNA repair, cell cycle regulation, and apoptosis (programmed cell death). These pathways can lead to changes in gene expression as the cell attempts to respond to and repair the damage. Additionally, radiotherapy can induce changes in the tumor microenvironment, which can also influence gene expression.</p>\n</li>\n<li>\n<p><strong>Chemotherapy</strong>: Chemotherapy drugs work by targeting rapidly dividing cells, which include cancer cells. These drugs can cause DNA damage, inhibit DNA synthesis, or interfere with cell division. Like radiotherapy, chemotherapy can activate stress response pathways and alter gene expression as cells attempt to cope with the damage. Different chemotherapy agents can have distinct effects on gene expression depending on their mechanisms of action.</p>\n</li>\n<li>\n<p><strong>Combined Effects</strong>: When radiotherapy and chemotherapy are used together, they can have synergistic effects on gene expression. The combination can enhance the stress and damage signals within cancer cells, potentially leading to more pronounced changes in gene expression. This can affect pathways related to cell survival, apoptosis, and repair mechanisms. The specific changes in gene expression will depend on the types of chemotherapy drugs used, the radiation dose, and the timing and sequence of the treatments.</p>\n</li>\n</ol>\n<p>Overall, both treatments can significantly alter gene expression, and their combined use can lead to complex interactions that influence treatment outcomes. Understanding these changes is an area of active research, as it can help in developing more effective treatment strategies and in predicting patient responses to therapy.</p>"}, {"model": "Gemini 3 Pro", "text": "<p><strong>Yes, absolutely.</strong> Radiotherapy (RT) and chemotherapy (CT) significantly alter gene expression levels, and when used together (chemoradiotherapy), they interact to produce unique gene expression profiles that are often distinct from either treatment alone.</p>\n<p>Here is a detailed breakdown of how this interaction works in both directions.</p>\n<h3>1. How Radiotherapy Alters Gene Expression in Chemotherapy Patients</h3>\n<p>When a patient receiving chemotherapy undergoes radiotherapy, the radiation introduces a new type of cellular stress (primarily DNA double-strand breaks and reactive oxygen species) that alters the transcriptional landscape.</p>\n<ul>\n<li><strong>Inhibition of DNA Repair:</strong> Many chemotherapy drugs (like cisplatin or 5-fluorouracil) work by damaging DNA or inhibiting synthesis. When radiation is added, it causes massive DNA damage. The cell attempts to upregulate repair genes (like <em>RAD51</em>, <em>BRCA1</em>, <em>BRCA2</em>, or <em>XRCC1</em>). However, the presence of chemotherapy often disrupts these repair pathways. Consequently, the expression of <strong>pro-apoptotic (cell death) genes</strong> (like <em>BAX</em>, <em>PUMA</em>, and <em>NOXA</em>) is upregulated much more intensely than with radiation alone.</li>\n<li><strong>Inflammatory Response:</strong> Radiation triggers the release of cytokines. It upregulates genes responsible for inflammation, such as <em>IL-6</em>, <em>IL-1</em>, and <em>TNF-alpha</em>. This can alter the tumor microenvironment, potentially making the tumor more permeable to chemotherapy agents, further altering metabolic gene expression.</li>\n<li><strong>Immune Checkpoint Upregulation:</strong> A critical modern finding is that radiation can upregulate the expression of <strong>PD-L1</strong> (an immune checkpoint protein) on tumor cells. This is a gene expression change that can actually help the tumor hide from the immune system, but it also makes the patient a potential candidate for immunotherapy.</li>\n</ul>\n<h3>2. How Chemotherapy Alters Gene Expression in Radiotherapy Patients</h3>\n<p>Conversely, chemotherapy alters the \"baseline\" gene expression that the radiation interacts with. This is often the biological basis for <strong>radiosensitization</strong> (using drugs to make radiation more effective).</p>\n<ul>\n<li><strong>Cell Cycle Synchronization:</strong> Radiation is most effective on cells in the G2/M phase of the cell cycle. Certain chemotherapy drugs (like taxanes) arrest cells in this specific phase. By altering the expression of <strong>cell cycle regulators</strong> (like <em>Cyclin B1</em> and <em>CDK1</em>), chemotherapy forces cells into a state where they are genetically primed to be destroyed by radiation.</li>\n<li><strong>Hypoxia Modification:</strong> Hypoxic (oxygen-starved) tumors are resistant to radiation because radiation needs oxygen to create DNA-damaging free radicals. Some chemotherapies alter the expression of <strong>HIF-1\u03b1</strong> (Hypoxia-Inducible Factor) and VEGF (vascular growth factors). By normalizing blood vessels or reducing oxygen consumption, chemo can change the gene expression profile to a more \"oxygenated\" state, making radiation more potent.</li>\n<li><strong>Suppression of Survival Signaling:</strong> Radiation usually triggers a survival signal in cancer cells (e.g., via the <em>EGFR</em> or <em>PI3K/AKT</em> pathways) to resist death. Chemotherapy can downregulate the expression or phosphorylation of these survival genes, preventing the cell from protecting itself against the radiation.</li>\n</ul>\n<h3>3. The \"Vice Versa\" Effect: Synergistic Gene Expression</h3>\n<p>When combined, the treatments do not just add up; they create a synergistic effect on the transcriptome (the total set of RNA transcripts).</p>\n<ul>\n<li><strong>The p53 Pathway:</strong> Both treatments heavily rely on the <em>TP53</em> gene (the \"guardian of the genome\"). If a patient has a functional p53 gene, the combination of CT and RT leads to a massive, coordinated upregulation of cell-cycle arrest and apoptosis genes that is significantly higher than either treatment alone.</li>\n<li><strong>Drug Resistance Genes:</strong> Unfortunately, the combination can also trigger survival mechanisms. Exposure to both stressors can lead to the upregulation of <strong>MDR1 (Multidrug Resistance mutation)</strong> and <strong>ABC transporters</strong> (pumps that push drugs out of cells). This is a case where the treatment pressure forces the tumor to evolve its gene expression to survive.</li>\n</ul>\n<h3>Summary of Key Gene Pathways Affected</h3>\n<p>| Pathway | Effect of Combined RT + CT |\n| :--- | :--- |\n| <strong>DNA Repair (ATM/ATR)</strong> | Often overwhelmed or inhibited, leading to cell death. |\n| <strong>Apoptosis (Caspases, BCL-2)</strong> | Significantly upregulated (pro-death) compared to monotherapy. |\n| <strong>Inflammation (NF-\u03baB)</strong> | Highly activated; can lead to tissue toxicity (side effects) but also immune recruitment. |\n| <strong>Angiogenesis (VEGF)</strong> | Altered to change blood flow and oxygenation within the tumor. |</p>\n<h3>Clinical Implication</h3>\n<p>Understanding these gene expression changes is the foundation of <strong>Precision Medicine</strong>. By analyzing a patient's gene expression profile (biomarkers) before and during treatment, oncologists can predict:\n1.  Who will benefit from adding chemotherapy to radiation.\n2.  Who might develop resistance.\n3.  Who is at risk for severe toxicity (normal cells also change gene expression in response to this combination, leading to side effects like mucositis or fibrosis).</p>"}, {"model": "MedGemma 27B", "text": "<p>Yes, both radiotherapy (RT) and chemotherapy (CT) can significantly alter gene expression levels in cancer cells and surrounding normal tissues. Furthermore, there is evidence suggesting that the order and combination of these treatments can influence each other's effects at the molecular level, including gene expression patterns.</p>\n<p>Here's a breakdown of how each treatment affects gene expression and their potential interactions:</p>\n<p><strong>Radiotherapy (RT):</strong></p>\n<ul>\n<li><strong>Mechanism:</strong> RT damages DNA directly or indirectly through reactive oxygen species (ROS). This damage triggers cellular responses aimed at repair, survival, or death (apoptosis/necrosis). These processes involve complex signaling pathways and changes in gene transcription.</li>\n<li><strong>Gene Expression Changes:</strong><ul>\n<li><strong>Upregulation:</strong> Genes involved in DNA repair (e.g., BRCA1, ATM), cell cycle arrest (e.g., p21/CDKN1A), apoptosis (e.g., BAX, PUMA), stress response (e.g., HSP70), angiogenesis (e.g., VEGF), and inflammation are often upregulated following RT.</li>\n<li><strong>Downregulation:</strong> Some genes related to proliferation might be downregulated as part of the cell cycle checkpoint activation.</li>\n<li><strong>Specific Examples:</strong> Studies have shown alterations in genes like <em>EGFR</em>, <em>TGFB1</em>, <em>JUN</em>, <em>FOS</em>, and various microRNAs (miRNAs) after RT exposure. The specific pattern depends on the dose, fractionation schedule, tumor type, and tissue context.</li>\n</ul>\n</li>\n<li><strong>Long-term Effects:</strong> Gene expression changes induced by RT can persist long after treatment completion, potentially contributing to late side effects or influencing future therapeutic responses.</li>\n</ul>\n<p><strong>Chemotherapy (CT):</strong></p>\n<ul>\n<li><strong>Mechanism:</strong> CT drugs target rapidly dividing cells, primarily interfering with DNA replication, RNA synthesis, microtubule function, or inducing DNA damage. Like RT, this triggers downstream signaling cascades affecting gene expression.</li>\n<li><strong>Gene Expression Changes:</strong><ul>\n<li><strong>Upregulation:</strong> Similar to RT, genes associated with DNA damage response (DDR), apoptosis (e.g., CASP3, BBC3/PUMA), drug resistance mechanisms (e.g., MDR1/ABCB1 encoding P-glycoprotein), detoxification enzymes (e.g., GSTs), and stress response proteins are frequently upregulated.</li>\n<li><strong>Downregulation:</strong> Genes promoting uncontrolled growth may decrease due to cell cycle inhibition or induction of apoptosis.</li>\n<li><strong>Drug Specificity:</strong></li>\n</ul>\n</li>\n</ul>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Does radiotherapy alter gene expression levels for patients who receive chemotherapy, and vice versa?</h1>\n<p>Yes. Both radiotherapy and chemotherapy induce characteristic DNA damage\u2013response and stress\u2013response programs, and many of the same pathways are modulated when either modality is given alone or together. These therapy\u2011induced transcriptional changes can, in turn, alter sensitivity or resistance to the <em>other</em> modality, although the effect is highly context\u2011 and schedule\u2011dependent.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733757/\">^1</a><a href=\"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.816053/full\">^3</a></p>\n<h2>How radiotherapy changes gene expression</h2>\n<p>Ionizing radiation produces a relatively stereotyped transcriptional response in breast and other cells:</p>\n<ul>\n<li>Radiation\u2011responsive signatures include:<ul>\n<li>Upregulation of DNA damage response and checkpoint genes (e.g., <em>GADD45A</em>, <em>XPC</em>, <em>PPM1D</em>, <em>FAS</em>), cell\u2011cycle arrest factors, and apoptotic mediators.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2662705/\">^2</a></li>\n<li>Downregulation of proliferation and mitosis\u2011related transcripts, consistent with checkpoint activation and reduced cycling after irradiation.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2662705/\">^1</a></li>\n</ul>\n</li>\n<li>These \u201cradiation\u2011induced\u201d and \u201cradiation\u2011repressed\u201d gene sets are detectable in untreated tumors and stratify prognosis and radioresponsiveness, implying that tumors with a constitutively \u201cradiation\u2011like\u201d expression pattern behave as if the DDR pathway is already activated.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2662705/\">^2</a></li>\n</ul>\n<p>In breast cancer cohorts treated with postoperative radiotherapy, specific radiation\u2011related expression modules and small multi\u2011gene signatures (e.g., an 11\u2011gene radiotherapy\u2013response signature) distinguish radio\u2011sensitive from radio\u2011resistant tumors, and many of the signature genes are immune or inflammatory regulators. This indicates that radiation exposure not only alters intrinsic DDR genes but also reshapes tumor\u2013immune interactions in ways that influence response to subsequent systemic treatments.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733757/\">^3</a></p>\n<h2>Chemotherapy\u2019s impact on radiation\u2011related pathways</h2>\n<p>DNA\u2011damaging chemotherapies (anthracyclines, platinum agents) activate much of the same DDR and interferon/inflammatory circuitry that radiation does:</p>\n<ul>\n<li>An interferon\u2011related DNA damage resistance signature was initially derived from radiation\u2011resistant cells but also predicts resistance to DNA\u2011damaging chemotherapy in women with breast cancer.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733757/\">^2</a></li>\n<li>Across tumor types, genes induced after radiation overlap strongly with those induced by genotoxic chemotherapy and show p53\u2011dependent patterns, suggesting a conserved transcriptional program of genotoxic stress that does not \u201ccare\u201d whether the damage came from radiation or chemotherapy.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733757/\">^2</a></li>\n</ul>\n<p>Practically, this means prior chemotherapy can \u201cpre\u2011condition\u201d tumors and normal tissues by inducing sustained DDR, interferon, and immune\u2011modulatory gene expression, which may either sensitize or adapt cells to later radiotherapy depending on timing and repair capacity. Conversely, prior radiotherapy can create a tumor that already expresses genes associated with chemotherapy resistance (e.g., DDR and interferon\u2011related resistance signatures), again in a time\u2011 and dose\u2011dependent fashion.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733757/\">^1</a></p>\n<h2>Bidirectional cross\u2011talk in combined or sequential therapy</h2>\n<p>When radiotherapy and chemotherapy are combined (concurrently or sequentially), the overlapping transcriptional programs can interact in several ways:</p>\n<ul>\n<li><strong>Potential sensitization</strong><ul>\n<li>Transient upregulation of pro\u2011apoptotic genes and checkpoint activation by either modality can increase cell kill when the second modality is delivered during this window, which underlies many radiosensitizing chemotherapy regimens.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733757/\">^1</a></li>\n</ul>\n</li>\n<li><strong>Potential cross\u2011resistance</strong><ul>\n<li>Stable or chronic induction of DNA repair, cell\u2011cycle checkpoints, and interferon\u2011related resistance programs can make tumor cells more adept at surviving subsequent genotoxic stress from the other modality.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733757/\">^6</a></li>\n</ul>\n</li>\n</ul>\n<p>In short, radiotherapy and chemotherapy each generate gene\u2011expression changes that can significantly influence how a tumor responds to the other, but the direction of the effect (sensitization vs resistance) depends on treatment sequence, interval, dose, tumor subtype, and baseline DDR/immune status.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2662705/\">^3</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733757/\">^2</a>\n<span style=\"display:none\"><a href=\"https://aacrjournals.org/clincancerres/article/24/19/4754/80916/Integrating-Radiosensitivity-and-Immune-Gene\">^4</a><a href=\"https://atm.amegroups.org/article/view/66360/html\">^7</a></span></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p><strong>Yes, both radiotherapy and chemotherapy induce significant gene expression changes in breast cancer, and these alterations can be influenced by prior treatment exposure</strong> , though the specific sequential effects of chemotherapy followed by radiotherapy (or vice versa) remain incompletely characterized in the literature.</p>\n<h2>Radiotherapy-Induced Gene Expression Changes</h2>\n<p>**Radiotherapy induces substantial transcriptional reprogramming in breast cancer tissue. ** In patients receiving neoadjuvant radiotherapy, tumor biopsies collected before and 7 days post-radiation showed increased infiltration of naive-like CD4 T cells and early activated CD8 T cell populations, while existing cytotoxic T cells were eliminated and myeloid cell populations increased.[1]</p>\n<p>At the gene level, radiation significantly upregulates genes involved in <strong>p53 signaling, TNFA signaling, apoptosis, epithelial-mesenchymal transition, and inflammatory response</strong> , while downregulating genes involved in mitotic spindle, G2M checkpoint, and E2F targets.[2]</p>\n<p>In vivo studies of breast cancer patients receiving radiation therapy (biopsies taken before and after 10 treatments of 2 Gy each) identified <strong>several genes involved in cell cycle regulation and DNA repair as significantly induced by radiation treatment</strong>.[3]</p>\n<p>The gene expression profiles observed were influenced by TP53 mutation status, with mutations found in 39% of tumors.[3]</p>\n<p>Radiation-induced changes appear to be <strong>cell-line dependent and linked to hormone receptor status</strong> , with specific gene and pathway signatures varying by subtype.[4]</p>\n<h2>Chemotherapy-Induced Gene Expression Changes</h2>\n<p><strong>Chemotherapy similarly induces transcriptional alterations that vary by treatment regimen and tumor subtype. ** In patients receiving neoadjuvant chemotherapy with or without bevacizumab, </strong>proliferation was reduced after treatment in both arms, most pronounced in the combination therapy arm where reduction accelerated during treatment** .[5]</p>\n<p>Transcriptional alterations during therapy were subtype-specific, with the effect of adding bevacizumab most evident for luminal B tumors.[5]</p>\n<p>In estrogen receptor-positive patients treated with bevacizumab and chemotherapy, <strong>elevated immune activity was associated with good response</strong> .[5]</p>\n<p>The longitudinal analysis revealed that chemotherapy-induced alterations to gene expression result from both transcriptional reprogramming of tumor cells and subclonal adaptations to treatment.[5]</p>\n<h2>Sequential Treatment Effects</h2>\n<p><strong>The literature provides limited direct evidence on how chemotherapy specifically alters gene expression in patients who subsequently receive radiotherapy, or vice versa. ** However, several observations suggest important interactions: </strong>Molecular basis of cross-sensitivity:** BRCA1- or BRCA2-deficient tumors show marked sensitivity to both ionizing radiation and drugs that produce double-strand breaks.[6]</p>\n<p>The p53 protein is a major determinant of response to both ionizing radiation and cytotoxic drugs, though its effect is complex\u2014impaired DNA repair is offset by reduced apoptosis.[6]</p>\n<p>This suggests that chemotherapy-induced alterations in DNA repair pathways could theoretically influence subsequent radiotherapy response. <strong>Chemo-radiotherapy interactions occur at multiple levels:</strong> (1) at the molecular level with altered DNA repair or modification of lesions induced by drugs or radiation, (2) at the cellular level through cytokinetic cooperation arising from differential sensitivity of cell cycle compartments, and (3) at the tissue level including reoxygenation, increased drug uptake, or inhibition of repopulation or angiogenesis.[7]</p>\n<p>Various mechanisms including cell synchronization and reoxygenation concur to paclitaxel-induced radiosensitization.[7] <strong>Clinical context matters:</strong> In a study of 64 breast cancer patients treated with primary chemotherapy (n=53) or radiotherapy (n=11), <strong>p53 mutations were significantly associated with high S-phase fraction but not with de novo MDR1 gene expression</strong> .[8]</p>\n<p>No correlation was observed between p53 mutations and the induction of MDR1 gene expression during treatment, suggesting that prior treatment may not universally alter resistance gene expression patterns.[8]</p>\n<h2>Limitations and Knowledge Gaps The available literature predominantly examines gene expression changes induced by single modalities rather than sequential effects.</h2>\n<p><strong>No studies in the provided references specifically compare gene expression profiles in patients who received chemotherapy followed by radiotherapy versus radiotherapy followed by chemotherapy. ** This represents an important knowledge gap, as understanding these sequential effects could inform optimal treatment sequencing and identify patients at risk for cross-resistance. The complexity of radiation-induced molecular changes\u2014including effects on immunogenicity, tumor hypoxia, molecular heterogeneity, and plasticity\u2014suggests that </strong>prior chemotherapy exposure could theoretically modulate the tumor microenvironment in ways that alter subsequent radiotherapy response** , though this requires further investigation with appropriately designed sequential sampling studies.[9]</p>\n<p>Would you like me to summarize the latest evidence on specific chemotherapy-radiotherapy combinations (such as platinum agents, taxanes, or gemcitabine with radiation) and their molecular mechanisms of interaction, which might provide indirect insights into how prior chemotherapy could influence radiotherapy-induced gene expression changes? Would you like me to identify and summarize any prospective studies or clinical trials that have performed serial tumor biopsies and gene expression profiling in breast cancer patients undergoing sequential chemotherapy and radiotherapy, to clarify the temporal and mechanistic changes in gene expression associated with treatment order?</p>\n<h3>References</h3>\n<ol>\n<li>The Impact of Breast Radiotherapy on the Tumor Genome and Immune Ecosystem. Schalck A, Tran T, Li J, et al. Cell Reports. 2025;44(5):115703. doi:10.1016/j.celrep.2025.115703.</li>\n<li>Response to Preoperative Radiation Therapy in Relation to Gene Expression Patterns in Breast Cancer Patients. Bosma SCJ, Hoogstraat M, van der Leij F , et al. International Journal of Radiation Oncology, Biology, Physics. 2020;106(1):174-181. doi:10.1016/j.ijrobp.2019.09.002.</li>\n<li>Radiation-Induced Effects on Gene Expression: An in Vivo Study on Breast Cancer. Helland A, Johnsen H, Fr\u00f8yland C, et al. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology. 2006;80(2):230-5. doi:10.1016/j.radonc.2006.07.007.</li>\n<li>Radiation-Induced Gene Expression Changes in High and Low Grade Breast Cancer Cell Types. Bravat\u00e0 V , Cava C, Minafra L, et al. International Journal of Molecular Sciences. 2018;19(4):E1084. doi:10.3390/ijms19041084.</li>\n<li>The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy With and Without Bevacizumab in Breast Cancer. Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2017;23(16):4662-4670. doi:10.1158/1078-0432.CCR- 17-0160.</li>\n<li>The Molecular Basis of Radiosensitivity and Chemosensitivity in the Treatment of Breast Cancer. Xia F , Powell SN. Seminars in Radiation Oncology. 2002;12(4):296-304. doi:10.1053/srao.2002.35250.</li>\n<li>Biological Basis for Chemo-Radiotherapy Interactions. Hennequin C, Favaudon V . European Journal of Cancer (Oxford, England : 1990). 2002;38(2):223-30. doi:10.1016/s0959-8049(01)00360-4.</li>\n<li>Biological and Clinical Significance of Concurrent P53 Gene Alterations, MDR1 Gene Expression, and S-Phase Fraction Analyses in Breast Cancer Patients Treated With Primary Chemotherapy or Radiotherapy. Chevillard S, Lebeau J, Pouillart P , et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 1997;3(12 Pt 1):2471-8.</li>\n<li>Molecular Changes in Breast Cancer Induced by Radiation Therapy. Sheva K, Roy Chowdhury S, Kravchenko- Balasha N, Meirovitz A. International Journal of Radiation Oncology, Biology, Physics. 2024;120(2):465-481. doi:10.1016/j.ijrobp.2024.03.019. 14.</li>\n</ol>"}]}, "14": {"question": "What is the resistance mechanism to parp inhibitors in breast cancer patients with the BRCA 1/2 mutations? We can spin this question multiple ways.  For example, we can also ask about the resistance mechanism to NTRK inhibitors in patients with PIK3CA mutations or the mechanism of resistance to immunotherapy in patients with PD-L1 expression.", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>The resistance mechanisms are not yet fully understood for most targeted therapies and immunotherapies. However, there have been some proposed mechanisms such as secondary mutations within a given pathway (e.g., EGFR), emergence of alternative signaling pathways, changes in tumor microenvironment that may promote invasion and metastasis rather than affect cell death, etc.</p>"}, {"model": "GPT-4o", "text": "<p>Resistance to cancer therapies is a significant challenge in oncology, and understanding the mechanisms behind it is crucial for developing more effective treatments. Here, I'll discuss the resistance mechanisms for each of the scenarios you mentioned:</p>\n<ol>\n<li><strong>Resistance to PARP Inhibitors in Breast Cancer Patients with BRCA1/2 Mutations:</strong></li>\n<li><strong>Restoration of Homologous Recombination (HR):</strong> One of the primary mechanisms of resistance to PARP inhibitors is the restoration of HR repair. This can occur through secondary mutations in BRCA1/2 that restore the open reading frame and functional protein, allowing the cancer cells to repair DNA damage effectively.</li>\n<li><strong>Drug Efflux:</strong> Increased expression of drug efflux pumps, such as P-glycoprotein, can reduce intracellular concentrations of PARP inhibitors, leading to resistance.</li>\n<li><strong>PARP1 Mutations:</strong> Mutations in PARP1 itself can alter the binding of PARP inhibitors, reducing their efficacy.</li>\n<li>\n<p><strong>Loss of 53BP1:</strong> Loss of proteins like 53BP1, which normally inhibit HR in BRCA1-deficient cells, can also restore HR and confer resistance.</p>\n</li>\n<li>\n<p><strong>Resistance to NTRK Inhibitors in Patients with PIK3CA Mutations:</strong></p>\n</li>\n<li><strong>Secondary Mutations in NTRK Genes:</strong> Acquired mutations in the NTRK gene that affect the binding of the inhibitor can lead to resistance.</li>\n<li><strong>Activation of Alternative Pathways:</strong> Activation of parallel signaling pathways, such as the PI3K/AKT/mTOR pathway (potentially enhanced by PIK3CA mutations), can provide alternative survival signals to the cancer cells.</li>\n<li>\n<p><strong>Histological Transformation:</strong> Some tumors may undergo histological changes that make them less dependent on NTRK signaling.</p>\n</li>\n<li>\n<p><strong>Resistance to Immunotherapy in Patients with PD-L1 Expression:</strong></p>\n</li>\n<li><strong>Loss of Antigen Presentation:</strong> Mutations or downregulation of components involved in antigen presentation, such as MHC molecules, can lead to immune evasion.</li>\n<li><strong>Tumor Microenvironment Changes:</strong> An immunosuppressive tumor microenvironment, characterized by regulatory T cells, myeloid-derived suppressor cells, and certain cytokines, can inhibit effective immune responses.</li>\n<li><strong>Alternative Immune Checkpoints:</strong> Upregulation of other immune checkpoint molecules, such as TIM-3 or LAG-3, can provide alternative pathways for immune evasion.</li>\n<li><strong>Genetic and Epigenetic Changes:</strong> Tumor cells may undergo genetic or epigenetic changes that reduce their immunogenicity or alter PD-L1 expression.</li>\n</ol>\n<p>Understanding these resistance mechanisms is crucial for developing combination therapies or next-generation inhibitors that can overcome or prevent resistance.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>To answer your primary question regarding <strong>PARP inhibitors (PARPi)</strong> in <strong>BRCA-mutated breast cancer</strong>, the mechanisms of resistance are fascinating because they represent a form of \"evolutionary escape\" by the tumor.</p>\n<p>PARP inhibitors work via <strong>synthetic lethality</strong>. BRCA1/2 mutations destroy the cell's ability to repair double-strand DNA breaks via Homologous Recombination (HR). PARP inhibitors block single-strand repair. When both fail, the cancer cell dies. Resistance occurs when the cancer cell finds a way to fix its DNA despite these blockades.</p>\n<p>Here are the four primary mechanisms of resistance:</p>\n<h3>1. Restoration of Homologous Recombination (HR) Capacity</h3>\n<p>This is the most clinically significant mechanism. The tumor effectively \"fixes\" the broken BRCA gene so it can repair DNA again.\n*   <strong>Secondary \"Reversion\" Mutations:</strong> The cancer develops a <em>new</em> mutation within the BRCA1 or BRCA2 gene. If the original mutation was a frameshift (creating a premature stop codon), the new mutation often deletes or inserts nucleotides to restore the reading frame. The resulting protein is slightly altered but functional enough to perform HR repair, rendering the PARP inhibitor ineffective.\n*   <strong>Epigenetic Reversion:</strong> In cases where BRCA is silenced by promoter hypermethylation (rather than a genetic mutation), the tumor may demethylate the promoter, re-expressing the functional protein.</p>\n<h3>2. Rewiring of DNA Repair Pathways (Loss of 53BP1)</h3>\n<p>This is a complex bypass mechanism.\n*   Normally, <strong>BRCA1</strong> promotes DNA end-resection (the first step of HR). A protein called <strong>53BP1</strong> opposes this; it blocks resection to force the cell into a different repair pathway (NHEJ).\n*   In BRCA1-mutated cells, 53BP1 wins, preventing HR.\n*   <strong>Resistance Mechanism:</strong> If the tumor <em>also</em> loses 53BP1 (via mutation or downregulation), the inhibition on end-resection is lifted. The cell can now perform Homologous Recombination even without functional BRCA1, causing resistance to the PARP inhibitor.</p>\n<h3>3. Protection of the Replication Fork</h3>\n<p>PARP inhibitors kill cells partly by \"trapping\" PARP on DNA, which causes the replication fork (the machinery copying DNA) to stall and collapse.\n*   <strong>Fork Stabilization:</strong> Resistant cells often downregulate proteins responsible for degrading stalled forks (like PTIP, EZH2, or MRE11). By stabilizing the replication fork, the cell prevents the catastrophic DNA damage that usually triggers cell death, allowing it to survive the drug's effect.</p>\n<h3>4. Drug Efflux (The \"Pump\" Mechanism)</h3>\n<p>This is a non-specific resistance mechanism seen in many chemotherapy contexts.\n*   <strong>Upregulation of ABCB1 (MDR1):</strong> The tumor increases the expression of P-glycoprotein efflux pumps. These pumps physically transport the PARP inhibitor out of the cell before it can bind to its target in the nucleus.</p>\n<hr />\n<h3>Addressing the \"Spin\": The Broader Context of Resistance</h3>\n<p>You mentioned framing this alongside other resistance patterns (NTRK/PIK3CA and IO/PD-L1). This is an excellent way to categorize resistance because these three scenarios represent the <strong>three pillars of drug resistance in oncology</strong>:</p>\n<p><strong>1. Target Alteration (The PARP/BRCA Example)</strong>\n*   <em>Concept:</em> The drug target or the pathway dependency changes.\n*   <em>Mechanism:</em> The cell restores the pathway the drug was trying to exploit (e.g., BRCA reversion mutations).</p>\n<p><strong>2. Bypass Signaling (The NTRK/PIK3CA Example)</strong>\n*   <em>Question:</em> Why do NTRK inhibitors fail in patients with co-occurring PIK3CA mutations?\n*   <em>Mechanism:</em> <strong>Downstream Activation.</strong> NTRK inhibitors shut off the signal at the top of the cascade. However, PIK3CA is downstream of NTRK. A mutation in PIK3CA acts as a permanent \"ON\" switch below the blockage. The cell no longer needs the upstream NTRK signal to grow because the downstream machinery is already active.</p>\n<p><strong>3. Microenvironment &amp; Immune Evasion (The IO/PD-L1 Example)</strong>\n*   <em>Question:</em> Why does immunotherapy fail even if the patient has high PD-L1 expression?\n*   <em>Mechanism:</em> <strong>Antigen Presentation Defects.</strong> PD-L1 expression only matters if the T-cell can \"see\" the tumor. Resistance often occurs because the tumor loses <strong>MHC Class I</strong> (Beta-2 microglobulin mutations). Without MHC-I, the tumor stops presenting antigens on its surface. It becomes invisible to the immune system, so \"releasing the brakes\" with a PD-L1 inhibitor is useless because the T-cells cannot recognize the target.</p>"}, {"model": "MedGemma 27B", "text": "<p>Okay, let's break down PARP inhibitor resistance mechanisms in <em>BRCA</em>-mutated breast cancer and then touch upon the other examples you provided (NTRK inhibitors + PIK3CA mutation, Immunotherapy + PD-L1). This requires understanding how these targeted therapies work and what pathways might compensate when they fail.</p>\n<p><strong>I. PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer</strong></p>\n<ul>\n<li><strong>Background:</strong> PARP (Poly ADP-ribose polymerase) enzymes are crucial for DNA single-strand break repair (SSB), particularly Base Excision Repair (BER). In cells with deficient Homologous Recombination (HR) due to mutations like <em>BRCA1/2</em>, inhibiting PARP leads to an accumulation of SSBs that cannot be repaired efficiently. These unrepaired SSBs stall replication forks, leading to double-strand breaks (DSBs) during replication. Since HR is already defective, the cell cannot effectively repair these DSBs, resulting in synthetic lethality \u2013 the tumor cell dies preferentially over normal cells (which have functional HR).</li>\n<li><strong>Resistance Mechanisms:</strong> When tumors initially respond but later progress on PARP inhibitors (like olaparib, talazoparib, rucaparib), several mechanisms contribute:<ol>\n<li><strong>Reversion Mutations in <em>BRCA1/2</em></strong>: The most common mechanism involves secondary mutations within the <em>BRCA1/2</em> gene itself. These \"reversion\" mutations often restore a partially functional protein, allowing some level of HR activity to resume, thus overcoming the synthetic lethal dependency on PARP inhibition. These mutations typically occur at specific sites (\"hotspots\") known to affect protein function.</li>\n<li><strong>Restoration of Functional BRCA Protein Expression</strong>: Sometimes, loss of heterozygosity (LOH) occurs after initial treatment, where the wild-type allele becomes dominant again, restoring full BRCA function. Alternatively, epigenetic changes could potentially reactivate the silenced wild-type allele.</li>\n<li><strong>Upstream Pathway Activation / Bypass Pathways</strong>: Tumor cells may activate alternative DNA damage response (DDR) pathways to cope with the increased genomic instability caused by PARP inhibition. Examples include:<ul>\n<li>Increased RAD51 levels or activity (part of the HR pathway): Even if BRCA is mutated, boosting other components of HR might help survival.</li>\n<li>Activation of Non-Homologous End Joining (NHEJ): While less accurate than HR, NHEJ can fix DSBs. Increased NHEJ efficiency</li>\n</ul>\n</li>\n</ol>\n</li>\n</ul>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>What is the resistance mechanism to parp inhibitors in breast cancer patients with the BRCA 1/2 mutations? We can spin this question multiple ways.  For example, we can also ask about the resistance mechanism to NTRK inhibitors in patients with PIK3CA mutations or the mechanism of resistance to immunotherapy in patients with PD-L1 expression.</h1>\n<p>In BRCA1/2\u2011mutated breast cancers, resistance to PARP inhibitors most often arises by restoring homologous recombination (HR) repair or otherwise reducing replication\u2011associated DNA damage, rather than by a single, uniform mutation. Other targeted agents (NTRK inhibitors, immunotherapy) show a similar theme: resistance typically reflects pathway reactivation or bypass plus microenvironmental and immune escape mechanisms.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5990439/\">^1</a><a href=\"https://www.oaepublish.com/articles/cdr.2019.50\">^3</a></p>\n<h2>PARP inhibitor resistance in BRCA1/2\u2011mutant breast cancer</h2>\n<p>Key mechanisms (primary or acquired) include:</p>\n<ul>\n<li><strong>Restoration of HR function</strong><ul>\n<li>Secondary \u201creversion\u201d mutations in <em>BRCA1</em> or <em>BRCA2</em> can restore an in\u2011frame, partially functional protein, re\u2011enabling HR repair and abolishing synthetic lethality with PARP inhibition.<a href=\"https://portlandpress.com/biochemsoctrans/article/53/01/225/235676/Where-is-my-gap-mechanisms-underpinning-PARP\">^2</a><a href=\"https://www.oaepublish.com/articles/cdr.2019.50\">^9</a></li>\n<li>Loss of 53BP1/REV7 (and components of the Shieldin complex) or other NHEJ\u2011promoting factors shifts DSB repair back toward HR, again reducing dependence on PARP.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5990439/\">^9</a></li>\n</ul>\n</li>\n<li><strong>Replication fork stabilization and gap suppression</strong><ul>\n<li>Reduced recruitment of nucleases (via alterations in EZH2, PTIP, or fork\u2011remodeling factors such as HLTF, ZRANB3, SMARCAL1) protects stalled replication forks from degradation, so PARP inhibition creates less lethal fork collapse.<a href=\"https://www.oaepublish.com/articles/cdr.2019.50\">^3</a></li>\n<li>Emerging models emphasize suppression of single\u2011stranded DNA gaps at replication forks as a central determinant of PARP inhibitor sensitivity; BRCA\u2011mutant cells that adapt to limit these gaps become resistant.<a href=\"https://academic.oup.com/narcancer/article/4/4/zcac042/6955906\">^4</a></li>\n</ul>\n</li>\n<li><strong>Alterations in PARP1 or drug handling</strong><ul>\n<li>Mutations or expression changes in PARP1 that reduce its binding to DNA or alter PARylation can blunt the \u201cPARP trapping\u201d effect critical for cytotoxicity, even in HR\u2011deficient cells.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10378018/\">^6</a><a href=\"https://www.oaepublish.com/articles/cdr.2019.50\">^9</a></li>\n<li>Upregulation of drug efflux pumps (e.g., P\u2011glycoprotein/ABCB1) decreases intracellular PARP inhibitor levels, producing pharmacologic resistance.<a href=\"https://www.oaepublish.com/articles/cdr.2019.50\">^2</a></li>\n</ul>\n</li>\n<li><strong>Microenvironment and immune factors</strong><ul>\n<li>PARP inhibitors can activate cGAS\u2011STING and type I interferon signaling, enhancing antitumor immunity; tumors that develop immunosuppressive microenvironments (e.g., increased MDSCs, exhausted T cells) may partially escape this component of PARP inhibitor efficacy.<a href=\"https://www.nature.com/articles/s41388-024-03227-6\">^3</a></li>\n</ul>\n</li>\n</ul>\n<h2>Conceptual parallels for NTRK inhibitors in PIK3CA\u2011mutant tumors</h2>\n<p>Data are richer in other cancers, but the resistance logic carries over to breast cancer with oncogenic fusions or driver mutations:</p>\n<ul>\n<li><strong>On\u2011target changes in NTRK</strong><ul>\n<li>Kinase domain mutations within the NTRK fusion (e.g., gatekeeper or solvent\u2011front mutations) reduce drug binding while preserving kinase signaling, leading to on\u2011target resistance to first\u2011generation TRK inhibitors.</li>\n</ul>\n</li>\n<li><strong>Bypass pathway activation and PI3K signaling</strong><ul>\n<li>Co\u2011existing <em>PIK3CA</em> mutations or acquired PI3K/AKT/mTOR activation can provide parallel survival/proliferation signals that diminish dependence on NTRK signaling, so blocking TRK alone becomes insufficient.</li>\n<li>Additional RTKs (MET, EGFR, HER2) or downstream RAS\u2013MAPK amplification can act as alternative conduits, functionally similar to what is seen with other kinase inhibitors.</li>\n</ul>\n</li>\n</ul>\n<p>In practice, resistance in this setting is usually a combination of mutations in the drug target itself plus amplification of bypass pathways that are already \u201cprimed\u201d by lesions such as <em>PIK3CA</em>.</p>\n<h2>Mechanisms of resistance to immunotherapy in PD\u2011L1\u2013positive tumors</h2>\n<p>Even in PD\u2011L1\u2013expressing breast cancers, many tumors do not respond or develop acquired resistance to checkpoint blockade:</p>\n<ul>\n<li><strong>Loss or reduction of antigenicity</strong><ul>\n<li>Tumors may lose neoantigens through clonal selection or reduce antigen presentation via mutations or downregulation of components such as \u03b22\u2011microglobulin or MHC class I, making them less visible to T cells despite PD\u2011L1 expression.</li>\n</ul>\n</li>\n<li><strong>Defects in interferon and T\u2011cell signaling</strong><ul>\n<li>Mutations or pathway alterations in JAK/STAT or IFN signaling can blunt the inflammatory response to T\u2011cell attack, limiting the efficacy of PD\u20111/PD\u2011L1 blockade.</li>\n</ul>\n</li>\n<li><strong>Immunosuppressive microenvironment</strong><ul>\n<li>Expansion of Tregs, MDSCs, and M2\u2011like macrophages, upregulation of alternative checkpoints (TIM\u20113, LAG\u20113, TIGIT), and metabolic competition in the TME can all maintain immune suppression independent of PD\u2011L1 status.</li>\n</ul>\n</li>\n<li><strong>Spatial/phenotypic exclusion of T cells</strong><ul>\n<li>Tumors may evolve \u201cimmune\u2011excluded\u201d or \u201cimmune\u2011desert\u201d architectures, with dense stromal barriers or chemokine changes preventing cytotoxic T cells from effectively infiltrating tumor nests.</li>\n</ul>\n</li>\n</ul>\n<p>If you are interested in a very specific clinical scenario (e.g., germline <em>BRCA2</em>\u2011mutated, HR\u2011positive/HER2\u2011negative metastatic breast cancer progressing on olaparib, or PD\u2011L1\u2013positive TNBC progressing on pembrolizumab\u2011based chemo), the resistance landscape can be mapped more narrowly with the relevant pathways and likely actionable escape routes in that context.\n<span style=\"display:none\"><a href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.967633/full\">^10</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8992504/\">^7</a></span></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>s in breast cancer patients with the BRCA 1/2 mutations? a. We can spin this question multiple ways. For example, we can also ask about the resistance mechanism to NTRK inhibitors in patients with PIK3CA mutations or the mechanism of resistance to immunotherapy in **Resistance to PARP inhibitors in BRCA1/2-mutant breast cancer occurs through both reversion and non- reversion mechanisms, while resistance to NTRK inhibitors primarily involves on-target kinase domain mutations and MAPK pathway activation. ** Resistance to PD-1/PD-L1 immunotherapy in breast cancer involves tumor- intrinsic alterations, immune cell dysfunction, and microenvironmental factors.</p>\n<h2>PARP Inhibitor Resistance in BRCA1/2-Mutant Breast Cancer</h2>\n<p>**BRCA reversion mutations are the most common resistance mechanism, occurring in approximately 40-60% of patients. ** In clinical studies, BRCA reversion mutations were detected in 43% of breast cancer patients at progression on olaparib, compared to only 9% receiving chemotherapy.[1]</p>\n<p>These reversions restore homologous recombination (HR) function through diverse mechanisms, with <strong>68% mediated by microhomology-mediated end joining (MMEJ)</strong> , suggesting DNA polymerase \u03b8 (POL\u03b8) plays a key role.[1]</p>\n<p>Novel reversion mechanisms include intragenic BRCA1/2 deletions with intronic breakpoints, secondary mutations forming novel splice acceptor sites, and de novo gene fusions placing BRCA1 under heterologous promoter control.[1] patients with PD- L1 expression. Importantly, <strong>reversions can be detected in circulating tumor DNA before clinical progression</strong> in some cases, and when detected before commencing subsequent treatment, they associate with significantly shorter time to progression.[2]</p>\n<p>All patients whose tumors demonstrated RAD51 foci post-resistance were intrinsically resistant to subsequent lines of DNA-damaging therapy.[2] <strong>Non-reversion resistance mechanisms differ between BRCA1- and BRCA2-deficient tumors. ** In preclinical models, HR restoration occurred in 62% of PARP inhibitor-resistant BRCA1-deficient tumors but none in BRCA2- deficient tumors. </strong>53BP1 loss is the prevalent resistance mechanism in HR-proficient BRCA1-deficient tumors** , while resistance in BRCA2-deficient tumors is mainly induced by PARG loss.[3]</p>\n<p>Additional non- reversion mechanisms include loss-of-function mutations in TP53BP1, RIF1, or PAXIP1, which restore HR through increased DNA end resection.[2]</p>\n<p>One patient acquired amplification of MRE11A, another mechanism promoting DNA end resection.[2]</p>\n<p>In cell line models, <strong>BRCA1 expression was reestablished in olaparib-resistant BRCA1-mutant cells, while PARP1 expression decreased</strong> .[4]</p>\n<p>In BRCA2-mutant resistant lines without reversion, increased expression of FANCD2, HPF1, and NAMPT was observed, suggesting enhanced replication fork protection and metabolic pathway adaptation.[4] <strong>Approximately 40-50% of BRCA1/2-mutated patients do not respond to PARP inhibitors due to preexisting innate resistance</strong> , and the majority who initially respond inevitably develop acquired resistance, though subsets of patients experience long-term response (&gt;2 years).[5]</p>\n<h2>NTRK Inhibitor Resistance (Note: Not Specifically Related to PIK3CA) The question asks about NTRK inhibitor resistance in patients with PIK3CA mutations, but</h2>\n<p><strong>NTRK inhibitors are indicated for NTRK fusion-positive tumors, not PIK3CA-mutant disease</strong> .[6]</p>\n<p>These are distinct molecular alterations with different therapeutic implications. <strong>In NTRK fusion-positive cancers, on-target resistance involving kinase domain mutations occurs in 83% of cases</strong> following first-generation TRK inhibitor therapy.[7]</p>\n<p>The most common mutations involve the <strong>solvent front (87%: NTRK3 G623R, NTRK1 G595R, NTRK2 G639L, NTRK3 G623E)</strong> followed by the gatekeeper region (13%: NTRK1 F589L, NTRK3 F617I).[7] <strong>Off-target resistance occurs in 11% of cases, mediated by genomic alterations that converge to activate the MAPK pathway</strong> .[8][7]</p>\n<p>Specific alterations include BRAF V600E mutation and MET amplification.[7]</p>\n<p>In patient- derived models, MAPK pathway-directed targeted therapy, administered alone or in combination with TRK inhibition, re-established disease control.[8]</p>\n<p>Interestingly, <strong>sequential use of second-generation TRK inhibitors alters evolutionary kinetics</strong> . Solvent front mutation loss was observed in two patients transitioning to second-generation therapy, with development of polyclonal resistance including KRAS G12A, new NTRK mutations, and gatekeeper mutations.[7]</p>\n<h2>PIK3CA Inhibitor Resistance For PIK3CA-mutant breast cancer treated with alpelisib (the FDA-approved PI3K\u03b1 inhibitor),</h2>\n<p><strong>50% of patients acquire genomic alterations within the PI3K pathway at resistance</strong> , including PTEN loss and activating AKT1 mutations.[6][9]</p>\n<p>Notably, <strong>emergent secondary resistance mutations in PIK3CA alter the inhibitor binding pocket</strong> .[9]</p>\n<p>Some mutations show differential effects on PI3K\u03b1-selective versus pan-PI3K inhibitors, but resistance induced by all mutations could be overcome by the novel allosteric pan-mutant-selective PI3K\u03b1 inhibitor RLY-2608.[9]</p>\n<h2>Immunotherapy Resistance in PD-L1-Positive Breast Cancer</h2>\n<p><strong>Resistance to PD-1/PD-L1 immunotherapy arises from multifaceted interactions among tumor-intrinsic alterations, immune cell dysfunction, and stromal microenvironmental factors</strong> .[10][11] <strong>Tumor-intrinsic mechanisms include:</strong> - Epigenetic silencing of antigen presentation machinery via EZH2/PRC2 - Oncogenic pathway-driven upregulation of PD-L1 - Genetic loss of IFN\u03b3 pathway components (JAK1/2, B2M) - Tumor antigen deletion - Alterations in PD-L1 expression within tumor cells[10][12] <strong>Immune cell dysfunction involves:</strong> - T cell exhaustion with co-expression of inhibitory receptors (PD-1, TIM-3, LAG-3) - Metabolic and epigenetic T cell reprogramming - Suppressive regulatory T cells - Increased immunosuppressive cells[10][12] <strong>Microenvironmental factors include:</strong> - Hypoxia-inducible factors - Immunosuppressive metabolites (IDO-mediated kynurenine) - Tumor-associated macrophages and MDSCs - Aberrant angiogenesis[10]</p>\n<p>Additional factors potentially affecting resistance include altered metabolism, microbiota composition, and DNA methylation patterns.[12]</p>\n<p>In the TOPACIO trial combining niraparib plus pembrolizumab in metastatic TNBC, the overall response rate was 21% in unselected patients, with numerically higher rates in patients with BRCA1/2 variants (47%) and PD-L1- positive tumors (32%).[13]</p>\n<p>However, the first randomized study adding atezolizumab to olaparib in germline BRCA1/2 carriers with advanced breast cancer did not show significant PFS benefit.[13]</p>\n<p>Would you like me to summarize the latest combination therapy strategies to overcome these specific resistance mechanisms, such as POL\u03b8 inhibitors to prevent BRCA reversions, MEK inhibitors for NTRK resistance, or novel checkpoint combinations for immunotherapy resistance? Would you like me to review and summarize the most recent clinical trial data on emerging agents specifically targeting these resistance mechanisms\u2014such as POL\u03b8 inhibitors for PARP resistance, next-generation TRK inhibitors for NTRK fusion mutations, and novel immunotherapy combinations for PD-L1-positive breast cancer\u2014 to help guide evidence-based therapeutic decisions?</p>\n<h3>References</h3>\n<ol>\n<li>BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer. Lukashchuk N, Armenia J, Tobalina L, et al. Journal of Clinical Oncology. 2022;40(Suppl 16):5559. doi:10.1200/JCO.2022.40.16_suppl.5559.</li>\n<li>Reversion and Non-Reversion Mechanisms of Resistance to PARP Inhibitor or Platinum Chemotherapy in BRCA1/2-mutant Metastatic Breast Cancer. Waks AG, Cohen O, Kochupurakkal B, et al. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2020;31(5):590-598. doi:10.1016/j.annonc.2020.02.008.</li>\n<li>Multi-Omics Analysis Reveals Distinct Non-Reversion Mechanisms of PARPi Resistance in BRCA1- Versus BRCA2-deficient Mammary Tumors. Bhin J, Paes Dias M, Gogola E, et al. Cell Reports. 2023;42(5):112538. doi:10.1016/j.celrep.2023.112538.</li>\n<li>Multi-Omics Characterization of Acquired Olaparib Resistance in BRCA1 and BRCA2 Mutant Breast Cancer Cell Lines. Anagho-Mattanovich HA, Mullari M, Anagho-Mattanovich M, et al. Molecular &amp; Cellular Proteomics : MCP . 2025;:101034. doi:10.1016/j.mcpro.2025.101034.</li>\n<li>Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches. Dilmac S, Ozpolat B. Cancers. 2023;15(14):3642. doi:10.3390/cancers15143642.</li>\n<li>FDA Orange Book. FDA Orange Book.</li>\n<li>Mechanisms of acquired resistance to TRK inhibitors. Harada G, Choudhury N, Schram A, et al. Journal of Clinical Oncology. 2022;40(Suppl 16):3104. doi:10.1200/JCO.2022.40.16_suppl.3104.</li>\n<li>Resistance to TRK Inhibition Mediated by Convergent MAPK Pathway Activation. Cocco E, Schram AM, Kulick A, et al. Nature Medicine. 2019;25(9):1422-1427. doi:10.1038/s41591-019-0542-z.</li>\n<li>Allosteric PI3K-alpha Inhibition Overcomes on-Target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations. Varkaris A, Fece de la Cruz F , Martin EE, et al. Cancer Discovery. 2023;. doi:10.1158/2159-8290.CD-23-0704.</li>\n<li>Overcoming Resistance to PD-1 and CTLA-4 Blockade Mechanisms and Therapeutic Strategies. Wang X, He J, Ding G, Tang Y , Wang Q. Frontiers in Immunology. 2025;16:1688699. doi:10.3389/fimmu.2025.1688699.</li>\n<li>Overcoming Resistance to Anti-Pd-L1 Immunotherapy: Mechanisms, Combination Strategies, and Future Directions. Mandal K, Barik GK, Santra MK. Molecular Cancer. 2025;24(1):246. doi:10.1186/s12943-025-02400-z.</li>\n<li>Tumor Immunotherapy Resistance: Revealing the Mechanism of PD-1 / PD-L1-mediated Tumor Immune Escape. Cui JW, Li Y , Yang Y , et al. Biomedicine &amp; Pharmacotherapy = Biomedecine &amp; Pharmacotherapie. 2024;171:116203. doi:10.1016/j.biopha.2024.116203.</li>\n<li>PARP Inhibitors for Breast Cancer Treatment: A Review. Morganti S, Marra A, De Angelis C, et al. JAMA Oncology. 2024;10(5):658-670. doi:10.1001/jamaoncol.2023.7322. 15.</li>\n</ol>"}]}, "15": {"question": "In the neoadjuvant setting, are there specific gene mutations that will predict tumor resistance to chemotherapy prior to surgery?  Can pre-operative radiotherapy influence these gene expression levels?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>The authors did not find any studies investigating this question. They found one study which showed that in patients with locally advanced rectal cancer treated by primary radiation and concurrent chemotherapy as a part of a multimodality treatment program, PTEN mRNA was significantly elevated compared with normal tissue controls.</p>"}, {"model": "GPT-4o", "text": "<p>In the neoadjuvant setting, certain gene mutations and expression profiles can indeed predict tumor resistance to chemotherapy. For example, mutations in the TP53 gene are often associated with resistance to various chemotherapeutic agents. Similarly, overexpression of the MDR1 gene, which encodes P-glycoprotein, can lead to multidrug resistance by actively pumping drugs out of cancer cells. Other genes, such as those involved in DNA repair pathways (e.g., BRCA1/2 mutations), can also influence sensitivity or resistance to specific chemotherapies.</p>\n<p>Gene expression profiling, such as the Oncotype DX or MammaPrint tests in breast cancer, can provide insights into the likelihood of response to chemotherapy. These tests analyze the expression of multiple genes to predict the benefit of chemotherapy and the risk of recurrence.</p>\n<p>Pre-operative radiotherapy can influence gene expression levels, potentially altering the tumor's biology and its response to subsequent treatments. Radiotherapy can induce changes in the tumor microenvironment, affect DNA repair mechanisms, and modulate immune responses, all of which can impact gene expression. For instance, radiation can induce the expression of genes involved in stress responses, apoptosis, and inflammation. These changes might either sensitize the tumor to chemotherapy or, conversely, lead to adaptive resistance mechanisms.</p>\n<p>Overall, the interplay between genetic mutations, gene expression, and treatment modalities like chemotherapy and radiotherapy is complex. Personalized treatment strategies that consider these factors are crucial for optimizing therapeutic outcomes in the neoadjuvant setting.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>This is a complex area of oncology because the answer depends heavily on the specific type of cancer (e.g., breast, rectal, lung). However, there are well-established biomarkers and mechanisms that address both parts of your question.</p>\n<p>Here is a breakdown of the specific gene mutations associated with neoadjuvant chemotherapy resistance and how radiotherapy influences gene expression.</p>\n<hr />\n<h3>1. Gene Mutations Predicting Resistance to Neoadjuvant Chemotherapy</h3>\n<p>Resistance is rarely defined by a single gene; it is usually a combination of mutations that alter DNA repair, cell cycle regulation, or drug transport.</p>\n<h4><strong>A. Breast Cancer (The most studied setting)</strong></h4>\n<ul>\n<li><strong><em>PIK3CA</em>:</strong> Mutations in this gene are often associated with resistance to neoadjuvant chemotherapy, particularly in HER2-positive and ER-positive breast cancers. These tumors may respond better when targeted therapies (like PI3K inhibitors) are added.</li>\n<li><strong><em>TP53</em>:</strong> The role of <em>TP53</em> is paradoxical. In some contexts (like estrogen-receptor-positive breast cancer), <em>TP53</em> mutations predict resistance to anthracycline/taxane-based chemotherapy. However, in Triple-Negative Breast Cancer (TNBC), <em>TP53</em> mutations are ubiquitous and do not necessarily predict resistance; in fact, mutant tumors sometimes respond <em>better</em> to DNA-damaging agents because they cannot pause the cell cycle to repair the damage.</li>\n<li><strong><em>BCL2</em>:</strong> High expression or amplification of this anti-apoptotic gene is a strong predictor of resistance, as the tumor cells are \"primed\" to survive the cell death signals triggered by chemotherapy.</li>\n</ul>\n<h4><strong>B. Rectal Cancer (Locally Advanced)</strong></h4>\n<ul>\n<li><strong><em>KRAS</em> and <em>BRAF</em>:</strong> Mutations in these genes are standard biomarkers. While primarily known for predicting resistance to EGFR inhibitors (like cetuximab), they are also associated with lower rates of Pathologic Complete Response (pCR) to standard neoadjuvant chemoradiotherapy (5-FU/Capecitabine).</li>\n<li><strong>Mismatch Repair Genes (<em>MLH1, MSH2, MSH6, PMS2</em>):</strong> Tumors that are \"Mismatch Repair Deficient\" (dMMR) or MSI-High are notoriously resistant to standard 5-FU chemotherapy. However, they are highly sensitive to immunotherapy (checkpoint inhibitors).</li>\n</ul>\n<h4><strong>C. Lung Cancer (NSCLC)</strong></h4>\n<ul>\n<li><strong><em>KEAP1</em> and <em>STK11</em> (LKB1):</strong> These are emerging as major markers of resistance. Patients with <em>KEAP1</em> or <em>STK11</em> mutations generally have poor responses to both chemotherapy and immunotherapy in the neoadjuvant setting.</li>\n<li><strong><em>ERCC1</em>:</strong> High expression (often driven by genetic polymorphisms) predicts resistance to platinum-based chemotherapies (cisplatin/carboplatin) because the tumor is too efficient at repairing the DNA cross-links caused by the drug.</li>\n</ul>\n<h4><strong>D. General Mechanisms (Pan-Cancer)</strong></h4>\n<ul>\n<li><strong><em>MDR1</em> / <em>ABCB1</em>:</strong> Genetic upregulation of this gene produces P-glycoprotein, a pump that physically ejects chemotherapy drugs from the cell, leading to multi-drug resistance.</li>\n</ul>\n<hr />\n<h3>2. Can Pre-operative Radiotherapy Influence Gene Expression?</h3>\n<p><strong>Yes, significantly.</strong> Radiotherapy (RT) is not just a physical tool to burn tumor cells; it is a biological stressor that fundamentally alters the molecular landscape of the surviving tumor cells.</p>\n<p>If a tumor is treated with radiation <em>before</em> or <em>during</em> chemotherapy, the radiation can induce changes in gene expression that may lead to <strong>acquired resistance</strong>.</p>\n<h4><strong>A. Upregulation of DNA Repair Genes</strong></h4>\n<p>Radiation causes double-strand DNA breaks. Tumor cells that survive radiation often do so by massively upregulating DNA repair pathways.\n*   <strong>Effect:</strong> Post-radiation tumors often show increased expression of <strong><em>XRCC1</em>, <em>RAD51</em>, and <em>ATM</em></strong>.\n*   <strong>Consequence:</strong> If chemotherapy (specifically platinum agents or PARP inhibitors) is administered after this upregulation, the tumor is now \"super-charged\" to repair the DNA damage caused by the chemo, rendering the drug less effective.</p>\n<h4><strong>B. Hypoxia-Induced Changes (<em>HIF-1\u03b1</em>)</strong></h4>\n<p>Radiation damages tumor blood vessels, leading to hypoxia (low oxygen).\n*   <strong>Effect:</strong> Hypoxia stabilizes the <strong><em>HIF-1\u03b1</em></strong> transcription factor.\n*   <strong>Consequence:</strong> <em>HIF-1\u03b1</em> activates downstream genes like <strong><em>VEGF</em></strong> (promoting new blood vessels) and <strong><em>MDR1</em></strong> (drug efflux pumps). This means radiation can inadvertently turn on the genes that pump chemotherapy out of the cell.</p>\n<h4><strong>C. Epithelial-Mesenchymal Transition (EMT)</strong></h4>\n<p>Radiotherapy can trigger a cellular program called EMT, where tumor cells change from a stationary state to a migratory, invasive state.\n*   <strong>Effect:</strong> Radiation decreases expression of <strong>E-cadherin</strong> (adhesion) and increases expression of <strong>Vimentin</strong> and <strong>Snail/Slug</strong>.\n*   <strong>Consequence:</strong> Cells undergoing EMT are inherently more resistant to chemotherapy and apoptosis (cell death). This is a known mechanism by which tumors metastasize or recur after radiation.</p>\n<h4><strong>D. Immune Checkpoint Upregulation</strong></h4>\n<ul>\n<li><strong>Effect:</strong> Radiation causes inflammation, which triggers tumor cells to upregulate <strong><em>CD274</em> (PD-L1)</strong> as a defense mechanism.</li>\n<li><strong>Consequence:</strong> While this might make the tumor resistant to immune attack, it paradoxically makes the tumor <strong>more sensitive</strong> to immunotherapy (PD-1/PD-L1 inhibitors) if used in the adjuvant setting.</li>\n</ul>\n<h3>Summary for Clinical Context</h3>\n<ol>\n<li><strong>Predicting Resistance:</strong> We look for <em>KRAS</em> (rectal), <em>KEAP1</em> (lung), and <em>PIK3CA</em> or dMMR status to predict who will fail standard chemo.</li>\n<li><strong>Radiotherapy Impact:</strong> RT changes the tumor biology. It can induce \"survival phenotypes\" (better DNA repair, EMT, drug pumps) that may make surviving cells harder to kill with subsequent chemotherapy. This is why <strong>concurrent chemoradiation</strong> (giving both at the same time) is often preferred over sequential treatment\u2014it attacks the tumor before it has time to adapt its gene expression.</li>\n</ol>"}, {"model": "MedGemma 27B", "text": "<p><strong>Predicting Chemotherapy Resistance via Gene Mutations in Neoadjuvant Setting:</strong></p>\n<p>Yes, certain gene mutations can indeed predict primary or acquired chemoresistance <em>before</em> surgery (neoadjuvant) and potentially guide treatment decisions. However, it's a complex area with ongoing research. Here\u2019s a breakdown of key points:</p>\n<ol>\n<li><strong>Established Biomarkers &amp; Tumor Types:</strong><ul>\n<li><strong>HER2 Amplification/Overexpression (Breast Cancer):</strong> While not strictly a mutation predicting <em>intrinsic</em> resistance, HER2 status is crucial for selecting anti-HER2 therapies (like trastuzumab). Tumors lacking HER2 may respond differently to standard chemotherapy regimens compared to those overexpressing it. High HER2 amplification might correlate with reduced response to some cytotoxic agents but enhanced sensitivity to targeted therapy.</li>\n<li><strong>BRCA1/2 Mutations (Ovarian, Breast, Prostate Cancers):</strong> Germline or somatic BRCA mutations often confer sensitivity to PARP inhibitors and platinum-based chemotherapies due to defects in DNA repair pathways. Conversely, lack of BRCA mutations might suggest different optimal strategies.</li>\n<li><strong>TP53 Mutations (Many Solid Tumors):</strong> TP53 is a critical tumor suppressor involved in cell cycle arrest and apoptosis. Mutations in TP53 are common across many cancers (e.g., breast, ovarian, lung, colorectal) and frequently associated with increased chemoresistance, aggressive behavior, and poorer prognosis. Specific \"hotspot\" mutations have been identified.</li>\n<li><strong>KRAS Mutations (Colorectal, Pancreatic, Lung Cancers):</strong> Activating KRAS mutations drive proliferation and survival signaling. They are well-known predictors of resistance to EGFR inhibitors (in NSCLC) and cetuximab/panitumumab (in CRC), although their direct impact on traditional chemotherapy efficacy varies depending on the drug and cancer type. For example, KRAS wild-type tumors generally benefit more from anti-EGFR therapy than mutant ones.</li>\n<li><strong>PIK3CA Mutations (Breast Cancer):</strong> These activating mutations in the PI3K pathway are linked to endocrine resistance (to tamoxifen/aromatase inhibitors) and sometimes chemoresistance, particularly in ER+/HER2- breast cancers.</li>\n<li><strong>Other Genes:</strong> Research continues to identify other potential predictive markers like alterations in genes related to drug efflux pumps (ABCB1/MDR1), detoxification enzymes (GSTs), DNA damage repair (other than BRCA), and apoptotic pathways.</li>\n</ul>\n</li>\n</ol>\n<p>2</p>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>In the neoadjuvant setting, are there specific gene mutations that will predict tumor resistance to chemotherapy prior to surgery?  Can pre-operative radiotherapy influence these gene expression levels?</h1>\n<p>In the neoadjuvant setting there are indeed genomic and transcriptomic features that enrich for resistance to chemotherapy, but there is no single mutation that reliably \u201cguarantees\u201d resistance across regimens and subtypes. Instead, predictive information tends to come from: (1) multi\u2011gene DNA repair mutation panels, (2) broader mutation patterns at baseline, and (3) gene\u2011expression signatures; pre\u2011operative radiotherapy can further reshape these expression programs in ways that may influence chemosensitivity.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12044986/\">^1</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7463925/\">^4</a></p>\n<h2>Mutations predicting poor neoadjuvant chemo response</h2>\n<p>Evidence is most developed for triple\u2011negative and high\u2011risk HER2+ disease, and depends on the regimen.</p>\n<ul>\n<li><strong>Single recurrent mutations (limited predictive power)</strong><ul>\n<li>In a TNBC cohort receiving paclitaxel\u2013carboplatin neoadjuvant therapy, common mutations in <em>TP53</em>, <em>BRCA1/2</em>, <em>PIK3CA</em>, <em>PTEN</em> and others did <strong>not</strong> differ significantly in frequency between pCR and non\u2011pCR groups, suggesting that single mutations alone are poor stand\u2011alone predictors of resistance.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7944335/\">^1</a></li>\n<li>In larger TNBC analyses, chemoresistant tumors are more likely to carry alterations in genes such as <em>BRCA1</em>, <em>ATR</em>, <em>ARID1A</em>, <em>XRCC3</em>, and tubulin\u2011associated genes, while chemosensitive tumors more often harbor mutations in genes like <em>COL1A2</em>, <em>APOBEC3B</em>, <em>PALB2</em>, and histone genes; however, the patterns are probabilistic rather than deterministic.<a href=\"https://www.sciencedirect.com/science/article/abs/pii/S0960977617304952\">^2</a></li>\n</ul>\n</li>\n<li><strong>DNA repair gene panels (HR pathway)</strong><ul>\n<li>For TNBC treated with paclitaxel\u2013carboplatin, a panel of 10 homologous recombination\u2013related genes (<em>PALB2</em>, <em>CHEK2</em>, <em>BRCA2</em>, <em>RAD51D</em>, <em>BRCA1</em>, <em>RAD51C</em>, <em>BRIP1</em>, <em>ATM</em>, <em>RAD50</em>, <em>BARD1</em>) distinguished responders from non\u2011responders: 75\u201378% of patients with at least one deleterious mutation in this panel achieved pCR, versus a substantially lower pCR rate in mutation\u2011negative patients.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7944335/\">^1</a></li>\n<li>This illustrates that <em>HR deficiency</em> generally predicts <strong>chemosensitivity</strong> to DNA\u2011damaging neoadjuvant regimens, whereas HR\u2011proficient tumors (lacking these alterations) are more likely to be resistant, particularly in TNBC.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7944335/\">^5</a></li>\n</ul>\n</li>\n<li><strong>Baseline mutation patterns and residual disease</strong><ul>\n<li>Whole\u2011exome sequencing of pre\u2011 and post\u2011neoadjuvant TNBC biopsies shows that chemoresistant residual tumors are enriched for mutations affecting phosphorylation/signaling pathways, while mutations in genes involved in adhesion, cytoskeleton, and DNA repair are depleted, consistent with selection of clones optimized for survival and signaling plasticity.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10815241/\">^2</a></li>\n<li>In ER+/HER2\u2013 disease, residual tumors after neoadjuvant chemo often acquire or enrich alterations in cell\u2011cycle, PI3K/AKT, and ESR1/FGFR pathways, but many of these can already be present at baseline, and their value as pre\u2011treatment resistance predictors is still being defined.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7463925/\">^9</a></li>\n</ul>\n</li>\n</ul>\n<h2>Gene-expression signatures predicting neoadjuvant resistance</h2>\n<p>Transcriptional programs tend to outperform single mutations as predictors of pre\u2011operative chemo response.</p>\n<ul>\n<li>A 12\u2011gene expression signature built from neoadjuvant\u2011resistant breast cancer cell lines and patient data stratifies patients into high\u2011 and low\u2011risk groups for neoadjuvant resistance; resistant tumors show upregulated DNA repair and metabolic pathways and downregulated membrane receptor signaling.<a href=\"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1035667/full\">^4</a></li>\n<li>Other neoadjuvant studies highlight that responders demonstrate immune activation and suppression of PI3K\u2011Akt and AGE\u2013RAGE signaling, whereas non\u2011pCR tumors show reduced cytokine/immune receptor activity, emphasizing that an \u201cimmune\u2011cold\u201d baseline expression phenotype predicts resistance even before therapy starts.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12337530/\">^3</a></li>\n</ul>\n<p>In practice, multigene signatures (HRD scores, proliferation/immune modules, neoadjuvant\u2011response signatures) are more clinically promising than any single mutation for predicting pre\u2011surgical chemoresistance.</p>\n<h2>Can pre\u2011operative radiotherapy alter gene expression and impact chemo response?</h2>\n<p>Pre\u2011operative or concurrent radiotherapy can substantially modify tumor gene expression, with potential effects on how tumors respond to systemic agents:</p>\n<ul>\n<li><strong>Radiation-induced expression changes</strong><ul>\n<li>Radiation activates DNA damage\u2013response, checkpoint, and apoptotic genes and represses proliferative transcripts, generating a \u201cradiation response\u201d signature that is measurable in both experimental models and patient tumors.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733757/\">^11</a></li>\n<li>Radiation also modulates immune and inflammatory gene expression (e.g., interferon and antigen\u2011presentation pathways), which overlaps with the immune activation seen in chemo\u2011responsive tumors and can influence subsequent sensitivity to cytotoxic or immunomodulatory drugs.<a href=\"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.816053/full\">^12</a></li>\n</ul>\n</li>\n<li><strong>Implications for neoadjuvant chemo</strong><ul>\n<li>Because DNA\u2011damaging chemotherapy and radiotherapy share much of the same DDR and interferon\u2011related transcriptional circuitry, pre\u2011operative radiation could theoretically:<ul>\n<li>Sensitize tumors to certain agents if delivered in a way that augments pro\u2011apoptotic and checkpoint signaling at the time chemotherapy is given.</li>\n<li>Promote cross\u2011resistance if it induces sustained upregulation of DNA repair and interferon\u2011related \u201cresistance signatures\u201d before chemotherapy.</li>\n</ul>\n</li>\n<li>The net effect likely depends on sequence, dose, and tumor subtype; current clinical practice still largely separates standard neoadjuvant chemotherapy and radiotherapy, and robust, subtype\u2011specific predictive models that fully integrate both pre\u2011op RT\u2011induced and baseline expression patterns are not yet standard.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7463925/\">^14</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733757/\">^12</a></li>\n</ul>\n</li>\n</ul>\n<h2>Practical takeaways for the neoadjuvant setting</h2>\n<ul>\n<li>Single mutations like <em>TP53</em>, <em>PIK3CA</em>, or <em>BRCA1/2</em> are insufficient alone to predict neoadjuvant resistance across regimens, although HR\u2011deficiency panels can predict <strong>sensitivity</strong> to platinum\u2011based NAC in TNBC.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7944335/\">^5</a></li>\n<li>Multi\u2011gene expression signatures capturing DNA repair, proliferation, and immune activity provide better pre\u2011operative risk stratification for chemoresistance than isolated genomic lesions.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12044986/\">^6</a><a href=\"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1035667/full\">^4</a></li>\n<li>Pre\u2011operative radiotherapy clearly alters gene expression in overlapping DDR and immune pathways, but how best to leverage this to enhance or avoid resistance to neoadjuvant chemotherapy remains an area of ongoing research rather than settled practice.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733757/\">^11</a><a href=\"https://www.sciencedirect.com/science/article/pii/S2452109421000890\">^14</a></li>\n</ul>\n<p>If you specify a concrete clinical scenario (e.g., stage II TNBC receiving paclitaxel\u2192AC vs paclitaxel\u2013carboplatin, or locally advanced HER2+ disease on neoadjuvant TCHP with consideration of pre\u2011op RT), the relevant mutation panels and expression signatures for that setting can be discussed in more detail.\n<span style=\"display:none\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/40790759/\">^7</a></span></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>e mutations that will predict tumor resistance to chemotherapy prior to surgery? Can pre- operative radiotherapy influence these gene expression levels? <strong>Yes, specific gene mutations and expression patterns can predict tumor resistance to neoadjuvant chemotherapy prior to surgery</strong> , with the most robust predictors varying by breast cancer subtype. Preoperative radiotherapy does induce significant gene expression changes, though its specific influence on chemotherapy resistance markers remains incompletely characterized.</p>\n<h2>Predictive Gene Mutations for Chemotherapy Resistance</h2>\n<p><strong>PIK3CA mutations are consistently associated with reduced chemotherapy sensitivity. ** In neoadjuvant studies, PIK3CA mutations correlated with lower pathologic complete response (pCR) rates (p=0.040 for ypT0/isypN0), and patients with PIK3CA mutations showed reduced sensitivity to anthracycline-taxane-based NAC. High tumor mutational burden (TMB) and specific mutational signatures predict better response: </strong>mutation signature 3 (BRCA-mediated DNA repair deficiency) was significantly associated with higher pCR rates<strong> (median signature weight 24% in pCR vs. 0% in residual disease, p=0.007). </strong>TP53 mutations show complex, subtype-dependent effects. ** TP53 mutations were associated with higher pCR rates overall (p=0.019 for ypT0/isypN0 and p=0.003 for ypT0/is), though the effect varies by molecular context. In contrast, <strong>CCND1 amplification (p=0.042) and MAPK pathway alterations (p=0.043) predict reduced NAC sensitivity</strong> . <strong>Novel resistance markers include CDKAL1 P409L missense variant</strong> , which decreased breast cancer cell sensitivity to docetaxel, and <strong>amplifications of ADGRA2 and ADRB3 at 8p11.23</strong> , which were uniquely present in NAC nonresponsive tumors and associated with worse response and poor prognosis. Conversely, deletion at 3p13 harboring FOXP1 was found in NAC responsive tumors.</p>\n<h2>DNA Repair Gene Expression as Predictive Biomarkers</h2>\n<p><strong>Lower expression of PALB2 and ERCC1 in pre-treatment biopsies correlates with pathologic complete response</strong> (p=0.005 and p=0.009, respectively). After adjustment for tumor grade and molecular subtype, PALB2 and ERCC1 remained significantly lower in the pCR group (p=0.014 and p=0.040). These alterations in DNA repair could represent suitable targets for therapy selection. Post-NAC analysis revealed that <strong>BRCA2, ATM, FANCA, and PARP1 showed lower expression in residual tumor samples compared to pre-NAC biopsies</strong> , suggesting dynamic changes in DNA repair capacity during treatment.</p>\n<h2>Gene Expression Signatures and Proliferation</h2>\n<p><strong>Proliferation signatures are the dominant predictors of chemotherapy response, accounting for 90.5% of predictive signatures in ER+/HER2- disease and 63.3% in triple-negative breast cancer. ** Within each receptor- based subgroup, tumors with high proliferation signature scores were significantly more likely to achieve pCR. </strong>Proliferation-independent predictive signatures differ by subtype:<strong> In ER+/HER2- breast cancer, immune activity signatures predict response independent of proliferation, while in TNBC, proliferation-independent signatures include immune response, DNA damage pathways, PI3K/AKT/Ras/EGFR signaling, and stemness phenotypes. Treatment-na\u00efve samples reveal that </strong>the direction of effect differs by subtype**: TNBC patients with high proliferation, high immune response, and low extracellular matrix (ECM) expression have better response and survival (HR 0.29, 95% CI 0.10-0.85; p=0.02), while in ER+ patients the opposite pattern predicts better outcomes (HR 4.73, 95% CI 1.51-14.8; p=0.008).</p>\n<h2>Preoperative Radiotherapy Effects on Gene Expression</h2>\n<p><strong>Preoperative radiotherapy induces biphasic molecular changes: early proliferation reduction and DNA damage within days, followed by adaptive immune activation within weeks. ** In the YOUNGSTER trial of 20 early-stage breast cancer patients receiving preoperative RT boost (5 \u00d7 2.67 Gy), early post-RT samples (3-5 days) showed significant downregulation of proliferation genes, PAM50 proliferation signature, and Ki67 IHC staining, along with increased DNA damage (\u03b3H2AX) and macrophage marker upregulation. In primary surgery samples collected 2-8 weeks post-RT, </strong>adaptive immune markers showed significant upregulation, along with a 14-gene immunoglobulin signature increase<strong> . Single-cell RNA sequencing from another cohort demonstrated increased infiltration of naive-like CD4 T cells and early activated CD8 T cell populations 7 days post-radiation, while existing cytotoxic T cells were eliminated and myeloid cell populations increased. </strong>At the gene level, radiation significantly upregulates genes involved in p53 signaling, TNFA signaling, apoptosis, epithelial-mesenchymal transition, and inflammatory response** , while downregulating genes involved in mitotic spindle, G2M checkpoint, and E2F targets. Several genes involved in cell cycle regulation and DNA repair were significantly induced by radiation treatment.</p>\n<h2>Interaction Between Radiotherapy and Chemotherapy Resistance</h2>\n<p>**The specific influence of preoperative radiotherapy on chemotherapy resistance gene expression patterns remains underexplored in the literature. ** While radiotherapy clearly modulates proliferation and DNA repair pathways\u2014the same pathways that predict chemotherapy response\u2014no studies directly compare chemotherapy resistance markers before and after preoperative radiotherapy in the neoadjuvant setting. The radiation-induced downregulation of proliferation genes could theoretically reduce chemotherapy sensitivity, since high proliferation predicts better chemotherapy response. However, the immune activation induced by radiotherapy might enhance subsequent immunotherapy efficacy, supporting potential combinatorial approaches. Would you like me to summarize the clinical utility of commercially available gene expression assays (Oncotype DX, MammaPrint, PAM50) for predicting neoadjuvant chemotherapy response when performed on core needle biopsies, and whether any prospective trials are evaluating their use to guide neoadjuvant treatment selection? Given the gaps in direct evidence, I would suggest we delve into the latest studies or ongoing clinical trials that specifically evaluate how preoperative radiotherapy alters the expression of chemotherapy resistance genes in breast cancer\u2014especially focusing on whether these molecular changes translate into clinically meaningful differences in neoadjuvant treatment outcomes. Would you like me to identify and summarize such research? 16.</p>"}]}, "16": {"question": "Is there data in the literature to suggest that pre-operative radiotherapy can reduce the rate of resistance?  If so, what gene expression levels change when radiotherapy is added?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>There are no studies directly addressing this question. However, a number of genes have been identified whose expression changes following radiation treatment (see Table I). It would be interesting to determine whether any of these genes might correlate with increased or decreased risk for development of resistance and could serve as potential targets for therapeutic intervention.</p>"}, {"model": "GPT-4o", "text": "<p>Pre-operative radiotherapy is commonly used in the treatment of certain cancers, such as rectal cancer, to reduce tumor size and improve surgical outcomes. There is evidence in the literature suggesting that pre-operative radiotherapy can also impact the tumor microenvironment and potentially reduce the rate of resistance to subsequent treatments. This is thought to occur through various mechanisms, including the induction of DNA damage, alteration of the tumor vasculature, and modulation of the immune response.</p>\n<p>Regarding gene expression changes, radiotherapy can lead to alterations in the expression of genes involved in DNA repair, cell cycle regulation, apoptosis, and immune response. Some of the key changes observed include:</p>\n<ol>\n<li>\n<p><strong>DNA Repair Genes</strong>: Radiotherapy can downregulate genes involved in DNA repair pathways, such as BRCA1 and RAD51, making cancer cells more susceptible to DNA damage.</p>\n</li>\n<li>\n<p><strong>Cell Cycle Regulation</strong>: Genes like CDKN1A (p21) and TP53 (p53) may be upregulated, leading to cell cycle arrest and allowing time for DNA repair or apoptosis.</p>\n</li>\n<li>\n<p><strong>Apoptosis</strong>: Pro-apoptotic genes such as BAX and BAK may be upregulated, while anti-apoptotic genes like BCL2 may be downregulated, promoting cell death in response to radiation-induced damage.</p>\n</li>\n<li>\n<p><strong>Immune Response</strong>: Radiotherapy can enhance the expression of genes involved in the immune response, such as those encoding for cytokines and chemokines, which can help recruit immune cells to the tumor site and enhance anti-tumor immunity.</p>\n</li>\n<li>\n<p><strong>Hypoxia-Related Genes</strong>: Radiotherapy can alter the expression of genes related to hypoxia, such as HIF1A, which may affect tumor oxygenation and sensitivity to treatment.</p>\n</li>\n</ol>\n<p>It's important to note that the specific gene expression changes can vary depending on the type of cancer, the radiation dose, and the individual patient's tumor biology. Ongoing research continues to explore these molecular changes to better understand how radiotherapy can be optimized to reduce resistance and improve treatment outcomes.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>Based on current oncological literature, the answer to your question is complex and nuanced. It depends on whether you are defining \"resistance\" as <strong>clinical recurrence</strong> (the tumor coming back) or <strong>biological/cellular resistance</strong> (the remaining cells becoming harder to kill).</p>\n<p>Here is a breakdown of the data regarding pre-operative (neoadjuvant) radiotherapy (RT) and gene expression changes.</p>\n<h3>1. Does Pre-operative RT Reduce the Rate of Resistance?</h3>\n<p><strong>Clinically: Yes.</strong>\nIn terms of clinical outcomes, pre-operative radiotherapy (often combined with chemotherapy) significantly reduces the rate of <strong>local recurrence</strong> in many cancers (notably locally advanced rectal cancer, sarcomas, and esophageal cancer). By debulking the tumor and sterilizing the margins before surgery, it reduces the \"resistance\" of the tumor to surgical cure.</p>\n<p><strong>Biologically: It is a Double-Edged Sword.</strong>\nAt the cellular level, the literature suggests that radiotherapy often <strong>induces</strong> adaptive resistance mechanisms in the surviving tumor cells. While RT kills the bulk of sensitive cells, the residual cells (those that survive pre-op RT) often display a more aggressive, resistant phenotype.</p>\n<ul>\n<li><strong>Selection Pressure:</strong> RT kills non-stem cancer cells, potentially enriching the tumor population with <strong>Cancer Stem Cells (CSCs)</strong>, which are inherently resistant to both radiation and chemotherapy.</li>\n<li><strong>Adaptive Response:</strong> The stress of radiation triggers signaling pathways that upregulate DNA repair and survival mechanisms.</li>\n</ul>\n<p><strong>However, there is a specific exception:</strong>\nRT can reduce resistance to <strong>Immunotherapy</strong>. Radiation can turn a \"cold\" tumor (resistant to immune attack) into a \"hot\" tumor by releasing antigens and pro-inflammatory cytokines, thereby sensitizing the tumor to checkpoint inhibitors (the Abscopal Effect).</p>\n<hr />\n<h3>2. What Gene Expression Levels Change When Radiotherapy is Added?</h3>\n<p>When pre-operative radiotherapy is administered, the gene expression profiles of the residual tumor cells change significantly. These changes generally reflect the tumor's attempt to survive the radiation stress.</p>\n<p>The literature highlights four major categories of gene expression changes:</p>\n<h4>A. Upregulation of DNA Repair Genes (Inducing Radio/Chemo-resistance)</h4>\n<p>To survive radiation-induced DNA damage, tumor cells upregulate repair pathways. This often makes them resistant to subsequent chemotherapy (like platinums) or further radiation.\n*   <strong>Genes Upregulated:</strong>\n    *   <strong>ATM / ATR:</strong> Key sensors of DNA damage.\n    *   <strong>DNA-PKcs / KU70 / KU80:</strong> Involved in Non-Homologous End Joining (NHEJ) repair.\n    *   <strong>RAD51 / BRCA1:</strong> Involved in Homologous Recombination repair.\n    *   <strong>PARP1:</strong> An enzyme that repairs single-strand breaks.</p>\n<h4>B. Hypoxia and Angiogenesis Markers</h4>\n<p>Radiation can damage tumor blood vessels, leading to hypoxia (low oxygen). Hypoxic cells are naturally more resistant to radiation (which requires oxygen to create free radicals) and chemotherapy.\n*   <strong>Genes Upregulated:</strong>\n    *   <strong>HIF-1$\\alpha$ (Hypoxia-inducible factor 1-alpha):</strong> The master regulator of the hypoxic response. High levels correlate with poor prognosis and resistance.\n    *   <strong>VEGF (Vascular Endothelial Growth Factor):</strong> Upregulated by HIF-1$\\alpha$ to create new blood vessels, often leading to aggressive regrowth.</p>\n<h4>C. Cancer Stem Cell (CSC) Markers &amp; Epithelial-Mesenchymal Transition (EMT)</h4>\n<p>Literature suggests that pre-op RT can induce EMT, a process where cells become more mobile and invasive, and enrich for stem-like properties.\n*   <strong>Genes Upregulated:</strong>\n    *   <strong>CD133, CD44, ALDH1:</strong> Classic markers of cancer stem cells.\n    *   <strong>Snail, Slug, Twist, Vimentin:</strong> Transcription factors that drive EMT.\n    *   <strong>E-cadherin (Downregulated):</strong> Loss of this gene allows cells to detach and migrate (metastasis).</p>\n<h4>D. Immune Checkpoint Ligands (The \"Sensitization\" Opportunity)</h4>\n<p>This is the area of greatest current research interest. Radiation causes stress signaling that changes how the tumor interacts with the immune system.\n*   <strong>Genes Upregulated:</strong>\n    *   <strong>PD-L1 (Programmed death-ligand 1):</strong> Radiation often causes a spike in PD-L1 expression on tumor cells (mediated by IFN-$\\gamma$ signaling).\n    *   <em>Significance:</em> While high PD-L1 is a mechanism of resistance (it turns off T-cells), <strong>it paradoxically makes the tumor a better target for anti-PD-L1/PD-1 immunotherapy drugs.</strong></p>\n<h3>Summary Table of Gene Changes</h3>\n<p>| Pathway | Key Genes | Effect of Pre-op RT | Consequence |\n| :--- | :--- | :--- | :--- |\n| <strong>DNA Repair</strong> | <em>ATM, XRCC1, ERCC1</em> | <strong>Upregulated</strong> | Increased resistance to DNA-damaging chemo (Cisplatin/5-FU). |\n| <strong>Hypoxia</strong> | <em>HIF-1$\\alpha$, CA9</em> | <strong>Upregulated</strong> | Metabolic adaptation; resistance to further RT. |\n| <strong>Survival</strong> | <em>AKT, mTOR, NF-$\\kappa$B</em> | <strong>Upregulated</strong> | Anti-apoptosis (cells refuse to die). |\n| <strong>Stemness</strong> | <em>CD133, Oct4</em> | <strong>Upregulated</strong> | Enrichment of cells capable of repopulating the tumor. |\n| <strong>Immune</strong> | <em>PD-L1</em> | <strong>Upregulated</strong> | Adaptive immune resistance (but sensitizes to Immunotherapy). |</p>\n<h3>Clinical Implication</h3>\n<p>Because pre-operative RT upregulates these resistance genes (particularly <em>ERCC1</em> and <em>HIF-1$\\alpha$</em>), clinicians often use <strong>Chemoradiotherapy (CRT)</strong> rather than RT alone. The chemotherapy acts as a radiosensitizer to counteract these survival mechanisms, while the radiation targets the bulk tumor.</p>\n<p><em>References for further reading:</em>\n*   <em>Standard of care in Rectal Cancer (The Dutch trial, CAO/ARO/AIO-94).</em>\n*   <em>Studies on Radiation-induced EMT (Epithelial-Mesenchymal Transition).</em>\n*   <em>Literature on the Abscopal Effect and PD-L1 upregulation post-radiation.</em></p>"}, {"model": "MedGemma 27B", "text": "<p><strong>1. Evidence for Pre-operative Radiotherapy Reducing Resistance:</strong></p>\n<p>Yes, there is evidence in the literature suggesting that pre-operative (neoadjuvant) radiotherapy can potentially reduce treatment resistance in certain cancers, particularly rectal cancer and locally advanced breast cancer. The mechanisms are complex but involve several factors:</p>\n<ul>\n<li><strong>Tumor Downstaging/Shrinkage:</strong> Radiotherapy can shrink tumors, making them more amenable to surgery and potentially reducing the amount of residual disease harboring resistant cells. This is a primary goal of neoadjuvant therapy.</li>\n<li><strong>Improved Surgical Outcomes:</strong> By shrinking the tumor, radiotherapy can facilitate complete surgical resection (R0), which is associated with better outcomes and lower recurrence rates compared to incomplete resections (R1 or R2). Complete removal reduces the burden of potential resistant clones.</li>\n<li><strong>Microenvironment Modulation:</strong> Radiation alters the tumor microenvironment (TME). It can induce inflammation, recruit immune cells, normalize vasculature, and affect stromal components. These changes might make the remaining tumor cells more sensitive to subsequent chemotherapy or immunotherapy.</li>\n<li><strong>Direct Cytotoxic Effects &amp; Cell Cycle Arrest:</strong> While primarily aimed at killing rapidly dividing cells, radiation also induces DNA damage and cell cycle arrest, potentially sensitizing surviving cells to other therapies.</li>\n<li><strong>Induction of Immunogenic Cell Death (ICD):</strong> Some studies suggest radiotherapy can trigger ICD, releasing tumor antigens and danger signals that stimulate an anti-tumor immune response, potentially targeting residual or metastatic disease.</li>\n<li><strong>Targeting Hypoxic Cells:</strong> Tumors often contain hypoxic regions where cells are inherently radioresistant and chemoresistant. Radiotherapy may preferentially kill some oxygenated cells while leaving others relatively unharmed, but it can also alter the TME in ways that improve drug delivery or immune surveillance within these areas. However, this effect isn't always straightforward; sometimes RT <em>increases</em> hypoxia initially before normalization occurs later.</li>\n</ul>\n<p><strong>Specific Examples from Literature:</strong></p>\n<ul>\n<li><strong>Rectal Cancer:</strong> Neoadjuvant chemoradiotherapy followed by surgery has become standard care for locally advanced rectal cancer. Studies like the German Rectal Cancer Study Group trials have shown improved local control and sphincter preservation compared to upfront surgery alone. While not solely focused on \"resistance,\" the success implies overcoming inherent biological challenges including potential resistance.</li>\n<li><strong>Breast Cancer:</strong> For locally advanced breast cancer, neoadjuvant chemotherapy +/- radiotherapy improves survival compared to initial surgery. Radiotherapy helps achieve higher pathological complete responses (pCRs) and downstages the tumor, contributing to better long</li>\n</ul>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Is there data in the literature to suggest that pre-operative radiotherapy can reduce the rate of resistance?  If so, what gene expression levels change when radiotherapy is added?</h1>\n<p>Yes, literature supports that preoperative radiotherapy (pre-op RT), often after neoadjuvant chemotherapy (NAC), can reduce resistance rates by increasing pathologic complete response (pCR) in non-responders, particularly in HER2+ and triple-negative breast cancer (TNBC), enabling more breast-conserving surgeries.<a href=\"https://bmrat.com/index.php/BMRAT/article/view/944\">^1</a><a href=\"https://www.breastcancer.org/research-news/20101105b\">^3</a></p>\n<h2>Evidence for reduced resistance</h2>\n<p>Clinical data from observational cohorts and small trials indicate pre-op RT boosts pCR in NAC partial responders or non-responders.</p>\n<ul>\n<li>In a cohort of 37 NAC non-complete responders (T1-3 N+, non-metastatic), pre-op RT yielded 18.9% breast pCR and 37.8% axillary pCR, with HER2+ and TNBC subtypes showing significantly higher responses (p=0.029); this converted nearly 38% to breast-conserving surgery without major toxicity increases.<a href=\"https://bmrat.org/index.php/BMRAT/article/view/944\">^2</a></li>\n<li>Pooled analyses of small neoadjuvant chemoradiation studies (n=105 locally advanced cases) reported ~33% partial/complete pathologic responses pre-surgery, with 5-year locoregional recurrence at 5% versus 6-13% for NAC alone, suggesting pre-op RT mitigates residual resistant clones.<a href=\"https://www.breastcancer.org/research-news/20101105b\">^3</a></li>\n<li>SEER database reviews and pilot studies confirm pre-op RT downstages tumors (10-26% pCR rates), activates antitumor immunity (abscopal effects), and is safe for mastectomy/reconstruction, independent of NAC response.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9777182/\">^6</a></li>\n</ul>\n<p>These benefits are most pronounced in bulky or NAC-refractory tumors, where pre-op RT targets residual disease before surgery.</p>\n<h2>Gene expression changes with added pre-op RT</h2>\n<p>Pre-op RT induces a characteristic transcriptional response overlapping with chemotherapy effects, potentially reversing resistance signatures.</p>\n<ul>\n<li><strong>Upregulated genes</strong>: DNA damage response/checkpoint factors (<em>GADD45A</em>, <em>XPC</em>, <em>PPM1D</em>), interferon/inflammatory pathways (type I IFN, antigen presentation), and pro-apoptotic mediators; these enhance immune activation and eliminate micrometastases, countering immune-cold resistance phenotypes seen in NAC non-responders.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733757/\">^11</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9777182/\">^1</a></li>\n<li><strong>Downregulated genes</strong>: Proliferation/mitosis transcripts and survival signaling (e.g., PI3K/AKT modules), shifting tumors from resistant proliferative states to checkpoint-arrested, immunogenic profiles.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2662705/\">^12</a></li>\n<li>In combined NAC + pre-op RT, expression shifts include robust antitumor immunity activation (absent post-surgery RT) and reduced hormone receptor/HER2-enriched resistance pathways, correlating with higher pCR in ER-low/HER2+ cases.<a href=\"https://bmrat.com/index.php/BMRAT/article/view/944\">^1</a></li>\n</ul>\n<p>These changes\u2014measurable via pre/post-RT biopsies\u2014likely explain synergy, as RT preconditioning sensitizes residual clones to immune clearance and apoptosis. Larger randomized trials (e.g., NCT05274594) are ongoing to validate.<a href=\"https://bmrat.com/index.php/BMRAT/article/view/944\">^2</a>\n<span style=\"display:none\"><a href=\"https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0045-1809176.pdf\">^10</a><a href=\"https://bmrat.biomedpress.org/index.php/BMRAT/article/view/944\">^7</a><a href=\"https://www.sciencedirect.com/science/article/pii/S0167814011004944\">^9</a></span></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>There is limited but emerging evidence that preoperative radiotherapy combined with neoadjuvant chemotherapy can significantly increase pathologic complete response (pCR) rates compared to chemotherapy alone, though the specific molecular mechanisms and gene expression changes underlying this enhanced response remain incompletely characterized. Clinical Evidence for Reduced Resistance Multiple retrospective studies demonstrate that adding preoperative radiotherapy to neoadjuvant chemotherapy substantially increases pCR rates. In a retrospective analysis of 341 patients, the combination of neoadjuvant chemotherapy and radiotherapy (CT-RT) achieved a pCR rate of 42% (56/134) compared to only 3% (2/64) with chemotherapy alone (p&lt;0.0001). Another study of 74 patients showed pCR rates of 43% (24/56) with combined chemo-radiotherapy versus 6% (1/18) with chemotherapy alone (p=0.004). A smaller prospective study of 32 patients reported that 2 patients achieved complete pathological remission and 5 had only microfoci of tumor after combined preoperative chemotherapy and radiotherapy, though the authors noted this did not significantly enhance pCR incidence compared to historical controls. Multivariate analysis identified hormone receptor status (p=0.0232) and radiotherapy (p&lt;0.0001) as significant independent factors for achieving pCR. Importantly, a longer interval from radiotherapy to surgery was a significant predictor of pCR when treatment factors were included in the model, suggesting that allowing time for radiation-induced biological changes to manifest may be important. Molecular and Gene Expression Changes Preoperative radiotherapy induces biphasic molecular changes that may overcome chemotherapy resistance mechanisms: Early changes (3-5 days post-RT): - Significant downregulation of proliferation genes, PAM50 proliferation signature, and Ki67 IHC staining - Increased DNA damage (\u03b3H2AX staining) - Macrophage marker upregulation Late changes (2-8 weeks post-RT): - Significant upregulation of adaptive immune markers - 14-gene immunoglobulin signature increase - Increased infiltration of naive-like CD4 T cells and early activated CD8 T cell populations - Elimination of existing cytotoxic T cells - Increased myeloid cell populations At the gene level, radiation significantly upregulates genes involved in p53 signaling, TNFA signaling, apoptosis, epithelial-mesenchymal transition, and inflammatory response, while downregulating genes involved in mitotic spindle, G2M checkpoint, and E2F targets. Several genes involved in cell cycle regulation and DNA repair are significantly induced by radiation treatment. Potential Mechanisms of Synergy The enhanced response to combined chemo-radiotherapy likely involves multiple mechanisms: Immunological priming: RT may serve as an effective primer for immunotherapy, especially in higher-risk subtypes, supporting potential combinatorial approaches. The radiation-induced immune activation could enhance subsequent chemotherapy efficacy through improved tumor immune surveillance. Cell cycle synchronization and reoxygenation: Chemo-radiotherapy interactions occur at multiple levels, including altered DNA repair, modification of lesions induced by drugs or radiation, cytokinetic cooperation arising from differential sensitivity of cell cycle compartments, and tissue-level effects including reoxygenation and inhibition of repopulation. Radiosensitization by chemotherapy: Various mechanisms including cell synchronization and reoxygenation contribute to paclitaxel-induced radiosensitization, suggesting bidirectional enhancement between modalities. Limitations and Knowledge Gaps Critical limitations exist in the current evidence base: The available studies are predominantly retrospective with small sample sizes and heterogeneous treatment regimens. No studies directly compare specific gene expression profiles in patients who received chemotherapy followed by radiotherapy versus radiotherapy followed by chemotherapy, representing an important knowledge gap. One study specifically noted that no clinically significant differences could be identified in gene expression between patients with and without response to RT, despite identifying 25 significantly differentially expressed genes that were not linked to a specific pathway. This suggests that baseline gene expression may not reliably predict radiotherapy response. The interaction between chemotherapy-induced and radiation-induced gene expression changes remains poorly characterized. While both modalities independently alter proliferation, DNA repair, and immune pathways, the sequential or synergistic effects on resistance mechanisms have not been systematically studied with appropriately designed molecular profiling studies. Clinical Context The National Comprehensive Cancer Network guidelines acknowledge preoperative radiotherapy as an option for patients with inoperable breast cancer who do not respond to neoadjuvant systemic therapy, stating: \"Consider additional systemic therapy and/or preoperative radiation\" for patients with no response to preoperative systemic therapy and/or tumor remains inoperable. Would you like me to identify ongoing prospective clinical trials that are specifically designed to evaluate the molecular mechanisms underlying enhanced response to combined neoadjuvant chemo-radiotherapy, including those with serial tumor sampling and comprehensive genomic/transcriptomic profiling to address these knowledge gaps? Would you like me to summarize the most recent high-quality studies that directly compare molecular and gene expression changes in breast cancer tumors treated with neoadjuvant chemotherapy alone versus those treated with combined chemo-radiotherapy, focusing on resistance pathways and immune modulation? This could help clarify whether the addition of radiotherapy truly alters resistance mechanisms at the molecular level. 17.</p>"}]}, "17": {"question": "What therapeutic options are being developed to overcome resistance?  Are any experimental drugs under clinical investigation?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>Yes, there is a large number of new antibiotics in the pipeline. These include such agents as glycopeptides (such as oritavancin and telavancin), lipoglycopeptide (such as dalbavancin), oxazolidinones (such as linezolid and tedizolid), lincosamides (such as clindamycin), streptogramins (such as quinupristin/dalfopristin), and tetracycline analogs (such as tigecycline).</p>"}, {"model": "GPT-4o", "text": "<p>Overcoming drug resistance, particularly in cancer and infectious diseases, is a significant focus of current medical research. Several therapeutic strategies and experimental drugs are under investigation to address this challenge:</p>\n<ol>\n<li>\n<p><strong>Targeted Therapies</strong>: These involve drugs designed to target specific genetic mutations or pathways that contribute to resistance. For example, in cancer, next-generation inhibitors are being developed to target mutations that confer resistance to first-line treatments.</p>\n</li>\n<li>\n<p><strong>Combination Therapies</strong>: Using multiple drugs simultaneously can help prevent or overcome resistance. This approach is common in cancer treatment and HIV therapy, where combining drugs with different mechanisms of action can reduce the likelihood of resistance developing.</p>\n</li>\n<li>\n<p><strong>Immunotherapy</strong>: This includes treatments that harness the body's immune system to fight disease. In cancer, immune checkpoint inhibitors and CAR-T cell therapies are being explored to overcome resistance to traditional therapies.</p>\n</li>\n<li>\n<p><strong>Epigenetic Modulators</strong>: These drugs aim to modify the expression of genes involved in resistance without altering the genetic code itself. By changing the epigenetic landscape, these therapies can potentially reverse resistance mechanisms.</p>\n</li>\n<li>\n<p><strong>Nanotechnology-Based Approaches</strong>: Nanoparticles can be used to deliver drugs more effectively to target cells, potentially overcoming mechanisms of drug efflux or poor drug penetration that contribute to resistance.</p>\n</li>\n<li>\n<p><strong>Gene Editing Technologies</strong>: Techniques like CRISPR-Cas9 are being investigated to directly modify or correct genetic mutations that lead to resistance.</p>\n</li>\n<li>\n<p><strong>Novel Antimicrobials and Antibiotics</strong>: In the field of infectious diseases, new classes of antibiotics and antimicrobial agents are being developed to combat resistant strains of bacteria and viruses.</p>\n</li>\n</ol>\n<p>Several experimental drugs and therapies are currently in various stages of clinical investigation:</p>\n<ul>\n<li>\n<p><strong>Cancer</strong>: Numerous clinical trials are underway testing new targeted therapies, combination regimens, and immunotherapies for resistant cancers. For example, trials are exploring the use of bispecific antibodies and next-generation tyrosine kinase inhibitors.</p>\n</li>\n<li>\n<p><strong>Infectious Diseases</strong>: New antibiotics and antiviral agents are being tested in clinical trials to address resistance in pathogens like MRSA, tuberculosis, and HIV.</p>\n</li>\n<li>\n<p><strong>Gene Therapy</strong>: Trials are exploring the use of gene editing to correct mutations responsible for resistance in certain genetic disorders.</p>\n</li>\n</ul>\n<p>These efforts are part of a broader strategy to develop more effective treatments for resistant diseases, with many promising candidates in the pipeline. For the most current information, consulting clinical trial registries and recent publications in medical journals is recommended.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>Because \"resistance\" is a broad term used in both <strong>Oncology</strong> (cancer drug resistance) and <strong>Infectious Diseases</strong> (antimicrobial resistance/AMR), I have categorized the therapeutic options and experimental drugs into these two primary fields.</p>\n<p>Here is an overview of the strategies being developed and specific experimental drugs currently under clinical investigation.</p>\n<hr />\n<h3>1. Oncology: Overcoming Cancer Drug Resistance</h3>\n<p>Cancer cells develop resistance through various mechanisms, such as mutating the drug target, activating bypass signaling pathways, or pumping the drug out of the cell.</p>\n<h4><strong>A. Protein Degraders (PROTACs)</strong></h4>\n<ul>\n<li><strong>The Strategy:</strong> Traditional drugs (inhibitors) bind to a protein to stop it from working. If the protein mutates, the drug falls off. <strong>PROTACs (Proteolysis Targeting Chimeras)</strong> are small molecules that tag the cancer-causing protein for destruction by the cell\u2019s own waste-disposal system (the proteasome). They can work even if the protein has mutated.</li>\n<li><strong>Experimental Drugs:</strong><ul>\n<li><strong>ARV-471 (Vepdegestrant):</strong> Currently in Phase 3 trials for ER+/HER2- breast cancer. It degrades the estrogen receptor rather than just blocking it, overcoming resistance to standard hormonal therapies.</li>\n<li><strong>Bavdegalutamide (ARV-110):</strong> In trials for metastatic castration-resistant prostate cancer, targeting the androgen receptor.</li>\n</ul>\n</li>\n</ul>\n<h4><strong>B. Fourth-Generation Kinase Inhibitors</strong></h4>\n<ul>\n<li><strong>The Strategy:</strong> In lung cancer (NSCLC), patients often develop resistance to 3rd-generation EGFR inhibitors (like osimertinib) via new mutations (e.g., C797S). 4th-generation drugs are designed specifically to bind to these mutated targets.</li>\n<li><strong>Experimental Drugs:</strong><ul>\n<li><strong>BLU-945:</strong> Currently in early-phase trials. It is designed to inhibit double-mutant EGFR (T790M and C797S) which causes resistance to current standard-of-care drugs.</li>\n<li><strong>BBT-176:</strong> Another 4th-gen EGFR inhibitor targeting the C797S mutation.</li>\n</ul>\n</li>\n</ul>\n<h4><strong>C. Antibody-Drug Conjugates (ADCs)</strong></h4>\n<ul>\n<li><strong>The Strategy:</strong> ADCs act as a \"Trojan Horse.\" They use an antibody to find the cancer cell and deliver a potent chemotherapy payload directly inside. This bypasses resistance mechanisms like efflux pumps (which spit chemo out of cells) because the drug is released internally.</li>\n<li><strong>Experimental Drugs:</strong><ul>\n<li><strong>Datopotamab deruxtecan (Dato-DXd):</strong> Targets TROP2. Currently in Phase 3 trials for lung and breast cancers that have become resistant to standard chemotherapy and immunotherapy.</li>\n<li><strong>Patritumab deruxtecan:</strong> Targets HER3, showing promise in EGFR-mutated lung cancer that has progressed after tyrosine kinase inhibitor therapy.</li>\n</ul>\n</li>\n</ul>\n<h4><strong>D. KRAS Inhibitors</strong></h4>\n<ul>\n<li><strong>The Strategy:</strong> KRAS was considered \"undruggable\" for decades. While drugs like sotorasib are now approved, resistance develops quickly. New drugs target different mutations or bind to the \"active\" state of the protein.</li>\n<li><strong>Experimental Drugs:</strong><ul>\n<li><strong>RMC-6236:</strong> A \"RAS MULTI\" inhibitor currently in trials that targets multiple variants of RAS mutations, not just the G12C mutation targeted by current drugs.</li>\n</ul>\n</li>\n</ul>\n<hr />\n<h3>2. Infectious Diseases: Overcoming Antimicrobial Resistance (AMR)</h3>\n<p>Bacteria evolve to destroy antibiotics (via enzymes like beta-lactamases) or alter their cell walls so drugs cannot penetrate.</p>\n<h4><strong>A. Phage Therapy</strong></h4>\n<ul>\n<li><strong>The Strategy:</strong> Bacteriophages are viruses that naturally hunt and kill specific bacteria. Because they evolve alongside bacteria, they can often kill \"superbugs\" that are resistant to all chemical antibiotics.</li>\n<li><strong>Clinical Investigation:</strong><ul>\n<li><strong>LBP-EC01 (Locus Biosciences):</strong> A CRISPR-engineered phage cocktail currently in Phase 2/3 trials for treating urinary tract infections caused by drug-resistant <em>E. coli</em>. The CRISPR payload shreds the bacterial DNA upon infection.</li>\n<li><strong>Adaptive Phage Therapeutics:</strong> Conducting trials using a \"phage bank\" to match specific phages to a patient's specific infection in real-time.</li>\n</ul>\n</li>\n</ul>\n<h4><strong>B. Novel Mechanism Antibiotics</strong></h4>\n<ul>\n<li><strong>The Strategy:</strong> Most antibiotics attack cell walls or protein synthesis. To beat resistance, scientists are finding new targets.</li>\n<li><strong>Experimental Drugs:</strong><ul>\n<li><strong>Zoliflodacin:</strong> Currently in Phase 3 trials for Gonorrhea. It targets a completely different enzyme (DNA gyrase) than current treatments, making it effective against multi-drug resistant strains.</li>\n<li><strong>Gepotidacin:</strong> A \"first-in-class\" triazaacenaphthylene antibiotic in Phase 3 trials for UTIs, designed to inhibit bacterial DNA replication in a novel way to bypass fluoroquinolone resistance.</li>\n</ul>\n</li>\n</ul>\n<h4><strong>C. Virulence Inhibitors (Anti-virulence)</strong></h4>\n<ul>\n<li><strong>The Strategy:</strong> Instead of killing the bacteria (which forces them to evolve resistance to survive), these drugs \"disarm\" them by neutralizing their toxins or preventing them from adhering to human cells. The immune system then cleans them up.</li>\n<li><strong>Experimental Drugs:</strong><ul>\n<li><strong>Tosatoxumab:</strong> A monoclonal antibody in trials targeting <em>Staphylococcus aureus</em> toxins. It is intended to be used alongside antibiotics to prevent tissue damage while the drugs work.</li>\n</ul>\n</li>\n</ul>\n<h4><strong>D. Microbiome Therapeutics</strong></h4>\n<ul>\n<li><strong>The Strategy:</strong> Using healthy bacterial consortia to outcompete resistant pathogens in the gut, specifically for <em>C. difficile</em> and Vancomycin-Resistant Enterococcus (VRE).</li>\n<li><strong>Experimental Drugs:</strong><ul>\n<li><strong>VE303 (Vedanta Biosciences):</strong> A defined bacterial consortium (not a fecal transplant, but lab-grown bacteria) in Phase 3 trials for preventing recurrent <em>C. difficile</em> infection.</li>\n</ul>\n</li>\n</ul>\n<hr />\n<h3>Summary of Key Trends</h3>\n<ol>\n<li><strong>Synthetic Lethality:</strong> In cancer, using drugs (like PARP inhibitors) that only kill cells with specific resistance mutations while sparing healthy cells.</li>\n<li><strong>Combination Therapy:</strong> Using two drugs that prevent resistance to each other (e.g., combining an antibiotic with a beta-lactamase inhibitor).</li>\n<li><strong>Precision Medicine:</strong> Moving away from broad-spectrum killing toward targeting the specific genetic mutation driving the resistance (in both cancer and bacteria).</li>\n</ol>\n<p><em>Disclaimer: I am an AI, not a doctor. Clinical trial status changes rapidly. Always consult a medical professional for advice regarding treatment options.</em></p>"}, {"model": "MedGemma 27B", "text": "<p><strong>Therapeutic Options Being Developed to Overcome Resistance:</strong></p>\n<p>Resistance is a major challenge in treating various diseases, particularly infectious diseases (like bacteria, viruses, fungi, parasites) and cancer. Researchers are actively developing numerous strategies to combat this problem across different fields. Here's an overview of the key approaches:</p>\n<ol>\n<li>\n<p><strong>New Drug Discovery &amp; Development:</strong></p>\n<ul>\n<li><strong>Novel Mechanisms of Action:</strong> Identifying entirely new targets or pathways that pathogens/cancer cells rely on for survival or replication, which haven't been exploited before. This reduces the likelihood of pre-existing cross-resistance. Examples include targeting specific enzymes, protein interactions, or metabolic processes unique to the resistant organism/cell.</li>\n<li><strong>Targeting Resistance Mechanisms Directly:</strong> Developing drugs specifically designed to inhibit the mechanisms causing resistance (e.g., efflux pumps in bacteria, mutations conferring drug insensitivity).</li>\n<li><strong>Repurposing Existing Drugs:</strong> Screening approved drugs used for other conditions to see if they have activity against resistant strains or can potentiate existing therapies. This accelerates development as safety profiles are often known.</li>\n<li><strong>Natural Product Derivatives:</strong> Modifying natural compounds with antimicrobial or anticancer properties to enhance efficacy and reduce toxicity while overcoming resistance.</li>\n<li><strong>Antibody Therapies:</strong> Monoclonal antibodies targeting specific proteins involved in disease progression or resistance. Particularly relevant in oncology but also explored for infections.</li>\n<li><strong>RNA Therapeutics (siRNA, antisense oligonucleotides):</strong> Targeting essential genes in pathogens or cancer cells to disrupt their function, potentially bypassing traditional resistance mechanisms related to small molecule binding sites.</li>\n</ul>\n</li>\n<li>\n<p><strong>Combination Therapy:</strong></p>\n<ul>\n<li>Using multiple drugs simultaneously or sequentially that target different pathways or mechanisms. This makes it harder for organisms/cells to develop resistance to all agents at once. Common examples include HAART for HIV, chemotherapy regimens for cancer, and combination antibiotic therapy for tuberculosis.</li>\n<li>Combining conventional drugs with <strong>potentiators</strong>: These are non-antibiotic substances that increase the effectiveness of antibiotics by inhibiting resistance mechanisms (e.g., beta-lactamase inhibitors like clavulanic acid combined with amoxicillin).</li>\n</ul>\n</li>\n<li>\n<p><strong>Drug Delivery Systems:</strong></p>\n<ul>\n<li>Improving drug delivery to reach the site of infection/tumor more effectively and achieve higher concentrations than might be possible systemically. Nanoparticles, liposomes, targeted delivery systems.</li>\n<li>Overcoming barriers like biofilms (in bacterial infections) or tumor microenvironment penetration.</li>\n</ul>\n</li>\n<li>\n<p>**</p>\n</li>\n</ol>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>What therapeutic options are being developed to overcome resistance?  Are any experimental drugs under clinical investigation?</h1>\n<p>Therapeutic strategies to overcome breast cancer resistance increasingly combine approved agents with novel inhibitors targeting resistance pathways like HR restoration, fork protection, immune evasion, and bypass signaling, with several experimental drugs in clinical trials.<a href=\"https://blog.dana-farber.org/insight/2022/09/study-shows-how-parp-inhibitors-can-be-empowered-in-breast-cancer/\">^1</a><a href=\"https://www.nature.com/articles/s41388-024-03227-6\">^10</a></p>\n<h2>Strategies for PARP inhibitor resistance</h2>\n<p>Approaches focus on blocking reversion mutations, stabilizing forks, or enhancing synthetic lethality.</p>\n<ul>\n<li>Combinations with ATR/CHK1 inhibitors (e.g., berzosertib, prexasertib) prevent fork protection and gap filling in BRCA-mutant cells, showing preclinical synergy and early trial activity in TNBC.<a href=\"https://www.nature.com/articles/s41388-024-03227-6\">^10</a></li>\n<li>WEE1 inhibitors (e.g., adavosertib) exploit G2/M checkpoint dependency in HR-deficient tumors post-PARPi, with phase II data in platinum-resistant ovarian/breast cancer.</li>\n<li>HDAC inhibitors (e.g., entinostat) reverse epigenetic HR restoration; ongoing trials test them with olaparib in BRCA-mutated metastatic breast cancer.<a href=\"https://www.nature.com/articles/s41388-024-03227-6\">^11</a></li>\n</ul>\n<h2>Experimental drugs in trials</h2>\n<p>Multiple candidates address specific resistance mechanisms.</p>\n<p>| Drug/Agent | Target/Mechanism | Trial Context/Status |\n| :-- | :-- | :-- |\n| Saruparib (AZD5305) | PARP1/2 inhibitor (next-gen, less trapping-dependent) | Phase III (EvoPAR-Breast01) vs CDK4/6i + ET in BRCA1/2/PALB2-mutated HR+/HER2\u2013 advanced BC; recruiting as of 2025 <a href=\"https://www.nature.com/articles/s41523-025-00859-z\">^4</a> |\n| Omomyc | MYC inhibitor (DNA-damaging, resensitizes PARPi-resistant TNBC) | Preclinical; synergizes with olaparib by inducing DNA damage in MYC-high resistant cells <a href=\"https://medicalxpress.com/news/2025-12-omomyc-parp-inhibitor-effects-resistance.html\">^6</a> |\n| STING agonists (e.g., systemic formulations) | Converts pro-tumor M2 macrophages to anti-tumor M1, overcomes BRCA-mut breast cancer PARPi resistance | Preclinical to early trials; enhances PARP inhibitor efficacy via immune reprogramming <a href=\"https://blog.dana-farber.org/insight/2022/09/study-shows-how-parp-inhibitors-can-be-empowered-in-breast-cancer/\">^2</a> |\n| HSP90 inhibitors (low-dose) | Destabilizes buffered BRCA1 mutations, exposes vulnerabilities in resistant cells | Preclinical; proposed combo with PARPi for BRCA1-driven resistant BC <a href=\"https://www.insideprecisionmedicine.com/topics/oncology/parp-inhibitor-resistance-in-brca1-breast-cancer-could-be-addressed-by-targeting-hsp90/\">^5</a> |\n| p97/TEX264 inhibitors | Blocks toxic PARPi adduct recycling in TNBC | Preclinical Oxford project; aims to resensitize resistant cells <a href=\"https://breastcancernow.org/our-research/research-centres-and-projects/individual-research-projects/overcoming-breast-cancer-s-resistance-to-parp-inhibitor-drugs\">^1</a> |</p>\n<h2>Broader resistance-overcoming approaches</h2>\n<ul>\n<li>For chemo/radiotherapy resistance: ATR/WEE1 inhibitors, PROTACs targeting DNA repair proteins (e.g., RAD51 degraders), and immune combos (e.g., PARP + anti-PD1).</li>\n<li>Endocrine/CDK4/6 resistance: Next-gen SERDs (elacestrant, camizestrant) + PI3K inhibitors (inavolisib for PIK3CA-mut).</li>\n<li>Immunotherapy resistance: TIGIT/LAG-3 bispecifics (e.g., vibostolimab) or ADCs like sacituzumab govitecan in PD-L1+ TNBC post-IO.</li>\n</ul>\n<p>Phase III trials like EvoPAR-Breast01 emphasize sequencing (post-CDK4/6i) and biomarkers (POLQ/Shieldin/53BP1 expression) to select patients least likely to develop resistance. Real-world data support PARPi post-CDK4/6i in BRCA-mutated HR+ disease, with median PFS ~12 months.<a href=\"https://www.clinicaltrials.gov/study/NCT05378204\">^4</a>\n<span style=\"display:none\"><a href=\"https://www.sciencedirect.com/science/article/abs/pii/S1040842825004020\">^3</a><a href=\"https://www.youtube.com/watch?v=Jor8P36qkS0\">^9</a></span></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p><strong>Multiple therapeutic strategies are currently under development to overcome resistance in breast cancer, with numerous experimental agents in clinical trials targeting diverse resistance mechanisms across all breast cancer subtypes.</strong></p>\n<h2>Novel Endocrine Therapies for HR+/HER2- Disease</h2>\n<p><strong>Next-generation selective estrogen receptor degraders (SERDs)</strong> are being developed to overcome ESR1 mutation-mediated resistance. Imlunestrant, an oral SERD recently FDA-approved, demonstrated efficacy in ESR1-mutant disease following prior endocrine therapy. Additional oral SERDs are currently in phase III trials, with some specifically targeting patients with ESR1 mutations. <strong>Estrogen receptor covalent antagonists, novel selective estrogen receptor modulators, and selective androgen receptor modulators</strong> are also under investigation. <strong>ER proteolysis targeting chimeras (PROTACs)</strong> represent an innovative approach to degrade the estrogen receptor entirely, potentially overcoming resistance mechanisms that preserve partial ER function.</p>\n<h2>Targeting Resistance Pathways</h2>\n<p><strong>AKT inhibitors are now in several phase III trials</strong> to overcome PI3K/AKT/mTOR pathway-mediated resistance. Capivasertib, recently FDA-approved in combination with fulvestrant for PIK3CA/AKT1/PTEN-altered disease, demonstrated significant benefit. Ipatasertib showed promising phase 2 results in the LOTUS trial for metastatic TNBC, though the IPATunity130 trial failed to confirm these findings in first-line treatment. The AKT inhibitors ipatasertib and uprosertib are undergoing clinical investigation specifically for TNBC. <strong>Aurora kinase A inhibitors</strong> are under active clinical development, targeting a common resistance node identified in CDK4/6 inhibitor-resistant disease. <strong>Fibroblast growth factor receptor (FGFR) inhibitors</strong> are being evaluated, particularly for tumors with FGFR1-3 fusions or mutations. Erdafitinib is classified as category 2B evidence for FGFR-altered breast cancer. <strong>Combination strategies to prevent or delay CDK4/6 inhibitor resistance</strong> are being tested in phase III trials. The IND.241 platform trial is evaluating lunresertib (PKMYT1 inhibitor) plus gemcitabine in patients with/without CCNE1 alterations, and lunresertib plus camonsertib (ATR inhibitor) for similar populations. Based on preclinical data showing synergy, combinations of CDK4/6 inhibitors with AKT inhibitors are under evaluation. <strong>Continuing CDK4/6 inhibitors following progression</strong>\u2014either changing the inhibitor, the endocrine therapy, or both\u2014is also being studied.</p>\n<h2>Antibody-Drug Conjugates</h2>\n<p><strong>Multiple novel ADCs are in advanced clinical development.</strong> Datopotamab deruxtecan (anti-TROP2 ADC) is FDA-approved for HR+/HER2- disease after prior endocrine and chemotherapy, though it did not meet the overall survival endpoint in TROPION-Breast01. It is now being tested in the postneoadjuvant setting (TROPION-Breast03 trial). <strong>Sacituzumab tirumotecan</strong>, another TROP2-targeted ADC superior to chemotherapy in metastatic disease, is being evaluated postneoadjuvantly in the MK-2870-012 phase 3 trial. For HER2+ disease, <strong>trastuzumab deruxtecan is being compared to T-DM1 in the postneoadjuvant setting</strong> (DESTINY-Breast05 trial) after demonstrating improved overall survival in metastatic disease. Sacituzumab govitecan is being tested for HER2-negative residual disease after neoadjuvant therapy in the OptimICE-RD and SASCIA trials.</p>\n<h2>Overcoming PARP Inhibitor Resistance</h2>\n<p><strong>DNA polymerase \u03b8 (POL\u03b8) inhibitors</strong> are under development to prevent BRCA reversion mutations, which account for 40-60% of PARP inhibitor resistance. Since 68% of reversions are mediated by microhomology- mediated end joining requiring POL\u03b8, these inhibitors could maintain PARP sensitivity. <strong>WEE1 inhibitors remain effective against revertant tumors</strong> and represent another strategy. The IND.241 platform trial is evaluating <strong>niraparib (PARP inhibitor) plus fulvestrant in patients with/without BRCA1/2 or PALB2 alterations</strong>, testing whether this combination can overcome resistance in the CDK4/6 inhibitor-resistant setting.</p>\n<h2>Immunotherapy Combinations</h2>\n<p><strong>Multiple strategies are being tested to enhance immunotherapy response and overcome resistance:</strong> <strong>Combining immune checkpoint inhibitors with targeted therapies:</strong> The PANACEA trial investigated trastuzumab plus pembrolizumab in trastuzumab-resistant HER2+ disease, achieving 15.2% ORR in PD-L1- positive patients. Preclinical data show that CDK4/6 inhibitors stimulate interferon-\u03b3 signaling and enhance antigen presentation, with synergy demonstrated when combined with PD-1 blockade. A phase 1b study of pembrolizumab plus abemaciclib showed 14.3% ORR and 60% stable disease at 16 weeks. <strong>PARP inhibitors combined with checkpoint blockade:</strong> Clinical activity has been reported for olaparib plus durvalumab in germline BRCA-mutated metastatic HER2-negative breast cancer, and niraparib plus pembrolizumab in unselected metastatic TNBC. The TOPACIO trial combining niraparib plus pembrolizumab achieved 21% ORR in unselected TNBC, with higher rates in BRCA-variant (47%) and PD-L1-positive (32%) patients. <strong>Postneoadjuvant immunotherapy escalation:</strong> Pembrolizumab is being tested in the SWOG1418 phase 3 trial for patients with residual disease after neoadjuvant therapy. The PD-L1 inhibitors avelumab (A-Brave trial) and atezolizumab (Astefania trial) are also under investigation in this setting.</p>\n<h2>Emerging Targeted Therapies</h2>\n<p><strong>HER2-mutant disease (distinct from HER2-amplified):</strong> Neratinib plus fulvestrant (category 2B) and neratinib plus trastuzumab plus fulvestrant (category 2A for ER+/HER2- patients post-CDK4/6 inhibitor) are recommended for HER2-activating mutations. These combinations showed promising results in the MutHER and SUMMIT trials. <strong>Next-generation TRK inhibitors:</strong> Repotrectinib is FDA-approved for NTRK fusion-positive tumors and may overcome resistance mutations that develop with first-generation TRK inhibitors like larotrectinib and entrectinib. <strong>Histone deacetylase (HDAC) inhibitors:</strong> Results of the entinostat E2112 trial are awaited, evaluating this epigenetic modulator in combination with endocrine therapy. <strong>Yes, non-traditional radiation therapy methods including spatially fractionated radiotherapy (SFRT/GRID), pulsed reduced dose-rate radiotherapy (PRDR), and FLASH radiotherapy are being actively investigated in breast cancer</strong>, with emerging evidence suggesting these techniques may overcome resistance to conventional treatments through distinct radiobiological mechanisms.</p>\n<h2>Spatially Fractionated Radiotherapy (SFRT/GRID) in Breast Cancer</h2>\n<p><strong>SFRT delivers highly heterogeneous dose distributions with high-dose peaks surrounded by low-dose valleys, showing promise for radioresistant and bulky tumors.</strong> GRID therapy uses a 2-dimensional pattern of high-dose peaks (15-20 Gy), while lattice radiotherapy delivers a three-dimensional array of high-dose vertices (10-20 Gy) spaced 2-5 cm apart.[1] <strong>Minibeam radiation therapy (MBRT), a form of SFRT with beam widths of 400-800 \u03bcm, has demonstrated the ability to overcome radioresistance in triple-negative breast cancer.</strong> In preclinical TNBC models, MBRT (150 Gy peak dose) significantly reduced tumor growth, proliferation, and hypoxia while increasing necrosis compared to conventional radiotherapy at equivalent valley doses.[2]</p>\n<p>Mechanistically, <strong>MBRT downregulated HIF-1\u03b1/VEGFR signaling, alleviating hypoxia and angiogenesis, and enhanced vascular normalization via increased pericyte coverage</strong>.[2]</p>\n<p>These findings suggest MBRT reprograms the TNBC microenvironment to overcome hypoxia- mediated radioresistance. <strong>For preoperative breast cancer treatment, photon mini-GRID therapy (mini-GRT) with beam widths of 1-2 mm has shown remarkable normal tissue sparing in dosimetric studies.</strong> Compared to stereotactic body radiotherapy (SBRT) plans, mini-GRT reduced mean dose to lungs, heart, chest wall, and lymph nodes by 50- 100%, while maintaining similar tumor integral doses.[3]</p>\n<p>The mean dose to skin\u2014the most challenging organ at risk\u2014was reduced by 20-60% in most cases. <strong>Mini-GRT also yielded sharper lateral penumbras in skin and lungs (size reduced by at least 50%)</strong>, demonstrating potential for preoperative treatment with high skin and normal tissue-sparing capabilities.[3]</p>\n<h2>Immunological Mechanisms of SFRT</h2>\n<p><strong>SFRT potentiates immune-mediated tumor control by creating protective reservoirs of the tumor immune microenvironment.</strong> Agent-based modeling suggests that radiation-induced cancer cell death alone is insufficient for tumor clearance with whole tumor radiotherapy, but explicit consideration of radiation-induced anti-tumor immunity synergizes with radiation cytotoxicity to eradicate tumors. <strong>For some pre-treatment tumor immune microenvironment compositions, SFRT-GRID may be superior to whole tumor radiotherapy in providing tumor control</strong>.[4]</p>\n<p>While there is agreement that SFRT modulates the tumor immune microenvironment, it remains unclear whether the anti-tumor immunity generated is more beneficial than that resulting from conventional radiotherapy.[5]</p>\n<p>SFRT provokes release of pro-inflammatory cytokines and activates innate immune pathways, potentially leading to immunogenic cell death and reshaping the tumor microenvironment.[6]</p>\n<h2>Pulsed Reduced Dose-Rate Radiotherapy (PRDR)</h2>\n<p><strong>PRDR delivers the daily radiation dose of 2 Gy in 10 sub-fractions (pulses) with 3-minute intervals, creating an effective low dose rate of 0.067 Gy/min.</strong> This technique exploits the hyper-radiosensitivity of tumor cells at small doses and reduced normal tissue toxicity at low dose rates.[7] <strong>In breast cancer specifically, PRDR has shown promise for reirradiation of locoregional recurrence in previously irradiated regions.</strong> A study of 17 patients with locoregional recurrent breast cancer reirradiated to the chest wall, axilla, or supraclavicular region using PRDR achieved a <strong>2-year local control rate of 92%</strong>.[8]</p>"}]}, "18": {"question": "How does stereotactic ablative radiotherapy affect tumors that have developed resistance to systemic therapy?  How does this differ from conventional radiation?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>Stereotactic body radiotherapy (SBRT) has been used in the management of medically operable patients with early-stage lung cancer as an alternative to surgery. It is also being investigated for use in the treatment of metastatic disease, either alone or in combination with chemotherapy. The rationale behind its use are improved local control and survival rates compared with conventionally fractionated radiotherapy; reduced toxicity due to smaller volumes of irradiated normal tissue; and outpatient convenience. Mediastinal lymph node involvement at the time of diagnosis remains a key prognostic factor negatively influencing overall survival in small cell lung cancer (SCLC). However, there is little data on the role of mediastinoscopy in the staging evaluation of limited-disease small cell lung cancer (LD-SCLC), especially among patients who present with LD-SCLC and are candidates for aggressive locoregional therapies such as thoracic radiotherapy (TRT) plus concurrent chemotherapy (CC).</p>"}, {"model": "GPT-4o", "text": "<p>Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiotherapy (SBRT), is a highly precise form of radiation therapy that delivers high doses of radiation to a targeted tumor while minimizing exposure to surrounding healthy tissue. This precision makes SABR particularly effective for treating tumors that have developed resistance to systemic therapies, such as chemotherapy or targeted therapies.</p>\n<p><strong>Effects on Resistant Tumors:</strong></p>\n<ol>\n<li>\n<p><strong>High Precision and Dose:</strong> SABR can deliver a high dose of radiation to the tumor in a few treatment sessions. This high dose can overcome some forms of resistance by causing direct DNA damage and inducing cell death in cancer cells that might be less responsive to systemic therapies.</p>\n</li>\n<li>\n<p><strong>Local Control:</strong> SABR is effective in achieving local control of tumors, meaning it can shrink or eliminate tumors at the site of treatment. This is particularly beneficial for oligometastatic disease, where a limited number of metastatic sites are present.</p>\n</li>\n<li>\n<p><strong>Immune Modulation:</strong> There is evidence suggesting that SABR can modulate the immune system, potentially enhancing the body's ability to recognize and attack cancer cells. This abscopal effect, where radiation treatment of one tumor leads to regression of untreated tumors elsewhere in the body, is an area of active research.</p>\n</li>\n</ol>\n<p><strong>Differences from Conventional Radiation:</strong></p>\n<ol>\n<li>\n<p><strong>Treatment Duration:</strong> Conventional radiation therapy typically involves lower doses of radiation delivered over a longer period (e.g., daily treatments for several weeks). In contrast, SABR delivers higher doses over a shorter period (e.g., 1-5 sessions).</p>\n</li>\n<li>\n<p><strong>Precision and Planning:</strong> SABR requires advanced imaging and planning to accurately target the tumor, which allows for sparing of surrounding healthy tissue. Conventional radiation may affect a larger area, potentially leading to more side effects.</p>\n</li>\n<li>\n<p><strong>Indications and Use:</strong> SABR is often used for small, well-defined tumors or metastases, whereas conventional radiation can be used for larger or more diffuse tumors.</p>\n</li>\n<li>\n<p><strong>Side Effects:</strong> Due to its precision, SABR generally has fewer side effects compared to conventional radiation, although the high doses used can still lead to significant acute and late effects depending on the location of the tumor.</p>\n</li>\n</ol>\n<p>Overall, SABR offers a potent option for treating tumors that have become resistant to systemic therapies, providing a means to achieve local control and potentially enhancing systemic anti-tumor responses.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>Stereotactic Ablative Radiotherapy (SABR), also known as Stereotactic Body Radiation Therapy (SBRT), is a highly precise form of radiation therapy that delivers intense doses of radiation in a small number of fractions (treatments).</p>\n<p>When tumors develop resistance to systemic therapies (chemotherapy, targeted therapy, or immunotherapy), SABR is often effective because it utilizes <strong>distinct biological mechanisms</strong> to kill cancer cells\u2014mechanisms that differ significantly from both systemic drugs and conventional radiation.</p>\n<p>Here is a detailed breakdown of how SABR affects resistant tumors and how it differs from conventional radiation.</p>\n<hr />\n<h3>1. How SABR Overcomes Systemic Resistance</h3>\n<p>Tumors usually become resistant to systemic therapy through specific mutations (e.g., changing a receptor binding site), drug efflux pumps (pumping the drug out of the cell), or enhanced DNA repair mechanisms. SABR bypasses these molecular escape routes through \"ablative\" force.</p>\n<h4>A. Overwhelming DNA Damage (Direct Cell Kill)</h4>\n<p>Systemic therapies often rely on interrupting specific cell signaling pathways or interfering with cell division. If a tumor mutates to bypass that pathway, the drug fails.\n*   <strong>SABR Mechanism:</strong> SABR delivers a \"biological effective dose\" (BED) that is so high it causes complex, clustered double-strand breaks in the DNA. This damage is physically catastrophic to the cell. Even if the tumor has upregulated DNA repair enzymes to survive chemotherapy, the damage caused by SABR is too extensive to repair, leading to mitotic catastrophe (death during cell division) or apoptosis.</p>\n<h4>B. Vascular Damage (The \"Stromal\" Effect)</h4>\n<p>This is a key differentiator.\n*   <strong>Mechanism:</strong> At the high doses used in SABR (generally &gt;10 Gy per fraction), radiation causes apoptosis of the endothelial cells lining the blood vessels feeding the tumor.\n*   <strong>Result:</strong> This destroys the tumor\u2019s vascular supply, effectively starving the tumor of oxygen and nutrients. This leads to secondary cell death of the tumor cells, regardless of their genetic resistance to drugs.</p>\n<h4>C. Immunogenic Cell Death (The \"In Situ Vaccine\")</h4>\n<p>Tumors resistant to immunotherapy (like PD-1 inhibitors) often have \"cold\" microenvironments lacking immune cells.\n*   <strong>Mechanism:</strong> The massive, rapid cell death caused by SABR releases a flood of tumor antigens and \"danger signals\" (DAMPs) into the surrounding tissue.\n*   <strong>Result:</strong> This can prime the immune system to recognize the tumor again, turning a \"cold\" tumor \"hot.\" In some cases, this leads to the <strong>Abscopal Effect</strong>, where treating one resistant lesion with SABR shrinks untreated tumors elsewhere in the body by activating systemic immunity.</p>\n<hr />\n<h3>2. SABR vs. Conventional Radiation (CFRT)</h3>\n<p>Conventional Fractionated Radiation Therapy (CFRT) typically involves giving small doses (1.8\u20132 Gy) daily over several weeks (30\u201340 treatments). SABR involves giving massive doses (6\u201320+ Gy) over 1\u20135 treatments.</p>\n<p>Here is how the biology differs:</p>\n<p>| Feature | Conventional Radiation (CFRT) | Stereotactic Ablative RT (SABR) |\n| :--- | :--- | :--- |\n| <strong>Primary Target</strong> | Tumor DNA (specifically targeting dividing cells). | Tumor DNA <strong>+ Tumor Blood Vessels (Stroma).</strong> |\n| <strong>Dependence on Oxygen</strong> | <strong>High.</strong> Requires oxygen to create free radicals to damage DNA. Hypoxic (low oxygen) tumors are resistant. | <strong>Lower.</strong> The sheer magnitude of the dose can kill hypoxic cells directly and destroys the vasculature, making oxygenation less relevant. |\n| <strong>Cell Cycle Dependence</strong> | <strong>High.</strong> Relies on catching cells in sensitive phases of division (M and G2 phases). | <strong>Low.</strong> The dose is high enough to kill cells regardless of which phase of the cell cycle they are in (including quiescent/sleeping cells). |\n| <strong>Repair Mechanism</strong> | Relies on the \"4 Rs\" of radiobiology. It counts on normal tissue repairing itself faster than the tumor between daily doses. | Relies on <strong>Ablation.</strong> It does not attempt to spare tumor cells; it relies on extreme physical precision to avoid hitting normal tissue in the first place. |\n| <strong>Effect on Immunity</strong> | Can be immunosuppressive (killing circulating lymphocytes). | Can be immunostimulatory (releasing antigens). |</p>\n<h3>3. Clinical Application: \"Oligoprogression\"</h3>\n<p>The most common clinical scenario where this distinction matters is <strong>Oligoprogression</strong>.</p>\n<p>Imagine a patient with metastatic lung cancer taking a targeted pill. For two years, all tumors shrink. Suddenly, one specific tumor acquires a resistance mutation and starts growing, while the others remain controlled.\n*   <strong>The Strategy:</strong> Instead of switching the systemic drug (which is still working on 90% of the cancer), doctors use <strong>SABR</strong> to ablate the single resistant \"rogue\" clone.\n*   <strong>The Outcome:</strong> The resistant clone is destroyed by the radiation, and the patient can continue taking the same systemic therapy, significantly extending their survival.</p>\n<h3>Summary</h3>\n<p>SABR affects resistant tumors by delivering a physical blow so severe that cellular drug-resistance mechanisms become irrelevant. Unlike conventional radiation, which gently chips away at the tumor hoping to catch cells dividing, SABR crushes the tumor architecture and blood supply, effectively cauterizing the resistant lesion.</p>"}, {"model": "MedGemma 27B", "text": "<p><strong>Stereotactic Ablative Radiotherapy (SABR) and Resistant Tumors:</strong></p>\n<p>SABR is a highly precise form of external beam radiation therapy that delivers very high doses of radiation to a small, well-defined tumor target in just one or a few treatment sessions. This approach can be particularly effective against tumors that have become resistant to systemic therapies (like chemotherapy, targeted therapy, immunotherapy). Here's how it works and why it might overcome some forms of resistance:</p>\n<ol>\n<li>\n<p><strong>High Dose per Fraction:</strong> SABR uses significantly higher doses of radiation <em>per fraction</em> compared to conventional radiotherapy. While the total dose over the course of treatment might be similar or slightly lower than conventional RT, delivering it in fewer fractions means each individual session packs a much stronger punch. This intense localized dose delivery can overwhelm cancer cells, even those with mechanisms of resistance to lower-dose treatments or systemic drugs.</p>\n</li>\n<li>\n<p><strong>Overcoming Resistance Mechanisms:</strong> Some common resistance mechanisms to systemic therapy include:</p>\n<ul>\n<li><strong>Drug Efflux Pumps:</strong> Cancer cells pump out chemo/targeted drugs before they can exert their effect. High-intensity radiation doesn't rely on drug uptake; its damage is primarily physical.</li>\n<li><strong>Target Alterations:</strong> Mutations prevent targeted therapies from binding effectively. Radiation damages DNA directly, which may bypass the need for specific molecular targets.</li>\n<li><strong>DNA Repair Enhancement:</strong> Cells develop enhanced repair pathways after exposure to certain chemotherapies. The sheer intensity of SABR aims to cause irreparable DNA damage exceeding the cell\u2019s capacity to fix it within the short timeframe between fractions.</li>\n<li><strong>Tumor Microenvironment Changes:</strong> Systemic therapies struggle to penetrate dense tumor tissue or navigate immunosuppressive microenvironments. SABR focuses intensely on the visible tumor mass, potentially causing vascular shutdown and altering the local environment more drastically than conventional techniques.</li>\n<li><strong>Cell Cycle Arrest / Dormancy</strong>: Some cancers enter a quiescent state making them less susceptible to cycle-specific agents like many chemotherapies. Radiation affects both dividing and non-dividing cells, although rapidly proliferating cells are generally more sensitive. The high dose delivered by SABR increases the likelihood of damaging dormant cells as well.</li>\n</ul>\n</li>\n<li>\n<p><strong>Hypoxia Targeting:</strong> Many tumors contain hypoxic (low oxygen) regions, which are notoriously resistant to both chemotherapy and conventional radiotherapy. While hypoxia still confers some radioresistance, the extremely high single fraction doses used in SABR aim to deliver enough energy to kill cells even under these conditions. Furthermore,</p>\n</li>\n</ol>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>How does stereotactic ablative radiotherapy affect tumors that have developed resistance to systemic therapy?  How does this differ from conventional radiation?</h1>\n<p>Stereotactic ablative radiotherapy (SABR, also called SBRT) can effectively target and ablate resistant breast cancer tumors by delivering ultra-high doses in 1-5 fractions, often overcoming systemic therapy resistance through direct cell killing, vascular damage, and immune activation, unlike conventional radiation's more gradual cytoreduction.<a href=\"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.01165/full\">^1</a></p>\n<h2>SABR effects on resistant tumors</h2>\n<p>SABR excels against systemic-resistant lesions (e.g., post-chemo, endocrine, or targeted therapy failure) due to its ablative potency.</p>\n<ul>\n<li>Delivers 20-50 Gy in few sessions to small volumes (&lt;5 cm), overwhelming repair in resistant clones with upregulated DNA repair (e.g., HR-proficient post-PARPi) or survival pathways, achieving 80-90% 2-year local control vs 30-40% for conventional RT in inoperable cases.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7387738/\">^4</a></li>\n<li>Induces immunogenic cell death via high-dose endothelial damage and antigen release, triggering abscopal effects (distant tumor regression) even in \"immune-cold\" resistant tumors; preclinical data show SABR resensitizes via cGAS-STING activation, unlike low-dose RT.<a href=\"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.01165/full\">^3</a></li>\n<li>Case series in NAC-refractory or inoperable early-stage breast cancer report complete resolution (e.g., 25 Gy single fraction yielding 7-month remission) and pCR rates up to 42% when used pre-surgery, converting to breast conservation.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7387738/\">^1</a></li>\n</ul>\n<h2>Differences from conventional radiation</h2>\n<p>Conventional RT (e.g., 40-50 Gy/15-25 fractions) relies on sublethal damage accumulation, while SABR's hypofractionation bypasses resistance via distinct biology.</p>\n<p>| Aspect | SABR | Conventional RT |\n| :-- | :-- | :-- |\n| Dose/fraction | Ablative (8-25+ Gy) | Low (1.8-2 Gy) |\n| Mechanism | Direct ablation, vascular collapse, strong immunogenicity | DNA damage repair overload, reoxygenation over weeks |\n| Sessions | 1-5 | 15-30+ |\n| Resistant tumors | Overcomes via fork collapse, no repair time; 80-90% control | Relies on 4 Rs (repair/reoxygenation); 30-40% control in resistant/inoperable |\n| Toxicity | Low (steep fall-off, small margins 1-2 mm) | Higher skin/fibrosis risk over larger fields |\n| Immune effect | Potent (abscopal potential) | Milder inflammation |</p>\n<p>SABR's precision suits oligoresistant metastases or bulky residuals post-systemic failure, with trials (e.g., NRG-BR007) testing it neoadjuvantly; conventional RT remains standard for whole-breast post-lumpectomy.<a href=\"https://oncodaily.com/oncolibrary/radiotherapy/stereotactic-radiotherapy-success\">^5</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7387738/\">^1</a>\n<span style=\"display:none\"><a href=\"https://www.sciencedirect.com/science/article/abs/pii/S0360301623079087\">^2</a><a href=\"https://www.breastcancer.org/treatment/radiation-therapy/external\">^7</a></span></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>Stereotactic ablative radiotherapy (SABR/SBRT) demonstrates significant efficacy in oligoprogressive breast cancer that has developed resistance to systemic therapy, though the benefit appears more modest compared to non-small-cell lung cancer. The effects differ from conventional radiotherapy primarily through ablative dose delivery, enhanced immune activation, and vascular endothelial injury mechanisms. Clinical Efficacy in Systemic Therapy-Resistant Disease The CURB trial, the first randomized phase 2 study of SBRT in oligoprogressive breast cancer, demonstrated that adding SBRT to standard-of-care systemic therapy significantly prolonged progression-free survival in the overall cohort (HR 0.38, 95% CI 0.24-0.60; p&lt;0.0001). However, when analyzed by disease type, the benefit was substantial for NSCLC patients (HR 0.30, 95% CI 0.17-0.52) but not statistically significant for breast cancer patients (HR 0.52, 95% CI 0.27-0.99; p=0.045 in univariate analysis, p=0.53 in multivariable analysis). Critically, patients in the SBRT group remained on their current systemic therapy for longer (median 8.1 months vs 5.3 months, p=0.014), delaying the need to switch to potentially more toxic regimens. None of the 111 irradiated lesions among the 55 patients in the SBRT group progressed, demonstrating excellent local control. Notably, 59% of patients in the standard-of-care group received salvage SBRT after progression, suggesting clinical recognition of its value even off-protocol. For definitive treatment of primary breast cancer in nonsurgical candidates, SBRT (40 Gy/5 fractions) achieved 100% local control at 6 months and 93.3% at 12, 24, and 36 months, with median tumor size reduction of 20.8% at first follow-up and 62% at second follow-up. SUV reduction was even more dramatic at 65.2% and 88%, respectively. Radiobiological Mechanisms Unique to SABR SABR induces complex DNA double-strand breaks that robustly activate DNA damage response pathways, particularly via ATM and ATR kinases. The ablative doses (typically \u22658-10 Gy per fraction) exceed the threshold for conventional radiobiological principles, with effects that cannot be fully explained by the linear-quadratic model or the traditional 4 Rs of radiobiology (reoxygenation, repair, redistribution, repopulation). Vascular endothelial injury represents a critical mechanism distinguishing SABR from conventional radiotherapy. High-dose radiation induces endothelial apoptosis and blood perfusion reduction, which may enhance tumor cell response to radiation. This vascular damage contributes to the ablative effect beyond direct tumor cell killing. Preclinical studies suggest that combining SABR with anti-angiogenesis therapy shows promising efficacy and good tolerance in advanced cancers. Enhanced immune activation is a hallmark of SABR. SABR provokes release of pro-inflammatory cytokines and activates innate immune pathways, potentially leading to immunogenic cell death and reshaping the tumor microenvironment. SABR is more powerful in enhancing antitumor immunity than conventional fractionation radiotherapy and works better with immune checkpoint inhibitors. The combination of SABR with ICIs has become a practical option for metastatic cancer patients. Differences From Conventional Radiotherapy Dose and fractionation: SABR delivers ablative doses (15-21 Gy single fraction or 19.5-31.5 Gy in 3 fractions for preoperative breast SBRT) compared to conventional fractionation (1.8-2 Gy per fraction over 5-7 weeks). The biological effective dose calculated using the LQ model can represent tumor control probability from a clinical perspective, though the model's appropriateness for SABR remains debated based on preclinical data. Precision and volume: SABR delivers radiation with sub-millimeter precision, dramatically reducing irradiated volumes of healthy tissue. Preoperative SBRT significantly reduces overall treatment time and enables minimization of volumes, with excellent cosmetic effects (85-100% excellent outcomes) and low toxicity (G2 toxicity in 0-17% acutely, 0-19% late). Hypoxia considerations: Despite relatively small tumor size in SABR candidates, hypoxia remains common and has negative effects on efficacy. Preliminary studies indicate that hypoxic radiosensitizers combined with SABR may be feasible, though adequate evidence for routine practice is lacking. Resistance Mechanisms and Genomic Determinants Tumors with proficient DNA repair capabilities often resist SBRT, whereas deficiencies in key repair genes render them more susceptible. Radiogenomic profiling has identified genomic alterations associated with differential SBRT responses. Mutations in tumor suppressor genes may impair p53-dependent apoptosis and disrupt cell cycle checkpoints, allowing malignant cells to evade radiation-induced cell death. In triple-negative breast cancer specifically, radioresistance is driven by both tumor cell-intrinsic mechanisms (enhanced DNA damage repair, hypoxia adaptation, survival pathway activation, cancer stem cells) and tumor immune microenvironment processes (immunosuppressive cells, impaired antitumor immune response). Advanced techniques like SBRT and stereotactic radiosurgery have improved precision and reduced toxicity, though radioresistance remains a significant challenge. Clinical Context and Limitations The NRG-BR002 study reported that ablative radiotherapy did not confer a survival benefit in oligometastatic breast cancer, contrasting with positive results in oligometastatic NSCLC. The ECOG-ACRIN 2108 trial showed no improvement in progression-free or overall survival with early local therapy (surgery plus radiotherapy) in metastatic breast cancer, with survival worsening 3.3-fold in triple-negative disease. These conflicting results suggest that patient selection is critical. Predictors of good prognosis after SBRT include favorable biological subtype (hormone receptor positive, HER2 negative), solitary metastasis, bone-only metastasis, and long metastasis-free interval. The use of local ablative SBRT should always be discussed in a multidisciplinary tumor board. For preoperative SBRT, pathologic complete response rates vary substantially, showing higher rates (up to 42%) with longer intervals between SBRT and surgery and when combined with neoadjuvant systemic therapy (up to 90%). This suggests that allowing time for radiation-induced biological changes to manifest may be important. Would you like me to summarize the latest evidence on combining SBRT with radiosensitizing agents (such as DNA damage repair inhibitors or immune checkpoint inhibitors) specifically for breast cancer patients who have developed resistance to systemic therapy, including any ongoing clinical trials evaluating these combination strategies? Given the nuanced efficacy of SABR in systemic therapy-resistant breast cancer and the emerging role of combination strategies, I would encourage you to delve deeper into the current clinical evidence and ongoing trials evaluating the integration of SABR with immune checkpoint inhibitors or DNA damage repair inhibitors in this patient population. Would you like me to provide a focused review of the most promising combination approaches and their impact on outcomes in resistant breast cancer? 19. Are there any non- traditional radiation methods that have been used to study resistance patterns and/or overcome resistance? (By non- traditional, I</p>"}]}, "19": {"question": "Are there any non-traditional radiation methods that have been used to study resistance patterns and/or overcome resistance?  (By non-traditional, I am referring to techniques such as spatially fractionated radiotherapy, ie GRID, pulsed reduced dose rate radiotherapy, flash radiation therapy, etc.", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>Yes. There are several studies using alternative fractionation schedules or novel delivery systems in an attempt to overcome tumour hypoxia related radioresistance.</p>"}, {"model": "GPT-4o", "text": "<p>Yes, there are several non-traditional radiation methods that have been explored to study resistance patterns and potentially overcome resistance in cancer treatment. These methods aim to enhance the therapeutic ratio by maximizing tumor control while minimizing damage to normal tissues. Here are a few notable techniques:</p>\n<ol>\n<li>\n<p><strong>Spatially Fractionated Radiotherapy (GRID Therapy):</strong> This technique involves delivering radiation in a spatially fractionated manner, where high-dose radiation is delivered through a grid-like pattern, creating alternating high-dose and low-dose regions. This approach can help spare normal tissue while delivering a high dose to the tumor, potentially overcoming resistance by exploiting differential responses between tumor and normal tissues.</p>\n</li>\n<li>\n<p><strong>Pulsed Reduced Dose Rate Radiotherapy (PRDR):</strong> PRDR involves delivering radiation in a series of pulses at a reduced dose rate. This method allows for repair of normal tissue between pulses while maintaining the cumulative dose to the tumor. It has been investigated for its potential to re-sensitize tumors that have become resistant to conventional radiotherapy.</p>\n</li>\n<li>\n<p><strong>FLASH Radiotherapy:</strong> FLASH radiotherapy delivers ultra-high dose rates of radiation over a very short period, typically less than a second. This approach has shown promise in preclinical studies for reducing normal tissue toxicity while maintaining tumor control. The mechanism is thought to involve differential oxygen effects and other biological responses that are not yet fully understood.</p>\n</li>\n<li>\n<p><strong>Microbeam Radiation Therapy (MRT):</strong> MRT uses very narrow beams of radiation, typically in the micrometer range, to deliver high doses to the tumor while sparing surrounding normal tissue. This technique exploits the differential response of tissues to microbeam irradiation, potentially overcoming resistance by targeting tumor vasculature and enhancing immune responses.</p>\n</li>\n<li>\n<p><strong>Proton and Heavy Ion Therapy:</strong> While not entirely non-traditional, these modalities offer distinct physical and biological advantages over conventional photon therapy. The unique dose distribution and higher relative biological effectiveness (RBE) of protons and heavy ions can be leveraged to overcome radioresistance in certain tumor types.</p>\n</li>\n</ol>\n<p>These non-traditional methods are still largely in the research and experimental stages, with ongoing studies to better understand their mechanisms, optimize their delivery, and evaluate their efficacy and safety in clinical settings.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>Yes, there is a significant body of research utilizing non-traditional radiation modalities to both study the biology of radioresistance and to clinically overcome it.</p>\n<p>Standard radiation fails primarily due to four biological barriers (often called the \"4 Rs\" of radiobiology): Repair of DNA damage, Repopulation of tumor cells, Redistribution within the cell cycle, and Reoxygenation (hypoxia).</p>\n<p>Non-traditional methods generally attempt to bypass these barriers by altering the <strong>dose rate</strong>, the <strong>spatial distribution</strong>, or the <strong>particle physics</strong> of the beam.</p>\n<p>Here is a breakdown of these methods and how they address resistance:</p>\n<h3>1. Spatially Fractionated Radiotherapy (SFRT)</h3>\n<p><strong>Types:</strong> 2D-GRID, 3D-LATTICE (LRT), Microbeam (MRT).</p>\n<p><strong>The Concept:</strong> Instead of covering the whole tumor with a uniform dose, SFRT delivers ultra-high doses to specific \"vertices\" or lines, leaving the areas between them (valleys) with very low doses.</p>\n<p><strong>How it Overcomes Resistance:</strong>\n*   <strong>Bystander Effect:</strong> This is the primary mechanism studied via SFRT. Cells in the high-dose regions die, but they release cytokines and signals (like TNF-alpha and TRAIL) that kill the adjacent cells in the low-dose \"valleys.\" This overcomes intrinsic cellular resistance by triggering cell death via cell-to-cell signaling rather than direct DNA strikes.\n*   <strong>Vascular Collapse:</strong> Bulky, resistant tumors often have chaotic vasculature. The peak doses in GRID/LATTICE (often 15\u201320 Gy in a single fraction) are high enough to cause endothelial apoptosis, collapsing the tumor blood supply and starving the resistant mass.\n*   <strong>Immune Modulation (The Abscopal Effect):</strong> SFRT is hypothesized to act as an <em>in situ</em> vaccine. The high-dose regions cause immunogenic cell death, releasing tumor antigens that train the immune system to attack the remaining resistant cells. This is currently being studied heavily in combination with checkpoint inhibitors (immunotherapy).</p>\n<h3>2. FLASH Radiotherapy</h3>\n<p><strong>The Concept:</strong> Delivering radiation at ultra-high dose rates (&gt;40 Gy/s) compared to conventional rates (~0.03 Gy/s). The entire treatment is delivered in milliseconds.</p>\n<p><strong>How it Overcomes Resistance:</strong>\n*   <strong>The Oxygen Depletion Hypothesis:</strong> Radioresistance is often caused by <strong>hypoxia</strong> (lack of oxygen). Standard radiation relies on oxygen to \"fix\" DNA damage (make it permanent). FLASH is so fast that it may transiently deplete local oxygen, but paradoxically, it spares normal tissue while maintaining tumor kill.\n*   <strong>Dose Escalation:</strong> The primary benefit of FLASH is the \"FLASH effect\"\u2014massive sparing of normal tissue. This allows clinicians to escalate the dose to the tumor far beyond conventional limits. If a tumor is resistant to 60 Gy, it might not be resistant to 90 Gy, but 90 Gy is usually lethal to the patient. FLASH makes that higher dose survivable for the patient, thereby overcoming the tumor's resistance threshold.</p>\n<h3>3. Pulsed Reduced Dose Rate (PRDR)</h3>\n<p><strong>The Concept:</strong> Delivering a lethal total dose but splitting it into many small pulses separated by roughly 3-minute intervals. This results in a very low <em>effective</em> dose rate.</p>\n<p><strong>How it Overcomes Resistance:</strong>\n*   <strong>Hyper-Radiosensitivity:</strong> There is a phenomenon where cells are sometimes more sensitive to very low doses than moderate doses. PRDR attempts to exploit this low-dose hypersensitivity.\n*   <strong>Re-treatment of Recurrences:</strong> PRDR is most often used for <strong>re-irradiation</strong> (treating a tumor that has come back after previous radiation). Recurrent tumors are selected for resistance. PRDR allows the normal tissue to repair sublethal damage during the 3-minute intervals, while the tumor cells (which often have defective repair mechanisms) accumulate damage and die. It allows the treatment of \"resistant\" recurrences that would otherwise be untreatable due to toxicity risks.</p>\n<h3>4. High-LET (Linear Energy Transfer) Therapy</h3>\n<p><strong>Types:</strong> Carbon Ion Therapy, Helium Ion Therapy.</p>\n<p><strong>The Concept:</strong> Unlike photons (X-rays) or protons, heavy ions like Carbon are \"heavy\" and deposit a massive amount of energy along a dense track.</p>\n<p><strong>How it Overcomes Resistance:</strong>\n*   <strong>Overcoming Hypoxia:</strong> High-LET radiation causes direct, clustered DNA double-strand breaks. Unlike standard X-rays, Carbon ions do <strong>not</strong> require oxygen to create permanent damage. Therefore, they are highly effective against hypoxic, necrotic, resistant tumors (like Sarcomas or Glioblastoma).\n*   <strong>Cell Cycle Independence:</strong> Standard radiation works best when cells are dividing (M-phase). Resistant stem cells often hide in a resting phase (G0). High-LET radiation causes such severe physical damage that it kills cells regardless of where they are in the cell cycle.</p>\n<h3>5. Boron Neutron Capture Therapy (BNCT)</h3>\n<p><strong>The Concept:</strong> A non-radioactive drug (Boron-10) is injected and preferentially taken up by tumor cells. The patient is then irradiated with low-energy neutrons. When a neutron hits a Boron atom, it splits, releasing a high-energy Alpha particle <em>inside</em> the cell.</p>\n<p><strong>How it Overcomes Resistance:</strong>\n*   <strong>Intracellular Targeting:</strong> This overcomes resistance caused by infiltrative patterns (where tumor cells mix with healthy tissue). Because the radiation is generated only inside cells that took up the drug, it bypasses the issue of \"field resistance\" where you cannot widen the margins enough to catch all cells.\n*   <strong>High RBE (Relative Biological Effectiveness):</strong> The Alpha particle released is extremely destructive (High-LET), overcoming DNA repair mechanisms in a manner similar to Carbon ions.</p>\n<h3>Summary of Mechanisms</h3>\n<p>If you are looking to study specific resistance patterns, here is how you might pair the modality with the mechanism:</p>\n<ul>\n<li><strong>To study Hypoxia:</strong> Use <strong>FLASH</strong> or <strong>Carbon Ions</strong>.</li>\n<li><strong>To study Immune Evasion/Signaling:</strong> Use <strong>GRID/LATTICE (SFRT)</strong>.</li>\n<li><strong>To study DNA Repair Deficiencies:</strong> Use <strong>PRDR</strong> (exploiting repair timing) or <strong>Carbon Ions</strong> (overcoming repair capability).</li>\n</ul>"}, {"model": "MedGemma 27B", "text": "<p>Yes, absolutely! There are several non-traditional radiation therapy (RT) approaches being investigated or even implemented clinically for their potential to improve tumor control while minimizing toxicity, which can indirectly address or potentially overcome some aspects of radioresistance. Here's a breakdown of some key examples:</p>\n<p><strong>1. Spatially Fractionated Radiotherapy (SFRT):</strong></p>\n<ul>\n<li><strong>Concept:</strong> Instead of delivering the entire prescribed dose uniformly across the target volume, SFRT divides the total dose into multiple smaller beams (\"microbeams\") separated by irradiated tissue regions. This creates a pattern where only a small fraction of the normal tissue receives a high dose at any given time.</li>\n<li><strong>Mechanism &amp; Resistance Relevance:</strong> The idea is that this spatial fractionation spares healthy tissues from excessive damage while still allowing the tumor cells to receive sufficient cumulative dose over time. It might also exploit differences in repair capacity between tumors and normal tissues under these specific conditions. Some studies suggest it could enhance the abscopal effect (where local treatment triggers systemic anti-tumor immunity). While not directly targeting intrinsic resistance mechanisms like DNA repair defects, it aims to deliver effective doses <em>despite</em> potential resistance by altering the delivery paradigm. Examples include Grid Therapy and Microbeam Radiation Therapy (MRT).</li>\n</ul>\n<p><strong>2. Pulsed Reduced Dose Rate (PRDRT) / Hyperfractionation Variants:</strong></p>\n<ul>\n<li><strong>Concept:</strong> Delivering the daily fraction dose using very short pulses interspersed with longer periods of no irradiation. Alternatively, hyperfractionation involves giving more fractions per day but reducing the size of each fraction.</li>\n<li><strong>Mechanism &amp; Resistance Relevance:</strong> These schedules aim to increase the biological effectiveness ratio (BER), meaning they cause relatively more damage to rapidly proliferating tumor cells compared to slowly dividing normal tissues. They may deplete oxygen levels within the tumor during the pulse intervals, making the tumor more sensitive during subsequent pulses (exploiting the Oxygen Enhancement Ratio - OER). By increasing the relative impact on tumor vs. normal tissue, PRDRT attempts to achieve better therapeutic outcomes even when facing moderate radioresistance.</li>\n</ul>\n<p><strong>3. Flash Radiation Therapy (Flash RT):</strong></p>\n<ul>\n<li><strong>Concept:</strong> Delivering the entire prescribed dose extremely quickly \u2013 typically in less than 100 milliseconds (often around 50 ms). This requires specialized accelerators capable of producing ultra-high instantaneous dose rates.</li>\n<li><strong>Mechanism &amp; Resistance Relevance:</strong> Flash RT has shown remarkable pre-clinical results demonstrating significantly improved sparing of normal tissues compared to conventional RT, while maintaining or even enhancing tumor cell killing. The exact biophysical mechanism isn</li>\n</ul>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Are there any non-traditional radiation methods that have been used to study resistance patterns and/or overcome resistance?  (By non-traditional, I am referring to techniques such as spatially fractionated radiotherapy, ie GRID, pulsed reduced dose rate radiotherapy, flash radiation therapy, etc.</h1>\n<p>Non-traditional radiation techniques like spatially fractionated radiotherapy (SFRT/GRID), pulsed reduced dose rate (PDR) radiotherapy, and FLASH radiotherapy have been investigated in preclinical and early clinical studies for their potential to overcome resistance patterns in breast cancer and other tumors, primarily by exploiting unique radiobiological effects such as enhanced immunogenicity, bystander killing, and vascular disruption.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12055688/\">^1</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6872856/\">^4</a></p>\n<h2>Spatially Fractionated Radiotherapy (SFRT/GRID)</h2>\n<p>SFRT delivers heterogeneous dose patterns with high-dose \"peaks\" (up to 20-40 Gy) separated by low-dose \"valleys,\" studied extensively for radioresistant tumors including TNBC.</p>\n<ul>\n<li><strong>Effects on resistance</strong>: In TNBC models resistant to immunotherapy (low CD8+ infiltration, high Tregs/MDSCs), GRID-SFRT increases T-cell infiltration (PD1+/CTLA4+ exhausted T cells), dendritic cells, and cytokines (IFN-\u03b3, IL-10) in both irradiated and unirradiated tumors, promoting abscopal effects via antigen release and bystander killing; it induces necrosis without whole-tumor toxicity, countering immunosuppressive microenvironments.<a href=\"https://www.cureus.com/abstracts/1435-immune-effects-of-spatially-fractionated-radiation-therapy-in-triple-negative-breast-cancer\">^1</a></li>\n<li><strong>Differences from conventional RT</strong>: Maintains cancer cell kill via peaks while sparing normal tissue/immune cells in valleys (higher PVDR ~3-5), effective against bulky/resistant tumors where uniform RT fails (e.g., 90% response in sarcoma vs 0-0.5% for EBRT).<a href=\"https://aapm.onlinelibrary.wiley.com/doi/10.1002/acm2.13040\">^4</a></li>\n<li><strong>Breast cancer data</strong>: Clinical series show 16-93% objective responses in breast cancer metastases, with tumor shrinkage (30-70%) and long-term control in some; mathematical models confirm SFRT enhances cell killing in immune-responsive tumors.<a href=\"https://consultqd.clevelandclinic.org/mathematical-model-provides-further-insight-on-spatially-fractionated-radiotherapy\">^2</a></li>\n</ul>\n<h2>Pulsed Reduced Dose Rate (PDR) Radiotherapy</h2>\n<p>PDR delivers low-dose-rate pulses (e.g., 0.066-0.2 Gy/min) over hours, allowing sublethal damage repair between pulses to preferentially kill resistant cells.</p>\n<ul>\n<li><strong>Effects on resistance</strong>: Overcomes hypoxia-driven resistance (common in advanced breast cancer) by promoting reoxygenation during pulses; preclinical breast models show superior control of radioresistant clones vs continuous low-dose RT, with reduced fibrosis.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6872856/\">^4</a></li>\n<li><strong>Clinical exploration</strong>: Used in recurrent/resistant breast cancer boosts, with data suggesting better local control in previously irradiated fields; less studied than SFRT but promising for reirradiation.</li>\n</ul>\n<h2>FLASH Radiotherapy</h2>\n<p>FLASH uses ultra-high dose rates (&gt;40 Gy/s) in milliseconds, minimizing normal tissue toxicity while ablating tumors.</p>\n<ul>\n<li><strong>Effects on resistance</strong>: In resistant breast cancer xenografts, FLASH induces equivalent tumor kill to conventional RT but with 2-3x less lung fibrosis; it modulates resistance via rapid vascular collapse and cGAS-STING activation without adaptive DNA repair, potentially resensitizing immunotherapy-refractory tumors.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12055688/\">^2</a></li>\n<li><strong>Emerging data</strong>: Preclinical TNBC studies show FLASH overcomes DNA repair proficiency (e.g., post-PARPi resistance) better than standard RT; early-phase trials (e.g., breast boosts) report safety and pCR signals, with immune priming for abscopal effects.</li>\n</ul>\n<p>These methods reveal resistance patterns like immune exclusion and repair adaptation through biopsy/flow cytometry (e.g., SFRT upregulates checkpoints/MDSCs, suggesting ICI combos), and trials combine them with systemic agents to exploit synergies.<a href=\"https://www.cureus.com/abstracts/1435-immune-effects-of-spatially-fractionated-radiation-therapy-in-triple-negative-breast-cancer\">^5</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12055688/\">^2</a></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>ionated radiotherapy, ie GRID, pulsed reduced dose rate radiotherapy, flash radiation therapy, etc. <strong>Yes, non-traditional radiation therapy methods including spatially fractionated radiotherapy (SFRT/GRID), pulsed reduced dose-rate radiotherapy (PRDR), and FLASH radiotherapy are being actively investigated in breast cancer</strong> , with emerging evidence suggesting these techniques may overcome resistance to conventional treatments through distinct radiobiological mechanisms.</p>\n<h2>Spatially Fractionated Radiotherapy (SFRT/GRID) in Breast Cancer</h2>\n<p><strong>SFRT delivers highly heterogeneous dose distributions with high-dose peaks surrounded by low-dose valleys, showing promise for radioresistant and bulky tumors. ** GRID therapy uses a 2-dimensional pattern of high-dose peaks (15-20 Gy), while lattice radiotherapy delivers a three-dimensional array of high-dose vertices (10-20 Gy) spaced 2-5 cm apart.[1] </strong>Minibeam radiation therapy (MBRT), a form of SFRT with beam widths of 400-800 \u03bcm, has demonstrated the ability to overcome radioresistance in triple-negative breast cancer. ** In preclinical TNBC models, MBRT (150 Gy peak dose) significantly reduced tumor growth, proliferation, and hypoxia while increasing necrosis compared to conventional radiotherapy at equivalent valley doses.[2]</p>\n<p>Mechanistically, <strong>MBRT downregulated HIF-1\u03b1/VEGFR signaling, alleviating hypoxia and angiogenesis, and enhanced vascular normalization via increased pericyte coverage</strong> .[2]</p>\n<p>These findings suggest MBRT reprograms the TNBC microenvironment to overcome hypoxia- mediated radioresistance. **For preoperative breast cancer treatment, photon mini-GRID therapy (mini-GRT) with beam widths of 1-2 mm has shown remarkable normal tissue sparing in dosimetric studies. ** Compared to stereotactic body radiotherapy (SBRT) plans, mini-GRT reduced mean dose to lungs, heart, chest wall, and lymph nodes by 50- 100%, while maintaining similar tumor integral doses.[3]</p>\n<p>The mean dose to skin\u2014the most challenging organ at risk\u2014was reduced by 20-60% in most cases. <strong>Mini-GRT also yielded sharper lateral penumbras in skin and lungs (size reduced by at least 50%)</strong> , demonstrating potential for preoperative treatment with high skin and normal tissue-sparing capabilities.[3]</p>\n<h2>Immunological Mechanisms of SFRT</h2>\n<p><strong>SFRT potentiates immune-mediated tumor control by creating protective reservoirs of the tumor immune microenvironment. ** Agent-based modeling suggests that radiation-induced cancer cell death alone is insufficient for tumor clearance with whole tumor radiotherapy, but explicit consideration of radiation-induced anti-tumor immunity synergizes with radiation cytotoxicity to eradicate tumors. </strong>For some pre-treatment tumor immune microenvironment compositions, SFRT-GRID may be superior to whole tumor radiotherapy in providing tumor control** .[4]</p>\n<p>While there is agreement that SFRT modulates the tumor immune microenvironment, it remains unclear whether the anti-tumor immunity generated is more beneficial than that resulting from conventional radiotherapy.[5]</p>\n<p>SFRT provokes release of pro-inflammatory cytokines and activates innate immune pathways, potentially leading to immunogenic cell death and reshaping the tumor microenvironment.[6]</p>\n<h2>Pulsed Reduced Dose-Rate Radiotherapy (PRDR)</h2>\n<p><strong>PRDR delivers the daily radiation dose of 2 Gy in 10 sub-fractions (pulses) with 3-minute intervals, creating an effective low dose rate of 0.067 Gy/min. ** This technique exploits the hyper-radiosensitivity of tumor cells at small doses and reduced normal tissue toxicity at low dose rates.[7] </strong>In breast cancer specifically, PRDR has shown promise for reirradiation of locoregional recurrence in previously irradiated regions. ** A study of 17 patients with locoregional recurrent breast cancer reirradiated to the chest wall, axilla, or supraclavicular region using PRDR achieved a <strong>2-year local control rate of 92%</strong> .[8]</p>\n<p>The median prior radiation dose was 60 Gy, and a median PRDR dose of 54 Gy (range 40-66 Gy) was delivered. Despite a median cumulative dose of 110 Gy (range 80-236 Gy), there was only one grade 3 and one grade 4 late toxicity.[8]</p>\n<p>Treatment was well tolerated with only 4 patients experiencing grade 3 acute skin toxicity. Eight patients received concomitant low-dose capecitabine for radiosensitization.[8]</p>\n<p>These results suggest PRDR is an effective method to reirradiate large volumes of previously irradiated tissue in selected patients with locoregional recurrences that have developed resistance to prior conventional radiotherapy.</p>\n<h2>FLASH Radiotherapy</h2>\n<p><strong>FLASH radiotherapy delivers ultra-high dose rates (typically &gt;40 Gy/s) and has demonstrated remarkable normal tissue sparing while maintaining tumor control in preclinical models. ** However, its application in breast cancer shows site-specific considerations. </strong>Treatment planning studies suggest FLASH-RT may be particularly beneficial for breast cancer. ** Analysis of five breast cancer patients showed <strong>positive netsparing for organs at risk, indicating that the FLASH effect outweighed increased toxicity from hypofractionation</strong> .[9]</p>\n<p>Even under conservative scenarios (higher tumor \u03b1/\u03b2 versus normal tissue \u03b1/\u03b2), most OARs showed positive netsparing.[9]</p>\n<p>This contrasts with glioblastoma and head- and-neck cases where no netsparing was observed. <strong>FLASH-RT appears beneficial for tumor sites where tumor \u03b1/\u03b2 \u2272 normal tissue \u03b1/\u03b2, such as breast and prostate</strong> .[9]</p>\n<p>The mechanisms underlying FLASH effects include radiolytic oxygen depletion, radical recombination, immune modulation, mitochondrial dynamics, and preservation of DNA integrity.[10]</p>\n<p>However, the differential sensitivity of healthy tissues versus tumors to FLASH radiotherapy remains incompletely explained.[11]</p>\n<h2>Combining Novel Techniques</h2>\n<p>**The combination of FLASH-RT and SFRT could represent a synergistic alliance. ** Both techniques use non- standard dose delivery methods to reduce normal tissue toxicity and increase the therapeutic index, though likely based on different mechanisms.[12]</p>\n<p>With therapeutic potential established separately for each technique, combining FLASH-RT and SFRT could be implemented in the near future.[12] <strong>SFRT is more powerful in enhancing antitumor immunity than conventional fractionation radiotherapy and works better with immune checkpoint inhibitors</strong> .[13]</p>\n<p>This suggests potential for triple combinations of SFRT, immunotherapy, and systemic agents to overcome resistance in breast cancer.</p>\n<h2>Clinical Implementation and Challenges</h2>\n<p><strong>SFRT can be clinically implemented through existing intensity-modulated radiotherapy, volumetric modulated arc therapy, image-guided technologies, and low-cost GRID collimators</strong> .[14]</p>\n<p>Despite pilot clinical results, multi- institutional trials and prospective standardized treatment regimens are still needed to evaluate the SFRT pilot experience.[14]</p>\n<p>For FLASH-RT, major challenges persist in optimizing radiation delivery protocols, unraveling precise biological mechanisms, and translating findings into clinical practice.[10]</p>\n<p>The influence of key technical parameters including radiation modality, total dose, dose rate, and fractionation schemes, alongside biological determinants such as tissue radiosensitivity and tumor heterogeneity, requires systematic analysis.[10]</p>\n<p>Would you like me to summarize the latest preclinical evidence on the specific molecular pathways and resistance mechanisms that are uniquely targeted by these non-traditional radiotherapy techniques in breast cancer, particularly focusing on how they differ from conventional radiotherapy's effects on DNA repair, hypoxia, and immune modulation? Would you like me to review and summarize the current clinical trial landscape\u2014including ongoing and completed studies\u2014evaluating SFRT, PRDR, and FLASH radiotherapy in breast cancer, with a focus on reported outcomes related to overcoming treatment resistance and safety profiles? This could help clarify how these promising techniques are translating from preclinical models to real-world patient care.</p>\n<h3>References</h3>\n<ol>\n<li>Optimizing GRID and Lattice Spatially Fractionated Radiation Therapy: Innovative Strategies for Radioresistant and Bulky Tumor Management. Ahmed MM, Wu X, Mohiuddin M, et al. Seminars in Radiation Oncology. 2024;34(3):310-322. doi:10.1016/j.semradonc.2024.05.002.</li>\n<li>Minibeam Radiation Therapy Remodels Tumor Microenvironment and Suppresses HIF-1\u03b1/VEGFR Axis to Overcome Radioresistance in Triple-Negative Breast Cancer. Fang Z, Zhou X, Zou P , et al. NPJ Precision Oncology. 2025;9(1):401. doi:10.1038/s41698-025-01178-z.</li>\n<li>Photon Mini-Grid Therapy for Preoperative Breast Cancer Tumor Treatment: A Treatment Plan Study. Corvino A, Schneider T, Vu-Bezin J, et al. Medical Physics. 2025;52(4):2493-2506. doi:10.1002/mp.17634.</li>\n<li>Spatially Fractionated GRID Radiation Potentiates Immune-Mediated Tumor Control. Bekker RA, Obertopp N, Redler G, et al. Radiation Oncology (London, England). 2024;19(1):121. doi:10.1186/s13014-024-02514-6.</li>\n<li>Alternative Radiotherapy Delivery Approaches to Modulate Radiation Response. Wilk J, Box C, Harrington K, Nill S, Oelfke U. Cancer Journal (Sudbury, Mass.). 2025 Jul-Aug 01;31(4):e0781. doi:10.1097/PPO.0000000000000781.</li>\n<li>Radiation-Induced Immune Response in Novel Radiotherapy Approaches FLASH and Spatially Fractionated Radiotherapies. Bertho A, Iturri L, Prezado Y . International Review of Cell and Molecular Biology. 2023;376:37-68. doi:10.1016/bs.ircmb.2022.11.005.</li>\n<li>Pulsed Low Dose-Rate Radiotherapy: Radiobiology and Dosimetry. Ma CMC. Physics in Medicine and Biology. 2022;67(3). doi:10.1088/1361-6560/ac4c2f.</li>\n<li>Pulsed Reduced Dose-Rate Radiotherapy: A Novel Locoregional Retreatment Strategy for Breast Cancer Recurrence in the Previously Irradiated Chest Wall, Axilla, or Supraclavicular Region. Richards GM, Tom\u00e9 WA, Robins HI, et al. Breast Cancer Research and Treatment. 2009;114(2):307-13. doi:10.1007/s10549-008-9995-3.</li>\n<li>Investigating the Therapeutic Potential of FLASH Radiotherapy - A Treatment Planning Study. H\u00f6rberger F , Petersson K, Ceberg S, et al. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology. 2025;209:110947. doi:10.1016/j.radonc.2025.110947.</li>\n<li>Unraveling the Dual Nature of FLASH Radiotherapy: From Normal Tissue Sparing to Tumor Control. Guo Y , Hao S, Huang Q, et al. Cancer Letters. 2025;630:217895. doi:10.1016/j.canlet.2025.217895.</li>\n<li>Mechanisms, Challenges and Opportunities for FLASH Radiotherapy in Cancer. Vozenin MC, Montay-Gruel P , Tsoutsou P , Limoli CL. Nature Reviews. Cancer. 2025;:10.1038/s41568-025-00878-9. doi:10.1038/s41568-025- 00878-9.</li>\n<li>Combining FLASH and Spatially Fractionated Radiation Therapy: The Best of Both Worlds. Schneider T, Fernandez-Palomo C, Bertho A, et al. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology. 2022;175:169-177. doi:10.1016/j.radonc.2022.08.004.</li>\n<li>Radiobiological and Treatment-Related Aspects of Spatially Fractionated Radiotherapy. Moghaddasi L, Reid P , Bezak E, Marcu LG. International Journal of Molecular Sciences. 2022;23(6):3366. doi:10.3390/ijms23063366.</li>\n<li>Addressing Challenges in Low-Income and Middle-Income Countries Through Novel Radiotherapy Research Opportunities. Abdel-Wahab M, Coleman CN, Eriksen JG, et al. The Lancet. Oncology. 2024;25(6):e270-e280. doi:10.1016/S1470-2045(24)00038-X.</li>\n<li>Can hyper- or hypo- fractionation alter resistance patter</li>\n</ol>"}]}, "20": {"question": "Can hyper- or hypo-fractionation alter resistance patterns as compared to conventionally fractionated radiation?", "responses": [{"model": "PMC-LLaMA 13B", "text": "<p>Yes. Hyper- and hypofractionation can change the pattern of radiosensitivity of tumor cells, normal tissue and PBMCs in vitro.</p>"}, {"model": "GPT-4o", "text": "<p>Hyper-fractionation and hypo-fractionation are two approaches to delivering radiation therapy that differ from the conventional fractionation schedule. These approaches can indeed influence resistance patterns in tumors, although the effects can vary depending on the specific context, including the type of cancer, the biological characteristics of the tumor, and the overall treatment plan.</p>\n<ol>\n<li>\n<p><strong>Hyper-fractionation</strong> involves delivering smaller doses of radiation per session but increasing the number of sessions. This approach aims to exploit the differential repair capabilities between normal and cancerous tissues, potentially reducing late side effects and allowing for a higher total dose to be delivered. By increasing the total dose, hyper-fractionation can potentially overcome resistance in some tumors, especially those with rapid repopulation rates.</p>\n</li>\n<li>\n<p><strong>Hypo-fractionation</strong> involves delivering larger doses of radiation per session over fewer sessions. This approach can be more convenient for patients and may enhance the biological effectiveness of the treatment due to the higher dose per fraction. Hypo-fractionation can be particularly effective in tumors with low alpha/beta ratios, such as prostate cancer, where it may overcome resistance by delivering a more potent dose per session.</p>\n</li>\n</ol>\n<p>Both hyper- and hypo-fractionation can alter the tumor microenvironment and influence the mechanisms of resistance. For example, they can affect the repair of sublethal damage, reoxygenation, repopulation, and redistribution of cancer cells within the cell cycle. These changes can either enhance or reduce the effectiveness of radiation therapy, depending on the specific tumor biology.</p>\n<p>Ultimately, the choice between hyper-fractionation, hypo-fractionation, and conventional fractionation should be based on a thorough understanding of the tumor's characteristics, patient-specific factors, and the goals of treatment. Clinical trials and ongoing research continue to refine these approaches to optimize outcomes and manage resistance in various cancer types.</p>"}, {"model": "Gemini 3 Pro", "text": "<p>Yes, hyper-fractionation and hypo-fractionation significantly alter resistance patterns compared to conventional fractionation. They do so by interacting differently with the fundamental biological mechanisms of tumor survival\u2014classically described as the \"4 Rs\" of radiobiology (Repair, Reassortment, Repopulation, and Reoxygenation)\u2014and by triggering distinct biological pathways (such as vascular damage and immune activation).</p>\n<p>Here is a detailed breakdown of how these fractionation schedules alter resistance patterns.</p>\n<hr />\n<h3>1. The Biological Basis: The $\\alpha/\\beta$ Ratio</h3>\n<p>To understand resistance, one must understand the Linear-Quadratic Model.\n*   <strong>High $\\alpha/\\beta$ ratio (e.g., 10 Gy):</strong> Tissues/tumors with rapid turnover (Head &amp; Neck squamous cell, most carcinomas). They respond linearly to dose; fractionation size matters less than total dose.\n*   <strong>Low $\\alpha/\\beta$ ratio (e.g., 1\u20133 Gy):</strong> Tissues/tumors with slow turnover (Prostate, Melanoma, Sarcoma). These are \"resistant\" to small doses because they have a high capacity to repair sublethal DNA damage between fractions.</p>\n<h3>2. Hypo-fractionation (Large doses, fewer fractions)</h3>\n<p><em>Examples: Stereotactic Body Radiation Therapy (SBRT), Stereotactic Radiosurgery (SRS).</em></p>\n<p>Hypo-fractionation alters resistance patterns by <strong>overwhelming repair mechanisms</strong> and engaging <strong>non-DNA targets</strong>.</p>\n<ul>\n<li>\n<p><strong>Overcoming Intrinsic Repair Resistance:</strong>\n    Tumors with a low $\\alpha/\\beta$ ratio (like prostate cancer or melanoma) are resistant to conventional fractionation (1.8\u20132 Gy) because they efficiently repair sublethal DNA damage in the hours between treatments.</p>\n<ul>\n<li><em>Alteration:</em> By delivering massive doses per fraction (6\u201320+ Gy), hypo-fractionation causes \"lethal\" rather than \"sublethal\" damage. The repair machinery is saturated and overwhelmed, rendering the tumor's intrinsic repair capacity irrelevant.</li>\n</ul>\n</li>\n<li>\n<p><strong>Vascular Ablation (The \"New Biology\"):</strong>\n    Conventional radiation relies on killing tumor clonogens (stem cells) via DNA damage.</p>\n<ul>\n<li><em>Alteration:</em> High-dose hypo-fractionation (usually &gt;10 Gy/fraction) triggers a distinct pathway: <strong>endothelial apoptosis</strong>. This causes the rapid collapse of the tumor vasculature. The tumor dies not just because the DNA is damaged, but because its blood supply is destroyed (indirect cell death). This bypasses resistance caused by high tumor burden or intrinsic cellular radioresistance.</li>\n</ul>\n</li>\n<li>\n<p><strong>Hypoxia:</strong>\n    Hypoxic cells are traditionally 2\u20133 times more resistant to radiation because oxygen is required to \"fix\" DNA damage (make it permanent).</p>\n<ul>\n<li><em>Alteration:</em> While hypoxia is still a factor, the extreme doses in SBRT are so high that they can kill hypoxic cells despite the lack of oxygen fixation. Furthermore, the vascular collapse mentioned above makes the hypoxic state of the cell less relevant, as the tissue is ablated regardless of oxygen status.</li>\n</ul>\n</li>\n</ul>\n<h3>3. Hyper-fractionation (Smaller doses, more frequent)</h3>\n<p><em>Examples: 1.2 Gy twice daily (BID).</em></p>\n<p>Hyper-fractionation alters resistance patterns by <strong>exploiting the cell cycle</strong> and <strong>sparing normal tissue to allow dose escalation</strong>.</p>\n<ul>\n<li>\n<p><strong>Overcoming Reassortment Resistance:</strong>\n    Cells are most resistant to radiation during the S-phase (DNA synthesis) and most sensitive during the G2/M phase.</p>\n<ul>\n<li><em>Alteration:</em> By treating more frequently (e.g., twice daily), hyper-fractionation increases the probability of \"catching\" tumor cells as they redistribute (reassort) into a sensitive phase of the cell cycle. This is particularly effective for rapidly dividing tumors that might cycle through a sensitive phase in the gap between conventional daily treatments.</li>\n</ul>\n</li>\n<li>\n<p><strong>Sensitizing via Oxygenation:</strong></p>\n<ul>\n<li><em>Alteration:</em> Smaller, frequent doses allow for continuous <strong>reoxygenation</strong>. As the outer layer of the tumor dies, the inner hypoxic core gains access to oxygen, becoming more sensitive to subsequent fractions. While conventional fractionation does this, hyper-fractionation optimizes the balance between killing aerated cells and allowing hypoxic cells to reoxygenate.</li>\n</ul>\n</li>\n<li>\n<p><strong>Allowing Dose Escalation:</strong>\n    Late-responding normal tissues (nerves, spinal cord) are very sensitive to large fraction sizes (they have low $\\alpha/\\beta$).</p>\n<ul>\n<li><em>Alteration:</em> By reducing the fraction size (e.g., to 1.1 or 1.2 Gy), you spare the normal tissue significantly. This allows the clinician to increase the <strong>total biological effective dose (BED)</strong> to the tumor. A tumor that is \"resistant\" simply because the safe conventional dose wasn't high enough may be controlled by the higher total dose made possible by hyper-fractionation.</li>\n</ul>\n</li>\n</ul>\n<h3>4. Accelerated Fractionation (Reducing overall time)</h3>\n<p><em>Often combined with hyper-fractionation.</em></p>\n<ul>\n<li><strong>Combating Repopulation:</strong>\n    A major mechanism of resistance in fast-growing tumors (like Head &amp; Neck cancer) is <strong>accelerated repopulation</strong>. About 3\u20134 weeks into treatment, tumor stem cells trigger a survival mechanism and begin dividing much faster to replace killed cells.<ul>\n<li><em>Alteration:</em> By shortening the overall treatment time (e.g., from 7 weeks to 5 weeks), the radiation \"outruns\" the tumor's ability to regenerate.</li>\n</ul>\n</li>\n</ul>\n<h3>Summary Comparison</h3>\n<p>| Feature | Conventional (1.8\u20132 Gy) | Hypo-fractionation (&gt;3 Gy - SBRT) | Hyper-fractionation (&lt;1.8 Gy) |\n| :--- | :--- | :--- | :--- |\n| <strong>Primary Resistance Target</strong> | Balances all 4 Rs | <strong>Repair</strong> (DNA repair capacity) | <strong>Reassortment</strong> &amp; <strong>Late Toxicity</strong> |\n| <strong>Effect on Low $\\alpha/\\beta$ Tumors</strong> | Inefficient (High resistance) | <strong>Highly Effective</strong> (Overcomes repair) | Ineffective (Increases resistance) |\n| <strong>Effect on Hypoxia</strong> | Dependent on reoxygenation | <strong>Less Dependent</strong> (Ablative/Vascular) | Highly dependent on reoxygenation |\n| <strong>Vascular Effect</strong> | Minimal / Slow | <strong>High</strong> (Vascular collapse) | Minimal |\n| <strong>Role of Repopulation</strong> | Vulnerable to repopulation | Treatment is too short for repopulation | Minimizes repopulation (if accelerated) |</p>\n<p><strong>Conclusion:</strong>\nYes. <strong>Hypo-fractionation</strong> overcomes resistance in slow-growing, repair-proficient tumors (prostate, sarcoma) and utilizes vascular damage to bypass cellular resistance. <strong>Hyper-fractionation</strong> overcomes resistance in fast-growing tumors by catching cells in sensitive cycles and allowing higher total doses by sparing normal tissue.</p>"}, {"model": "MedGemma 27B", "text": "<p>Yes, both hyperfractionation and hypofractionation can potentially alter tumor radioresistance patterns compared to conventional fractionation (CF). Here's a breakdown of how they might do so:</p>\n<p><strong>1. Hyperfractionation:</strong></p>\n<ul>\n<li><strong>Definition:</strong> Delivering smaller doses per fraction but increasing the total number of fractions over a longer period (e.g., 1.15 Gy twice daily instead of 2 Gy once daily).</li>\n<li><strong>Mechanism for Altering Resistance:</strong><ul>\n<li><strong>Reduced Repair Time:</strong> The shorter interval between fractions leaves less time for sublethal damage repair within the tumor cells. This is particularly relevant for rapidly proliferating tumors where DNA repair mechanisms are highly active. By reducing the opportunity for repair, hyperfractionation aims to overcome acquired resistance due to efficient repair pathways.</li>\n<li><strong>Increased Oxygen Effect:</strong> Some studies suggest that hyperfractionation may enhance the therapeutic ratio by exploiting differences in oxygen levels between normal tissues and hypoxic tumor regions. Hypoxic cells are more resistant to radiation, but their sensitivity increases when reoxygenated. Frequent dosing might promote better reoxygenation in certain parts of the tumor.</li>\n<li><strong>Targeting Different Cell Populations:</strong> It might preferentially kill slowly cycling cells while sparing actively dividing stem cells, which could be beneficial in some contexts. Conversely, it might also target radiosensitive populations more effectively before they become resistant.</li>\n</ul>\n</li>\n<li><strong>Clinical Relevance:</strong> Often used in head and neck cancers, cervical cancer, and sometimes breast cancer, aiming to improve local control and reduce toxicity by targeting specific cell cycle phases or overcoming repair.</li>\n</ul>\n<p><strong>2. Hypofractionation:</strong></p>\n<ul>\n<li><strong>Definition:</strong> Delivering larger doses per fraction but decreasing the total number of fractions over a shorter period (e.g., 3 Gy once daily instead of 1.8 Gy five times weekly). Includes techniques like Stereotactic Body Radiation Therapy (SBRT) / Stereotactic Ablative Radiotherapy (SABR), proton therapy with RBE considerations, etc.</li>\n<li><strong>Mechanism for Altering Resistance:</strong><ul>\n<li><strong>Overcoming Repopulation:</strong> For slow-growing tumors, CF allows significant repopulation during treatment. Hypofractionation delivers higher doses quickly, potentially killing more cells before substantial regrowth occurs, thus overcoming resistance related to proliferation.</li>\n<li><strong>Exploiting Differential Response:</strong> Larger dose fractions induce greater initial damage. While this causes more acute toxicity, it might disproportionately affect sensitive tumor cells compared to relatively radioresistant normal tissues, especially</li>\n</ul>\n</li>\n</ul>"}, {"model": "Perplexity", "text": "<p><img src=\"https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png\" style=\"height:64px;margin-right:32px\"/></p>\n<h1>Can hyper- or hypo-fractionation alter resistance patterns as compared to conventionally fractionated radiation?</h1>\n<p>Yes, hyper- and hypo-fractionation can alter resistance patterns in breast cancer compared to conventional fractionation (1.8-2 Gy/fraction over 5-6 weeks), primarily by exploiting differences in tumor repopulation, DNA repair kinetics, and cancer stem cell (CSC) sensitivity, with hypofractionation often showing advantages against resistant phenotypes.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6128144/\">^1</a><a href=\"https://www.bmj.com/content/386/bmj-2023-079089\">^5</a></p>\n<h2>Hypofractionation effects on resistance</h2>\n<p>Hypofractionation (e.g., 2.65-3.3 Gy/13-16 fractions or ultra-hypo like 5-6 Gy/5 fractions) reduces opportunities for resistant subclones to repopulate between fractions.</p>\n<ul>\n<li>Breast CSCs (CD44+/CD24low/ALDH1+), which drive radioresistance via enhanced DNA repair (NHEJ/HR) and survival signaling (PI3K/AKT/mTOR), exhibit lower \u03b1/\u03b2 ratios (~4-10 Gy) than differentiated cells; hypofractionation preferentially kills them due to less repair time per dose, maintaining tumor control probability (TCP) even in CSC-rich tumors.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12384436/\">^2</a></li>\n<li>In models with high CSC fractions (e.g., TNBC lines like MDA-MB-231), hypo schemes require smaller dose escalations to match conventional TCP, unlike conventional fractionation where CSCs survive and expand.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6128144/\">^2</a></li>\n</ul>\n<p>Meta-analyses confirm equivalent oncologic outcomes (recurrence/survival) with moderate hypofractionation (MHF) vs conventional (CF), but improved cosmesis and acute toxicity, suggesting it mitigates resistance-linked fibrosis/EMT.<a href=\"https://www.bmj.com/content/386/bmj-2023-079089\">^5</a></p>\n<h2>Hyperfractionation effects</h2>\n<p>Hyperfractionation (e.g., 1.2 Gy twice daily) aims to escalate total dose while sparing late-responding normal tissue (\u03b1/\u03b2 ~3 Gy).</p>\n<ul>\n<li>Accelerates treatment to limit repopulation in rapidly proliferating resistant tumors but risks enhanced repair in proficient DDR clones (e.g., BRCA-proficient post-PARPi); less studied in breast cancer, with data showing similar local control to CF but higher acute mucositis.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6128144/\">^9</a></li>\n<li>May select against hypoxic/resistant cores less effectively than hypo, as smaller doses allow reoxygenation but permit adaptive repair upregulation (e.g., FEN1, ATM).<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12384436/\">^1</a></li>\n</ul>\n<h2>Key differences vs conventional fractionation</h2>\n<p>| Fractionation | Dose/Fx (Gy) | Resistance impact | Breast cancer evidence |\n| :-- | :-- | :-- | :-- |\n| Conventional | 1.8-2 | Allows CSC repair/repopulation; higher late effects in resistant stroma | Standard post-lumpectomy; equivalent long-term control but more skin toxicity<a href=\"https://www.bmj.com/content/386/bmj-2023-079089\">^5</a> |\n| Hypo (MHF/UHF) | 2.65-6 | Kills CSCs (low \u03b1/\u03b2); limits repopulation; immune priming | Non-inferior OS/DFS; better for CSC-high TNBC; UK START trials confirm<a href=\"https://www.bmj.com/content/386/bmj-2023-079089\">^2</a> |\n| Hyper | 1.1-1.2 (BID) | Reduces repopulation but risks DDR adaptation | Limited breast data; similar control, higher acute risks<a href=\"https://www.sciencedirect.com/science/article/abs/pii/S0305737210000824\">^9</a> |</p>\n<p>Hypofractionation emerges as optimal for overcoming intrinsic CSC/repair-mediated resistance, supported by trials like FAST-Forward (UHF non-inferior), while hyperfractionation suits select accelerated needs.<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6128144/\">^5</a>\n<span style=\"display:none\"><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8797773/\">^10</a><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11613145/\">^4</a><a href=\"https://pubmed.ncbi.nlm.nih.gov/11741498/\">^7</a></span></p>\n<div align=\"center\">\u2042</div>"}, {"model": "OpenEvidence", "text": "<p>ation? Both hyperfractionation and hypofractionation can alter resistance patterns in breast cancer compared to conventionally fractionated radiotherapy, though through different radiobiological mechanisms, with hypofractionation showing particular promise for overcoming certain forms of radioresistance while hyperfractionation may enhance tumor cell killing in specific contexts. Hypofractionation and Resistance Mechanisms Hypofractionation (larger doses per fraction, fewer total fractions) exploits the low \u03b1/\u03b2 ratio of breast cancer tissue (approximately 3-4 Gy), which is similar to or lower than late-responding normal tissues. This radiobiological characteristic means that breast cancer is more sensitive to changes in fraction size than many other tumor types. Four randomized trials testing fraction sizes of 2.7-3.3 Gy with 10-year follow-up in almost 8,000 patients provide robust evidence that there are no advantages in terms of safety or effectiveness of persisting with 2.0 Gy fractions in breast cancer patients. Moderate hypofractionation (40-42.5 Gy in 15-16 fractions) has become the standard of care, with the NCCN guidelines recommending it as the preferred regimen for whole breast radiotherapy. Long-term results confirm that moderate hypofractionated whole breast irradiation is both safe and effective, with no specific subgroup identified for whom hypofractionation produces worse outcomes in terms of efficacy or normal tissue effects\u2014 including variations by age, systemic therapies (chemotherapy, endocrine therapy, anti-HER2 therapy), tumor grade, or molecular subtype. Ultra-hypofractionation (26 Gy in 5 fractions) demonstrates non-inferior local control compared to moderate hypofractionation (40 Gy in 15 fractions), with hazard ratios of 0.67 (95% CI 0.38-1.16) at median 6-year follow-up in the FAST-Forward trial. Importantly, the 5-day schedule causes milder early skin reactions and similar rates of late adverse effects, suggesting it may overcome certain resistance mechanisms while maintaining or improving the therapeutic ratio. The radiobiological basis for hypofractionation's effectiveness against resistance involves multiple mechanisms: Enhanced vascular damage: Higher doses per fraction (\u22658-10 Gy in SABR/SBRT contexts) induce endothelial apoptosis and blood perfusion reduction, which may enhance tumor cell response beyond direct cell killing. This vascular injury contributes to ablative effects that can overcome hypoxia-mediated radioresistance. Immune activation: Hypofractionated regimens provoke greater release of pro-inflammatory cytokines and activate innate immune pathways more effectively than conventional fractionation, potentially leading to immunogenic cell death and reshaping the tumor microenvironment. This enhanced immune activation may overcome immune-mediated resistance mechanisms. DNA damage complexity: Ablative doses induce complex DNA double-strand breaks that robustly activate DNA damage response pathways via ATM and ATR kinases, potentially overwhelming repair mechanisms that confer resistance to conventional fractionation. Hyperfractionation and Resistance Patterns Hyperfractionation (smaller doses per fraction, more total fractions, often delivered multiple times daily) exploits different radiobiological principles that may overcome specific resistance mechanisms. In a preclinical study comparing conventional (2 Gy) and fractionated (1.2 + 1.2 Gy) doses in breast cancer cell lines, fractionated regimens showed differential effects on radiation-induced adaptive response (RIAR) compared to conventional dosing. Specifically: - MCF-7 cells (ER+ breast cancer) showed decreased survival with fractionated dosing, indicating absence of RIAR and suggesting enhanced tumor cell killing - MDA-MB-231 cells (triple-negative) demonstrated RIAR in fractionated dosing but not conventional dosing, indicating cell-type-specific responses - Normal cells (MCF-10A) showed absence of RIAR in both regimens, suggesting potential for therapeutic gain These findings suggest that compared to conventional regimens, fractionated regimens may improve therapeutic efficacy by minimizing damage to healthy cells while enhancing tumor cell killing in certain breast cancer subtypes. The mechanism underlying hyperfractionation's potential to overcome resistance involves exploiting the hyper- radiosensitivity of tumor cells at small doses and allowing less time for sublethal damage repair between fractions, potentially preventing the development of radioresistance that can occur with longer interfraction intervals. Clinical Evidence and Comparative Effectiveness Meta-analyses comparing hypofractionation to conventional fractionation show no statistical differences in local recurrence, disease-free survival, or overall survival, but demonstrate reduced toxicity with hypofractionation. Specifically: - Acute radiation dermatitis (grade \u22652): Risk ratio 0.54 (95% CI 0.49-0.61, p&lt;0.001) favoring hypofractionation after breast-conserving therapy - Hyperpigmentation: RR 0.77 (0.62-0.95, p=0.02) favoring hypofractionation - Breast shrinkage (grade \u22652): RR 0.92 (0.85-0.99, p=0.03) favoring hypofractionation - Skin toxicity: Odds ratio 0.43 (95% CI 0.33-0.55, p&lt;0.01) favoring hypofractionation - Patient fatigue: OR 0.73 (0.60-0.88, p&lt;0.01) favoring hypofractionation Importantly, several systematic reviews show significantly less radiation-related acute toxicity with moderate hypofractionation compared to conventional schedules, reinforcing the radiobiological basis that acute-reacting tissues have higher sensitivity to total dose rather than dose per fraction. Subtype-Specific Considerations No trials have identified specific molecular subtypes for whom hypofractionation produces inferior outcomes. Available evidence shows no difference in terms of local recurrence at 5 years for ductal carcinoma in situ, and no differential effects according to tumor grade, molecular subtype, or use of systemic therapies including chemotherapy, endocrine therapy, and anti-HER2 therapy. This universality across subtypes suggests that the radiobiological advantages of hypofractionation\u2014exploiting the low \u03b1/\u03b2 ratio of breast tissue\u2014transcend molecular heterogeneity and may overcome resistance mechanisms common across breast cancer subtypes. Integration With Systemic Therapy The sequencing and integration of fractionation schedules with systemic therapy may influence resistance patterns. Available data suggest that sequential or concurrent endocrine therapy with radiotherapy is acceptable, though initiating endocrine therapy at completion of radiotherapy may be preferred due to compounding side effects. CDK4/6 inhibitors (abemaciclib, ribociclib) should be initiated after completion of radiotherapy, while adjuvant HER2-targeted therapy may be delivered concurrently. The ability to deliver hypofractionated regimens more quickly may allow earlier initiation of systemic therapies, potentially preventing the development of systemic resistance during prolonged local treatment. Clinical Implementation Current NCCN guidelines recommend hypofractionated dosing as the standard approach: - Whole breast: 40-42.5 Gy in 15-16 fractions (preferred); 45-50.4 Gy in 25-28 fractions may be considered in selected cases - Ultra-hypofractionation: 26.5 Gy in 5 fractions (once weekly) for selected patients &gt;50 years with early-stage, node-negative disease - Post-mastectomy/chest wall: 40-42.5 Gy in 15-16 fractions or 45-50.4 Gy in 25-28 fractions - Regional nodes: 39-42 Gy (moderate hypofractionation) or 46-50 Gy (conventional fractionation) Would you like me to summarize the latest evidence on how specific molecular markers or genomic profiles might predict differential responses to hypofractionated versus conventionally fractionated radiotherapy, potentially enabling personalized fractionation selection to optimize outcomes and minimize resistance development? Would you like me to review and synthesize the most recent clinical trial data comparing long-term local control and recurrence rates for hypofractionated versus conventionally fractionated radiotherapy specifically in high- risk breast cancer subtypes, such as triple-negative or HER2-positive disease, to clarify whether resistance patterns differ in these populations?</p>"}]}};
    const Q_IDS = Object.keys(DATA).sort((a,b) => parseInt(a)-parseInt(b));
    let currentQIndex = 0;

    const selectEl = document.getElementById('q-select');
    const qTextEl = document.getElementById('question-text');
    const gridEl = document.getElementById('response-grid');

    function init() {
        // Populate Dropdown
        Q_IDS.forEach((id, idx) => {
            const opt = document.createElement('option');
            opt.value = idx;
            const text = DATA[id].question;
            opt.text = `Q${id}: ` + (text.length > 50 ? text.substring(0, 50) + '...' : text);
            selectEl.appendChild(opt);
        });
        
        renderQuestion();
    }

    function changeQ(delta) {
        const newIndex = parseInt(selectEl.value) + delta;
        if (newIndex >= 0 && newIndex < Q_IDS.length) {
            selectEl.value = newIndex;
            renderQuestion();
        }
    }

    function renderQuestion() {
        currentQIndex = selectEl.value;
        const qId = Q_IDS[currentQIndex];
        const data = DATA[qId];

        // Update Header
        qTextEl.textContent = `Q${qId}: ${data.question}`;

        // Update Grid
        gridEl.innerHTML = '';
        
        data.responses.forEach(res => {
            const card = document.createElement('div');
            card.className = 'card';
            card.setAttribute('data-model', res.model);
            
            // Convert simple markdown-like bolding if needed, but otherwise keep as text
            // The python script already replaced newlines with <br>
            
            card.innerHTML = `
                <h3>${res.model}</h3>
                <div class="card-content">${res.text}</div>
            `;
            gridEl.appendChild(card);
        });
    }

    init();
</script>

</body>
</html>
